ࡱ> o q X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n {`  bjbjFF 5 ,,8u8   T(KĽĽĽ\$ \t.d`Lj:R LU$h9 ///  TTT/x   T/TTol  srT `NĽK:Wq"}m0.yq!>6Dsrsr u f%$T%(**z wlWT^   .////\t\t\t'Ė\t\t\t't 8%L(P     CDAR1AIS0010R010 Additional Information Specification 0010: Drug Prior Authorization Attachment Release 1.0 Based on HL7 CDA Standard Release 1.0, with supporting LOINC Tables Draft - December 2006 This page intentionally blank Table of Contents  TOC \o "1-3" \h \z \u   HYPERLINK \l "_Toc122939381" 1 Introduction  PAGEREF _Toc122939381 \h 1  HYPERLINK \l "_Toc122939382" 1.1 LOINC Codes and Structure  PAGEREF _Toc122939382 \h 2  HYPERLINK \l "_Toc122939383" 1.2 Revision History  PAGEREF _Toc122939383 \h 4  HYPERLINK \l "_Toc122939384" 1.3 Privacy Concerns in Examples  PAGEREF _Toc122939384 \h 4  HYPERLINK \l "_Toc122939385" 1.4 HL7 Attachment-CDA Document Variants  PAGEREF _Toc122939385 \h 4  HYPERLINK \l "_Toc122939386" 1.5 Request for Information versus Request for Service  PAGEREF _Toc122939386 \h 4  HYPERLINK \l "_Toc122939387" 2 LOINC Codes  PAGEREF _Toc122939387 \h 5  HYPERLINK \l "_Toc122939388" 2.1 Supporting Documentation  PAGEREF _Toc122939388 \h 5  HYPERLINK \l "_Toc122939389" 2.2 Scope Modification Codes  PAGEREF _Toc122939389 \h 5  HYPERLINK \l "_Toc122939390" 2.3 Special Considerations  PAGEREF _Toc122939390 \h 5  HYPERLINK \l "_Toc122939391" 2.4 Attachment Data Components  PAGEREF _Toc122939391 \h 6  HYPERLINK \l "_Toc122939392" 2.4.1 Drug Request - Unspecified Therapeutic Category Attachment  PAGEREF _Toc122939392 \h 6  HYPERLINK \l "_Toc122939393" 2.4.2 NSAIDS - COX2 Inhibitors Attachment  PAGEREF _Toc122939393 \h 6  HYPERLINK \l "_Toc122939394" 2.4.3 Growth Hormone Attachment  PAGEREF _Toc122939394 \h 6  HYPERLINK \l "_Toc122939395" 2.4.4 Proton Pump Inhibitors Attachment  PAGEREF _Toc122939395 \h 7  HYPERLINK \l "_Toc122939396" 2.4.5 Erectile Dysfunction (ED) Agents Attachment  PAGEREF _Toc122939396 \h 7  HYPERLINK \l "_Toc122939397" 2.4.6 Narcotic (OPIOID) Agonists Attachment  PAGEREF _Toc122939397 \h 8  HYPERLINK \l "_Toc122939398" 2.4.7 Imidazole - Related Antifungals Attachment  PAGEREF _Toc122939398 \h 8  HYPERLINK \l "_Toc122939399" 3 Drug Prior Authorization Attachment Value Tables  PAGEREF _Toc122939399 \h 8  HYPERLINK \l "_Toc122939400" 3.1 Drug Request - Unspecified Therapeutic Category (UTC) Service Value Table  PAGEREF _Toc122939400 \h 9  HYPERLINK \l "_Toc122939401" 3.2 NSAIDS - COX2 Inhibitors Value Table  PAGEREF _Toc122939401 \h 12  HYPERLINK \l "_Toc122939402" 3.3 Growth Hormone (GH) Value Table  PAGEREF _Toc122939402 \h 15  HYPERLINK \l "_Toc122939403" 3.4 Proton Pump Inhibitors (PPI) Value Table  PAGEREF _Toc122939403 \h 23  HYPERLINK \l "_Toc122939404" 3.5 Erectile Dysfunction (ED) Agents Value Table  PAGEREF _Toc122939404 \h 27  HYPERLINK \l "_Toc122939405" 3.6 Narcotic(Opioid) Agonists Value Table  PAGEREF _Toc122939405 \h 32  HYPERLINK \l "_Toc122939406" 3.7 Imidazole - Related Antifungals Value Table  PAGEREF _Toc122939406 \h 37  HYPERLINK \l "_Toc122939407" 4 Coding Examples  PAGEREF _Toc122939407 \h 43  HYPERLINK \l "_Toc122939408" 4.1 Scenario  PAGEREF _Toc122939408 \h 43  HYPERLINK \l "_Toc122939409" 4.1.1 Drug Prior Authorization Attachment, Human-Decision Variant (XML body)  PAGEREF _Toc122939409 \h 44  HYPERLINK \l "_Toc122939410" 4.1.2 Drug Prior Authorization Attachment, Human-Decision Variant (non-XML body)  PAGEREF _Toc122939410 \h 49  HYPERLINK \l "_Toc122939411" 4.1.3 Coded Drug Prior Authorization Attachment, Computer-Decision Variant  PAGEREF _Toc122939411 \h 52  HYPERLINK \l "_Toc122939412" 5 Response Code Sets  PAGEREF _Toc122939412 \h 58  HYPERLINK \l "_Toc122939413" 5.1 HL70136: Yes-No Indicator  PAGEREF _Toc122939413 \h 58  HYPERLINK \l "_Toc122939414" 5.2 HL79038: Drug Prescribed, Therapy Type  PAGEREF _Toc122939414 \h 58  HYPERLINK \l "_Toc122939415" 5.3 HL79039: UTC, Diagnosis Confirmed By  PAGEREF _Toc122939415 \h 58  HYPERLINK \l "_Toc122939416" 5.4 HL79040: Reason Prior Therapy Discontinued  PAGEREF _Toc122939416 \h 59  HYPERLINK \l "_Toc122939417" 5.5 HL79041: NSAIDS/PPI Related Concurrent Therapy, Type  PAGEREF _Toc122939417 \h 59  HYPERLINK \l "_Toc122939418" 5.6 HL79042: NSAID Use, Duration  PAGEREF _Toc122939418 \h 59  HYPERLINK \l "_Toc122939419" 5.7 HL79043: Yes-No-Unknown Indicator  PAGEREF _Toc122939419 \h 59  HYPERLINK \l "_Toc122939420" 5.8 HL79044: Radiology Diagnosis Confirmation, Study Type  PAGEREF _Toc122939420 \h 60  HYPERLINK \l "_Toc122939421" 5.9 HL79045: Laboratory Diagnosis Confirmation, Study/Test  PAGEREF _Toc122939421 \h 60  HYPERLINK \l "_Toc122939422" 5.10 HL79046: GH, Patient History Documented Onset  PAGEREF _Toc122939422 \h 60  HYPERLINK \l "_Toc122939423" 5.11 HL79047: GH, Patient History Information Hypothalmic Pituitary Disease Induced By  PAGEREF _Toc122939423 \h 60  HYPERLINK \l "_Toc122939424" 5.12 HL79048: Treatment Status  PAGEREF _Toc122939424 \h 61  HYPERLINK \l "_Toc122939425" 5.13 HL79049: GHD Childhood Information, Puberty Status  PAGEREF _Toc122939425 \h 61  HYPERLINK \l "_Toc122939426" 5.14 HL79050: GH Dysfunction Adult Information, Secondary Causes  PAGEREF _Toc122939426 \h 61  HYPERLINK \l "_Toc122939427" 5.15 HL79051: Nutritional Information, Assessment Indicator  PAGEREF _Toc122939427 \h 61  HYPERLINK \l "_Toc122939428" 5.16 HL79052: Parental Height, Availability Indicator  PAGEREF _Toc122939428 \h 61  HYPERLINK \l "_Toc122939429" 5.17 HL79053: Diagnosis Confirmation and Level of Treatment Needed, Procedure Employed  PAGEREF _Toc122939429 \h 62  HYPERLINK \l "_Toc122939430" 5.18 HL79054: Diagnosis Confirmation and Level of Treatment Needed, GERD By Endoscopy Type  PAGEREF _Toc122939430 \h 62  HYPERLINK \l "_Toc122939431" 5.19 HL79055: H-Pylori Information, Status  PAGEREF _Toc122939431 \h 62  HYPERLINK \l "_Toc122939432" 5.20 HL79056: H-Pylori Information, Confirmed By  PAGEREF _Toc122939432 \h 62  HYPERLINK \l "_Toc122939433" 5.21 HL79057: ED, Related Diagnosis Confirmation, Confirmed By  PAGEREF _Toc122939433 \h 63  HYPERLINK \l "_Toc122939434" 5.22 HL79058: ED, Patient History Pulmonary Hypertension Functional Level  PAGEREF _Toc122939434 \h 63  HYPERLINK \l "_Toc122939435" 5.23 HL79059: ED, Patient History Evaluation Type  PAGEREF _Toc122939435 \h 63  HYPERLINK \l "_Toc122939436" 5.24 HL79060: ED, Patient History ED Related To  PAGEREF _Toc122939436 \h 63  HYPERLINK \l "_Toc122939437" 5.25 HL79061: ED, Treatment of Related Causes Psychogenic Causes of ED Treatment  PAGEREF _Toc122939437 \h 64  HYPERLINK \l "_Toc122939438" 5.26 HL79062: ED, Treatment of Related Causes Drug Induced Option  PAGEREF _Toc122939438 \h 64  HYPERLINK \l "_Toc122939439" 5.27 HL79063: ED Concurrent Therapy, Type  PAGEREF _Toc122939439 \h 64  HYPERLINK \l "_Toc122939440" 5.28 HL79064: Narcotic (Opioid) Agonists, Patient History Pain Syndrome Source  PAGEREF _Toc122939440 \h 64  HYPERLINK \l "_Toc122939441" 5.29 HL79065: Narcotic (Opioid) Agonists, Patient History Pain Syndrome History  PAGEREF _Toc122939441 \h 65  HYPERLINK \l "_Toc122939442" 5.30 HL79066: Narcotic (Opioid) Agonists, Patient History Pain Syndrome Persistence  PAGEREF _Toc122939442 \h 65  HYPERLINK \l "_Toc122939443" 5.31 HL79067: Narcotic (Opioid) Agonists, Complicating Conditions  PAGEREF _Toc122939443 \h 65  HYPERLINK \l "_Toc122939444" 5.32 HL79068: Opioid Related Concurrent Pain Therapy, Opioid Level  PAGEREF _Toc122939444 \h 65  HYPERLINK \l "_Toc122939445" 5.33 HL79069: Drug Prescribed, Topical Therapy - Reason  PAGEREF _Toc122939445 \h 66  HYPERLINK \l "_Toc122939446" 5.34 HL79070: Imidazole Related Antifungals, Diagnosis Confirmed By  PAGEREF _Toc122939446 \h 66  HYPERLINK \l "_Toc122939447" 5.35 HL79071: Fungal Infection Information, Location  PAGEREF _Toc122939447 \h 66  HYPERLINK \l "_Toc122939448" 5.36 HL79072: Immune Compromise Information, Cause  PAGEREF _Toc122939448 \h 66  HYPERLINK \l "_Toc122939449" 5.37 HL79073: Immune Compromise Information, Verified By  PAGEREF _Toc122939449 \h 66  HYPERLINK \l "_Toc122939450" 5.38 HL79074: Co-Morbid Condition Information, Liver Dysfunction Confirmed By  PAGEREF _Toc122939450 \h 67  HYPERLINK \l "_Toc122939451" 5.39 HL79075: Level of Functional Impairment  PAGEREF _Toc122939451 \h 67  HYPERLINK \l "_Toc122939452" 5.40 HL79076: Imidazole Related Antifungals, Prior Therapy Type  PAGEREF _Toc122939452 \h 67  HYPERLINK \l "_Toc122939453" 5.41 I9C : ICD-9-CM  PAGEREF _Toc122939453 \h 67  HYPERLINK \l "_Toc122939454" 5.42 IC10: ICD-10-CM  PAGEREF _Toc122939454 \h 67  HYPERLINK \l "_Toc122939455" 5.43 iso+: Extended ISO Units Codes  PAGEREF _Toc122939455 \h 68  HYPERLINK \l "_Toc122939456" 5.44 NDC: National Drug Code  PAGEREF _Toc122939456 \h 68  HYPERLINK \l "_Toc122939457" 5.45 RXNC: RxNorm SCD (Semantic Clinical Drug)  PAGEREF _Toc122939457 \h 68  HYPERLINK \l "_Toc122939458" 5.46 RXNB: RxNorm SBD (Semantic Branded Drug)  PAGEREF _Toc122939458 \h 68  HYPERLINK \l "_Toc122939459" 5.47 DEA: Drug Enforcement Administration  PAGEREF _Toc122939459 \h 68  HYPERLINK \l "_Toc122939460" 5.48 HCI: HCIdea  PAGEREF _Toc122939460 \h 69  HYPERLINK \l "_Toc122939461" 5.49 NPI: National Provider Identifier  PAGEREF _Toc122939461 \h 69  HYPERLINK \l "_Toc122939462" 5.50 PTX: Health Care Provider Taxonomy  PAGEREF _Toc122939462 \h 70  HYPERLINK \l "_Toc122939463" 5.51 Miscellaneous OID References  PAGEREF _Toc122939463 \h 70  HYPERLINK \l "_Toc122939464" 5.51.1 Unique Instance Identifier  PAGEREF _Toc122939464 \h 70  HYPERLINK \l "_Toc122939465" 5.51.2 person_name.type_cd  PAGEREF _Toc122939465 \h 70  HYPERLINK \l "_Toc122939466" 5.51.3 Proprietary Provider ID  PAGEREF _Toc122939466 \h 70  HYPERLINK \l "_Toc122939467" 5.51.4 Example OID  PAGEREF _Toc122939467 \h 70  Index of Tables and Figures  TOC \h \z \t "Caption" \c  HYPERLINK \l "_Toc122939468" Table 1.1 Relationship of LOINC Codes, X12N Transactions, and HL7 CDA Documents.  PAGEREF _Toc122939468 \h 3  HYPERLINK \l "_Toc122939469" Table 2.1 LOINC codes for a complete Drug Prior Authorization attachment data set  PAGEREF _Toc122939469 \h 5  HYPERLINK \l "_Toc122939470" Table 2.4.1 Data Components for Drug Request - Unspecified Therapeutic Category (UTC) Attachment  PAGEREF _Toc122939470 \h 6  HYPERLINK \l "_Toc122939471" Table 2.4.2 Data Components for NSAIDS - COX2 Inhibitors Attachment  PAGEREF _Toc122939471 \h 6  HYPERLINK \l "_Toc122939472" Table 2.4.3 Data Components for Growth Hormone (GH) Attachment  PAGEREF _Toc122939472 \h 6  HYPERLINK \l "_Toc122939473" Table 2.4.4 Data Components for Proton Pump Inhibitors (PPI) Attachment  PAGEREF _Toc122939473 \h 7  HYPERLINK \l "_Toc122939474" Table 2.4.5 Data Components for Erectile Dysfunction Agents Attachment  PAGEREF _Toc122939474 \h 7  HYPERLINK \l "_Toc122939475" Table 2.4.6 Data Components for Narcotic Agonists Attachment  PAGEREF _Toc122939475 \h 8  HYPERLINK \l "_Toc122939476" Table 2.4.7 Data Components for Imidazole - Related Antifungals Attachment  PAGEREF _Toc122939476 \h 8  HYPERLINK \l "_Toc122939477" Table 3.1 Drug Request - Unspecified Therapeutic Category Value Table  PAGEREF _Toc122939477 \h 9  HYPERLINK \l "_Toc122939478" Table 3.2 NSAIDS - COX2 Inhibitors Value Table  PAGEREF _Toc122939478 \h 12  HYPERLINK \l "_Toc122939479" Table 3.3 Growth Hormone Value Table  PAGEREF _Toc122939479 \h 15  HYPERLINK \l "_Toc122939480" Table 3.4 Proton Pump Inhibitors Value Table  PAGEREF _Toc122939480 \h 23  HYPERLINK \l "_Toc122939481" Table 3.5 Erectile Dysfunction Agents Value Table  PAGEREF _Toc122939481 \h 27  HYPERLINK \l "_Toc122939482" Table 3.6 Narcotic(Opioid) Agonists Value Table  PAGEREF _Toc122939482 \h 32  HYPERLINK \l "_Toc122939483" Table 3.7 Imidazole - Related Antifungals Value Table  PAGEREF _Toc122939483 \h 37  HYPERLINK \l "_Toc122939484" Figure 4.1 Drug Prior Authorization Additional Data  PAGEREF _Toc122939484 \h 43  HYPERLINK \l "_Toc122939485" Example 4.1.1 Drug Prior Authorization Attachment, Human-Decision Variant (XML body)  PAGEREF _Toc122939485 \h 44  HYPERLINK \l "_Toc122939486" Figure 1. Rendered Human-Decision Variant (XML body)  PAGEREF _Toc122939486 \h 46  HYPERLINK \l "_Toc122939487" Example 4.1.2 Drug Prior Authorization Attachment, Human-Decision Variant (non-XML body)  PAGEREF _Toc122939487 \h 49  HYPERLINK \l "_Toc122939488" Figure 2. Rendered Human-Decision Variant (non-XML body)  PAGEREF _Toc122939488 \h 50  HYPERLINK \l "_Toc122939490" Example 4.1.2 Drug Prior Authorization Attachment, Computer-Decision Variant  PAGEREF _Toc122939490 \h 52  HYPERLINK \l "_Toc122939491" Figure 3. Rendered Human-Decision Variant (non-XML body)  PAGEREF _Toc122939491 \h 56  HYPERLINK \l "_Toc122939492" Table 5.1 Yes-No Indicator  PAGEREF _Toc122939492 \h 58  HYPERLINK \l "_Toc122939493" Table 5.2 Drug Prescribed, Therapy Type  PAGEREF _Toc122939493 \h 58  HYPERLINK \l "_Toc122939494" Table 5.3 UTC, Diagnosis Confirmed By  PAGEREF _Toc122939494 \h 58  HYPERLINK \l "_Toc122939495" Table 5.4 Reason Prior Therapy Discontinued  PAGEREF _Toc122939495 \h 59  HYPERLINK \l "_Toc122939496" Table 5.5 NSAIDS COX 2 Inhibitors, Concurrent Therapy - Type  PAGEREF _Toc122939496 \h 59  HYPERLINK \l "_Toc122939497" Table 5.6 NSAID Use, Duration  PAGEREF _Toc122939497 \h 59  HYPERLINK \l "_Toc122939498" Table 5.7 HL7 NSAID Use, Duration  PAGEREF _Toc122939498 \h 59  HYPERLINK \l "_Toc122939499" Table 5.8 Radiology Diagnosis Confirmation, Study Type  PAGEREF _Toc122939499 \h 60  HYPERLINK \l "_Toc122939500" Table 5.9 Laboratory Diagnosis Confirmation, Study/Test  PAGEREF _Toc122939500 \h 60  HYPERLINK \l "_Toc122939501" Table 5.10 GH, Patient History Documented Onset  PAGEREF _Toc122939501 \h 60  HYPERLINK \l "_Toc122939502" Table 5.11 GH, Patient History Information Hypothalmic Pituitary Disease Induced By  PAGEREF _Toc122939502 \h 60  HYPERLINK \l "_Toc122939503" Table 5.12 Treatment Status  PAGEREF _Toc122939503 \h 61  HYPERLINK \l "_Toc122939504" Table 5.13 GHD Childhood Information, Puberty Status  PAGEREF _Toc122939504 \h 61  HYPERLINK \l "_Toc122939505" Table 5.14 GH Dysfunction Adult Information, Secondary Causes  PAGEREF _Toc122939505 \h 61  HYPERLINK \l "_Toc122939506" Table 5.15 Nutritional Information, Assessment Indicator  PAGEREF _Toc122939506 \h 61  HYPERLINK \l "_Toc122939507" Table 5.16 Parental Height, Availability Indicator  PAGEREF _Toc122939507 \h 62  HYPERLINK \l "_Toc122939508" Table 5.17 Diagnosis Confirmation and Level Treatment Needed, Procedure Employed  PAGEREF _Toc122939508 \h 62  HYPERLINK \l "_Toc122939509" Table 5.18 Diagnosis Confirmation and Level of Treatment Needed, GERD By Endoscopy Type  PAGEREF _Toc122939509 \h 62  HYPERLINK \l "_Toc122939510" Table 5.19 H-Pylori Information, Status  PAGEREF _Toc122939510 \h 62  HYPERLINK \l "_Toc122939511" Table 5.20 H-Pylori Information, Confirmed By  PAGEREF _Toc122939511 \h 62  HYPERLINK \l "_Toc122939512" Table 5.21 ED, Related Diagnosis Confirmation, Confirmed By  PAGEREF _Toc122939512 \h 63  HYPERLINK \l "_Toc122939513" Table 5.22 ED, Patient History Pulmonary Hypertension Functional Level  PAGEREF _Toc122939513 \h 63  HYPERLINK \l "_Toc122939514" Table 5.23 ED, Patient History Evaluation Type  PAGEREF _Toc122939514 \h 63  HYPERLINK \l "_Toc122939515" Table 5.24 ED, Patient History ED Related To  PAGEREF _Toc122939515 \h 63  HYPERLINK \l "_Toc122939516" Table 5.25 ED, Treatment of Related Causes Psychogenic Causes of ED Treatment  PAGEREF _Toc122939516 \h 64  HYPERLINK \l "_Toc122939517" Table 5.26 ED, Treatment of Related Causes Drug Induced Option  PAGEREF _Toc122939517 \h 64  HYPERLINK \l "_Toc122939518" Table 5.27 ED Concurrent Therapy, Type  PAGEREF _Toc122939518 \h 64  HYPERLINK \l "_Toc122939519" Table 5.28 Narcotic (Opioid) Agonists, Patient History Pain Syndrome Source  PAGEREF _Toc122939519 \h 64  HYPERLINK \l "_Toc122939520" Table 5.29 Narcotic (Opioid) Agonists, Patient History Pain Syndrome History  PAGEREF _Toc122939520 \h 65  HYPERLINK \l "_Toc122939521" Table 5.30 Narcotic (Opioid) Agonists, Patient History Pain Syndrome Persistance  PAGEREF _Toc122939521 \h 65  HYPERLINK \l "_Toc122939522" Table 5.31 Narcotic (Opioid) Agonists, Complicating Conditions  PAGEREF _Toc122939522 \h 65  HYPERLINK \l "_Toc122939523" Table 5.32 Opioid Concurrent Pain Therapy, Opioid Level  PAGEREF _Toc122939523 \h 65  HYPERLINK \l "_Toc122939524" Table 5.33 Drug Prescribed, Topical Therapy - Reason  PAGEREF _Toc122939524 \h 66  HYPERLINK \l "_Toc122939525" Table 5.34 Imidazole Related Antifungals, Diagnosis Confirmed By  PAGEREF _Toc122939525 \h 66  HYPERLINK \l "_Toc122939526" Table 5.35 Fungal Infection Information, Location  PAGEREF _Toc122939526 \h 66  HYPERLINK \l "_Toc122939527" Table 5.36 Immune Compromise Information, Cause  PAGEREF _Toc122939527 \h 66  HYPERLINK \l "_Toc122939528" Table 5.37 Immune Compromise Information, Verified By  PAGEREF _Toc122939528 \h 66  HYPERLINK \l "_Toc122939529" Table 5.38 Co-Morbid Condition Information, Liver Dysfunction Confirmed By  PAGEREF _Toc122939529 \h 67  HYPERLINK \l "_Toc122939530" Table 5.39 Level of Functional Impairment  PAGEREF _Toc122939530 \h 67  HYPERLINK \l "_Toc122939531" Table 5.40 Imidazole Related Antifungals, Prior Therapy Type  PAGEREF _Toc122939531 \h 67  Introduction This publication provides the LOINC code values specific to a Drug Prior Authorization attachment for the following applications. Those codes that define the attachment or attachment components used in transactions such as those defined by the ASC X12N 278 (005010X215) Health Care Services Review Response and the ASC X12N 275 (005010X215) Additional Information to Support a Health Care Services Review Implementation Guides which are products of the insurance subcommittee, X12N, of Accredited Standards Committee X12., All of the codes may be used in HL7 Clinical Document Architecture (CDA) documents designed for inclusion in the BIN segment of the 275 transaction as described in the HL7 Additional Information Specification Implementation Guide The format of this document and the methods used to arrive at its contents are prescribed in the HL7 Additional Information Specification Implementation Guide. Additional Information Specification 0010: Drug Prior Authorization Attachment is designed to facilitate the transmission of information necessary to evaluate and support the medical necessity for a drug being ordered for a patient. As the deployment of e-Prescribing and Electronic Health Records expands and the technology matures, it is anticipated that this AIS will become an integral part of a fully automated prescription, authorization and delivery process. Most health plans make use of a prior authorization process, either for specified classes of drugs or for atypical use of a drug. The attachment component specifications included represent the most commonly requested documentation requirements. These were developed in collaboration with the National Council for Prescription Drug Programs (NCPDP), Work Group 11 Prescriber/Pharmacist Interface, Prior Authorization Transfer Task Group. Additional components will be developed as the industry needs are assessed and defined. Section 2 of this document defines the LOINC codes used to request Drug Prior Authorization attachments and the LOINC codes of each component in an attachment. Section 3 further describes each component of the Drug Prior Authorization attachment, the cardinality of the components and their answer parts, and the description, data types, codes, and units of each answer part. Section 4 presents coding examples, with a narrative scenario, an XML example, and a display image of each example attachment using a popular browser. Section 5 further describes the code sets used in the response to each answer part of the attachment. Note: All LOINC codes and descriptions are copyrighted by the Regenstrief Institute, with all rights reserved. See  HYPERLINK "http://www.LOINC.org" http://www.LOINC.org. LOINC Codes and Structure LOINC codes are used for several purposes: In the X12N 278 transaction set, LOINC codes identify the attachment or attachment components being requested to support a claim or encounter. In the HL7 CDA document, LOINC codes are used to identify the attachment, the attachment components, and their answer parts. This is returned in the X12N 275 transaction set. LOINC modifier codes may be used in the 278 transaction to further define the specificity of a request. Table 1.1 Relationship of LOINC Codes, X12N Transactions, and HL7 CDA Documents. X12N 278X12N 275HL7 CDA Purpose of AttachmentHealth Care Services Review ResponseAdditional Information to Support a Health Care Services ReviewProvide controlled content for X12N 275 BIN segmentLOINC Modifier CodesUsed in the STC segment to limit the scope or time frame of a request for information. e.g., Send information for up to 90 days before the related request. Reiterated in the STC segmentNot used in the CDA documentLOINC Attachment IdentifierUsed in the STC segment to request an attachment in its entirety, e.g., Send the Proton Pump Inhibitors Attachment.Reiterated in the STC segmentUsed in the element of the headerLOINC Attachment ComponentUsed in the STC segment to request a specific attachment component or part of a clinical report, .e.g., Send the H-Pylori Treatment InformationReiterated in the STC segmentUsed in the computer-decision CDA variant in the element of a
to identify the attachment component being provided, e.g., This is information regarding H-Pylori Treatment. LOINC Attachment Component Answer PartNot used in the 278Not used in the 275 except within the CDA instance document in the BIN segment.Used in the computer-decision CDA variant in the element of a , an element within a or a element within a to identify the answer part of an attachment component being provided, e.g., This is the patients current height. Revision History DatePurposeInitial Release for ReviewDecember 2005First BallotMarch 2006Privacy Concerns in Examples The names of natural persons that appear in the examples of this book are intentionally fictional. Any resemblance to actual natural persons, living or deceased is purely coincidental. HL7 Attachment-CDA Document Variants As described in the HL7 Additional Information Specification Implementation Guide, there are two variants of a CDA document when used as an attachment. The human-decision variant is used solely for information that will be rendered for a person to look at, in order to make a decision. HL7 provides a non-normative style sheet for this purpose. There are two further alternatives within the human-decision variant. non_xml body: The information can be sent with a CDA header structured in XML, along with a "non_xml body" that references scanned images of documents that contain the submitted information xml body: the information can be sent as free text in XML elements that organize the material into sections, paragraphs, tables and lists as described in the HL7 Additional Information Specification Implementation Guide. The computer-decision variant has the same content as the human-decision variant, but additional coded and structured information is included so that a computer could provide decision support based on the document. Attachments in the computer-decision variant can be rendered for human decisions using the same style sheet that HL7 provides for rendering documents formatted according to the human-decision variant. Request for Information versus Request for Service This attachment specification for Drug Prior Authorization defines a send-me-what-you-have attachment. It asks for a set of Drug Prior Authorization attachment components needed for the Drug Prior Authorization process. It is not asking for any additional data capture efforts. For example, if the request for data is to send the length of time the patient is expected to need the medication at the requested dose level, it is not asking the provider to obtain additional information if they dont already have this information. In any attachment component answer part it may sometimes be impossible to send a required answer and necessary to send, instead, a reason why the information is not available. In the human decision variant the sender shall supplement the natural language explanation of why the information is not available with local markup. In the computer-decision variant the sender shall include local markup to describe the reason that the information is not available as described in the Data Types section of the HL7 Additional Information Specification Implementation LOINC Codes Supporting Documentation Table 2.1 defines the LOINC codes used to request a complete attachment data set for Drug Prior Authorization. The use of any of these codes in the 278 HI or PWK segments represents an explicit request for the complete set of data components relevant to the drug prior authorization. The provider shall return all data components for which data is available. The provider may choose to return images of pages that constitute the requested information by using the element of the CDA as described in the HL7 Additional Information Specification Implementation Guide. The set of data components for the Drug Prior Authorization attachment, identified by individual LOINC codes, is defined in Section 2.4. NOTE: The LOINC values represented in this draft ballot version are included as representative examples and are not the actual LOINC values that will be used for this attachment. Once the AIS has been approved, the actual LOINC values will be requested from Regenstrief and included in the final published version. The final check digit (after the hyphen) indicates for example purposes only, the specific drug attachment category. Where a component or answer part is re-used in the document, the sample LOINC value is repeated to indicate this re-use. The final check digit will be an x to indicate that it is used in more than one drug attachment category. Table 2.1 LOINC codes for a complete Drug Prior Authorization attachment data set LOINC codeAttachment Name99999-1Drug Request Unspecified Therapeutic Category Attachment99999-2NSAIDS COX2 Inhibitors Attachment99999-3Growth Hormone Attachment99999-4Proton Pump Inhibitors Attachment99999-5Erectile Dysfunction Agents Attachment99999-6Narcotic (Opioid) Agonists Attachment99999-7Imidazole Related Antifungals Attachment Scope Modification Codes The HL7 publication LOINC Modifier Codes (for use with ASC X12N Implementation Guides when Requesting Additional Information) provides code values for further defining the specificity of a request for additional information. Both time window and item selection modifier codes are defined. This publication is available from HL7, and is in the download package with the AIS documents. Special Considerations Intentionally left blank. Attachment Data Components Individual LOINC codes are defined for each data component of the attachment specific to the therapeutic drug category listed in Table 2.1. These LOINC codes are listed in sections 2.4.1 to 2.4.7 respectively. For example, the data components comprising the cardiac rehabilitation attachment (LOINC 18824-3) appear in Table 2.4.2. Each table is headed by the LOINC code defining the complete attachment. The LOINC codes in Table 2.1 represent requests for complete Drug Prior Authorization attachments. However, the requester also has the option of focusing on a specific component of the attachment through the use of the LOINC codes defined in the following tables. In this case the provider will respond with information, where available, specific to the requested data components. These LOINC codes may be used in ASC X12N 278 as defined in the associated Implementation Guide and will be mirrored in the corresponding ASC X12N 275 response. In addition, these LOINC codes are used in the element of the computer-decision variant of HL7 Additional Information Specification Implementation Guide. The questions that these LOINC codes represent are the result of a significant industry outreach project and represent the complete set of Drug Prior Authorization attachment components at this time. Additional drug therapeutic categories may be added to this document at a later date. Drug Request - Unspecified Therapeutic Category Attachment Table 2.4.1 Data Components for Drug Request - Unspecified Therapeutic Category (UTC) Attachment LOINC CodeDescription99999-1DRUG REQUEST - UNSPECIFIED THERAPEUTIC CATEGORY ATTACHMENT90010-xPRESCRIBER INFORMATION (COMPOSITE)90020-xPRESCRIBER CONTACT INFORMATION (COMPOSITE)90030-xDRUG PRESCRIBED (COMPOSITE)90040-1UTC, MEDICAL NECESSITY INFORMATION90050-1UTC, RELATED DIAGNOSIS INFORMATION (COMPOSITE)90060-1UTC, ADDITIONAL CONFIRMATION INFORMATION90070-xMEDICARE ESRD CERTIFICATION DATE90080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS (COMPOSITE)90090-xCONCURRENT THERAPY (COMPOSITE)NSAIDS - COX2 Inhibitors Attachment Table 2.4.2 Data Components for NSAIDS - COX2 Inhibitors Attachment LOINC CodeDescription99999-2NSAIDS - COX2 INHIBITORS ATTACHMENT90010-xPRESCRIBER INFORMATION (COMPOSITE)90020-xPRESCRIBER CONTACT INFORMATION (COMPOSITE)90030-xDRUG PRESCRIBED (COMPOSITE)90100-2NSAIDS-COX2 INHIBITORS, RELATED DIAGNOSIS90080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS (COMPOSITE)90090-xCONCURRENT THERAPY (COMPOSITE)90110-xNSAIDS/PPI RELATED CONCURRENT THERAPY (COMPOSITE)90120-2NSAID USE (COMPOSITE) Growth Hormone Attachment Table 2.4.3 Data Components for Growth Hormone (GH) Attachment LOINC CodeDescription99999-3GROWTH HORMONE ATTACHMENT90010-xPRESCRIBER INFORMATION (COMPOSITE)90020-xPRESCRIBER CONTACT INFORMATION (COMPOSITE)90030-xDRUG PRESCRIBED (COMPOSITE)90130-3GH, RELATED DIAGNOSIS90140-3RADIOLOGICAL DIAGNOSIS CONFIRMATION INFORMATION (COMPOSITE)90150-3LABORATORY DIAGNOSIS CONFIRMATION INFORMATION (COMPOSITE)90160-3GH, PATIENT HISTORY INFORMATION (COMPOSITE)90170-3GHD CHILDHOOD INFORMATION (COMPOSITE)90180-3GH DYSFUNCTIONADULT INFORMATION (COMPOSITE)90190-3WASTING SYNDROME INFORMATION (COMPOSITE)90200-3NUTRITIONAL INFORMATION (COMPOSITE)90210-3LABORATORY GH STIMULATION (COMPOSITE)90220-3PHYSICIAL FINDINGS, PATIENT HEIGHT (COMPOSITE)90230-3PHYSICIAL FINDINGS, PATIENT WEIGHT (COMPOSITE)90240-3PATIENT BODY MASS INDEX (COMPOSITE)90250-3PARENTAL HEIGHT (COMPOSITE)90080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS (COMPOSITE)90090-xCONCURRENT THERAPY (COMPOSITE) Proton Pump Inhibitors Attachment Table 2.4.4 Data Components for Proton Pump Inhibitors (PPI) Attachment LOINC CodeDescription99999-4PROTON PUMP INHIBITORS ATTACHMENT90010-xPRESCRIBER INFORMATION (COMPOSITE)90020-xPRESCRIBER CONTACT INFORMATION (COMPOSITE)90030-xDRUG PRESCRIBED (COMPOSITE)90260-4PPI, RELATED DIAGNOSIS90270-4DIAGNOSIS CONFIRMATION AND LEVEL OF TREATMENT NEEDED (COMPOSITE)90280-4PPI, PATIENT HISTORY STRICTURE PRESENT90080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS (COMPOSITE)90090-xCONCURRENT THERAPY (COMPOSITE)90110-xNSAIDS/PPI RELATED CONCURRENT THERAPY (COMPOSITE)90290-4H-PYLORI INFORMATION (COMPOSITE)90300-4H-PYLORI TREATMENT (COMPOSITE) Erectile Dysfunction (ED) Agents Attachment Table 2.4.5 Data Components for Erectile Dysfunction Agents Attachment LOINC CodeDescription99999-5ERECTILE DYSFUNCTION AGENTS ATTACHMENT90010-xPRESCRIBER INFORMATION (COMPOSITE)90020-xPRESCRIBER CONTACT INFORMATION (COMPOSITE)90030-xDRUG PRESCRIBED (COMPOSITE)90310-5ED, RELATED DIAGNOSIS90320-5ED, RELATED DIAGNOSIS CONFIRMATION INFORMATION (COMPOSITE)90330-5ED, PATIENT HISTORY INFORMATION (COMPOSITE)90340-5ED, TREATMENT OF RELATED CAUSES (COMPOSITE)90080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS (COMPOSITE)90090-xCONCURRENT THERAPY (COMPOSITE)90340-5ED RELATED CONCURRENT THERAPY (COMPOSITE) Narcotic (OPIOID) Agonists Attachment Table 2.4.6 Data Components for Narcotic Agonists Attachment LOINC CodeDescription99999-6NARCOTIC (OPIOID) AGONISTS ATTACHMENT90010-xPRESCRIBER INFORMATION (COMPOSITE)90020-xPRESCRIBER CONTACT INFORMATION (COMPOSITE)90030-xDRUG PRESCRIBED (COMPOSITE)90360-6NARCOTIC (OPIOID) AGONISTS, RELATED DIAGNOSIS90370-6NARCOTIC (OPIOID) AGONISTS, PATIENT HISTORY (COMPOSITE)90380-6NARCOTIC (OPIOID) AGONISTS, COMPLICATING CONDITIONS INFORMATION (COMPOSITE)90390-6NARCOTIC (OPIOID) AGONISTS, LABORATORY INFORMATION (COMPOSITE)90080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS (COMPOSITE)90090-xCONCURRENT THERAPY (COMPOSITE)90400-6OPIOD RELATED CONCURRENT PAIN THERAPY (COMPOSITE)90410-6NARCOTIC (OPIOID) AGONISTS, USE FOR TREATMENT OF OPIOID ADDICTION Imidazole - Related Antifungals Attachment Table 2.4.7 Data Components for Imidazole - Related Antifungals Attachment LOINC CodeDescription99999-7IMIDAZOLE - RELATED ANTIFUNGALS ATTACHMENT90010-xPRESCRIBER INFORMATION (COMPOSITE)90020-xPRESCRIBER CONTACT INFORMATION (COMPOSITE)90030-xDRUG PRESCRIBED (COMPOSITE)90420-7DRUG PRESCRIBED, TOPICAL THERAPY (COMPOSITE)90430-7IMIDAZOLE - RELATED ANTIFUNGALS, RELATED DIAGNOSIS INFORMATION (COMPOSITE)90440-7FUNGAL INFECTION INFORMATION (COMPOSITE)90450-7IMMUNE COMPROMISE INFORMATION (COMPOSITE)90460-7CO-MORBID CONDITION INFORMATION (COMPOSITE)90070-xMEDICARE ESRD CERTIFICATION DATE90470-7LEVEL OF FUNCTIONAL IMPAIRMENT90480-7INPATIENT TREATMENT Information (COMPOSITE)90080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS (COMPOSITE)90490-7IMIDAZOLE - RELATED ANTIFUNGALS, PRIOR THERAPY TYPE90090-xCONCURRENT THERAPY (COMPOSITE)Drug Prior Authorization Attachment Value Tables Each of the tables in this section further describes the LOINC components listed in the above corresponding table, along with the expected answer part(s) for each question, including the data type, cardinality, and codes/units for each answer. The minimum attachment data set equates to the required components; those identified in the value table, below, with cardinality (Card) of {1,1} (component is required and has one and only one occurrence) or {1,n} (component is required and has one or more occurrences). Those data components with a cardinality of {0,1} (if available has one and only one occurrence) or {0,n} (if available may have one or more occurrences) shall be sent if available. Drug Request - Unspecified Therapeutic Category (UTC) Service Value Table Table 3.1 Drug Request - Unspecified Therapeutic Category Value Table LOINC code Component AnswerValueData TypeCardResponse Code / Numeric Units90010-xPRESCRIBER INFORMATION Information about the practitioner prescribing the drug. 1,190011-xPRESCRIBER INFORMATION, NAME This is the name of the practitioner prescribing the drug. PN1,190012-xPRESCRIBER INFORMATION, IDENTIER This may be repeated to convey multiple identifiers such as the National Provider Identifier (NPI), Drug Enforcement Act number (DEA), Special DEA number, HCIdea Number or proprietary provider identifier. Note: If the provider is a covered entity under HIPAA and the NPI is mandated for use, the NPI must be sent as one of the identifiers and the legacy provider identifier must not be used. CX1,nNPI DEA HCIdea Proprietary Provider ID See note at left.90013-xPRESCRIBER INFORMATION, SPECIALTY TAXONOMY CODE This is the Taxonomy code that represents the medical specialty of the prescriber. CE1,1PTX90020-xPRESCRIBER CONTACT INFORMATION Contact information for the individual prescribing the drug. 0,190021-xPRESCRIBER CONTACT INFORMATION, PHONE NUMBER The phone number of the individual prescribing the drug. TX1,190022-xPRESCRIBER CONTACT INFORMATION, FAX NUMBER The fax number of the individual prescribing the drug. TX0,190030-xDRUG PRESCRIBED This is information about the drug requested in the prior authorization. 1,190031-xDRUG PRESCRIBED, NAME This is the descriptive name of the drug prescribed. TX1,190032-xDRUG PRESCRIBED, DRUG CODE This is the code identifier for the drug prescribed as defined by Representative NDC, RxNorm SCD or RxNorm SBD. CE1,1NDC RxNorm SCD RxNorm SBD90033-xDRUG PRESCRIBED, THERAPY TYPE This is used to convey the historical use of the prescribed drug as part of the patients therapy. INTRQ Initial Therapy CNTRQ Continued Therapy RPLRQ Replacement Therapy ADDRQ Add on Therapy CE1,1HL79038 90034-xDRUG PRESCRIBED, SELF ADMINISTERED INDICATOR This indicator defines if the drug can be self administered. N No Y Yes 0,1HL7013690040-1UTC, MEDICAL NECESSITY INFORMATION Additional information as required to support the medical necessity of the requested medication therapy. This is submitted based on the plan or UMO's defined requirements for the drug.  0,1 90040-1 TX1,190050-1UTC, RELATED DIAGNOSIS INFORMATION Diagnosis information related to the prescribed drug. 1,190051-1UTC, RELATED DIAGNOSIS This is the related diagnosis of the patient for which the drug is a prescribed therapy. Note: Prior to U.S. adoption of ICD-10-CM, use ICD-9-CM in the U.S. domain. After adoption as the standard for defining diagnoses in the US, use only ICD-10-CM for requests in the US. CE1,1IC9 IC10 90052-1UTC, DIAGNOSIS CONFIRMED BY This conveys the means by which the diagnosis was established- diagnostic procedures and/or clinical observation. LABT Laboratory Examination RADT Radiological Examination OTDX Other Diagnostic Examination CLNE Clinical Evaluation CE0,nHL7903990053-1UTC, DIAGNOSIS CONFIRMED BY DATE OF CLINICAL EVALUATION This is the date the confirmatory clinical evaluation was performed. DT0190060-1UTC, ADDITIONAL confirmation information This is used to convey information about the diagnostic study used to confirm the diagnosis. It is required when the answer to Unspecified Therapeutic Category, Diagnosis Confirmed By is equal to LABT Laboratory Examination, RADT Radiological Examination, or OTDX Other Diagnostic Examination. 0,n 90061-1UTC, additional CONFIRMATION information - Name of TesT This is used to convey the name of the diagnostic study used to confirm the diagnosis. TX0,1 90062-1UTC, ADDITIONAL confirmation information - TesT RESULT This is the result of the diagnostic procedure by which the diagnosis was confirmed. It is required when the answer to Unspecified Therapeutic Category, Diagnosis Confirmed By is equal to LABT Laboratory Examination. NM0,1iso+ ans+ 90063-1UTC, additional CONFIRMATION information - DATE of TesT OR OBSERVATION This is the date the confirmatory diagnostic study. DT1,190070-xMEDICARE ESRD CERTIFICATION DATE The date the patient was certified by Medicare as having End Stage Renal Disease. 0,190070-x DT1,190080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS Information about other drugs previously prescribed for treatment of this condition with less than optimal outcomes. 0,n90081-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG NAME This is the descriptive name of the drug previously used to treat the diagnosis. TX1,190082-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS, - DRUG CODE The code assigned to the drug previously used to treat the diagnosis as defined by: Representative NDC, RxNorm SCD, or RxNorm SBD. CE1,1NDC RxNorm SCD RxNorm SBD90083-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DURATION OF THERAPY Duration of previous therapy in days. NM1,1iso+90084-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED Reason prior drug therapy was discontinued. NTEFF Not or No Longer Effective SDEFT Side Effects/Tolerance NTCMP Not Compatible OTH Other CE1,1HL7904090085-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED, OTHER If Drug History, Prior Therapy for Diagnosis - Reason Prior Therapy Discontinued is equal to OTH Other, then this is required. TX0,190086-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS REASON PRIOR THERAPY DISCONTINUED, INCOMPATIBLE DRUG NAME The descriptive name of the drug incompatible with the prior therapy. If Drug History, Prior Therapy for Diagnosis Reason Prior Therapy Discontinued equals NTCMP Not Compatible, then this is required. TX0,n90090-xCONCURRENT THERAPY Drugs the patient is currently on, for this or other diagnoses, which may impact the requested drug. 0,n90091-xCONCURRENT THERAPY, DRUG NAME The descriptive name of the drug used in concurrent therapy, for this or other diagnoses, which may impact the requested drug. TX0,190092-xCONCURRENT THERAPY, DRUG CODE The code assigned to the concurrent drug as defined by: Representative NDC, RxNorm SCD, or RxNorm SBD. CE1,1NDC RxNorm SCD RxNorm SBD NSAIDS - COX2 Inhibitors Value Table Table 3.2 NSAIDS - COX2 Inhibitors Value Table LOINC code Component AnswerValueData TypeCardResponse Code / Numeric Units90010-xPRESCRIBER INFORMATION Information about the practitioner prescribing the drug. 1,190011-xPRESCRIBER INFORMATION, NAME This is the name of the practitioner prescribing the drug. PN1,190012-xPRESCRIBER INFORMATION, IDENTIER This may be repeated to convey multiple identifiers such as the National Provider Identifier (NPI), Drug Enforcement Act number (DEA), Special DEA number, HCIdea Number or proprietary provider identifier. Note: If the provider is a covered entity under HIPAA and the NPI is mandated for use, the NPI must be sent as one of the identifiers and the proprietary provider identifier must not be used. CX1,nNPI DEA HCIdea Proprietary Provider ID See note at left.90013-xPRESCRIBER INFORMATION, SPECIALTY TAXONOMY CODE This is the Taxonomy code that represents the medical specialty of the prescriber. CE1,1PTX90020-xPRESCRIBER CONTACT INFORMATION Contact information for the individual prescribing the drug. 0,190021-xPRESCRIBER CONTACT INFORMATION, PHONE NUMBER This is the phone number of the individual prescribing the drug. TX1,190022-xPRESCRIBER CONTACT INFORMATION, FAX NUMBER This is the fax number of the individual prescribing the drug. TX0,190030-xDRUG PRESCRIBED This is information about the drug requested in the prior authorization. 1,190031-xDRUG PRESCRIBED, NAME This is the descriptive name of the drug prescribed. TX1,190032-xDRUG PRESCRIBED, DRUG CODE This is the code identifier for the drug prescribed as defined by Representative NDC, Rx Norm SCD, or RxNorm SBD. CE1,1NDC RxNorm SCD RxNorm SBD90033-xDRUG PRESCRIBED, THERAPY TYPE This is used to convey the historical use of the prescribed drug as part of the patients therapy. INTRQ Initial Therapy CNTRQ Continued Therapy RPLRQ Replacement Therapy ADDRQ Add on Therapy CE1,1HL7903890034-xDRUG PRESCRIBED, SELF ADMINISTERED INDICATOR This indicator defines if the drug can be self administered. N No Y Yes 0,1HL7013690100-2NSAIDS-COX2 INHIBITORS, RELATED DIAGNOSIS Diagnosis information related to the prescribed drug. 1,190100-2NSAIDS-COX2 INHIBITORS, RELATED DIAGNOSIS This is the related diagnosis of the patient for which the drug is a prescribed therapy. Note: Prior to U.S. adoption of ICD-10-CM, use ICD-9-CM in the U.S. domain. After adoption as the standard for defining diagnoses in the US, use only ICD-10-CM for requests in the US. CE1,1IC9 IC1090080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS Information about other drugs previously prescribed for treatment of this condition with less than optimal outcomes. 0,n90081-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG NAME This is the descriptive name of the drug previously used to treat the diagnosis. TX1,190082-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG CODE The code assigned to the drug previously used to treat the diagnosis as defined by: Representative NDC, RxNorm SCD, or RxNorm SBD. CE1,1NDC RxNorm SCD RxNorm SBD90083-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS, DURATION OF THERAPY Duration of previous therapy in days. NM1,1iso+90084-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS, REASON PRIOR THERAPY DISCONTINUED Reason prior drug therapy was discontinued. NTEFF Not or No Longer Effective SDEFT Side Effects/Tolerance NTCMP Not Compatible OTH Other CE1,1HL7904090085-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED, OTHER Description of the other reason for discontinued therapy. If Drug History, Prior Therapy for Diagnosis - Reason Prior Therapy Discontinued equals "OTH" Other, then this is required. TX0,190086-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS REASON PRIOR THERAPY DISCONTINUED, INCOMPATIBLE DRUG NAME The descriptive name of the drug incompatible with the prior therapy. If Drug History, Prior Therapy for Diagnosis Reason Prior Therapy Discontinued equals NTCMP Not Compatible, then this is required. TX 0,n90090-xCONCURRENT THERAPY Drugs the patient is currently on, for this or other diagnoses, which may impact the requested drug. 0,n90091-xCONCURRENT THERAPY, DRUG NAME The descriptive name of the drug used in concurrent therapy, for this or other diagnoses, which may impact the requested drug. TX0,190092-xCONCURRENT THERAPY, DRUG CODE The code assigned to the concurrent drug as defined by: Representative NDC, RxNorm SCD, or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD90110-xNSAIDS/PPI RELATED CONCURRENT THERAPY NSAID/PPI related drugs being used concurrently with the requested drug.0,190111-xNSAIDS/PPI RELATED CONCURRENT THERAPY, TYPE Concurrent NSAIDS/PPI related drug therapies being used for treatment of this or other conditions. See section 5 for the list of valid codes. CE1,1HL7904190112-xNSAIDS/PPI RELATED CONCURRENT THERAPY, OTHER TYPE The descriptive name of the NSAIDS/PPI related drug(s) used in concurrent therapy. Required when NSAIDS/PPI Related Concurrent Therapy, Type equals OTH Other.TX0,190120-xNSAID USE Extended NSAID use and associated problems. 1,190121-2NSAID USE, DURATION The length of time NSAID use is or has been required. G21 NSAID use greater than 21 days L21 NSAID use less than 21 days CE1,1HL7904290122-2NSAID USE, INDUCED GI RISK FACTORS Indicator of whether gastrointestinal risk factors are/have been induced by NSAID use. Y Yes N No U Unknown CE1,1HL79043 Growth Hormone (GH) Value Table Table 3.3 Growth Hormone Value Table LOINC code Component AnswerValueData TypeCardResponse Code / Numeric Units90010-xPRESCRIBER INFORMATION Information about the practitioner prescribing the drug. 1,190011-xPRESCRIBER INFORMATION, NAME This is the name of the practitioner prescribing the drug. PN1,190012-xPRESCRIBER INFORMATION, IDENTIER This may be repeated to convey multiple identifications such as the National Provider Identifier (NPI0, the Drug Enforcement Act (DEA) number, Special DEA number, HCIdea number or proprietary identifier. Note: If the provider is a covered entity under HIPAA and the NPI is mandated for use, the NPI must be sent as one of the identifiers and the legacy provider identifier must not be used. CX1,nNPI DEA HCIdea Proprietary Provider ID See note at left.90013-xPRESCRIBER INFORMATION, SPECIALITY TAXONOMY CODE This is the Taxonomy code that identifies the medical specialty of the prescriber CE1,1PTX90020-xPRESCRIBER CONTACT INFORMATION Contact information for the individual prescribing the drug. 0,190021-xPRESCRIBER CONTACT INFORMATION, PHONE NUMBER The phone number of the individual prescribing the drug. TX1,190023-xPRESCRIBER CONTACT INFORMATION, FAX NUMBER The fax number of the individual prescribing the drug. TX0,190030-xDRUG PRESCRIBED This is information about the drug requested in the prior authorization. 1,190031-xDRUG PRESCRIBED, NAME This is the descriptive name of the drug prescribed. TX1,190032-xDRUG PRESCRIBED, DRUG CODE This is the code identifier for the drug prescribed as defined by: Representative NDC, RxNorm SCD or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD90033-xDRUG PRESCRIBED, THERAPY TYPE This is used to convey the historical use of the prescribed drug as part of the patient's therapy. INTRQ Initial Therapy CNTRQ Continued Therapy RPLRQ Replacement Therapy ADDRQ Add on Therapy CE1,1HL7903890034-xDRUG PRESCRIBED, SELF ADMINISTERED INDICATOR This indicator defines if the drug can be self administered. N No Y Yes 0,1HL7013690130-3GH, RELATED DIAGNOSIS This is the related diagnosis of the patient for which the drug is a prescribed therapy. Note: Prior to U.S. adoption of ICD-10-CM, use ICD-9-CM in the U.S. domain. After adoption as the standard for defining diagnoses in the US, use only ICD-10-CM for requests in the US. 1,190130-3CE1,1IC9 IC1090140-3RADIOLOGICAL DIAGNOSIS CONFIRMATION INFORMATION Diagnostic procedures and criteria confirming the diagnosis and level of treatment need. 0,n90141-3RADIOLOGY DIAGNOSIS CONFIRMATION INFORMATION, STUDY TYPE These are the radiological studies used to confirm the diagnosis. Epiphyseal status or bone age is required for childhood growth hormone deficiency.. BAE Bone Age BDY Bone Density MRI MRI ESX X-Ray to Determine Epiphyseal Status CE1,1HL7904490142-3RADIOLOGICAL DIAGNOSIS CONFIRMATION INFORMATION, STUDY RESULT Result of the radiological study performed. Required when diagnosis is confirmed by radiological study. TX1,190143-3RADIOLOGICAL DIAGNOSIS CONFIRMATION INFORMATION, STUDY DATE Date the radiological study performed. Required when diagnosis confirmed by radiological study. DT1,190150-3LABORATORY DIAGNOSIS CONFIRMATION INFORMATION Diagnostic procedures and criteria confirming the diagnosis and level of treatment need. 0,n90151-3LABORATORY DIAGNOSIS CONFIRMATION INFORMATION, STUDY/TEST These are laboratory studies used to confirm Growth Hormone Deficiency/Dysfunction. See section 5 for a list of valid codes. CE1,nHL79045 90152-3LABORATORY DIAGNOSIS CONFIRMATION INFORMATION, OTHER STUDY/TEST NAME This is used to convey the name of the other test used to confirm GHD. It is required when Diagnosis Confirmation Information Laboratory Confirmation equals "OTH" Other. TX0,190153-3LABORATORY DIAGNOSIS CONFIRMATION INFORMATION, STUDY/TEST RESULT This is the result of laboratory study used to confirm the diagnosis. NM1,1iso+ ans+90154-3LABORATORY DIAGNOSIS CONFIRMATION INFORMATION, STUDY/TEST DATE This is the date that the test confirming the diagnosis of GHD was performed. DT1,190160-3GH, PATIENT HISTORY INFORMATION Patient history related to the prescribed drug. 1,190161-3GH, PATIENT HISTORY INFORMATION DOCUMENTED ONSET Documented onset of hypothalamic pituitary disease or GH deficiency/dysfunction. AO Adult Onset CO Childhood Onset UO Unknown Onset CE0,1HL79046 90162-3GH, PATIENT HISTORY INFORMATION HYPOTHALMIC PITUITARY DISEASE INDUCED BY This describes conditions and/or treatments leading to HPD. PTT Pituitary Tumor IRR Irradiation SUG Surgery HMN Hormone Dysfunction or Therapy TRA Trauma CE0,nHL7904790163-3GH, PATIENT HISTORY INFORMATION GHD TREATMENT STATUS This describes the treatment status, i.e., whether GH Therapy has been attempted in the past, is ongoing or is just begin. See section 5 for the list of valid codes. CE1,1HL7904890164-3GROWTH HORMONE, PATIENT HISTORY INFORMATION GHD TREATMENT DATE This is the date the current/most current GH treatment initiated/to be initiated. DT0,190170-3GROWTH HORMONE DEFICIENCY (GHD) CHILDHOOD INFORMATION Information about growth hormone deficiency in childhood. 0,190171-3GHD CHILDHOOD INFORMATION, SMALL FOR GESTATIONAL AGE INDICATOR This conveys information about the size of the child at birth, if known. N No Y Yes CE0,1HL7013690172-3GHD CHILDHOOD INFORMATION, PUBERTY STATUS This information describes the status of the child relative to the onset of puberty if known. BP Pre-pubertal AP Post Pubertal PS Pubertal CE1,1HL7904990173-3GHD CHILDHOOD INFORMATION, THERAPY BY PEDIATRIC ENDOCRINOLOGIST OR NEPHROLOGIST INDICATOR This conveys whether therapeutic intervention for the treatment of childhood GHD is recommended and managed by a Pediatric Endocrinologist or Nephrologists. N No Y Yes CE1,1HL7013690180-3GH DYSFUNCTION ADULT INFORMATION This conveys information about Adult GH Dysfunction related to factors other than endocrine disorders 0,1 90181-3GH Dysfunction Adult Information, Secondary Causes This conveys information about Adult GH Dysfunction related to factors other than endocrine disorders. A Age O Obesity D Depression OTH Other CE1,nHL79050 90182-3GHD Dysfunction Adult Information, Other SECONDARY CAUSES Description of the other causes of adult GH dysfunction. Required when GH Dysfunction Adult, Secondary Causes equals "OTH" other. TX0,190190-3WASTING SYNDROME INFORMATION This provides information about the patient's concurrent Wasting Syndrome 1,190191-3WASTING SYNDROME INFORMATION, OCCURANCE INDICATOR This conveys whether the patient has a Wasting Syndrome in addition to the GHD. N No Y Yes CE1,1HL70136 90192-3WASTING SYNDROME INFORMATION, WEIGHT LOSS EQUAL TO OR GREATER THAN 10% This conveys whether the patient has experienced unintentional weight loss equal to or greater than 10% of body mass. N No Y Yes CE0,1HL7013690193-3WASTING SYNDROME INFORMATION, DUE TO TREATABLE CONDITION INDICATOR This defines whether the Wasting Syndrome is due to a treatable condition, e.g. an autoimmune disorder. N No Y Yes CE0,1HL7013690194-3WASTING SYNDROME INFORMATION, TREATABLE CONDITION STATUS INDICATOR This indicates whether the treatable condition that is precipitating the Wasting Syndrome is being treated. Required if answer to Wasting Syndrome Information, Due to Treatable Condition Indicator equals "Y" Yes. N No Y Yes CE0,1HL7013690200-3NUTRITIONAL INFORMATION The information in this section is used to convey whether the nutritional intake, both quantity and variety, is a contributory factor in the GHD. 0,1 90201-3NUTRITIONAL INFORMATION, ASSESSMENT INDICATOR This conveys whether there has been an assessment of the patient's diet and nutritional status. Information on nutritional assessment is required if patient has Wasting Syndrome. CMP Completed PLD Planned CE0,1 HL7905190202-3NUTRITIONAL INFORMATION, ASSESSMENT DATE This is the date of scheduled or completed nutritional assessment. DT1,1 90203-3NUTRITIONAL INFORMATION, CONCURRENT THERAPY INDICATOR This is used to convey whether the patient is receiving nutritional counseling and treatment. N No Y Yes CE0,1HL70136 90210-3LABORATORY GH STIMULATION Provocative growth hormone stimulation, a minimum of 2 tests required. 1,n90211-3LABORATORY GH STIMULATION, AGENT NAME This is the name of the stimulation agent used to induce GH release in the GH stimulation test. TX1,190212-3LABORATORY GH STIMULATION, PEAK VALUES This reports the peak values of GH activity achieved with provocative stimulation by named agent. NM1,niso+ ans+90213-3LABORATORY GH STIMULATION, DATE This is the date GH Stimulation testing was performed. DT1,190220-3PHYSICAL FINDINGS, PATIENT HEIGHT This is used to report the height of the patient as measured at named intervals. 0,190221-3PHYSICAL FINDINGS, PATIENT HEIGHT AT BIRTH This is the patient's height at birth or in the neonatal period. Height will be reported in iso+ units of either cm (centimeters) or in (inches). NM0,1iso+ ans+ 90222-3PHYSICAL FINDINGS, CURRENT PATIENT HEIGHT This is the patient's height at the time of the request. Height will be reported in iso+ units of either cm (centimeters) or in (inches). NM1,1iso+ ans+90223-3PHYSICAL FINDINGS, CURRENT PATIENT HEIGHT - DATE OF MEASUREMENT This is the date that the current height measured DT1,190224-3PHYSICAL FINDINGS, BASELINE PATIENT HEIGHT This is the baseline height measured at least six months prior to request for GH therapy. It is used for assessing growth rate before and after GH therapy Height will be reported in iso+ units of either cm (centimeters) or in (inches). NM1,1iso+ ans+90225-3PHYSICAL FINDINGS, BASELINE PATIENT HEIGHT - DATE OF MEASUREMENT This the date the baseline height was measured. DT1,190226-3PHYSICAL FINDINGS PATIENT HEIGHT AT ONSET OF TREATMENT This is the patient height as measured immediately prior to treatment initiation. Required if Treatment has been initiated. Height will be reported in iso+ units of either cm (centimeters) or in (inches). NM0,1iso+ ans+90227-3PHYSICAL FINDINGS PATIENT HEIGHT AT ONSET OF TREATMENT DATE OF MEASUREMENT This is the date of measurement at or immediately prior to onset of treatment. Required if treatment has been initiated. DT0,190228-3PHYSICAL FINDINGS, PATIENT HEIGHT AT LAST RENEWAL This is the patient height as measured when GH therapy last requested. Height will be reported in iso+ units of either cm (centimeters) or in (inches). NM0,1iso+ ans+90229-3PHYSICAL FINDINGS, PATIENT HEIGHT AT LAST RENEWAL, DATE OF MEASUREMENT This is the date the height was measured for the last request for renewal. DT0,190230-3PHYSICAL FINDINGS, PATIENT WEIGHT Weight of the patient at given intervals. 0,190231-3PHYSICAL FINDINGS PATIENT WEIGHT AT BIRTH This is the weight of the patient at birth. Weight will be reported as either iso+ units of gm (grams) or kg (kilograms) or ans+ units of oz (ounces) or lb (pounds). NM0,1iso+ ans+ 90232-3PHYSICAL FINDINGS, CURRENT PATIENT WEIGHT This is the weight of the patient as of the time of this request. Weight will be reported as either iso+ units of gm (grams) or kg (kilograms) or ans+ units of oz (ounces) or lb (pounds). NM1,1iso+ ans+90233-3PHYSICAL FINDINGS, CURRENT PATIENT WEIGHT - DATE OF MEASUREMENT This is the date the current weight was measured. DT1,190234-3PHYSICAL FINDINGS, BASELINE PATIENT WEIGHT Baseline weight, at least six months prior to request for GH therapy. Weight will be reported as either iso+ units of gm (grams) or kg (kilograms) or ans+ units of oz (ounces) or lb (pounds). NM1,1iso+ ans+90235-3PHYSICAL FINDINGS, BASELINE PATIENT WEIGHT - DATE OF MEASUREMENT This is the date baseline weight was measured DT1,190236-3PHYSICAL FINDINGS, PATIENT WEIGHT AT ONSET OF TREATMENT This is the patient's weight as measured when treatment initiated. Required if treatment has been initiated. Weight will be reported as either iso+ units of gm (grams) or kg (kilograms) or ans+ units of oz (ounces) or lb (pounds). NM0,1iso+ ans+90237-3PHYSICAL FINDINGS, PATIENT WEIGHT AT ONSET OF TREATMENT - DATE OF MEASUREMENT This is the patient weight as measured at or immediately prior to the onset of treatment. Required if treatment has been initiated. DT0,190238-3PHYSICAL FINDINGS, PATIENT WEIGHT AT LAST RENEWAL This is the patient weight as measured when GH therapy was last requested. Weight will be reported as either iso+ units of gm (grams) or kg (kilograms) or ans+ units of oz (ounces) or lb (pounds). NM0,1iso+ ans+90239-3PHYSICAL FINDINGS, PATIENT WEIGHT LAST RENEWAL - DATE OF MEASUREMENT This is the date the patient weight was measured for the last renewal request. DT0,190240-3PATIENT BODY MASS INDEX This is information regarding the patient's body mass index.  0,190241-3PATIENT BODY MASS INDEX, CURRENT This the patient's Body Mass Index (BMI) as calculated at the time of the request Must be reported in iso+ units of IU (international units). NM1,1iso+90242-3PATIENT BODY MASS INDEX, AT ONSET OF TREATMENT This is the Body Mass Index as calculated at the time of onset of GH treatment. Must be reported in iso+ units of IU (international units). NM0,1iso+90250-3PARENTAL HEIGHT Parental height information. May be required for coverage of childhood GH therapy. 0,190251-3PARENTAL HEIGHT, AVAILABILITY INDICATOR This reflects the availability of parental height information. MK Mother Known FK Father Known BK Both Known BU Both Unknown CE1,1HL7905290252-3PARENTAL HEIGHT, MOTHER Mother's height if known. Required if the Parental Height, Availability Indicator equals "MK" mother known or "BK" both known. Height will be reported in iso+ units of either cm (centimeters) or in (inches). NM0,1iso+ ans+90253-3PARENTAL HEIGHT, FATHER Father's height if known. Required if the Parental Height, Availability Indicator equals "FK" father known or "BK" both known. Height will be reported in iso+ units of either cm (centimeters) or in (inches). NM0,1iso+ ans+90080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS Information about other drugs previously prescribed for treatment of this condition with less than optimal outcomes. 0,n90081-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG NAME This is the descriptive name of the drug previously used to treat the diagnosis. TX1,190082-xDRUG HISTORY - PRIOR THERAPY FOR DIAGNOSIS, - DRUG CODE The code assigned to the drug previously used to treat the diagnosis as defined by: Representative NDC, RxNorm SCD or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD90083-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DURATION OF THERAPY Duration of previous therapy in days. NM1,1iso+90084-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED This is the reason that prior drug therapy was discontinued. NTEFF Not or No Longer Effective SDEFT Side Effects/Tolerance NTCMP Not Compatible OTH Other CE1,1HL7904090085-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - NAME OF INCOMPATIBLE DRUG(S) The descriptive name of the drug Incompatible with the prior therapy. If Drug History, Prior Therapy for Diagnosis - Reason Prior Therapy Discontinued equals "NTCMP" Not Compatible, then this is required. TX 0,n90086-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON(S) PRIOR THERAPY DISCONTINUED, OTHER Description of the other reason for discontinued therapy. If Drug History, Prior Therapy for Diagnosis - Reason Prior Therapy Discontinued equals "OTH" Other, then this is required. TX0,190090-xCONCURRENT THERAPY Drugs the patient is currently on, for this or other diagnoses, which might impact the requested drug.0,n90091-xCONCURRENT THERAPY, DRUG NAME The descriptive name of the drug(s) used in concurrent therapy, for this or other diagnoses, which may impact the requested drug. TX0,190092-xCONCURRENT THERAPY, DRUG CODE The code assigned to the concurrent drug as defined by: Representative NDC, RxNorm SCD, or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD Proton Pump Inhibitors (PPI) Value Table Table 3.4 Proton Pump Inhibitors Value Table LOINC code Component AnswerValueData TypeCardResponse Code / Numeric Units90010-xPRESCRIBER INFORMATION Information about the practitioner prescribing the drug. 1,190011-xPRESCRIBER INFORMATION, NAME This is the name of the practitioner prescribing the drug. PN1,190012-xPRESCRIBER INFORMATION, IDENTIER This may be repeated to convey multiple identifiers such as the DEA number, NPI, HCIdea Number or proprietary provider identifier. Note: If the provider is a covered entity under HIPAA and the NPI is mandated for use, the NPI must be sent as one of the identifiers and the legacy provider identifier must not be used. CX1,nNPI DEA HCIdea Proprietary Provider ID See note at left.90013-xPRESCRIBER INFORMATION, SPECIALITY TAXONOMY CODE This is the Taxonomy code that identifies the medical specialty of the prescriber CE1,1PTX90020-xPRESCRIBER CONTACT INFORMATION Contact information for the individual prescribing the drug. 0,190021-xPRESCRIBER CONTACT INFORMATION, PHONE NUMBER The phone number of the individual prescribing the drug. TX1,190022-xPRESCRIBER CONTACT INFORMATION, FAX NUMBER The fax number of the individual prescribing the drug. TX0,190030-xDRUG PRESCRIBED This is information about the drug requested in the prior authorization. 1,190031-xDRUG PRESCRIBED, NAME This is the descriptive name of the drug prescribed. TX1,190032-xDRUG PRESCRIBED, DRUG CODE This is the code identifier for the drug prescribed as defined by: Representative NDC, RxNorm SCD or RxNorm SBD . CE1,1NDC RxNorm SCD RxNorm SBD90033-xDRUG PRESCRIBED, THERAPY TYPE This is used to convey the historical use of the prescribed drug as part of the patient's therapy. INTRQ Initial Therapy CNTRQ Continued Therapy RPLRQ Replacement Therapy ADDRQ Add on Therapy CE1,1HL7903890034-xDRUG PRESCRIBED, SELF ADMINISTERED INDICATOR N No Y Yes CE0,1HL7013690260-4PPI, RELATED DIAGNOSIS This is the related diagnosis of the patient for which the drug is a prescribed therapy. Note: Prior to U.S. adoption of ICD-10-CM, use ICD-9-CM in the U.S. domain. After adoption as the standard for defining diagnoses in the US, use only ICD-10-CM for requests in the US. 1,190260-4 CE1,1IC9 IC1090270-4DIAGNOSIS CONFIRMATION AND LEVEL OF TREATMENT NEEDED Diagnosis procedures and criteria confirming the diagnosis and level of treatment needed. 1,1 90271-4DIAGNOSIS CONFIRMATION AND LEVEL OF TREATMENT NEEDED, PROCEDURE EMPLOYED These are procedures performed to establish the diagnosis. BMS Barium Studies EGD Endoscopy BIO Biopsy CE1,nHL7905390272-4DIAGNOSIS CONFIRMATION AND LEVEL OF TREATMENT NEEDED, GERD BY ENDOSCOPY TYPE This is the level of severity of GERD as confirmed by endoscopy. Required when GERD confirmed by endoscopy. See section 5 for the list of valid codes. CE0,1HL7905490280-4PPI, PATIENT HISTORY - STRICTURE PRESENT This conveys information that esophageal stricture is present with the related diagnosis. Required if the related diagnosis is "Barrett Esophagus". 0,190280-4 N No Y Yes CE1,1HL7013690080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS Information about other drugs previously prescribed for treatment of this condition with less than optimal outcomes. 0,n90081-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG NAME This is the descriptive name of the drug previously used to treat the diagnosis. TX1,190082-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG CODE The code assigned to the drug previously used to treat the diagnosis as defined by: Representative NDC, RxNorm SCD or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD90083-xDRUG HISTORY,PRIOR THERAPY FOR DIAGNOSIS - DURATION OF THERAPY Duration of previous therapy in days. NM1,1iso+90084-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED This is the reason that the prior drug therapy was discontinued. NTEFF Not or No Longer Effective SDEFT Side Effects/Tolerance NTCMP Not Compatible OTH Other CE1,1HL7904090085-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS, REASON(S) PRIOR THERAPY DISCONTINUED, OTHER Description of the other reason for discontinued therapy. If Drug History, Prior Therapy for Diagnosis - Reason Prior Therapy Discontinued equals "OTH" Other, then this is required.TX0,190086-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - INCOMPATIBLE DRUG NAME The descriptive name of the drug incompatible with the prior therapy. If Drug History, Prior Therapy for Diagnosis Reason Therapy Discontinued equals "NTCMP" Not Compatible, then this is required. TX 0,n90090-xCONCURRENT THERAPY Drugs the patient is currently on, for this or other diagnoses, which might impact the requested drug. 0,n90091-xCONCURRENT THERAPY, DRUG NAME The descriptive name of the drug(s) used in concurrent therapy, for this or other diagnoses, which may impact the requested drug. TX0,190092-xCONCURRENT THERAPY, DRUG CODE The code assigned to the ordered drug as defined by: Representative NDC, RxNorm SCD, or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD90110-xNSAIDS/PPI RELATED CONCURRENT THERAPY NSAID/PPI related drugs being used concurrently with the requested drug.0,190111-xNSAIDS/PPI RELATEDE, CONCURRENT THERAPY, TYPE Concurrent NSAIDS/PPI related drug therapies being used for treatment of this or other conditions. See section 5 for the list of valid codes.CE1,1HL7904190112-xNSAIDS/PPI RELATED CONCURRENT THERAPY, OTHER TYPE The descriptive name of the NSAIDS/PPI related drug(s) used in concurrent therapy. Required when NSAIDS/PPI Related Concurrent Therapy, Type equals OTH Other.TX0,190290-4H-PYLORI INFORMATION H-Pylori status in relation to the need for PPI. 0,190291-4H-PYLORI INFORMATION, STATUS This is the documented H-Pylori status of the patient. PS Positive NE Negative CE1,1HL7905690292-4H-PYLORI INFORMATION, CONFIRMED BY This conveys the method used to confirm H-Pylori. See section 5 for the list of valid codes. CE1,nHL7905790293-4H-PYLORI INFORMATION, CONFIRMED BY - OTHER Description of the method used to confirm the presence of H-Pylori, required when the response to H-Pylori Information, Confirmed by equals "OTH" Other. TX0,190300-4H-PYLORI TREATMENT H-Pylori treated or being treated. 0,190301-4H-PYLORI TREATMENT, CDA PROTOCOL INDICATOR This conveys whether the treatment of H-Pylori is/was/will be done in compliance with CDA protocols. N No Y Yes CE1,1HL7013690302-4H-PYLORI TREATMENT, START DATE This is the date that treatment of H-Pylori began or is to begin. DT0,190303-4H-PYLORI TREATMENT, END DATE Date treatment of H-Pylori was or is expected to be completed. DT0,1 Erectile Dysfunction (ED) Agents Value Table Table 3.5 Erectile Dysfunction Agents Value Table LOINC code Component AnswerValueData TypeCardResponse Code / Numeric Units90010-xPRESCRIBER INFORMATION Information about the practitioner prescribing the drug. 1,190011-xPRESCRIBER INFORMATION, NAME This is the name of the practitioner prescribing the drug. PN1,190012-xPRESCRIBER INFORMATION, IDENTIER This may be repeated to convey multiple identifiers such as the DEA number, NPI, HCIdea Number or proprietary provider identifier. Note: If the provider is a covered entity under HIPAA and the NPI is mandated for use, the NPI must be sent as one of the identifiers and the legacy provider identifier must not be used. CX1,nNPI DEA HCIdea Proprietary Provider ID See note at left.90013-xPRESCRIBER INFORMATION, SPECIALITY TAXONOMY CODE This is the Taxonomy code that identifies the medical specialty of the prescriber. CE1,1PTX90020-xPRESCRIBER CONTACT INFORMATION Contact information for the individual prescribing the drug. 0,190021-xPRESCRIBER CONTACT INFORMATION, PHONE NUMBER The phone number of the individual prescribing the drug. TX1,190022-xPRESCRIBER CONTACT INFORMATION, FAX NUMBER The fax number of the individual prescribing the drug. TX0,190030-xDRUG PRESCRIBED This is information about the drug requested in the prior authorization. 1,190031-xDRUG PRESCRIBED, NAME This is the descriptive name of the drug prescribed. TX1,190032-xDRUG PRESCRIBED, DRUG CODE This is the code identifier for the drug prescribed as defined by: Representative NDC, RxNorm SCD or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD90033-xDRUG PRESCRIBED, THERAPY TYPE This is used to convey the historical use of the prescribed drug as part of the patient's therapy. INTRQ Initial Therapy CNTRQ Continued Therapy RPLRQ Replacement Therapy ADDRQ Add on Therapy CE1,1HL7903890034-xDRUG PRESCRIBED, SELF ADMINISTERED INDICATOR This indicator defines if the drug can be self administered. N No Y Yes 0,1HL7013690310-5ERECTILE DYSFUNCTION, RELATED DIAGNOSIS This is the related diagnosis of the patient for which the drug is a prescribed therapy. Note: Prior to U.S. adoption of ICD-10-CM, use ICD-9-CM in the U.S. domain. After adoption as the standard for defining diagnoses in the US, use only ICD-10-CM for requests in the US. 1,190310-5 CE1,1IC9 IC1090320-5ED, RELATED DIAGNOSIS CONFIRMATION INFORMATION This is information about how the diagnosis was confirmed. 1,n90321-5ED, RELATED DIAGNOSIS CONFIRMATION CONFIRMED BY This reports tests used to confirm the ED diagnosis See section 5 for the list of valid codes. CE1,nHL7905790322-5ED, RELATED DIAGNOSIS CONFIRMATION ED DIAGNOSIS CONFIRMED BY, OTHER This is used to convey the name of the other test used to confirm ED. It is required when Erectile Dysfunction, Patient History ED Diagnosis Confirmed By equals "OTH" Other. TX0,190323-5ED, RELATED DIAGNOSIS CONFIRMATION RESULT This is the result of the test confirming diagnosis of ED NM1,1iso+90324-5ED, RELATED DIAGNOSIS CONFIRMATION - DATE This is the date that the test confirming diagnosis of ED was performed. DT1,190330-5ED, PATIENT HISTORY INFORMATION This is information relating to the history of the patient. 1,190331-5ED, PATIENT HISTORY PULMONARY HYPERTENSION FUNCTIONAL LEVEL Functional Level of Individual with Primary Pulmonary Hypertension, Peripheral Artery Hypertension or Pulmonary Artery Hypertension C1 Class I C2 Class II C3 Class III C4 Class IV CE0,1HL7905890332-5ED, PATIENT HISTORY EVALUATION TYPE COMPLETED This conveys whether the patient has been evaluated for general health or contributory factors. GH General Health Status Evaluation UC Investigation of Underlying Causes of Primary Condition NA Not applicable CE1,1HL7905990333-5ED, PATIENT HISTORY ED LEVEL INDICATOR This indicator defines whether the dysfunction is present 50% or more of the time in the last 6 months. Y Yes N No CE1,1HL7013690334-5ED, PATIENT HISTORY ED RELATED TO This is used to convey information related to other conditions resulting in ED See section 5 for the list of valid codes. CE0,nHL7906090340-5ED, TREATMENT OF RELATED CAUSES Treatment status of conditions precipitating ED.  0,1 90341-5ED, TREATMENT OF RELATED CAUSES TREATMENT OF REVERSIBLE CAUSES STATUS Treatment status of conditions precipitating ED. See section 5 for the list of valid codes. CE1,1HL7904890342-5ED, TREATMENT OF RELATED CAUSES RADIATION THERAPY STATUS This is used to convey the status of Radiation Therapy, It is required if the related diagnosis is Testicular Cancer. See section 5 for the list of valid codes. CE0,1HL7904890343-5ED, TREATMENT OF RELATED CAUSES RADIATION THERAPY START DATE This is the date that radiation therapy began. It is required if radiation therapy is planned or in progress. DT0,190344-5ERECTILE DYSFUNCTION, TREATMENT OF RELATED CAUSES RADIATION THERAPY END DATE This is the date that radiation therapy was or is expected to be completed. Required when Radiation Therapy employed for treatment. DT0,190345-5ED, TREATMENT OF RELATED CAUSES SURGICAL TREATMENT INDICATOR This conveys information about whether the related condition can or has been treated with surgery. It is required if the related diagnosis is Testicular Cancer. CMP Completed PLD Planned CE0,1HL7905190346-5ED, TREATMENT OF RELATED CAUSES SURGERY DATE This is the date that surgery was or is expected to be accomplished. Required when Surgery is employed for treatment of Testicular Cancer. DT0,190347-5ED, TREATMENT OF RELATED CAUSES PSYCHOGENIC CAUSES OF ED TREATMENT This conveys information about whether the psychogenic components of ED can or have been treated and if so, by what method. PSY Psychotherapy BHT Behavior Therapy OTT Other Therapy NOT No Therapy CE0,1HL7906190348-5ED, TREATMENT OF RELATED CAUSES ED DRUG INDUCED INDICATOR This is used to convey whether the ED is secondary to drugs being taken by the patient. N No Y Yes CE0,1HL7013690349-5ED, TREATMENT OF RELATED CAUSES DRUG INDUCED OPTION This is used to define the options, if any, for altering the use of drug that is precipitating ED. RDU Reduction in Drug Use DCT Discontinue Drug Use CGD Change Drug DCN Drug Cannot be Changed or Discontinued CE0,1HL7906290080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS Information about other drugs previously prescribed for treatment of this condition with less than optimal outcomes. 0,n90081-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG NAME This is the descriptive name of the drug previously used to treat the diagnosis. TX1,190082-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG CODE The code assigned to the drug previously used to treat the diagnosis as defined by: Representative NDC, RxNorm SCD, or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD90083-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS, - DURATION OF THERAPY Duration of previous therapy in days. NM1,1iso+90084-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED Reason prior drug therapy was discontinued. NTEFF Not or No Longer Effective SDEFT Side Effects/Tolerance NTCMP Not Compatible OTH Other CE1,1HL7904090085-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED, OTHER Description of the other reason for discontinued therapy. If Drug History, Prior Therapy for Diagnosis - Reason Prior Therapy Discontinued equals "OTH" Other, then this is required. TX0,190086-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS Reason Prior Therapy Discontinued, NAME OF INCOMPATIBLE DRUG(S) The descriptive name of the drug incompatible with the prior therapy. If Drug History, Prior Therapy for Diagnosis - Reason Prior Therapy Discontinued equals "NTCMP" Not Compatible, then this is required. TX 0,190090-xCONCURRENT THERAPY Drugs the patient is currently on, for this or other diagnoses, which might impact the requested drug. 0,n90091-xCONCURRENT THERAPY, DRUG NAME The descriptive name of the drug(s) used in concurrent therapy, for this or other diagnoses, which may impact the requested drug. TX0,190092-xCONCURRENT THERAPY, DRUG CODE The code assigned to the concurrnt drug as defined by: Representative NDC, RxNorm SCD, or RxNorm SBDCE1,1NDC RxNorm SCD RxNorm SBD90350-5ED RELATED CONCURRENT THERAPY ED related drugs being used concurrently with the requested drug. 0,190351-5ED RELATED CONCURRENT THERAPY, TYPE Concurrent ED related drug therapies being used for treatment of this or other conditions. See section 5 for the list of valid codes. CE1,1HL7906390352-5ED RELATED CONCURRENT THERAPY, DRUG NAME(S) The descriptive name of the ED related drug(s) used in concurrent therapy. Required when ED Related Concurrent Therapy, Type equals OTH Other. TX0,1 Narcotic(Opioid) Agonists Value Table Table 3.6 Narcotic(Opioid) Agonists Value Table LOINC code Component AnswerValueData TypeCardResponse Code / Numeric Units90010-xPRESCRIBER INFORMATION Information about the practitioner prescribing the drug. 1,190011-xPRESCRIBER INFORMATION, NAME This is the name of the practitioner prescribing the drug. PN1,190012-xPRESCRIBER INFORMATION, IDENTIER This may be repeated to convey multiple identifiers such as the DEA number, NPI, HCIdea Number or proprietary provider identifier. Note: If the provider is a covered entity under HIPAA and the NPI is mandated for use, the NPI must be sent as one of the identifiers and the legacy provider identifier must not be used. CX1,nNPI DEA HCIdea Proprietary Provider ID See note at left.90013-xPRESCRIBER INFORMATION, SPECIALITY TAXONOMY CODE Taxonomy code that identifies the medical specialty of the prescriber CE1,1PTX90020-xPRESCRIBER CONTACT INFORMATION Contact information for the individual prescribing the drug. 0,190021-xPRESCRIBER CONTACT INFORMATION, PHONE NUMBER The phone number of the individual prescribing the drug. TX1,190022-xPRESCRIBER CONTACT INFORMATION, FAX NUMBER The fax number of the individual prescribing the drug. TX0,190030-xDRUG PRESCRIBED This is information about the drug requested in the prior authorization. 1,190031-xDRUG PRESCRIBED, NAME This is the descriptive name of the drug prescribed. TX1,190032-xDRUG PRESCRIBED, DRUG CODE This is the code identifier for the drug prescribed as defined by: Representative NDC, RxNorm SCD or RxNorm SBD. CE1,1NDC RxNorm SCD RxNorm SBD90033-xDRUG PRESCRIBED, THERAPY TYPE This is used to convey the historical use of the prescribed drug as part of the patients therapy. INTRQ Initial Therapy CNTRQ Continued Therapy RPLRQ Replacement Therapy ADDRQ Add on Therapy CE1,1HL7903890034-xDRUG PRESCRIBED, SELF ADMINISTERED INDICATOR This indicator defines if the drug can be self administered. N No Y Yes CE0,1HL7013690360-6NARCOTIC (OPIOID) AGONISTS, RELATED DIAGNOSIS This is the related diagnosis of the patient for which the drug is a prescribed therapy. Note: Prior to U.S. adoption of ICD-10-CM, use ICD-9-CM in the U.S. domain. After adoption as the standard for defining diagnoses in the US, use only ICD-10-CM for requests in the US. 1,190360-6 CE1,1IC9 IC1090370-6NARCOTIC (OPIOID) AGONISTS, PATIENT HISTORY Patient history related to the prescribed drug. 1,190371-6NARCOTIC (OPIOID) AGONISTS, PATIENT HISTORY PAIN SYNDROME SOURCE This conveys information regarding the source or type of pain the patient is experiencing. See section 5 for the list of valid codes. CE1,1HL7906490372-6NARCOTIC (OPIOID) AGONISTS, PATIENT HISTORY PAIN SYNDROME SOURCE, OTHER Description of the source of the Pain Syndrome. Required when the answer to Opioid Agonists, Patient History Pain Syndrome Source equals OTH, other. TX0,1  90373-6NARCOTIC (OPIOID) AGONISTS, PATIENT HISTORY PAIN SYNDROME FRENQUENCY Frequency with which pain occurs. CP Constant Pain ITP Intermittent Pain ICP Incidental Pain CE1,1HL79065 90374-6NARCOTIC (OPIOID) AGONISTS, PATIENT HISTORY PAIN SYNDROME Persistence Anticipated duration/persistence of pain. AL Acute Limited less than 30 Days CR Chronic CRP Chronic Progressive CPR Chronic Progressive with Escalating Opioid CE1,1HL7906690380-6NARCOTIC (OPIOID) AGONISTS, COMPLICATING CONDITION INFORMATION Information about co-morbid conditions complicating or exacerbating pain management. 1,n 90381-6NARCOTIC (OPIOID) AGONISTS, COMPLICATING CONDITIONS Co-morbid conditions complicating or exacerbating pain management. See section 5 for the list of valid codes. CE1,1HL79067 90382-6NARCOTIC (OPIOID) AGONISTS, COMPLICATING CONDITIONS, OTHER Description of co-morbid condition. Required when answer to Complicating Condition equals OTH Other. TX0,190390-6Narcotic (Opioid) Agonists, Laboratory information Report of drug screens performed since last review or escalation of drug therapy. 1,n 90391-6Narcotic (Opioid) Agonists, Laboratory Name of Test The name of the test used to verify the presence of the Opioid. TX1,1 90392-6Narcotic (Opioid) Agonists, Laboratory - Date of Test Date test performed DT1,1 90393-6Narcotic (Opioid) Agonists, Laboratory TEST Result This conveys the results of the drug screen. NM1,1iso+90080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS Information about other drugs previously prescribed for pain management, both opioid and non-opioid, with less than optimal outcomes. 0,n90081-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS DRUG NAME Name of drug previously used for pain management. TX1,190082-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS DRUG CODE The code assigned to the drug previously used to treat the diagnosis as defined by: Representative NDC, RxNorm SCD or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD90083-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DURATION OF THERAPY Duration of previous therapy in days. NM1,1iso+90084-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS REASON PRIOR THERAPY DISCONTINUED This is the reason that the prior pain therapy was discontinued. NTEFF Not or No Longer Effective SDEFT Side Effects/Tolerance NTCMP Not Compatible OTH Other CE1,1HL904090085-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED, OTHER Description of the other reason for discontinued therapy. If Drug History, Prior Therapy for Pain Management Reason Prior Therapy Discontinued equals OTH Other, then this is required. TX0,190086-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS INCOMPATIBLE DRUG NAME The descriptive name of the drug Incompatible with the prior therapy. If Drug History, Prior Therapy for Diagnosis Reason Prior Therapy Discontinued equals NTCMP Not Compatible, then this is required. TX 0,190090-xCONCURRENT THERAPY Drugs the patient is currently on, for this or other diagnoses, which might impact the requested drug. 0,190091-xCONCURRENT THERAPY, DRUG NAME The descriptive name of the drug(s) used in concurrent therapy, for this or other diagnoses, which may impact the requested drug. TX0,190092-xCONCURRENT THERAPY DRUG CODE The code assigned to the concurrent drug as defined by: Representative NDC, RxNorm SCD, or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD90400-6OPIOID RELATED CONCURRENT PAIN THERAPY Concurrent drug therapies used in pain management. 0,190401-6OPIOID RELATED CONCURRENT PAIN THERAPY, NAME Descriptive name of the Opioid and non-Opioid drugs used concurrently for pain management.TX0,190402-6OPIOID RELATED CONCURRENT PAIN THERAPY, DRUG CODE The code assigned to the concurrent drug as defined by: Representative NDC, RxNorm SCD, or RxNorm SBD.CE1,1NDC RxNorm SCD RxNorm SBD90403-6OPIOID RELATED CONCURRENT PAIN THERAPY, OPIOID LEVEL Level of concurrent Opioid therapy. RDL Recommended Dose Level HPL High Potency Dose Level 24L 24 Hour High Potency Dose Level OTL Opioid Tolerant CE0,1HL7906890410-6Narcotic (Opioid) Agonist, Use for Treatment of Opioid Addiction Use of Narcotic (Opioid) Agonists for the treatment of opioid addiction. 0,190411-6Narcotic (Opioid) Agonist, Use for Treatment of Opioid Addiction - Opioid Discontinued This conveys whether the addicted drug has been discontinued. N No Y Yes CE1,1HL7013690412-6Narcotic (Opioid) Agonist, Use for Treatment of Opioid Addiction - Date Opioid Discontinued Date that the object drug of the addiction was discontinued or is planned to be discontinued DT1,190413-6Narcotic (Opioid) Agonist, Use for Treatment of Opioid Addiction - Induction TherAPy Date Initiated Date induction therapy initiated or to be initiated. DT1,190414-6Narcotic (Opioid) Agonist Use for Treatment of Opioid Addiction, Induction Therapy Date Oral Initiated Date to switch to oral medication if induction therapy initiated with injectable drug. DT0,190415-6Narcotic (Opioid) Agonist Use for Treatment of Opioid Addiction - Duration Planned length of time on agonist treatment. NM1,1iso+90416-6Narcotic (Opioid) Agonist, Use for Treatment of Opioid Addiction - dose Titration Description of the titration plan or the agonist including time line.TX1,1 Imidazole - Related Antifungals Value Table Table 3.7 Imidazole - Related Antifungals Value Table LOINC code Component AnswerValueData TypeCardResponse Code / Numeric Units90010-xPRESCRIBER INFORMATION Information about the practitioner prescribing the drug. 1,190011-xPRESCRIBER INFORMATION, NAME This is the name of the practitioner prescribing the drug. PN1,190012-xPRESCRIBER INFORMATION, IDENTIER This may be repeated to convey multiple identifications such as the National Provider Identifier [NPI], the Drug Enforcement Act [DEA] number, Special DEA number, HCIdea number or proprietary identifier. Note: If the provider is a covered entity under HIPAA and the NPI is mandated for use, the NPI must be sent as one of the identifiers and the legacy provider identifier must not be used. CX1,nNPI DEA HCIdea Proprietary Provider ID See note at left.90013-xPRESCRIBER INFORMATION, SPECIALTY TAXONOMY CODE Taxonomy code that identifies the medical specialty of the prescriber CE1,1PTX90020-xPRESCRIBER CONTACT INFORMATION Contact information for the individual prescribing the drug. 0,190021-xPRESCRIBER CONTACT INFORMATION, PHONE NUMBER The phone number of the individual prescribing the drug. TX1,190022-xPRESCRIBER CONTACT INFORMATION, FAX NUMBER The fax number of the individual prescribing the drug. TX0,190030-xDRUG PRESCRIBED This is information about the drug requested in the prior authorization. 1,190031-xDRUG PRESCRIBED, NAME This is the descriptive name of the drug prescribed. TX1,190032-xDRUG PRESCRIBED, DRUG CODE This is the code identifier for the drug prescribed as defined by: Representative NDC, RxNorm SCD or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD90033-xDRUG PRESCRIBED, THERAPY TYPE This is used to convey the historical use of the prescribed drug as part of the patient's therapy. INTRQ Initial Therapy CNTRQ Continued Therapy RPLRQ Replacement Therapy ADDRQ Add on Therapy CE1,1HL79038 90034-xDRUG PRESCRIBED, SELF ADMINISTERED INDICATOR This indicator defines if the drug can be self administered. N No Y Yes CE0,1HL7013690420-7Drug Prescribed, TOPICAL THERAPY Information about why a topical therapy was prescribed. 0,190421-7Drug Prescribed, TOPICAL THERAPY - REASON The reason a topical therapy was prescribed. UTS Unable to swallow HDS Hepatic Dysfunction OTH Other (If used, then Topical Therapy Reason Other must be completed) CE1,1HL7906990422-7Drug Prescribed, TOPICAL THERAPY- REASON, OTHER Description of reason for topical therapy, required when response to Drug Prescribed, Topical Therapy - Reason equals "OTH" Other. TX0,190430-7IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS Diagnosis information related to the prescribed drug. 1,190431-7IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS This is the related diagnosis of the patient for which the drug is a prescribed therapy. Note: Prior to U.S. adoption of ICD-10-CM, use ICD-9-CM in the U.S. domain. After adoption as the standard for defining diagnoses in the US, use only ICD-10-CM for requests in the US. CE1,1IC9 IC10 90432-7IMIDAZOLE-RELATED ANTIFUNGALS, DIAGNOSIS CONFIRMED BY This conveys the diagnostic procedures used to establish the diagnosis. See section 5 for the list of valid codes. CE0,nHL79070 90433-7IMIDAZOLE-RELATED ANTIFUNGALS, DIAGNOSIS CONFIRMED BY - OTHER Name/description of other test used to confirm the diagnosis. Required when the answer to Patient History, Diagnosis Confirmed equals "OTH" Other. TX0,190440-7FUNGAL INFECTION INFORMATION Information about the fungal infection. 1,190441-7FUNGAL INFECTION INFORMATION, LOCATION This defines the general site of the fungal infection. FN Finger Nail TN Toe Nail OTH Other (If used, then Fungal Infection Information, Location Other must be completed) CE1,nHL7907190442-7FUNGAL INFECTION INFORMATION, LOCATION OTHER Description of the location of the fungal infection. Required when Fungal Infection Information, Location equals "OTH" Other TX0,190443-7FUNGAL INFECTION INFORMATION, NUMBER OF NAILS Enumerates the number of affected finger and or toe nails. NM0,1iso+90450-7IMMUNE COMPROMISE INFORMATION Information regarding the source and verification of the patients immune compromise. 0,n90451-7IMMUNE COMPROMISE INFORMATION, CAUSE This conveys the cause of the patient's immune compromise. DIS Disease TRP Transplant MED Medical Intervention NA Not Applicable CE1,nHL7907290452-7IMMUNE COMPROMISE INFORMATION, VERIFIED BY This identifies the laboratory procedure used to verify immune compromise. CD4 CD4 Count ANC ANC Count WBC White Blood Cell Count CE0,nHL7907390460-7Co-morbid Conditon Information Information regarding the presence of other conditions as factor in the existence and treatment of the fungal infection. 0,1 90461-7Co-morbid Conditon Information, LIVER DYSFUNCTION Indicator This provides information regarding the presence of liver dysfunction as factor in the continuation and treatment of the fungal infection.. N No Y Yes 0,1HL7013690462-7Co-morbid Conditon Information, LIVER DYSFUNCTION - CONFIRMED BY This defines the tests used to verify the liver dysfunction. See section 5 for the list of valid codes. CE1,1HL7907490463-7Co-morbid Conditon Information, LIVER DYSFUNCTION COMFIRMED BY OTHER Description of test used to confirm Liver Dysfunction. Required when the response to Co-morbid Condition Information, Liver Dysfunction - Confirmed By equals "OTH" Other. TX0,1 90464-7Comorbid Conditon Information, MEDICARE ESRD CERTIFICATION - Indicator This provides information regarding the presence of End Stage Renal Disease as factor in the continuation and treatment of the fungal infection, based on Medicare ESRD certification. Y Yes N No CE1,1H7013690070-xMEDICARE ESRD CERTIFICATION DATE Date patient was certified by Medicare as having End Stage Renal Disease 0,190070-x. DT1,190470-7LEVEL OF FUNCTIONAL IMPAIRMENT This conveys functional limitations resulting from or exacerbating the fungal infection. 0,190470-7 See section 5 for the list of valid codes. CE1,n HL7907590480-7INPATIENT TREATMENT Information Required if the patient is being discharged from an inpatient hospital stay during which anti-fungal treatment was administered.0,190481-7INPATIENT TREATMENT Information, IV Anti-Fungal Therapy Indicator Indicator to define whether IV Anti-fungal therapy was provided during the admission. N No Y Yes CE1,1HL7013690482-7INPATIENT TREATMENT Information, IV Anti-Fungal Therapy Agent(s) Name of the IV Therapy Agents given during the hospital stay. TX0,190080-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS Information about other drugs previously prescribed for treatment of this condition with less than optimal outcomes. 0,n90081-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG NAME This is the descriptive name of the drug previously used to treat the diagnosis.TX1,190082-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG CODE The code assigned to the drug previously used to treat the diagnosis as defined by: Representative NDC, RxNorm SCD or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD90083-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DURATION OF THERAPY Duration of previous therapy in days. NM1,1iso+90084-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON(S) PRIOR THERAPY DISCONTINUED This is the reason that the prior drug therapy was discontinued. NTEFF Not or No Longer Effective SDEFT Side Effects/Tolerance NTCMP Not Compatible OTH Other CE1,1HL7904090085-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS, REASON PRIOR THERAPY DISCONTINUED OTHER Description of the other reason for discontinued therapy. If Drug History, Prior Therapy for Diagnosis - Reason Prior Therapy Discontinued equals "OTH" Other, then this is required. TX0,190086-xDRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - INCOMPATIBLE DRUG NAME The descriptive name of the drug(s) incompatible with the prior therapy. If Drug History, Prior Therapy for Diagnosis - Reason Prior Therapy Discontinued equals "NTCMP" Not Compatible, then this is required. TX 0,n90490-7IMIDAZOLE-RELATED ANTIFUNGALS, PRIOR THERAPY TYPE The route of the previously used medication for treatment of the fungal infection.  90490-7IMIDAZOLE-RELATED ANTIFUNGALS, PRIOR THERAPY TYPE Type of drug therapy previously used for treatment of the fungal infection. ORL Oral TOP Topical INJ Injectible IV Intravenous CE 0,1HL79076 90090-xCONCURRENT THERAPY Drugs the patient is currently on, for this or other diagnoses, which may impact the requested drug. 0,n90091-xCONCURRENT THERAPY, DRUG NAME This is the descriptive name of the drugs) the patient is currently on, for this or other diagnoses, which might impact the requested drug. TX0,190092-xCONCURRENT THERAPY, DRUG CODE The code assigned to the concurrent drug as defined by: Representative NDC, RxNorm SCD, or RxNorm SBD CE1,1NDC RxNorm SCD RxNorm SBD Coding Examples Scenario Sara J. Smith is a 50 year old female receiving care for hepatic dysfunction and a persistent fungal infection of her right foot. She returned to her physician, Robert J Podell, MD, a Hepatologist (Taxonomy 207RI0008X) for a follow-up evaluation on 12/28/2005. Ms. Smiths medical record number is 184569 The findings at this time revealed that the medication, Tinactin Cream, had not proved effective in controlling the Tenea Pedis infection. Because of her diminished liver function Ms. Smith is unable to take a systemic anti-fungal medication, so Dr. Podell decides to order Oxistat Cream, 1%, 60 gram tube (NDC-0173-0423-04) as a replacement therapy. Ms. Smith has medical and drug coverage through Aetna Insurance, Plan ID 10567432.Her Aetna patient ID is 352584768003G. The Plans drug benefit is administered by ReadiRx PBM. On checking the Plan formulary, Dr. Podell finds that Oxistat Cream is a covered benefit requiring prior authorization. Using the Plans Antifungal PA Attachment and criteria for coverage of coverage of Oxistat Cream, he reviews Ms. Smiths medical record to assure that she meets the criteria and to collect the information needed for the request. Dr. Podells Aetna provider ID is 4376557IM. The following information was collected from the medical record. The diagnosis requiring the use of the ordered drug is 110.4 - Tinea Pedis. This diagnosis was confirmed by KOH Preparation performed on 9/15/2004. The use of a topical drug is required because of Liver Dysfucntion as confirmed by a 7/15/2004 Hepatic Function Panel. The fungal infection is located between the toes of her right foot and at this point is not causing or impacted by any function limitations. The previous treatment which proved ineffective, was with Tinactin Cream, NDC-0085-0715-07. The request associated with this CDA document is identified by the value XA728302 as its attachment control number. This is used for linking purposes within the 278 and 275. Figure 4.1 Drug Prior Authorization Additional Data PRESCRIBER NAME Podell MD, Robert J PRESCRIBER IDENTIFIER 4376557IM PRESCRIBER TAXONOMY 207RI0008X PRESCRIBER CONTACT PHONE # 765-228-1234 PRESCRIBER CONTACT FAX # 765-228-3123 DRUG PRESCRIBED, NAME (TEXT) Oxistat, Cream, 1%, 60-g tube DRUG PRESCRIBED, DRUG CODE 0173-0423-04 DRUG PRESCRIBED, THERAPY TYPE Replacement (RPLRQ) DRUG PRESCRIBED, REASON FOR Hepatic Dysfunction (HDS) TOPICAL THERAPY RELATED DIAGNOSIS (TEXT) Tinea Pedia RELATED DIAGNOSIS (CODE) 110.4 RELATED DIAGNOSIS CONFIRMED BY KOH Preparation (KOH) INFECTION LOCATION Between toes, right foot (OTH) LIVER DYSFUNCTION INDICATOR Yes (Y) LIVER DYSFUNTION CONFIRMED BY Hepatic Function Panel (HFP) MEDICARE ESRD CERTIFICATION Yes (Y) INDICATOR PRIOR THERAPY, DRUG NAME Tinactin, Cream PRIOR THERAPY, DRUG CODE 0085-0715-07 PRIOR THERAPY, DURATION 90 days PRIOR THERAPY, RREASON PRIOR Not or no longer effective (NTEFF) THERAPY DISCONTINUED PRIOR THERAPY, TYPE Topical (TOP) Drug Prior Authorization Attachment, Human-Decision Variant (XML body) The right column of the example below contains the single HL7 document in the human-decision variant that conveys this report in its entirety. The left column provides help in relating the example to the scenario and to the Value Table. Example 4.1.1 Drug Prior Authorization Attachment, Human-Decision Variant (XML body) Header Provider Identification Patient Identification Attachment Control Number Prescriber Information (Name, Identifier and Taxonomy)
Robert J. Podell, MD 4376557IM Hepatologist (207RI0008X)Prescriber Contact Information (phone and fax numbers)
(765) 228-1234 (765) 228-3123Drug Prescribed Information (Name of Drug, Drug Code and Therapy Type)
Oxistat Cream, 1%, 60g tube 0173-0423-04 (NDC) Replacement (RPLRQ)Drug Prescribed, Reason for Topical Therapy
Hepatic Dysfunction (HDS) Related Diagnosis Information (Diagnosis Description and Code and how the diagnosis was confirmed)
Tinea Pedia (ICD-9-CM 110.4) KOH Preparation (KOH) Fungal Infection Location
Between Toes, right foot (OTH) Liver Dysfunction Information (Indicator and how it was confirmed)
yes (Y) Hepatic Function Panel (HFP) Medicare ESRD Certification Indicator
Yes (Y) Drug History, Prior Therapy for Diagnosis (Prior Therapy Drug Name, Code, Duration, and Reason for Discontinuance)
Tinactin Cream 0085-0715-07 (NDC) 90 days Not or no longer effective (NTEFF)Prior Therapy Type
Topical (TOP)  Figure 1 shows the human-decision variant (XML body) as rendered by a popular browser. Figure 1. Rendered Human-Decision Variant (XML body) Drug Prior Authorization Attachment Provider:Robert J Podell, MDPatient:Sara J SmithProvider's Pt ID:352584768003GAttachment Control Number:XA728302 PRESCRIBER INFORMATION PRESCRIBER INFORMATION, NAME. Robert J. Podell, MD PRESCRIBER INFORMATION, IDENTIFIER. 4376557IM PRESCRIBER INFORMATION, SPECIALTY TAXONOMY. Hepatologist (207RI0008X) PRESCRIBER CONTACT INFORMATION PRESCRIBER CONTACT INFORMATION, PHONE NUMBER. (765) 228-1234 PRESCRIBER CONTACT INFORMATION, FAX NUMBER. (765) 228-3123 DRUG PRESCRIBED DRUG PRESCRIBED, NAME. Oxistat Cream, 1%, 60g tube DRUG PRESCRIBED, DRUG CODE. 0173-0423-04 (NDC) DRUG PRESCRIBED, THERAPY TYPE. Replacement (RPLRQ) DRUG PRESCRIBED, REASON FOR TOPICAL THERAPY Hepatic Dysfunction (HDS) IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS. Tinea Pedia (ICD-9-CM 110.4) IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS - CONFIRMED BY. KOH Preparation (KOH) FUNGAL INFECTION LOCATION Between Toes, right foot (OTH) CO-MORBID CONDITION INFORMATION CO-MORBID CONDITION INFORMATION, LIVER DYSFUNCTION INDICATOR. yes (Y) CO-MORBID CONDITION INFORMATION, LIVER DYSFUNCTION CONFIRMED BY. Hepatic Function Panel (HFP) MEDICARE ESRD CERTIFICATION INDICATOR Yes (Y) DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG NAME. Tinactin Cream DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG CODE. 0085-0715-07 (NDC) DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DURATION OF THERAPY. 90 days DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED. Not or no longer effective (NTEFF) IMIDAZOLE-RELATION ANTIFUNGALS, PRIOR THERAPY TYPE Topical (TOP) Drug Prior Authorization Attachment, Human-Decision Variant (non-XML body) The right column of the example below contains the single HL7 Additional Information CDA document in the human-decision variant that conveys this report in its entirety. The left column provides help in relating the example to the scenario and to the Value Table. Example 4.1.2 Drug Prior Authorization Attachment, Human-Decision Variant (non-XML body) Header Provider Identification Patient Identification Attachment Control Number MIME Reference for Antifungal Report Base64 Encoded Antifungal Report (this is an example of a portion of the MIME packaging) --192.168.0.132.1.111780.1044168570.525.24086 Content-Type: image/tif Content-Transfer-Encoding: base64 Content-Disposition: attachment; filename=Antifungal report.tif R0lGODlhAAJ9AfAAAP///wAAACwAAAAAAAJ9AUAC/wQShrqcb06SrNITm57bTvqB0dWRUMal nmqubkuib0lDyHIrYz2zPPzDZUbEou5oJNpiuVPDIXngptIqkIP5aFesq2eIDGLDPhksiU47 nsVbiOqeotjtnPp+f8a17FAFTrez95Yid6FkZ4e24cdocSiIJzlJWWl5WekWNVjot9kUZ8YZ tfmpF/q5VmWFmRl4xBkrO6topNmKm6u7y9vr+/u7J+k5WVure5wJlhTafKuICrwGBkhrfS2c (Editors note: 149 lines have been suppressed for readability.) SmW6Sr0UTL2M5ut4yN5k7soG7vici6fc6QHbTh+khPZMrOHMrvfaCpkaUNm0rvTUBcSEJ6cQ o+wwjU0oJrAQ74fqZ+jewudY7N5KEOPm6rVEcMoOqbVaD/1ubkQyba+eiRj0TwZ/LteWkAmt Yf8QcMwmRGuCkAajRZjSYm+ojQq30FL6zu24EAzrJ8XCkAzl4fTKEA3TUA3XkA3b0A3fEA7j 0C0IAAUAOw== --192.168.0.132.1.111780.1044168570.525.24086 Figure 2 shows the human-decision variant (non-XML body) as rendered by a popular browser. Figure 2. Rendered Human-Decision Variant (non-XML body) Imidazol-Related Antifungals Attachment Provider:Robert J Podell, MDPatient:Sara J SmithProvider's Pt ID:352584768003GAttachment Control Number:XA728302  HYPERLINK "file:///D:\\Documents%20and%20Settings\\bzdtfz\\Local%20Settings\\Temp\\prescription-glasses.gif" Click here to view report.  Coded Drug Prior Authorization Attachment, Computer-Decision Variant The right column of the example below contains the single HL7 Additional Information CDA document in the computer-decision variant that conveys this report in its entirety. The left column provides help in relating the example to the scenario and to the Value Table. Example 4.1.2 Drug Prior Authorization Attachment, Computer-Decision Variant Header Provider Identification Patient Identification Attachment Control Number Prescriber Information (Name, Identifier and Taxonomy)
Robert J. Podell, MD ROBERT J PODELL MD 4376557IM 207RI0008X Hepatologist Prescriber Contact Information (phone and fax numbers)
(765)228-1234 (765)228-3123Drug Prescribed Information (Name of Drug, Drug Code and Therapy Type)
Oxistat Cream, 1%, 60g tube 0173-0423-04 Oxistat Cream, 1%, 60g tube Replacement (RPLRQ) Drug Prescribed, Reason for Topical Therapy
Hepatic Dynsfunction (HDS) Related Diagnosis Information (Diagnosis Description and Code and how the diagnosis was confirmed)
Tinea Pedia 110.4 (ICD-9-CM) KOH Preparation (KOH) Fungal Infection Location
Between toes, right foot Co-Morbid Condition Information (Liver Dysfunction) (Indicator and how it was confirmed)
Yes (Y) Hepatic Function Panel (HFP) Medicare ESRD Certification Indicator
Yes (Y) Drug History, Prior Therapy for Diagnosis (Prior Therapy Drug Name, Code, Duration, and Reason for Discontinuance)
Tinactin Cream 0085-0715-07 (NDC) 90 days 90 Not or no longer effective (NTEFF) Prior Therapy Type
Topical (TOP)  Figure 3 shows a portion of the computer-decision variant as rendered by a popular browser. It includes the medications rendered as a table. Figure 3. Rendered Human-Decision Variant (non-XML body) Imidazol-Related Antifungals Attachment Provider:Robert J Podell, MDPatient:Sara J SmithProvider's Pt ID:352584768003GAttachment Control Number:XA728302 PRESCRIBER INFORMATION PRESCRIBER INFORMATION, NAME. Robert J. Podell, MD PRESCRIBER INFORMATION, IDENTIFIER. 4376557IM PRESCRIBER INFORMATION, SPECIALTY TAXONOMY. 207RI0008X Hepatologist PRESCRIBER CONTACT INFORMATION PRESCRIBER CONTACT INFORMATION, PHONE NUMBER. (765)228-1234 PRESCRIBER CONTACT INFORMATION, FAX NUMBER. (765)228-3123 DRUG PRESCRIBED DRUG PRESCRIBED, NAME. Oxistat Cream, 1%, 60g tube DRUG PRESCRIBED, DRUG CODE. 0173-0423-04 Oxistat Cream, 1%, 60g tube DRUG PRESCRIBED, THERAPY TYPE. Replacement (RPLRQ) DRUG PRESCRIBED, REASON FOR TOPICAL THERAPY Hepatic Dynsfunction (HDS) IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS. Tinea Pedia 110.4 (ICD-9-CM) IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS - CONFIRMED BY. KOH Preparation (KOH) FUNGAL INFECTION LOCATION - OTHER Between toes, right foot CO-MORBID INFORMATION CO-MORBID INFORMATION, LIVER DYSFUNCTION INDICATOR. Yes (Y) CO-MORBID INFORMATION, LIVER DYSFUNCTION CONFIRMED BY. Hepatic Function Panel (HFP) MEDICARE ESRD CERTIFICATION INDICATOR Yes (Y) DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG NAME. Tinactin Cream DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG CODE. 0085-0715-07 (NDC) DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DURATION OF THERAPY. 90 days DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED. Not or no longer effective (NTEFF) DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED Topical (TOP) Response Code Sets This section describes response codes that may be used in the computer-decision variant when the value table indicates a coded with exception (CE) data type or to represent units when the attachment component is of the numeric (NM) data type. The entry in the value table that refers to these code sets is used in the subsection titles. The values for some code sets appear directly in this document. In other cases, the section cites another document as the source. HL70136: Yes-No Indicator The OID for this table is 2.16.840.1.113883.12.136. Table 5.1 Yes-No Indicator CodeDescriptionAdditional CommentsNNoYYesHL79038: Drug Prescribed, Therapy Type The OID for this table is 2.16.840.1.113883.12.9038. Table 5.2 Drug Prescribed, Therapy Type CodeDescriptionAdditional CommentsINTRQInitial TherapyCNTRQContinued TherapyRPLRQReplacement TherapyADDRQAdd-on TherapyHL79039: UTC, Diagnosis Confirmed By The OID for this table is 2.16.840.1.113883.12.9039. Table 5.3 UTC, Diagnosis Confirmed By CodeDescriptionAdditional CommentsLABTLaboratory ExaminationRADTRadiological ExaminationOTDXOther Diagnostic ExaminationCLNEClinical EvaluationHL79040: Reason Prior Therapy Discontinued The OID for this table is 2.16.840.1.113883.12.9040. Table 5.4 Reason Prior Therapy Discontinued CodeDescriptionAdditional CommentsNTEFFNot or No Longer EffectiveSDEFTSide Effects/ToleranceNTCMPNot CompatibleNot compatible with other required drugs.OTHOtherIf used, then Reason Prior Therapy Discontinued Other must be completedHL79041: NSAIDS/PPI Related Concurrent Therapy, Type The OID for this table is 2.16.840.1.113883.12.9041. Table 5.5 NSAIDS COX 2 Inhibitors, Concurrent Therapy - Type CodeDescriptionAdditional CommentsCRTCCorticosteroidANCGAnti-coagulantANPLAnti-plateletPPIProton Pump InhibitorH2RAH2 Receptor AntagonistNSADNSAIDSBPHNBiphosphonateANNPAnti-neoplasticFAPFor Familial Adenomatous PolposisASALASA<325mg/dayASAGASA>325mg/dayOTHOtherIf used, then Drug History, Other Drug Type must be completed.HL79042: NSAID Use, Duration The OID for this table is 2.16.840.1.113883.12.9042. Table 5.6 NSAID Use, Duration CodeDescriptionAdditional CommentsG21NSAID Use greater than 21 daysL21NSAID Use less than 21 daysHL79043: Yes-No-Unknown Indicator The OID for this table is 2.16.840.1.113883.12.9043. Table 5.7 HL7 NSAID Use, Duration CodeDescriptionAdditional CommentsYYesNNoUUnknown HL79044: Radiology Diagnosis Confirmation, Study Type The OID for this table is 2.16.840.1.113883.12.9044. Table 5.8 Radiology Diagnosis Confirmation, Study Type CodeDescriptionAdditional CommentsBAEBone AgeBDYBone DensityMRIMagnetic Resonance Imaging (MRI)ESXX-Ray to Determine Epiphyseal StatusHL79045: Laboratory Diagnosis Confirmation, Study/Test The OID for this table is 2.16.840.1.113883.12.9045. Table 5.9 Laboratory Diagnosis Confirmation, Study/Test CodeDescriptionAdditional CommentsIGB3IGFBP3IGF1IGF1ITTInsulin ToleranceACTHACTHTSHTSHLIPLipid LevelGHACombined GHRH and Arginine If ITT contraindicated.GTPGonadotropinFTSTFree TestosteroneGTGenetic TestingOTHOtherIf used, then Laboratory Diagnosis Confirmation Information, Other Study/Test Name must be used.HL79046: GH, Patient History Documented Onset The OID for this table is 2.16.840.1.113883.12.9046. Table 5.10 GH, Patient History Documented Onset CodeDescriptionAdditional CommentsAOAdult OnsetCOChildhood OnsetUOUnknown OnsetHL79047: GH, Patient History Information Hypothalmic Pituitary Disease Induced By The OID for this table is 2.16.840.1.113883.12.9047. Table 5.11 GH, Patient History Information Hypothalmic Pituitary Disease Induced By CodeDescriptionAdditional CommentsPTTPituitary TumorIRRIrradiationSUGSurgeryHMNHormone Dysfunction or TherapyTRATraumaHL79048: Treatment Status The OID for this table is 2.16.840.1.113883.12.9048. Table 5.12 Treatment Status CodeDescriptionAdditional CommentsATIn Progress/Active TreatmentITInitial Course of TreatmentCPCompletedPTPreviously TreatedNTNew Course of TreatmentPLPlannedHL79049: GHD Childhood Information, Puberty Status The OID for this table is 2.16.840.1.113883.12.9049. Table 5.13 GHD Childhood Information, Puberty Status CodeDescriptionAdditional CommentsBPPre-pubertalAPPost PubertalPSPubertalHL79050: GH Dysfunction Adult Information, Secondary Causes The OID for this table is 2.16.840.1.113883.12.9050. Table 5.14 GH Dysfunction Adult Information, Secondary Causes CodeDescriptionAdditional CommentsAAgeOObesityDDepressionOOtherIf used, then Secondary Causes Other must be completed.HL79051: Nutritional Information, Assessment Indicator The OID for this table is 2.16.840.1.113883.12.9051. Table 5.15 Nutritional Information, Assessment Indicator CodeDescriptionAdditional CommentsCMPCompletedPLDPlannedHL79052: Parental Height, Availability Indicator The OID for this table is 2.16.840.1.113883.12.9052. Table 5.16 Parental Height, Availability Indicator CodeDescriptionAdditional CommentsMKMother KnownFKFather KnownBKBoth KnownBUBoth UnknownHL79053: Diagnosis Confirmation and Level of Treatment Needed, Procedure Employed The OID for this table is 2.16.840.1.113883.12.9053. Table 5.17 Diagnosis Confirmation and Level Treatment Needed, Procedure Employed CodeDescriptionAdditional CommentsBMSBarium StudiesEGDEndoscopyBIOBiopsyHL79054: Diagnosis Confirmation and Level of Treatment Needed, GERD By Endoscopy Type The OID for this table is 2.16.840.1.113883.12.9054. Table 5.18 Diagnosis Confirmation and Level of Treatment Needed, GERD By Endoscopy Type CodeDescriptionAdditional CommentsERSV1Erosive Grade 1ERSV2Erosive Grade 2ERSV3Erosive Grade 3ERSV4Erosive Grade 4NERSVNon ErosiveHL79055: H-Pylori Information, Status The OID for this table is 2.16.840.1.113883.12.9055. Table 5.19 H-Pylori Information, Status CodeDescriptionAdditional CommentsPSPositiveNENegativeHL79056: H-Pylori Information, Confirmed By The OID for this table is 2.16.840.1.113883.12.9056. Table 5.20 H-Pylori Information, Confirmed By CodeDescriptionAdditional CommentsSROLSerologyURBTUrease Breath TestFSGSFeasting Serum GastrinB1HABasal 1 Hour Acid OutputSCSTSecretion Simulation TestOTHOtherIf used, then H-Pylori Information Confirmed by Other is required.HL79057: ED, Related Diagnosis Confirmation, Confirmed By The OID for this table is 2.16.840.1.113883.12.9057. Table 5.21 ED, Related Diagnosis Confirmation, Confirmed By CodeDescriptionAdditional CommentsTSTTertosterone LevelPRLProlactin LevelTHYThyroid LevelNANot ApplicableOTHOther TestIf used, then ED, Related Diagnosis Confirmation, Confirmed By Other is required.HL79058: ED, Patient History Pulmonary Hypertension Functional Level The OID for this table is 2.16.840.1.113883.12.9058. Table 5.22 ED, Patient History Pulmonary Hypertension Functional Level CodeDescriptionAdditional CommentsC1Class IC2Class IIC3Class IIIC4Class IVHL79059: ED, Patient History Evaluation Type The OID for this table is 2.16.840.1.113883.12.9059. Table 5.23 ED, Patient History Evaluation Type CodeDescriptionAdditional CommentsGHGeneral Health Status EvaluationUCInvestigation of Underlying Causes of Primary ConditionNANot ApplicableHL79060: ED, Patient History ED Related To The OID for this table is 2.16.840.1.113883.12.9060. Table 5.24 ED, Patient History ED Related To CodeDescriptionAdditional CommentsENDEndocrine DisorderURSUrogenital SurgerySPCSpinal Cord InjuryTSCTesticular Cancer PSGPsychogenicHL79061: ED, Treatment of Related Causes Psychogenic Causes of ED Treatment The OID for this table is 2.16.840.1.113883.12.9061. Table 5.25 ED, Treatment of Related Causes Psychogenic Causes of ED Treatment CodeDescriptionAdditional CommentsPSYPsychotherapyBHTBehavior TherapyOTTOther TherapyNOTNo TreatmentHL79062: ED, Treatment of Related Causes Drug Induced Option The OID for this table is 2.16.840.1.113883.12.9062. Table 5.26 ED, Treatment of Related Causes Drug Induced Option CodeDescriptionAdditional CommentsRDUReduction in Drug UseDCTDiscontinue Drug UseCGDChange DrugDCNDrug Cannot be Change or DiscontinuedHL79063: ED Concurrent Therapy, Type The OID for this table is 2.16.840.1.113883.12.9063. Table 5.27 ED Concurrent Therapy, Type CodeDescriptionAdditional CommentsNTTNitrateAPBAlpha-BlockerSRISSRIPGNProstaglandin for PPHETAEndothelium for PAHVDPVasodilator for PAHOEDOther ED MedicationIf used, then ED Concurrent Therapy, Other Type is required.HL79064: Narcotic (Opioid) Agonists, Patient History Pain Syndrome Source The OID for this table is 2.16.840.1.113883.12.9064. Table 5.28 Narcotic (Opioid) Agonists, Patient History Pain Syndrome Source CodeDescriptionAdditional CommentsBPNBone PainJPNJoint PainMSTOther Somatic Pain (Muscle./Soft Tissue)VPNVisceral PainNPNNeuropathic PainOTHOther Pain SyndromeIf used, then Pain Syndrome Other is required.HL79065: Narcotic (Opioid) Agonists, Patient History Pain Syndrome History The OID for this table is 2.16.840.1.113883.12.9065. Table 5.29 Narcotic (Opioid) Agonists, Patient History Pain Syndrome History CodeDescriptionAdditional CommentsCPConstant PainITPIntermittent PainICPIncidental PainHL79066: Narcotic (Opioid) Agonists, Patient History Pain Syndrome Persistence The OID for this table is 2.16.840.1.113883.12.9066. Table 5.30 Narcotic (Opioid) Agonists, Patient History Pain Syndrome Persistance CodeDescriptionAdditional CommentsALAcute Limited Less Than 30 DaysCRChronicCRPChronic ProgressiveCPRChronic Progressive with Escalating OpioidHL79067: Narcotic (Opioid) Agonists, Complicating Conditions The OID for this table is 2.16.840.1.113883.12.9067. Table 5.31 Narcotic (Opioid) Agonists, Complicating Conditions CodeDescriptionAdditional CommentsBRABronchial AsthmaPAIParalytic IleumDiagnosed or suspected.PSYPsychiatric ConditionLDYLiver DysfunctionKDYKidney DysfunctionCRPOther Chronic Pulmonary ConditionOTHOtherIf used, then Other Complicating Conditions is requiredHL79068: Opioid Related Concurrent Pain Therapy, Opioid Level The OID for this table is 2.16.840.1.113883.12.9068. Table 5.32 Opioid Concurrent Pain Therapy, Opioid Level CodeDescriptionAdditional CommentsRDLRecommended, Dose LevelHPLHigh Potency Dose Level24L24 Hour High Potency Dose LevelOTLOpioid TolerantHL79069: Drug Prescribed, Topical Therapy - Reason The OID for this table is 2.16.840.1.113883.12.9069. Table 5.33 Drug Prescribed, Topical Therapy - Reason CodeDescriptionAdditional CommentsUTSUnable to SwallowHDSHepatic DysfunctionOTHOtherHL79070: Imidazole Related Antifungals, Diagnosis Confirmed By The OID for this table is 2.16.840.1.113883.12.9070. Table 5.34 Imidazole Related Antifungals, Diagnosis Confirmed By CodeDescriptionAdditional CommentsFCLFungal CulturePASPAS Stain ResultsKOHKOH PreparationNBPNail BiopsyOTHOtherHL79071: Fungal Infection Information, Location The OID for this table is 2.16.840.1.113883.12.9071. Table 5.35 Fungal Infection Information, Location CodeDescriptionAdditional CommentsFNFinger NailTNToe NailOTHOtherHL79072: Immune Compromise Information, Cause The OID for this table is 2.16.840.1.113883.12.9072. Table 5.36 Immune Compromise Information, Cause CodeDescriptionAdditional CommentsDISDiseaseTRPTransplantMEDMedical InterventionNANot ApplicableHL79073: Immune Compromise Information, Verified By The OID for this table is 2.16.840.1.113883.12.9073. Table 5.37 Immune Compromise Information, Verified By CodeDescriptionAdditional CommentsCD4CD4 CountANCANC CountWBCWhite Blood Cell CountHL79074: Co-Morbid Condition Information, Liver Dysfunction Confirmed By The OID for this table is 2.16.840.1.113883.12.9074. Table 5.38 Co-Morbid Condition Information, Liver Dysfunction Confirmed By CodeDescriptionAdditional CommentsHFPHepatic Function PanelTALSGPT, ALTTASSGOT, ASTOTHOtherHL79075: Level of Functional Impairment The OID for this table is 2.16.840.1.113883.12.9075. Table 5.39 Level of Functional Impairment CodeDescriptionAdditional CommentsALAmbulation LimitationsCOContracturesDY Dyspnea with Minimum ExertionELEndurance LimitationsPAPainful AmbulationHL79076: Imidazole Related Antifungals, Prior Therapy Type The OID for this table is 2.16.840.1.113883.12.9076. Table 5.40 Imidazole Related Antifungals, Prior Therapy Type CodeDescriptionAdditional CommentsORLOralTOPTopicalINJInjectibleIVIntravenousI9C : ICD-9-CM International Classification of Diseases, 9th Clinical Modification. The OID for this table is 2.16.840.1.113883.6.2. IC10: ICD-10-CM International Classification of Diseases, 10th Clinical Modification. The OID for this table is 2.16.840.1.113883.x.x. iso+: Extended ISO Units Codes ISO 2955-1983 and extensions as defined in HL7 Version 2.4 Figure 7-9. Due to its length the table is included in the HL7 Additional Information Specification Implementation Guide rather than in this Additional Information Specification. The OID for this table is 2.16.840.1.113883.6.2. NDC: National Drug Code The National Drug Code (NDC), administered by the FDA, provides a unique code for each distinct drug, dose form, manufacturer, and package. (Available from the National Drug Code Director, FDA, Rockville, MD, and other sources.) The OID for this table is 2.16.840.1.113883.5.141. RXNC: RxNorm SCD (Semantic Clinical Drug) RxNorm, a standardized nomenclature for clinical drugs, is produced by the National Library of Medicine. In this context, a clinical drug is a pharmaceutical product given to (or taken by) a patient with a therapeutic or diagnostic intent. In RxNorm, the name of a clinical drug combines its ingredients, strengths, and form. RxNorm follows a standard format in the naming of clinical drugs. Drugs named in disparate ways in various other vocabularies are normalized according to RxNorms naming conventions. RxNorm SCD includes ingredient plus strength and dose form. (Example: Fluoxetine 4 MG/ML Oral Solution). RxNorm can be obtained from the National Library of Medicine at: www.nlm.nih.gov. The OID for this table is 2.16.840.1.113883.5.x.xxx. RXNB: RxNorm SBD (Semantic Branded Drug) RxNorm, a standardized nomenclature for clinical drugs, is produced by the National Library of Medicine. In this context, a clinical drug is a pharmaceutical product given to (or taken by) a patient with a therapeutic or diagnostic intent. In RxNorm, the name of a clinical drug combines its ingredients, strengths, and form. RxNorm follows a standard format in the naming of clinical drugs. Drugs named in disparate ways in various other vocabularies are normalized according to RxNorms naming conventions. RxNorm SBD includes ingredient, strength, and dose form plus brand name. ( Example: Fluoxetine 4 MG/ML Oral Solution [Prozac]). RxNorm can be obtained from the National Library of Medicine at: www.nlm.nih.gov. The OID for this table is 2.16.840.1.113883.x.xxx. DEA: Drug Enforcement Administration [Change this description to describe the DEA Number and where to get more information on the DEA Number. See NDC] The US Drug Enforcement Administration is charged by statute the maintenance of controls against diversion of controlled substances and with the registration of all manufacturers and distributors of controlled substances and practitioners dispensing schedule III, IV or V drugs. The DEA number is assigned to practitioners meeting the criteria for dispensing, ordering and management of a patient on narcotic therapy. Further information and Application for a DEA number may be obtained at  HYPERLINK "http://www.dea.gov" www.dea.gov Special DEA: Drug Enforcement Administration The US Drug Enforcement Administration is charged by statute the maintenance of controls against diversion of controlled substances and with the registration of all manufacturers and distributors of controlled substances and practitioners dispensing schedule III, IV or V drugs. The DEA number is assigned to practitioners meeting the criteria for dispensing, ordering and management of a patient on narcotic therapy. The Drug Addiction Treatment Act of 2000 (DATA2000) allows qualified physicians to practice medication-assisted opioid addiction therapy with specifically FDA-approved Schedule III, IV or V narcotic medications. The practitioner must submit a notice of intent to the Center for Substance Abuse Treatment (CSAT) a component of the Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services. Upon approval the DEA assigns a special identification number in addition to the practitioners regular DEA number. To obtain further information contact  HYPERLINK "http://www.samhsa.gov" www.samhsa.gov and search waiver qualifications. Further information and Application for a DEA number may be obtained at  HYPERLINK "http://www.dea.gov" www.dea.gov. The OID for this table is 2.16.840.1.113883.x.xxx. HCI: HCIdea HCIdea"! is an NCPDP prescriber identity management database solution designed to address the needs of organizations wishing to identify prescribers of drugs. An NCPDP HCIdea"! Prescriber Identity Layout is available upon request. For information about obtaining the NCPDP HCIdea"! file and the current (version 1.1) file format, please contact Robin Ebert at 480-477-1000, ext. 118 or  HYPERLINK "mailto:rebert@hcidea.org" rebert@HCIdea.org Contact Information National Council of Prescription Drug Programs (NCPDP) 9240 East Raintree Drive Scottsdale, AZ 85260 (480) 477-1000 (480) 767-1042 (fax) The OID for this table is 2.16.840.1.113883.x.xxx. NPI: National Provider Identifier On January 23, 2004, the Secretary of HHS published a final rule (Federal Register volume 69, page 3434) which establishes the standard for a unique health identifier for health care providers for use in the health care system, and announces the adoption of the National Provider Identifier (NPI) as that standard. It also establishes the implementation specifications for obtaining and using the standard unique health identifier for health care providers. For more information contact the US Department of Health and Human Services, Centers for Medicare and Medicaid Services (CMS), 7500 Security Blvd., Baltimore, MD 21244 The DHHS Administrative Simplification web site is http://aspe.hhs.gov/admnsimp . The OID for this table is 2.16.840.1.113883.4.6 PTX: Health Care Provider Taxonomy The National Uniform Claim Committee (NUCC) maintains the Health Care Provider Taxonomy. The code set is available through Washington Publishing. See:  HYPERLINK "http://www.wpc-edi.com/codes/" http://www.wpc-edi.com/codes/ The OID for this table is 2.16.840.1.113883.6.101. Miscellaneous OID References This section contains a list of OID references used in the construct of the CDA header and body not otherwise noted in the above code set and table references. Unique Instance Identifier The OID 2.16.840.1.113883.3.933 is used to identify the unique instance ID for this document. person_name.type_cd OID 2.16.840.1.113883.12.200 is an object identifier for the person_name.type_cd component. Proprietary Provider ID OID 2.16.840.1.113883.12.200 is an object identifier for the person_name.type_cd component. Example OID In some instances in the example, OID 2.16.840.1.113883.19.7.xxx was used where xxx represents an author assigned number. This is used for demonstration purposes only. The actual OID for that concept will be included in the final published version of the document. --End of document--  LOINC is a registered trademark of Regenstrief Institute and the LOINC Committee. The LOINC database and LOINC Users Guide are copyright 1998-2005 Regenstrief Institute and the LOINC Committee and the LOINC database codes and names are available at no cost from  HYPERLINK "http://www.LOINC.org" http://www.LOINC.org. Regenstrief Institute, 1050 Wishard Blvd., Indianapolis, IN 46202 Email: LOINC@regenstrief.org Information on this and other X12N/HIPAA-related implementation guides is available from the Washington Publishing Company, PMB 161, 5284 Randolph Rd., Rockville, MD 20852-2116. Phone: 800-972-4334. or hyperlink "http://www.wpc-edi.com/" http://www.wpc-edi.com/  Within this Health Level Seven document, references to the transaction defined by these X12N implementation guides will be abbreviated by calling them 275 and 277.  Health Level Seven, Inc. 3300 Washtenaw Ave., Suite 227, Ann Arbor, MI 48104-4250. ( HYPERLINK "http://www.hl7.org" http://www.hl7.org)     Additional Information Specification 0010: PharmPA AttachmentCDAR1AIS0010R010 Additional Information Specification 0010: PharmPA AttachmentCDAR1AIS0010R010 Page  PAGE 48 November 2005Copyright 1998-2005 Health Level Seven, Inc. All rights reserved. Release 1.0 Draft Standard Copyright 1998-2005 Health Level Seven, Inc. All rights reserved. 8<>?CWbctwø×}qdUI;hQ7hU6mHnHuh56mHnHuhh56mHnHuhh56CJ]hQ7hU5CJ]hQ7hUCJH*hQ7hU5CJmHnHuhQ7hU5CJhQ7hUCJ,hQ7hUCJ,mHnHuhpCJ,mHnHuhQ7hU5CJ,hQ7hU5CJ(mHnHuhQ7hU5CJ(hQ7hU5CJ\hQ7hUmHnHudefghijkl$dd1$[$\$a$gdS $ d\$a$gd9dd[$\$$hdd[$\$`ha$gdcB|F   % & ' ( ) E F G H I ̽{r_QrQ7_Q2jh]uh]u>*B*UmHnHphuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHuh]umHnHuhQ7h(&&0J)mHnHu$jhQ7h(&&0J)UmHnHu hQ7hUCJOJQJ^JaJhQ7hU5CJOJQJ^JhQ7hUCJOJQJ^J hQ7hUhQ7hU5CJ\hQ7hUCJ]hQ7hU56CJh6mHnHu' x / v % B 1qRW*. $ % $ $ $ $dd1$[$\$a$gd(&&I J V W X r s t u v w x y z Ҳßݖ|iXßiݖ jwh]uUmHnHu$h]u:CJPJaJmHnHtHu2jh]uh]u>*B*UmHnHphuh]umHnHu$jhh]sh]u0J)UmHnHu j}h]uUmHnHujh]uUmHnHuh]umHnHuhh]sh]u0J)mHnHu'h]u5;CJPJaJmHnHtHu!   ) * + , - . / 0 1 M N O P S T p q r ŲŧӲ~dŲŧSӲ jkh]uUmHnHu2jh]uh]u>*B*UmHnHphuh]umHnHu jqh]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu2jh]uh]u>*B*UmHnHphu     ! " T U V p q r ߼ߩߞ~dߩߞS j_h]uUmHnHu2jh]uh]u>*B*UmHnHphu jeh]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHu2jh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu r s t u v w x  ӲӲ{j{ӲPӲ2jh]uh]u>*B*UmHnHphu jYh]uUmHnHu'h]u5;CJPJaJmHnHtHu2jh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHujh]uUmHnHuh]umHnHu    ! " # $ % & ' C D E F I J b c d ~  ¯¡~¡m¯¡S2jh]uh]u>*B*UmHnHphu jMh]uUmHnHu2jh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHu jSh]uUmHnHujh]uUmHnHuh]umHnHu     ! " < = > ? @ A B C D ` a ߘ~mߘ jA h]uUmHnHu2j h]uh]u>*B*UmHnHphuh]umHnHu jG h]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu#a b c h i +,-./012ŴũӴŀfŴũUӴ j5 h]uUmHnHu2j h]uh]u>*B*UmHnHphuh]umHnHu j; h]uUmHnHujh]uUmHnHuh]umHnHu!h]uCJPJaJmHnHtHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu2j h]uh]u>*B*UmHnHphu!23OPQRWXqrsλ񟐟e񟐟T j)h]uUmHnHu2j h]uh]u>*B*UmHnHphu j/ h]uUmHnHujh]uUmHnHuh]umHnHu!h]uCJPJaJmHnHtHu$jhh]sh]u0J)UmHnHu2j h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu #$OPQklmnopqrsݾݾ̾ݾeݾ̾2jh]uh]u>*B*UmHnHphu j#h]uUmHnHuh]umHnHu2jh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu!h]uCJPJaJmHnHtHu$jhh]sh]u0J)UmHnHujh]uUmHnHu!012LMNOPQRSTpqrst±££o±£U£2jh]uh]u>*B*UmHnHphu jh]uUmHnHu2jh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu!h]uCJPJaJmHnHtHu$jhh]sh]u0J)UmHnHuh]umHnHujh]uUmHnHu jh]uUmHnHutu567QRSTUVWXYuvҲßݖ|iXßiݖ j h]uUmHnHu$h]u:CJPJaJmHnHtHu2jh]uh]u>*B*UmHnHphuh]umHnHu$jhh]sh]u0J)UmHnHu jh]uUmHnHujh]uUmHnHuh]umHnHuhh]sh]u0J)mHnHu'h]u5;CJPJaJmHnHtHu!vwx{| #$%'()*ŲŧӲ~dŲŧSӲ jh]uUmHnHu2jh]uh]u>*B*UmHnHphuh]umHnHu jh]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu2jh]uh]u>*B*UmHnHphu *+,HIJKNOwxy ߼ߩߞ~dߩߞS jh]uUmHnHu2jvh]uh]u>*B*UmHnHphu jh]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHu2j|h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu    ,-./23XYZtuvxyz{|}ӲӲ~ӲdӲ2jjh]uh]u>*B*UmHnHphu jh]uUmHnHu2jph]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHujh]uUmHnHuh]umHnHu"{C#EmM/  B% $ . $ $ $ % $    !"<=>@ABCDEab¯¡~¡jYj¡ jh]uUmHnHu'h]u5;CJPJaJmHnHtHu2jdh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHuh]umHnHujh]uUmHnHu jh]uUmHnHubcdghpqrŲŧӲ~dSŧ!h]uCJPJaJmHnHtHu2jXh]uh]u>*B*UmHnHphuh]umHnHu jh]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu2j^h]uh]u>*B*UmHnHphu !"#$%ABCDIJ"±££o±£U£2jLh]uh]u>*B*UmHnHphu jh]uUmHnHu2jRh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu!h]uCJPJaJmHnHtHu$jhh]sh]u0J)UmHnHuh]umHnHujh]uUmHnHu jh]uUmHnHu!"#$>?@BCDEFGcdefghz{|±££l[l£ jh]uUmHnHu'h]u5;CJPJaJmHnHtHu2jFh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu!h]uCJPJaJmHnHtHu$jhh]sh]u0J)UmHnHu jh]uUmHnHujh]uUmHnHuh]umHnHu #$JKLfghjklmŲŧӲ~dŲŧSӲ j h]uUmHnHu2j: h]uh]u>*B*UmHnHphuh]umHnHu jh]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu2j@h]uh]u>*B*UmHnHphu mno*+,FGH߼ߩߞ~dߩߞS j"h]uUmHnHu2j."h]uh]u>*B*UmHnHphu j!h]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHu2j4!h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu HJKLMNOklmnqr  (ӲӲ~ӲdӲ2j"$h]uh]u>*B*UmHnHphu j#h]uUmHnHu2j(#h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHujh]uUmHnHuh]umHnHu"()*,-./01MNOPSTuvw¯¡~¡m¯¡S¡2j&h]uh]u>*B*UmHnHphu j%h]uUmHnHu2j%h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHuh]umHnHujh]uUmHnHu j$h]uUmHnHu 34569:qrs׳}l׳ j'h]uUmHnHu2j'h]uh]u>*B*UmHnHphuh]umHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHu j&h]uUmHnHujh]uUmHnHuh]umHnHuhh]sh]u0J)mHnHu     +,-.23ŲŧӲ~dŲŧSӲ j)h]uUmHnHu2j)h]uh]u>*B*UmHnHphuh]umHnHu j(h]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu2j (h]uh]u>*B*UmHnHphu     +,-.23fgh߼ߩߞ~dߩߞS ju+h]uUmHnHu2j*h]uh]u>*B*UmHnHphu j{*h]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHu2j)h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu     ,-./34klmӲӲ~ӲdӲ2j,h]uh]u>*B*UmHnHphu jo,h]uUmHnHu2j+h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHujh]uUmHnHuh]umHnHu"  &'()-.¯¡~¡m¯¡S¡2j.h]uh]u>*B*UmHnHphu jc.h]uUmHnHu2j-h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHuh]umHnHujh]uUmHnHu ji-h]uUmHnHu . !;<=?@ABCD`a׳}l׳ jW0h]uUmHnHu2j/h]uh]u>*B*UmHnHphuh]umHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHu j]/h]uUmHnHujh]uUmHnHuh]umHnHuhh]sh]u0J)mHnHu abcgh    ! # $ % & ŲŧӲ~dŲŧSӲ jK2h]uUmHnHu2j1h]uh]u>*B*UmHnHphuh]umHnHu jQ1h]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu2j0h]uh]u>*B*UmHnHphu B& 9!!'""F##I$$y%%&''(|(())**4+++m,,% $ & ' ( D E F G K L !!!2!3!4!߼ߩߞ~dߩߞS j?4h]uUmHnHu2j3h]uh]u>*B*UmHnHphu jE3h]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHu2j2h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu 4!6!7!8!9!:!;!W!X!Y!Z!^!_!!!!!!!!!!!!!!!!!!!""" "ӲӲ~ӲdӲ2j5h]uh]u>*B*UmHnHphu j95h]uUmHnHu2j4h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHujh]uUmHnHuh]umHnHu" "!"""$"%"&"'"(")"E"F"G"H"L"M"""""""""""""""""""¯¡~¡m¯¡S¡2j7h]uh]u>*B*UmHnHphu j-7h]uUmHnHu2j6h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHuh]umHnHujh]uUmHnHu j36h]uUmHnHu "##$#%#?#@#A#C#D#E#F#G#H#d#e#f#g#k#l###############׳}l׳ j!9h]uUmHnHu2j8h]uh]u>*B*UmHnHphuh]umHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHu j'8h]uUmHnHujh]uUmHnHuh]umHnHuhh]sh]u0J)mHnHu #####&$'$($B$C$D$F$G$H$I$J$K$g$h$i$j$n$o$$$$$$$$$$$ŲŧӲ~dŲŧSӲ j;h]uUmHnHu2j:h]uh]u>*B*UmHnHphuh]umHnHu j:h]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu2j9h]uh]u>*B*UmHnHphu $$$$$$%%%V%W%X%r%s%t%v%w%x%y%z%{%%%%%%%%%%%%%߼ߩߞ~dߩߞS j =h]uUmHnHu2j<h]uh]u>*B*UmHnHphu j<h]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHu2j;h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu %%%%%&&&&& &$&%&c&d&e&&&&&&&&&&&&&&&&&&&&ӲӲ~ӲdӲ2j>h]uh]u>*B*UmHnHphu j>h]uUmHnHu2j=h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHujh]uUmHnHuh]umHnHu"&&&&''''' '!'"'#'''('i'j'k''''''''''''''''¯¡~¡m¯¡S¡2jt@h]uh]u>*B*UmHnHphu j?h]uUmHnHu2jz?h]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHuh]umHnHujh]uUmHnHu j>h]uUmHnHu ''''''(((((((#($(%(&(*(+(Y(Z([(u(v(w(y(z({(|(}(~(((׳}mm\׳ jAh]uUmHnHuhh]sh]u0J)mHnHsH u2jnAh]uh]u>*B*UmHnHphuh]umHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHu j@h]uUmHnHujh]uUmHnHuh]umHnHuhh]sh]u0J)mHnHu ((((((((((((((((())))))j)k)l))))))))ŲŧӲ~dŲŧSӲ jCh]uUmHnHu2jbCh]uh]u>*B*UmHnHphuh]umHnHu jBh]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu2jhBh]uh]u>*B*UmHnHphu ))))))))))))))))))))*****#*$*a*b*c*}*~**߼ߩߞ~dߩߞS jEh]uUmHnHu2jVEh]uh]u>*B*UmHnHphu jDh]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHu2j\Dh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu *****************************+++++-+ӲӲ~ӲdӲ2jJGh]uh]u>*B*UmHnHphu jFh]uUmHnHu2jPFh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHujh]uUmHnHuh]umHnHu"-+.+/+1+2+3+4+5+6+R+S+T+U+Y+Z+x+y+z++++++++++++++++¯¡~¡m¯¡S¡2j>Ih]uh]u>*B*UmHnHphu jHh]uUmHnHu2jDHh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHuh]umHnHujh]uUmHnHu jGh]uUmHnHu +++++++++++++,,,, ,!,J,K,L,f,g,h,j,k,l,m,n,o,,,׳}l׳ jJh]uUmHnHu2j8Jh]uh]u>*B*UmHnHphuh]umHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHu jIh]uUmHnHujh]uUmHnHuh]umHnHuhh]sh]u0J)mHnHu ,,,,,,,,,,,,,,,,,,,,,--(-)-*-D-E-F-H-I-J-K-ŲŧӲ~dŲŧSӲ jLh]uUmHnHu2j,Lh]uh]u>*B*UmHnHphuh]umHnHu jKh]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu2j2Kh]uh]u>*B*UmHnHphu ,K-- .t..>///T0V0X0u0%11\22c33v445 6|66T7, $ $dda$gd>.x. $ % $ K-L-M-i-j-k-l-p-q-|-}-~-------------------...߼ߩߞ~dߩߞS jNh]uUmHnHu2j Nh]uh]u>*B*UmHnHphu jMh]uUmHnHujh]uUmHnHuh]umHnHu$h]u:CJPJaJmHnHtHu2j&Mh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$jhh]sh]u0J)UmHnHu .... . . .'.(.).*.../.Q.R.S.m.n.o.q.r.s.t.u.v...........ӲӲ~ӲdӲ2jPh]uh]u>*B*UmHnHphu jOh]uUmHnHu2jOh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHujh]uUmHnHuh]umHnHu"............./////7/8/9/;//?/@/\/]/¯¡~¡m\m¡ jQh]uUmHnHu!h]uCJPJaJmHnHtHu2jQh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu$h]u:CJPJaJmHnHtHu$jhh]sh]u0J)UmHnHuh]umHnHujh]uUmHnHu jPh]uUmHnHu]/^/_/e/f/y/z/{////////////////////wӰӢnT2jSh]uh]u>*B*UmHnHphuh]umHnHu jRh]uUmHnHujh]uUmHnHuh]umHnHuhh]sh]u0J)mHnHu!h]uCJPJaJmHnHtHu#hh]sh]u0J)^JmHnHtHu$jhh]sh]u0J)UmHnHu2jRh]uh]u>*B*UmHnHphu////////00000%0&0102030M0N0O0Q0R0S0T0U0±£n]±J$jhQ7h(&&0J)UmHnHu jyTh]uUmHnHu#hh]sh]u0J)^JmHnHtHu2jSh]uh]u>*B*UmHnHphuh]umHnHuhh]sh]u0J)mHnHu!h]uCJPJaJmHnHtHu$jhh]sh]u0J)UmHnHuh]umHnHujh]uUmHnHu jSh]uUmHnHuU0V0X0Y0u0v0000000001111 1!1"1#1$1˸f[L[;L[L jsUh]uUmHnHujh]uUmHnHuh]umHnHu2jTh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHuhQ7h-*0J)mHnHu$jhQ7h-*0J)UmHnHuhQ7hU5CJOJQJhQ7h-*5CJOJQJ hQ7hU"hQ7hU:CJaJmHnHu$1%1&1'1C1D1E1F11111111111111111:2;2<2V2W2X2Y2Z2[2ͪ͟e͟T jgWh]uUmHnHu2jVh]uh]u>*B*UmHnHphu jmVh]uUmHnHujh]uUmHnHuh]umHnHu2jUh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu [2\2]2^2z2{2|2}22222222222223333A3B3C3]3^3_3`3a3b3ͪ͟e͟T j[Yh]uUmHnHu2jXh]uh]u>*B*UmHnHphu jaXh]uUmHnHujh]uUmHnHuh]umHnHu2jWh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu b3c3d3e33333333333333333 4 4 44T4U4V4p4q4r4s4t4u4ͪ͟e͟T jO[h]uUmHnHu2jZh]uh]u>*B*UmHnHphu jUZh]uUmHnHujh]uUmHnHuh]umHnHu2jYh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu u4v4w4x444444444444444445555`5a5b5|5}5~5555ͪ͟e͟T jC]h]uUmHnHu2j\h]uh]u>*B*UmHnHphu jI\h]uUmHnHujh]uUmHnHuh]umHnHu2j[h]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu 5555555555566666 6 6 6 6(6)6*6+6Y6Z6[6u6v6w6y6z6{6ͪ͟e͟T j7_h]uUmHnHu2j^h]uh]u>*B*UmHnHphu j=^h]uUmHnHujh]uUmHnHuh]umHnHu2j]h]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu {6|6}6~666666666666666667777172737M7N7O7Q7R7S7ͪ͟e͟T j+ah]uUmHnHu2j`h]uh]u>*B*UmHnHphu j1`h]uUmHnHujh]uUmHnHuh]umHnHu2j_h]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu S7T7U7V7r7s7t7u7777777777777777788858687898:8;8ͪ͟e͟T jch]uUmHnHu2jbh]uh]u>*B*UmHnHphu j%bh]uUmHnHujh]uUmHnHuh]umHnHu2jah]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu T77<88,99<::T;;`<<)==>>>K??@@@NAA%BB"CC,DD2E, $ ;8<8=8>8Z8[8\8]88888888888888888 9 9 9%9&9'9)9*9+9ͪ͟e͟T jeh]uUmHnHu2jdh]uh]u>*B*UmHnHphu jdh]uUmHnHujh]uUmHnHuh]umHnHu2jch]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu +9,9-9.9J9K9L9M99999999999999999:::5:6:7:9:::;:ͪ͟e͟T jgh]uUmHnHu2jfh]uh]u>*B*UmHnHphu j fh]uUmHnHujh]uUmHnHuh]umHnHu2jeh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu ;:<:=:>:Z:[:\:]:::::::::::::::::1;2;3;M;N;O;Q;R;S;ͪ͟e͟T jhh]uUmHnHu2j~hh]uh]u>*B*UmHnHphu jhh]uUmHnHujh]uUmHnHuh]umHnHu2jgh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu S;T;U;V;r;s;t;u;;;;;;;;;;;;;<<<<=<><?<Y<Z<[<]<^<_<ͪ͟e͟T jjh]uUmHnHu2jrjh]uh]u>*B*UmHnHphu jih]uUmHnHujh]uUmHnHuh]umHnHu2jxih]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu _<`<a<b<~<<<<<<<<<<<<<<<<<<<<==="=#=$=&='=(=ͪ͟e͟T jlh]uUmHnHu2jflh]uh]u>*B*UmHnHphu jkh]uUmHnHujh]uUmHnHuh]umHnHu2jlkh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu (=)=*=+=G=H=I=J=p=q=r=====================>>ͪ͟e͟T jnh]uUmHnHu2jZnh]uh]u>*B*UmHnHphu jmh]uUmHnHujh]uUmHnHuh]umHnHu2j`mh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu >>>> >!>">#>a>b>c>}>~>>>>>>>>>>>>>>>>>>>>>ͪ͟e͟T jph]uUmHnHu2jNph]uh]u>*B*UmHnHphu joh]uUmHnHujh]uUmHnHuh]umHnHu2jToh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu >>>>????(?)?*?D?E?F?H?I?J?K?L?M?i?j?k?l??????????ͪ͟e͟T jrh]uUmHnHu2jBrh]uh]u>*B*UmHnHphu jqh]uUmHnHujh]uUmHnHuh]umHnHu2jHqh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu ????????@@@9@:@;@=@>@?@@@A@B@^@_@`@a@@@@@@@@@@ͪ͟e͟T jth]uUmHnHu2j6th]uh]u>*B*UmHnHphu jsh]uUmHnHujh]uUmHnHuh]umHnHu2j*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu @@@@@@@@+A,A-AGAHAIAKALAMANAOAPAlAmAnAoAAAAAAAAAAͪ͟e͟T jvh]uUmHnHu2j*vh]uh]u>*B*UmHnHphu juh]uUmHnHujh]uUmHnHuh]umHnHu2j0uh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu AAAAAAAABBBBB B"B#B$B%B&B'BCBDBEBFBBBBBBBBBBͪ͟e͟T jxh]uUmHnHu2jxh]uh]u>*B*UmHnHphu jwh]uUmHnHujh]uUmHnHuh]umHnHu2j$wh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu BBBBBBBBBCCCCCC C!C"C#C$C@CACBCCCuCvCwCCCCCCCͪ͟e͟T jzh]uUmHnHu2jzh]uh]u>*B*UmHnHphu jyh]uUmHnHujh]uUmHnHuh]umHnHu2jyh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu CCCCCCCC D D D%D&D'D)D*D+D,D-D.DJDKDLDMDDDDDDDDDDͪ͟e͟T j|h]uUmHnHu2j|h]uh]u>*B*UmHnHphu j{h]uUmHnHujh]uUmHnHuh]umHnHu2j {h]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu DDDDDDDDEEE+E,E-E/E0E1E2E3E4EPEQERESEEEEEEEEEEͪ͟e͟T jw~h]uUmHnHu2j}h]uh]u>*B*UmHnHphu j}}h]uUmHnHujh]uUmHnHuh]umHnHu2j}h]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu 2EE"FF"GG'HHII8JJPKKCLL>MM*NN'OOOOOOOgdRs $dda$gd>., $ EEEEEEEEEFFFFFF F!F"F#F$F@FAFBFCFFFFFFFFFFͪ͟e͟T jkh]uUmHnHu2jh]uh]u>*B*UmHnHphu jqh]uUmHnHujh]uUmHnHuh]umHnHu2j~h]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu FFFFFFFFFGGGGGG G!G"G#G$G@GAGBGCGqGrGsGGGGGGGͪ͟e͟T j_h]uUmHnHu2jh]uh]u>*B*UmHnHphu jeh]uUmHnHujh]uUmHnHuh]umHnHu2jh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu GGGGGGGGHHH H!H"H$H%H&H'H(H)HEHFHGHHHHHHHHHHHHͪ͟e͟T jSh]uUmHnHu2jփh]uh]u>*B*UmHnHphu jYh]uUmHnHujh]uUmHnHuh]umHnHu2j܂h]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu HHHHHHHHHHHIIIIIIIII3I4I5I6IIIIIIIIIIͪ͟e͟T jGh]uUmHnHu2jʅh]uh]u>*B*UmHnHphu jMh]uUmHnHujh]uUmHnHuh]umHnHu2jЄh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu IIIIIIIIJJJ1J2J3J5J6J7J8J9J:JVJWJXJYJJJJJJJJJJͪ͟e͟T j;h]uUmHnHu2jh]uh]u>*B*UmHnHphu jAh]uUmHnHujh]uUmHnHuh]umHnHu2jĆh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu JJJJJJJJ-K.K/KIKJKKKMKNKOKPKQKRKnKoKpKqKKKKKKKKKKͪ͟e͟T j/h]uUmHnHu2jh]uh]u>*B*UmHnHphu j5h]uUmHnHujh]uUmHnHuh]umHnHu2jh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu KKKKKKKK L!L"LL@LALBLCLDLELaLbLcLdLLLLLLLLLLͪ͟e͟T j#h]uUmHnHu2jh]uh]u>*B*UmHnHphu j)h]uUmHnHujh]uUmHnHuh]umHnHu2jh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHu LLLLLLLLMMM7M8M9M;MM?M@M\M]M^M_MMMMMͪ͟eUhh]u0J)mHnHsH u2jh]uh]u>*B*UmHnHphu jh]uUmHnHujh]uUmHnHuh]umHnHu2jh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu$jhh]u0J)UmHnHu!h]uCJPJaJmHnHtHuMMMMMMMMMMMMMNN N#N$N%N'N(N)N*N+N,NHNINJNKNNNNN±££o±£U£2jh]uh]u>*B*UmHnHphu jh]uUmHnHu2jh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu!h]uCJPJaJmHnHtHu$jhh]u0J)UmHnHuh]umHnHujh]uUmHnHu jh]uUmHnHu NNNNNNNNNNNNNOOO O!O"O$O%O&O'O(O)OEOFOGOHOOOOO±££o±£U£2jh]uh]u>*B*UmHnHphu jh]uUmHnHu2jh]uh]u>*B*UmHnHphuh]umHnHuhh]u0J)mHnHu!h]uCJPJaJmHnHtHu$jhh]u0J)UmHnHuh]umHnHujh]uUmHnHu j h]uUmHnHu OOOOOOOOOOOOOOPPPPPPQQQSQ±~pi\iSGiGi?iGi?hQ7hU6hQ7hUmHnHuhpmHnHujhQ7hU0J'U hQ7hUhQ7hU5CJOJQJhQ7hUCJaJmHnHuhQ7h-*CJaJmHnHu$jhQ7h-*0J)UmHnHu!h]uCJPJaJmHnHtHu$jhh]u0J)UmHnHuh]umHnHujh]uUmHnHu jh]uUmHnHuOAPQRSS3WXY]ZwZZ3[[L\\\\\\$$$$If^a$ $$$If+$$ & FgdF/t dd[$\$gd<  ^$a$gdIW, & FgdF/t$a$gdgSQTQQQQQtRRRSQSSS~SST*hQ7hU5hQ7hU6aJhQ7hUaJhmHnHuh hQ7hUhQ7hU6hph]6hphU63ibzb{bbbbbb`TK $$$If $$$$Ifa$kd™$$Ifl40$ t"P 04 lap $$$If$$$bbbbx &$$$If $$$$Ifa$qkd$$Ifl0$ t"P04 labbbbx &$$$If $$$$Ifa$qkd($$Ifl0$ t"P04 labbbbx &$$$If $$$$Ifa$qkd$$Ifl0$ t"P04 labbbbx &$$$If $$$$Ifa$qkdV$$Ifl0$ t"P04 labbbbx &$$$If $$$$Ifa$qkd$$Ifl0$ t"P04 labbbccldse1fghhhj'm{{y & FgdF/t$a$gdgqkd$$Ifl0$ t"P04 la 'm3mNmmnnopr ss&s$$& #$/Ifa$b$gd$& #$/Ifb$gd$f+ dd[$\$gdB$dd[$\$a$gdB mmmmnQnUninTooooopppp\qq)r*rKrrrrrrrr's,s-s.s/sisjskspsqsrsssssssssssssssssssss½½½½븰hQ7hUCJOJQJhhQ7hRsh hF/thhQ7hUh h#$.h hF/t5hF/thF/t5hUhQ7hU6hQ7hUmHnHuhmHnHu hQ7hU hy%hU hy%hi:&s's/sjsr^$& #$/Ifb$gd$f$$& #$/Ifa$b$gd$fukd$$IfT40pnP  6 4 ae4pTjskssssz$& #$/Ifb$gd$f$$& #$/Ifa$b$gd$fYkd۞$$IfT0pnP 6 4 ae4Tssssz$& #$/Ifb$gd$f$$& #$/Ifa$b$gd$fYkd]$$IfT0pnP 6 4 ae4Tssssz$& #$/Ifb$gd$f$$& #$/Ifa$b$gd$fYkdߟ$$IfT0pnP 6 4 ae4Tssstz$& #$/Ifb$gd$f$$& #$/Ifa$b$gd$fYkda$$IfT0pnP 6 4 ae4Tssssttttttt(t.t/t0tCtDtEtJtKtLtMtwtxtyttu,vEvFvGvvv$w%w4x8xLxyyzzI{M{a{w{{{ ||#|û÷ÝÖÍÖûÍÖÁÁhQ7hUmHnHuhmHnHu hQ7hRs hQ7h\h@ZhUB*phh =B*phhphQ7hU6 hQ7hUhQ7h-h hR4h h#$.hhQ7hUCJOJQJhhQ7hRsh hF/thhQ7hUh2tttDtz$& #$/Ifb$gd$f$$& #$/Ifa$b$gd$fYkd$$IfT0pnP 6 4 ae4TDtEtMtxtz$& #$/Ifb$gd$f$$& #$/Ifa$b$gd$fYkde$$IfT0pnP 6 4 ae4Txtytzttv,vGvbvwvy{|y||z $1$Ifgd@+1$gd$f$1$gd$f$a$gdg Ykd$$IfT0pnP 6 4 ae4T #|8|g|h|n|y|||||||||||}}}}}4}5}:};}<}Y}Z}_}`}a}b}}}óБxxxl]l]hQ7hiB*CJhphhiB*CJhphhQ7hITNCJhhQ7hITNB*CJhphhF/tB*CJhph*hQ7hU5B*CJhmHnHphuhQ7hU5B*CJhphh#$.5B*CJhphhQ7hUCJhhQ7hUB*CJhphhihQ7hUmHnHu hQ7hU!|||||xx $1$Ifgd@mkdi$$IfT(440L"t 64 (af4pT $$1$Ifa$gdRs|||}v$If^`gdITN $$Ifa$gdITNlkdK$$IfT(40L"t 64 (af4pT}} }4}z$If^`gdITN $$Ifa$gdITNhkd$$If(40# 64 (af4p4}5}=}Y}z$If^`gdITN $$Ifa$gdITNhkd$$If(40# 64 (af4pY}Z}b}}z$If^`gdITN $$Ifa$gdITNhkdP$$If(40# 64 (af4p}}}}z$If^`gdITN $$Ifa$gdITNhkd$$If(40# 64 (af4p}}}}}}}}}}}}}}}}}}}}~~~ ~!~X~Y~^~_~`~~~~~~~~~οڵښڵڵڵxnhQ7hUCJhhQ7hUB*CJhph hQ7hUhQ7hUmHnHuh?hB*CJhphhQ7hiB*CJhphhQ7hITNCJhhQ7hWd!B*CJhphhiB*CJhphhQ7hITNB*CJhphhF/tB*CJhphhQ7hiCJh'}}}}z$If^`gdITN $$Ifa$gdITNhkd$$If(40# 64 (af4p}}}~z$If^`gdITN $$Ifa$gdITNhkdH$$If(40# 64 (af4p~~"~X~z$If^`gdITN $$Ifa$gdITNhkd$$If(40# 64 (af4pX~Y~a~~z$If^`gdITN $$Ifa$gdITNhkd$$If(40# 64 (af4p~~~~~oX$$& #$/Ifa$b$gdQ$& #$/Ifb$gdQ +$^a$gd:$1$gd$fhkd@$$If(40# 64 (af4p -tt$& #$/Ifb$gdQvkd$$If(440n#"t  6 4 (ae4f4p !-.356XYZ_ab#$%*,-KLM¶¶¶¶zn¶¶hiB*CJhphhQ7hWd!B*CJhphhQ7hgWB*CJhphhQ7hUB*CJhphhQ7hRsB*CJhphh#$.B*CJhphhQ7hUCJh*hQ7hU5B*CJhmHnHphuhQ7hU5B*CJhphh#$.5B*CJhph+-.6YsW$& #$/If^`b$gdQ$$& #$/Ifa$b$gdQukd$$If(40n#"t  6 4 (ae4f4pYZbuY$& #$/If^`b$gdQ$$& #$/Ifa$b$gdQskd$$If(40n#"t  6 4 (ae4f4puY$& #$/If^`b$gdQ$$& #$/Ifa$b$gdQskdd$$If(40n#"t  6 4 (ae4f4puY$& #$/If^`b$gdQ$$& #$/Ifa$b$gdQskd$$If(40n#"t  6 4 (ae4f4p$uY$& #$/If^`b$gdQ$$& #$/Ifa$b$gdQskd֭$$If(40n#"t  6 4 (ae4f4p$%-LuY$& #$/If^`b$gdQ$$& #$/Ifa$b$gdQskd$$If(40n#"t  6 4 (ae4f4pLMUuY$& #$/If^`b$gdQ$$& #$/Ifa$b$gdQskdH$$If(40n#"t  6 4 (ae4f4pMRSTUȀ̀ !/{n^H*hQ7hU5B*CJhmHnHphuhQ7hU5B*CJhphh#$.5B*CJhphhi hQ7hUhQ7hUmHnHuhQ7hUCJhQ7hUCJhhQ7hUB*CJhphhQ7hgWB*CJhphhQ7hCCJhhQ7hCB*CJhphhoB*CJhphhCB*CJhphh#$.B*CJhphuY$& #$/If^`b$gdQ$$& #$/Ifa$b$gdQskd$$If(40n#"t  6 4 (ae4f4p€ |vm $$Ifa$$If +$^a$gd:skd$$If(40n#"t  6 4 (ae4f4p!;$Ifmkds$$IfT(440D%t t"4 (af4pT/;<AghmƁǁȁɁˁ́ށ߁$%*+,-fghmnopٴ٥ٙxٙٙhxٙٙhxhiB*CJhmH phsH hihiCJhmH sH $hihiB*CJhmH phsH hiB*CJhphhQ7hUB*CJhphhE_B*CJhphhQ7hE_CJhhQ7hE_B*CJhphh#$.B*CJhphhQ7hUCJhhQ7hU5B*CJhph&;<Dgv$If^`gdE_ $$Ifa$gdE_lkdZ$$IfT(40D%t t"4 (af4pTghpv$If^`gdE_ $$Ifa$gdE_lkd$$IfT(40D%t t"4 (af4pTv$If^`gdE_ $$Ifa$gdE_lkd$$IfT(40D%t t"4 (af4pTɁ߁y$If^`gd1 $$Ifa$lkdl$$IfT(40D%t t"4 (af4pT߁$y$If^`gd1 $$Ifa$lkd$$IfT(40D%t t"4 (af4pT$%-gy$If^`gd1 $$Ifa$lkdĵ$$IfT(40D%t t"4 (af4pTghpy$If^`gd1 $$Ifa$lkdp$$IfT(40D%t t"4 (af4pT˂y$If^`gd1 $$Ifa$lkd$$IfT(40D%t t"4 (af4pTʂ˂̂т҂ӂԂ 12389:;GR^_`efghyzŃƃǃ̃̓΃σ*+,123ٷٷٷٷٷٷhiB*CJhphhihCJaJhhB*CJhphhQ7hUCJhhE_B*CJhphhQ7hUB*CJhphh#$.B*CJhphh^B*CJhph>˂̂Ԃy$If^`gd1 $$Ifa$lkdȷ$$IfT(40D%t t"4 (af4pT 2y$If^`gd1 $$Ifa$lkdt$$IfT(40D%t t"4 (af4pT23;_y$If^`gd1 $$Ifa$lkd $$IfT(40D%t t"4 (af4pT_`hy$If^`gd1 $$Ifa$lkd̹$$IfT(40D%t t"4 (af4pTƃy$If^`gd1 $$Ifa$lkdx$$IfT(40D%t t"4 (af4pTƃǃσy$If^`gd1 $$Ifa$lkd$$$IfT(40D%t t"4 (af4pT+y$If^`gd1 $$Ifa$lkdл$$IfT(40D%t t"4 (af4pT+,4Py$If^`gd1 $$Ifa$lkd|$$IfT(40D%t t"4 (af4pT34OPQVXYprτ#:;BCYeflۮۊzdz*hQ7hU5B*CJhmHnHphuhQ7hU5B*CJhphh#$.5B*CJhphhi hQ7hUhQ7hUmHnHuhQ7hUCJhAi'B*CJhphh^B*CJhphh#$.B*CJhphhQ7hUCJhhB*CJhphhQ7hUB*CJhph%PQYy$If^`gd1 $$Ifa$lkd($$IfT(40D%t t"4 (af4pTy$If^`gd1 $$Ifa$lkdԽ$$IfT(40D%t t"4 (af4pTۄ#.:}t $$Ifa$$If +$8^8a$gd:lkd$$IfT(40D%t t"4 (af4pT:;Ce$Ifkkd,$$If(440D%t t"4 (af4pefnx$If^`gd4 $$Ifa$gd4jkd$$If(40D%t t"4 (af4plŅƅ˅ GTUZ[\]ņƆˆ'(ϴϴϏÅyjyjhQ7hCB*CJhphhCB*CJhphhQ7hiCJhhQ7hiB*CJhphhQ7hTCJhhTB*CJhphhQ7hTB*CJhphhiB*CJhphhoB*CJhphh#$.B*CJhphhQ7h4CJhhQ7h4B*CJhph(Ņz$If^`gd4 $$Ifa$gd4hkd$$If(40D%t t"4 (af4pŅƅ΅z$If^`gd4 $$Ifa$gd4hkdu$$If(40D%t t"4 (af4p z$If^`gd4 $$Ifa$gd4hkd$$If(40D% t"4 (af4p Tz$If^`gdT $$Ifa$gdThkd$$If(40D% t"4 (af4pTU]z$If^`gdT $$Ifa$gdThkdm$$If(40D% t"4 (af4pņz$If^`gd4 $$Ifa$gd4hkd$$If(40D% t"4 (af4pņƆΆz$If^`gd4 $$Ifa$gd4hkd$$If(40D% t"4 (af4p(z$If^`gd4 $$Ifa$gd4hkde$$If(40D% t"4 (af4p()1R}$If^`gd1 $$Ifa$hkd $$If(40D% t"4 (af4p()./01:EQRSXYZ[yz{|ȇ ڿ˵˵ˁtdtThQ7hU5B*CJhphhQ7hRs5B*CJhphho5B*CJhphhQ7hUB*CJhph hQ7hUh{;mHnHuhQ7hUmHnHuhQ7hUCJhQ7hUCJhhihMCJaJhhQ7hUB*CJhphhQ7h4B*CJhphhoB*CJhphhQ7hCCJh RS[z}$If^`gd1 $$Ifa$hkd$$If(40D%t t"4 (af4pz{|x $$Ifa$$If +$8^8a$gd:hkd]$$If(40D%t t"4 (af4p6$Ifkkd$$If(440D%t t"4 (af4p*67<bchˆÈĈƈȈوڈۈ$%&STYZ[\^{ʾzznhB*CJhphhQ7h{;B*hphhQ7h{;B*CJhphh{;B*CJhphhQ7hWd!B*hphhQ7hWd!B*CJhphhoB*CJhphhQ7hU5B*CJhphhQ7hU5B*CJhph*hQ7hU5B*CJhmHnHphu&67?bx$If^`gd f $$Ifa$gd fjkd$$If(40D%t t"4 (af4pbckz$If^`gd f $$Ifa$gd fhkd$$If(40D%t t"4 (af4pz$If^`gd f $$Ifa$gd fhkdN$$If(40D%t t"4 (af4pĈڈz$If^`gd f $$Ifa$gd fhkd$$If(40D%t t"4 (af4pڈۈz$If^`gd f $$Ifa$gd fhkd$$If(40D%t t"4 (af4p'Sz$If^`gd f $$Ifa$gd fhkdF$$If(40D%t t"4 (af4pST\z$If^`gd f $$Ifa$gd fhkd$$If(40D%t t"4 (af4p{|ljȉ͉!"#$,5>PUj{̱pg]Pho5B*CJhphhQ7hUCJhhQ7hUCJhQ7hUB*CJhph hQ7hUhMmHnHuhQ7hUmHnHuhQ7hUCJhQ7hQB*hphhQ7hQB*CJhphhQB*CJhphhoB*CJhphhQ7hWd!B*hphhQ7hWd!B*CJhphhAi'B*CJhphljz$If^`gd f $$Ifa$gd fhkd$$If(40D%t t"4 (af4pljȉЉz$If^`gd f $$Ifa$gd fhkd>$$If(40D%t t"4 (af4p"z$If^`gd f $$Ifa$gd fhkd$$If(40D%t t"4 (af4p"#$Js\$$& #$/Ifa$b$gd@$& #$/Ifb$gd@ +$^a$gd:hkd$$If(40D%t t"4 (af4p͊rr$& #$/Ifb$gd@xkd6$$IfT(440P8"x  6 4 (ae4f4pT̊͊Ίӊ-.3RSXYZ[µ«ҡ|||papaWhQ7hCJhhQ7hB*CJhphhB*CJhphhQ7hrCJhhQ7hrB*CJhphhoB*CJhphhQ7hUCJhhQ7hU5CJhM5CJmHnHuhQ7hU5CJmHnHuhQ7hU5B*CJhphho5B*CJhphhQ7hRs5B*CJhph͊Ί֊q`$If^`gd f$$& #$/Ifa$b$gd@wkd.$$IfT(40P8"x  6 4 (ae4f4pT-q`$If^`gd f$$& #$/Ifa$b$gd@wkd$$IfT(40"F  6 4 (ae4f4pT-.6Rq`$If^`gd f$$& #$/Ifa$b$gd@wkd$$IfT(40"F  6 4 (ae4f4pTRS[q`$If^`gd f$$& #$/Ifa$b$gd@wkds$$IfT(40"F  6 4 (ae4f4pTʋq`$If^`gd f$$& #$/Ifa$b$gd@wkd0$$IfT(40"F  6 4 (ae4f4pTʋˋЋыҋӋ %&'(O[ghmΌόԌՌ֌׌ STUϴêϒσwmhQ7hCCJhhQB*CJhphhQ7hCB*CJhphhCB*CJhphhB*CJhphhQ7hCJhhQ7hB*CJhphhB*CJhphhoB*CJhphhQ7hrCJhhQ7hrB*CJhphhTB*CJhph)ʋˋӋq`h$If^h`gd$$& #$/Ifa$b$gd@wkd$$IfT(40"F  6 4 (ae4f4pT (gq`$If^`gd f$$& #$/Ifa$b$gd@wkd$$IfT(40"F  6 4 (ae4f4pTghpq`$If^`gd f$$& #$/Ifa$b$gd@wkdg$$IfT(40"F  6 4 (ae4f4pTΌq`$If^`gd f$$& #$/Ifa$b$gd@wkd$$$IfT(40"F  6 4 (ae4f4pTΌό׌ q`$If^`gd f$$& #$/Ifa$b$gd@wkd$$IfT(40"F  6 4 (ae4f4pT Tq`h$If^h`gd$$& #$/Ifa$b$gd@wkd$$IfT(40"F  6 4 (ae4f4pTTUV̍׍xri $$Ifa$$If +$8^8a$gd:wkd[$$IfT(40"F  6 4 (ae4f4pTUVu̍ CDIwx}Ҏӎ؎َڎ˾ˌ}s}s}s}}g}s}}[hOB*CJhphhTB*CJhphhQ7hrCJhhQ7hrB*CJhphhoB*CJhph*hQ7hU5B*CJhmHnHphuhQ7hU5B*CJhphho5B*CJhphhQ7hUCJhhQ7hUB*CJhph hQ7hUhQ7hUmHnHuhQ7hUCJ#$Ifkkd$$If(440D%t t"4 (af4p Cx$If^`gdr $$Ifa$gdrjkd$$If(40D%t t"4 (af4pCDLwz$If^`gdr $$Ifa$gdrhkd$$If(40D%t t"4 (af4pwxz$If^`gdr $$Ifa$gdrhkda$$If(40D%t t"4 (af4pҎz$If^`gdr $$Ifa$gdrhkd $$If(40D%t t"4 (af4pҎӎێ&z,$If^,`gdAi' $$Ifa$gdrhkd$$If(40D%t t"4 (af4p &',-.@KXY^_`.:GHMϫt#hQ7hm ;B*CJaJhphhm ;B*CJaJhphh#$.B*CJhphhQ7h?hCJhh?hB*CJhphhTB*CJhphhoB*CJhphhQ7hrCJhhAi'B*CJhphhB*CJhphhQ7hrB*CJhph-&'/Xz$If^`gdr $$Ifa$gdrhkdY$$If(40D%t t"4 (af4pXYaz$If^`gdr $$Ifa$gdrhkd$$If(40D%t t"4 (af4pz$If^`gdr $$Ifa$gdrhkd$$If(40D%t t"4 (af4pɏz$If^`gdr $$Ifa$gdrhkdQ$$If(40D%t t"4 (af4pz$If^`gdr $$Ifa$gdrhkd$$If(40D%t t"4 (af4pGz$If^`gdr $$Ifa$gdrhkd$$If(40D%t t"4 (af4pGHPz$If^`gdr $$Ifa$gdrhkdI$$If(40D%t t"4 (af4pÐz$If^`gdr $$Ifa$gdrhkd$$If(40D%t t"4 (af4pÐĐɐ̐֐א256erٷ|ujaUuQuUuUuhghQ7hUmHnHuhQ7hUaJhQ7hUCJaJ hQ7hUhhQ7hrCJhhOhOB*CJhphhOhrB*CJhphhQ7hrB*CJhphhQ7hTCJhhTB*CJhphhOB*CJhphhQ7hTB*CJhphh^B*CJhphhoB*CJhphÐĐ̐z$If^`gdr $$Ifa$gdrhkd$$If(40D%t t"4 (af4p&'Tēxoooboo ^gdBgdB$^a$gdBgdB$a$gdBhkdA$$If(40D%t t"4 (af4p ē,r}Ŕ $$1$Ifa$+gdB rĔƔ͔&+!ȸsdssXhITNB*CJhphhQ7ho!B*CJhphhQ7haB*CJhphhQ7h 'B*CJhphhy%B*CJhphh B*CJhphhQ7hITNB*CJhphhQ7hITN5B*CJhphh 5B*CJhph#hQ7hU5CJOJQJ^JaJ/hQ7hU5B*CJOJQJ^JaJhphŔƔΔ;0000 $1$Ifgd5Hkd$$IfH44r0p$P@ 2$(4 Ha(f4p2 $%&.K_Q>>P$1$If^`Pgd5H $$1$Ifa$gd5Hkd$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5HL> $$1$Ifa$gd5Hkd$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5HP$1$If^`Pgd5HDEHLst $$1$Ifa$gd5H $1$Ifgd5H $1$Ifgd ' xj___QQ_ $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5Hkd$$IfH4r0$P@$4 Ha(f4$Fuw|ٙ=BΚ| ŹŹ⃹tdUhsXhJmB*CJhphhQ7hJm5B*CJhphhQ7hJmB*CJhphhsXB*CJhphhy%B*CJhphhQ7h6B*CJhphhQ7hwB*CJhphh B*CJhphhQ7hITN5B*CJhphh 5B*CJhphhQ7hITNB*CJhphhQ7hy%B*CJhph!'Fxmmmm__m $$1$Ifa$gd5H $1$Ifgd5Hkd7$$IfH4r0$P@$4 Ha(f4xbWWWIIW $$1$Ifa$gd5H $1$Ifgd5H$P$1$If^`Pa$gd5Hkd$$IfH4r0$P@$4 Ha(f4 6mnquvxj___QQ_ $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5Hkd$$IfH4r0$P@$4 Ha(f4vwؙٙڙޙߙxmmmm__m $$1$Ifa$gd5H $1$Ifgd5HkdV$$IfH4r0$P@$4 Ha(f4ߙ347;<xj___QQ_ $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5Hkd $$IfH4r0$P@$4 Ha(f4<=E`њҚ՚ٚxj___QQ_ $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5Hkd$$IfH4r0$P@$4 Ha(f4}xi]]]]OO $$1$Ifa$gd5H $$$Ifgd5H$$$$Ifa$gd5Hkdu$$IfH4r0$P@$4 Ha(f4BmaUUUIU $$$Ifgdy% $$$Ifgds $$$Ifgd5Hkd*$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5HɜƷƨƌ||l|]|]Q]Q]|Ah}EvhP5B*CJhphh B*CJhphh}Evhy%B*CJhphh}Evhg5B*CJhphh}Evhy%5B*CJhphh 5B*CJhphhIhJmB*CJhphhIhIB*CJhphhQ7hJmB*CJhphhQ7hJm5B*CJhphhJmB*CJhphhsXhJmB*CJhphhsXhy%B*CJhphɜSGG $$$Ifgd} $kd$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $$$Ifgdy%Skd$$IfH4r0$P@$4 Ha(f4 $$1$Ifa$gd} $ $1$Ifgd} $ $$$Ifgd} $ ՝ %&'(Ĵ}qbVGV7hQ7hK5B*CJhphhQ7hKB*CJhphh B*CJhphhQ7hITNB*CJhphhOB*CJhphhP5B*CJhphhg5B*CJhphhQ7hITN5B*CJhphh 5B*CJhphhQ7hy%5B*CJhphhQ7hy%B*CJhphhy%hy%B*CJhphh}Evh}EvB*CJhphh}Evhy%B*CJhph_SSSS $$$Ifgd5HkdI$$IfH4r0$P@$4 Ha(f4 $1$Ifgd} $ $$1$Ifa$gd} $ (?_PDD $$$IfgdK$$$$Ifa$gdKkd$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H(+?l%+9QRS]^bcejk巨rbVG;h B*CJhphhQ7hy%B*CJhphhKB*CJhphhQ7hP/5B*CJhphhE_hrWB*CJhphhE_B*CJhphhy%B*CJhphh}Evhy%B*CJhphhE_h^7B*CJhphhQ7hK5B*CJhphhQ7h^7B*CJhphhQ7hrWB*CJhphhQ7hKB*CJhphhgB*CJhphRSVZ^cdHkd$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $1$IfgdK $$$Ifgd5Hklmpsuvw|}ɺɮɺɮueVeIh 5B*CJhphh}Evh}EvB*CJhphh}Evh]JC5B*CJhphh}EvhgB*CJhphh}Evh]JCB*CJhphhQ7hsXB*CJhphhKB*CJhphhy%B*CJhphhQ7h|>B*CJhphhQ7hKB*CJhphhgB*CJhphhQ7hK5B*CJhphh B*CJhphdm9\vwz~ $1$Ifgd5H $$1$Ifa$gd5H $1$IfgdK $$$IfgdK$$$$Ifa$gdK ɠxi]]QF $1$IfgdK $$$IfgdK $$$Ifgd]JC$$$$Ifa$gdKkdh$$IfH4r0$P@$4 Ha(f4Huv_SGGG $$$IfgdK $$$Ifgd5Hkd$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H"$.H*tuv{|}κκwgXLXL=h}Evho!B*CJhphh B*CJhphh}Evhw$B*CJhphh}Evhw$5B*CJhphh}EvhPB*CJhph#h}EvhP;B*CJaJhph h}EvhgB*CJaJhph h}EvhPB*CJaJhph&h}EvhP5;B*CJaJhph&h}Evhg5;B*CJaJhphh 5B*CJhphh}EvhP5B*CJhphvw{|}עTH< $$$IfgdK $$$Ifgd5Hkd$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $1$IfgdKǢɢ֢ע/0235689RWXYZ]_jv۷whwXLLwh B*CJhphh}Evho!5B*CJhphh}Evh]JCB*CJhphh}Evho!B*CJhphh}EvhdB*CJhph h}EvhD&B*CJaJhph h}Evhw$B*CJaJhph#h}Evho!;B*CJaJhph#h}EvhP;B*CJaJhph#h}Evhw$;B*CJaJhph#h}Evhg;B*CJaJhphע/03789Hkd$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $1$IfgdK $$$IfgdK9Znorv{ $1$Ifgd5H $$1$Ifa$gd5H $1$IfgdK $$$IfgdK $$$Ifgdw$ $$$Ifgd5Hܣlmnoqrtuvz{̮̟̽~n~_P_PP@_h}Evho!5B*CJhphh}Evho!B*CJhphh}EvhdB*CJhphh}EvhD&5B*CJhphh}Evhg5B*CJhph h}EvhgB*CJaJhphh}EvhgB*CJhphh}Evh]JCB*CJhphh}EvhD&B*CJhphh}EvhSB*CJhph#h}Evhd;B*CJaJhph#h}Evhw$;B*CJaJhph!xl`TTI $1$IfgdK $$$IfgdK $$$Ifgdw$ $$$Ifgd5Hkd<$$IfH4r0$P@$4 Ha(f4ʤѤڤ !$%&IJĠĠp`pQBhQ7ho!B*CJhphh]JCho!B*CJhphh}EvhD&5B*CJhphh}Evh]JCB*CJhphh}EvhSB*CJhph#h}Evhd;B*CJaJhph#h}Evh]JC;B*CJaJhph#h}Evhw$;B*CJaJhph#h}Evhg;B*CJaJhphh}Evho!B*CJhphh}EvhdB*CJhphh B*CJhph!%&'/P_SGGG $$$IfgdK $$$Ifgd5Hkd$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H&',-.P]¥ѥҥҶҘҌҘqaQahQ7hP5B*CJhphhQ7hITN5B*CJhphhghKB*CJhphh?hB*CJhphh B*CJhphhQ7hKB*CJhphhsXhKB*CJhphhsXhPB*CJhphh?h5B*CJhphhQ7hK5B*CJhphh 5B*CJhphhQ7ho!5B*CJhphTE9 $$$IfgdK$$$$Ifa$gdKkd$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $1$IfgdKťH< $$$Ifgd5Hkd[$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $1$IfgdK $$$IfgdKťefgklmSkd$$IfH4r0$P@$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $$$Ifgd5HfmrǦ <?IgǧȧΧ"%:FO_񙊙{l]]hQ7h9B*CJhphhQ7h FB*CJhphhQ7hP/B*CJhphhQ7h)]B*CJhphhQ7hWd!B*CJhphhQ7hNB*CJhphhQ7hB*CJhphhQ7hPB*CJhphh B*CJhphhQ7hITN5B*CJhphhQ7hITNB*CJhph$mu Fkd$$IfH4r0$P@$4 Ha(f4 $$1$Ifa$gd5H $1$IfgdWd! $1$Ifgd5H $$1$Ifa$gd5H IΧϧҧ֧Fkdz$$IfH4r0$P@$4 Ha(f4 $$1$Ifa$gd5H $1$IfgdWd! $1$Ifgd5H $$1$Ifa$gd5H:`adhmnvQkd/$$IfH4r0$P@$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5H _nsŨRSuwy~`bguŪƪʪϪЪD呁rcrTrTrrhQ7hVGiB*CJhphhQ7hP/B*CJhphhQ7h}e*B*CJhphhQ7hg5B*CJhphhQ7hgB*CJhphhgB*CJhphhDB*CJhphhQ7h9B*CJhphhQ7hB*CJhphhQ7hd %B*CJhphh B*CJhphhQ7hITNB*CJhph vŨ:Sgilpxy_kd$$IfH4r0$P@$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H yשXY\`abQkd$$IfH4r0$P@$4 Ha(f4 $$1$Ifa$gd} $ $1$Ifgd} $ $$1$Ifa$gd} $bjЪѪQkdN$$IfH4r0$P@$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5H D[ëɫͫ')0578JLĵĥyjy[O[@4hB*CJhphhghVGiB*CJhphh B*CJhphhQ7hITNB*CJhphhQ7h>B*CJhphhQ7h5HB*CJhphhQ7hITN5B*CJhphh 5B*CJhphhQ7h}e*5B*CJhphhQ7hVGiB*CJhphhQ7h}e*B*CJhphhQ7hD&B*CJhphhQ7hd %B*CJhphhQ7hP/B*CJhphë()*./08_Q $$1$Ifa$gd5Hkd$$IfH4r0$P@$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H LQUVXwԬլ֬٬ܬݬ߬)^ӵ{ocTEThQ7h&B*CJhphhQ7h9B*CJhphhB*CJhphh B*CJhphhgB*CJhphhQ7hITNB*CJhphhQ7hITN5B*CJhphhQ7hKB*CJhphhQ7hVGiB*CJhphhghAB*CJhphhghVGiB*CJhphhghKB*CJhphhghITNB*CJhph8Vլ֬٬ݬެ߬TF $$1$Ifa$gd5Hkd$$IfH4r0$P@$4 Ha(f4 $$1$Ifa$gd5H $1$IfgdK $1$Ifgd5HmnorvTRkdm$$IfH4r0$P@$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd9 $1$Ifgd5H ^am٭ 8:?AB˿saTD4hQ7hU5B*CJhphhQ7hRs5B*CJhphh 5B*CJhph#hQ7hU5CJOJQJ^JaJ)hI5B*CJOJQJ^JaJhph/hQ7hK5B*CJOJQJ^JaJhph/hQ7hU5B*CJOJQJ^JaJhph hQ7hUhQ7hUmHnHuhQ7hU5hQ7hITNB*CJhphhQ7h9B*CJhphhQ7hAB*CJhph 9 $$1$Ifa$ +$8^8a$gd:9:BY;3333$1$Ifkd"$$IfH44r0$P@ 24 Ha(f4p2BXY ,-mگߵЗЗЗyЗj[j[jyj[jjhQ7hI B*CJhphhQ7hyB*CJhphhQ7hB*CJhphhQ7hB*CJhphhQ7hUB*CJhphhQ7hRsB*CJhphh B*CJhphhQ7hMZB*CJhphhQ7hgWB*CJhphhQ7hU5B*CJhphhQ7hgW5B*CJhph#eZJJJP$1$If^`P $$1$Ifa$kdQ$$IfH4r0$P@4 Ha(f4$1$If $$1$Ifa$ -eW $$1$Ifa$gdkd$$IfH4r0$P@4 Ha(f4$1$If $$1$Ifa$ Ű8eZ $$1$Ifa$kd$$IfH4r0$P@4 Ha(f4$1$If $$1$Ifa$ İŰ԰߰ )*78Ӵә{l_OOhQ7h5B*CJhphh 5B*CJhphhQ7hD&B*CJhphhQ7hMZB*CJhphhQ7h FB*CJhphhQ7h 'B*CJhphh B*CJhphhQ7hU5B*CJhphhQ7hB*CJhphhQ7hyB*CJhphhQ7hUB*CJhphhQ7hgWB*CJhphekdp$$IfH4r0$P@4 Ha(f4$1$If $$1$Ifa$  89;Cz{}~+,abcҶ񧘉񧘉|mhQ7h FB*CJhphh 5B*CJhphhQ7hB*CJhphhQ7hB*CJhphhQ7hUB*CJhphh B*CJhphhQ7h5B*CJhphhQ7hU5B*CJhphhQ7hMZB*CJhphhQ7hB*CJhph* 9z{~xe]]]RR] $$1$Ifa$$1$If$P$1$If^`Pa$kd%$$IfH4r0$P@4 Ha(f4xjbbbWWb $$1$Ifa$$1$If $$1$Ifa$gdkd$$IfH4r0$P@4 Ha(f4abcghxmeeeZZe $$1$Ifa$$1$If $1$Ifgdkd$$IfH4r0$P@4 Ha(f4cfinpqóƳ˳ͳγ߳+:LOY_`cd}ĵĵyjyjyĵhQ7hAB*CJhphhQ7hfB*CJhphhQ7hB*CJhphhQ7hMZB*CJhphhQ7hB*CJhphhQ7hUB*CJhphhQ7h!6B*CJhphh B*CJhphhQ7hU5B*CJhphhQ7h5B*CJhph$hiqijųxjbbbWWb $$1$Ifa$$1$If $$1$Ifa$gd!6kdD$$IfH4r0$P@4 Ha(f4ųƳγ\]`d~xmeeeZZe $$1$Ifa$$1$If $$1$Ifa$kd$$IfH4r0$P@4 Ha(f4~norvxi]]]]RR $$1$Ifa$ $$$IfgdbA$$$$Ifa$gd!6kd$$IfH4r0$P@4 Ha(f4noqruvy|}ĵӦӦpapUpIphIB*CJhphh8FB*CJhphhQ7ha=eB*CJhphhQ7h8FB*CJhphh B*CJhphha=eB*CJhphhQ7hMZB*CJhphhQ7hcCB*CJhphhQ7hB*CJhphhQ7hfB*CJhphhQ7hUB*CJhphhQ7hEB*CJhphhQ7hVXB*CJhphv~paUUUUUU $$$Ifgd$%$$$$Ifa$gd$%kdc$$IfH4r0$P@4 Ha(f4$1$If Cyz_SGGG $$$IfgdbA $$$Ifgd!6kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%1BCXxyz{~²–xi¢]N]?hQ7hUB*CJhphhQ7h!6B*CJhphh B*CJhphhQ7hMZB*CJhphhQ7hcCB*CJhphhQ7h4B*CJhphhOB*CJhphhQ7hcC5B*CJhphhQ7hMZ5B*CJhphhQ7hU5B*CJhphhQ7h!65B*CJhphh 5B*CJhphhQ7h8F5B*CJhphz{ eVJJJ $$$Ifgdq$$$$Ifa$gdbAkd$$IfH4r0$P@4 Ha(f4$1$If $$1$Ifa$ XZƷǷɷʷͷηѷҷַ׷طݷ߷ĸӸөsdWGhQ7h!65B*CJhphh 5B*CJhphhQ7ha=eB*CJhphha=eB*CJhphhUB*CJhphhQ7hUB*CJhphhQ7hcCB*CJhphhQ7hMZB*CJhphh}EvB*CJhphh}Evh}EvB*CJhphhE_h}EvB*CJhphhQ7hqB*CJhphhsXhqB*CJhph ƷǷʷηҷ׷طMkd$$IfH4r0$P@4 Ha(f4$1$If $$1$Ifa$ $$$IfgdbA $$$Ifgd}Evط Mkd7 $$IfH4r0$P@4 Ha(f4$1$If $$1$Ifa$ $$$IfgdbA $$$Ifgd!6߷ ƸǸ稜xiZxKhQ7hWd!B*CJhphhQ7hVXB*CJhphhQ7hFnB*CJhphhQ7hqB*CJhphhQ7hUB*CJhphhQ7h!6B*CJhphh B*CJhphhQ7hMZB*CJhphhQ7hB*CJhphhQ7hq5B*CJhphhQ7h5B*CJhphhQ7hU5B*CJhphǸ !"Lkd $$IfH4r0$P@4 Ha(f4 $$1$Ifa$ $1$IfgdWd!$1$If $$1$Ifa$gd!6"')*68SV`aʹֹٹ %&⸩⋚|m^⸩OhQ7h#B*CJhphhQ7hQ1B*CJhphhQ7hMZB*CJhphhQ7hAB*CJhphhQ7h)]B*CJhphhQ7hFnB*CJhphhQ7hqB*CJhphhQ7hB*CJhphhQ7h!6B*CJhphh B*CJhphhQ7hUB*CJhphhQ7hAhtB*CJhph"*a Okd $$IfH4r0$P@4 Ha(f4 $$1$Ifa$ $1$Ifgd)]$1$If $$1$Ifa$ Pvwz~WkdV $$IfH4r0$P@4 Ha(f4 $$1$Ifa$$1$If $$1$Ifa$gd!6&OP[duvwyz}~غٺ+,fgz{}⚋|mmammRhQ7hEB*CJhphhDB*CJhphhQ7hAhtB*CJhphhQ7hqB*CJhphhQ7h!6B*CJhphh B*CJhphhQ7hQ1B*CJhphhQ7hMZB*CJhphhQ7hWd!B*CJhphhQ7h9B*CJhphhQ7hUB*CJhphhQ7hB*CJhph ٺ,Ng{} $$1$Ifa$$1$If $$1$Ifa$ ޼߼ ʺʺ٫}p`P@Pha=eh^5B*CJhphha=ehU5B*CJhphha=eh!65B*CJhphh 5B*CJhphhQ7hu 5B*CJhphhQ7hAB*CJhphhQ7h~B*CJhphhQ7hu B*CJhphhQ7ha=e5B*CJhphhQ7ha=eB*CJhphh B*CJhphhQ7hUB*CJhphha=eB*CJhphvh]]]OO] $$1$Ifa$gd} $ $1$Ifgd} $ $$1$Ifa$gd} $kd $$IfH4- r0$P@4 Ha(f4xj__WI> $$1$Ifa$ $$1$Ifa$gdW$1$If $1$IfgdW $$1$Ifa$gd!6kd $$IfH4r0$P@4 Ha(f4 rstxeZO $1$IfgdC $1$Ifgd!6kdy $$IfH4r0$P@4 Ha(f4$1$If $$1$Ifa$ rstwxzɾ #&').01CENҲxlxl]N?l?hsXh*GB*CJhphhQ7hUB*CJhphhQ7h!6B*CJhphhB*CJhphhghB*CJhphhQ7h5B*CJhphhQ7hB*CJhphh B*CJhphhQ7hU5B*CJhphha=eh^5B*CJhphha=ehU5B*CJhphha=ehD&B*CJhphhQ7hCB*CJhphxyz #'pbWWWII $$1$Ifa$gd8 $1$Ifgd8 $$1$Ifa$gd8kd.$$IfH4r0$P@4 Ha(f4$1$If'()1OmbWWWLL $$1$Ifa$ $1$Ifgd*G $$1$Ifa$kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd8NOnoٿۿ QRSVWxh[hO@h[hha=ehCB*CJhphhCB*CJhphhC5B*CJhphha=ehC5B*CJhphh 5B*CJhphhQ7hUB*CJhphhQ7h*GB*CJhphhsXhD&B*CJhphhsXhMZB*CJhph"hsXhP hP B*CJhphhsXh~B*CJhphhsXhP B*CJhphhsXhUB*CJhphڿۿ RSWXpeeZLLe $$1$Ifa$gd8 $1$IfgdC $1$Ifgd8kd$$IfH4r0$P@4 Ha(f4$1$IfXYa!%xj_____QQ $$1$Ifa$gd8 $1$Ifgd8 $$1$Ifa$gd8kdM$$IfH4r0$P@4 Ha(f4 WY^ags!$+,.356 %&ŹŭŹԹԹ㭞rbRbhQ7h*G5B*CJhphhQ7hU5B*CJhphhQ7h!65B*CJhphh 5B*CJhphhsXhB*CJhphhQ7hB*CJhphhB*CJhphhCB*CJhphhsXhCB*CJhphhQ7hCB*CJhphh B*CJhphhQ7hC5B*CJhph%-.6i m_QQ $$1$Ifa$gd8 $$1$Ifa$gd8kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd8&RSTXYxppppeep $$1$Ifa$$1$Ifkd$$IfH4r0$P@4 Ha(f4&RSTWZ_`abuv "#Ҷwh\MhQ7hbKVB*CJhphhBB*CJhphhQ7hEB*CJhph"hQ7hP hP B*CJhphhQ7hP B*CJhphhQ7hUB*CJhphhQ7h!6B*CJhphh B*CJhphhQ7h*G5B*CJhphhQ7hU5B*CJhphhQ7hMZB*CJhphhQ7h*GB*CJhphYZbvxmeeeeeeZZ $$1$Ifa$$1$If $$1$Ifa$kdl$$IfH4r0$P@4 Ha(f4 3pb $$1$Ifa$gd!6kd!$$IfH4r0$P@4 Ha(f4$1$If #23foӲӟ}qj^jZj^j^jhihQ7hUmHnHu hQ7hUhBB*CJhphhQ7hEB*CJhph$hphMZB*CJhmH phsH $hph!6B*CJhmH phsH "hQ7hP hP B*CJhphhQ7hI B*CJhphhQ7hP B*CJhphhQ7hUB*CJhphhQ7h!6B*CJhph ecaU +$^a$gd:kd$$IfH4r0$P@4 Ha(f4$1$If $$1$Ifa$ $.3QR0kd$$IfH44r0p$P@ 2(4 Ha(f4p2 $$1$Ifa$3PRWq!#$E;=LȸsddUhQ7h)5B*CJhphhQ7h1*%B*CJhphhQ7hB*CJhphhB*CJhphhQ7hlB*CJhphh B*CJhphhQ7hbKVB*CJhphhQ7hbKV5B*CJhphh 5B*CJhph#hQ7hU5CJOJQJ^JaJ/hQ7hU5B*CJOJQJ^JaJhph!RZq_Q $$1$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% Lkdo$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%P$1$If^`Pgd$%$E $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd$% Lxj___QQ_ $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd$%kd$$$IfH4r0$P@4 Ha(f4xmmmm__m $$1$Ifa$gd$% $1$Ifgd$%kd$$IfH4r0$P@4 Ha(f4elq^_`a  }qehYFXB*CJhphhbKVB*CJhphhQ7h%B*CJhphhQ7hB*CJhph"hQ7h1*%h1*%B*CJhphhQ7h1*%B*CJhphh%B*CJhphh B*CJhphhQ7hbKV5B*CJhphh 5B*CJhphhQ7hbKVB*CJhph'LxbWWWIIW $$1$Ifa$gd$% $1$Ifgd$%$P$1$If^`Pa$gd$%kd$$IfH4r0$P@4 Ha(f4xj___QQ_ $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd$%kdC$$IfH4r0$P@4 Ha(f4 defjkxmmmm__m $$1$Ifa$gd$% $1$Ifgd$%kd$$IfH4r0$P@4 Ha(f4kltxj___QQ_ $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4`adhxj_TTFF_ $$1$Ifa$gd$% $1$Ifgd1*% $1$Ifgd$% $$1$Ifa$gd$%kdb$$IfH4r0$P@4 Ha(f4 rsvzxi]]]]OO $$1$Ifa$gd$% $$$Ifgd$%$$$$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4zm^RRRFR $$$Ifgd% $$$Ifgd$%$$$$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% 2SGGG $$$Ifgdikd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd%2EFGKMRST`eglԵ{oo_SSh B*CJhphhihi5B*CJhphh}EvB*CJhphh}Evh}EvB*CJhphhE_h}EvB*CJhphhiB*CJhphh} hi5B*CJhphhQ7hiB*CJhphhQ7hi5B*CJhphh 5B*CJhphhQ7hbKV5B*CJhphhQ7hbKVB*CJhphEFGKLMGkd6$$IfH4r0$P@4 Ha(f4 $1$Ifgd} $ $$1$Ifa$gd} $ $$$Ifgd}Ev $$$IfgdiMUVY]afgDkd$$IfH4r0$P@4 Ha(f4 $1$Ifgd} $ $$1$Ifa$gd} $ $$$Ifgdi$$$$Ifa$gd} $lmnow|:@69=ACHIJKX|}7:=@EFGHhO5B*CJhphh} B*CJhphh B*CJhphh}Ev5B*CJhphhQ7h} B*CJhphh} 5B*CJhphh} h} 5B*CJhphh 5B*CJhphhQ7h} 5B*CJhph2goSkd$$IfH4r0$P@4 Ha(f4 $1$Ifgd} $ $$1$Ifa$gd} $ $$$Ifgd} $A236:B $1$Ifgd} $ $$1$Ifa$gd} $ $$$Ifgd} $$$$$Ifa$gd} $ BCKxi]]]OO $$1$Ifa$gd} $ $$$Ifgd} $$$$$Ifa$gd} $kdU $$IfH4r0$P@4 Ha(f4?m^RRRD $$1$Ifa$gd} $ $$$Ifgd} $$$$$Ifa$gd} $kd !$$IfH4r0$P@4 Ha(f4 $1$Ifgd} $89:>_SSSS $$$Ifgd} $kd!$$IfH4r0$P@4 Ha(f4 $1$Ifgd} $ $$1$Ifa$gd} $ >?@Hm^RRRRR $$$Ifgd} $$$$$Ifa$gd} $kdt"$$IfH4r0$P@4 Ha(f4 $1$Ifgd} $HRSabw J[ MXLMX]^_`btָָ֬֐shi5B*CJhphhQ7hbKV5B*CJhphhwz,5B*CJhphh|{h} B* CJhphh} B* CJhph"hQ7h} h:B*CJhphh B*CJhphhQ7h} B*CJhphh} B*CJhphh} h} B*CJhph, a_PD $$$Ifgd} $$$$$Ifa$gd} $kd)#$$IfH4r0$P@4 Ha(f4 $1$Ifgd} $ $$1$Ifa$gd} $a SD$$$$Ifa$gd} $kd#$$IfH4r0$P@4 Ha(f4 $1$Ifgd} $ $$1$Ifa$gd} $ $$$Ifgd} $_Skd$$$IfH4r0$P@4 Ha(f4 $1$Ifgd} $ $$1$Ifa$gd} $ $$$Ifgd} $NORVW $1$Ifgd} $ $$1$Ifa$gd} $ $$$Ifgd} $$$$$Ifa$gd} $WX`xllll^^S $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%kdH%$$IfH4r0$P@4 Ha(f4t7BCDE"ĵĵ|mmmamĵĵmah} B*CJhphhQ7hUB*CJhphhQ7h)5B*CJhphhQ7hB*CJhphhQ7h1*%B*CJhphhiB*CJhphhQ7hS0B*CJhphhwz,B*CJhphhQ7hbKVB*CJhphhQ7hbKV5B*CJhphhQ7hS05B*CJhph&DEWmxi]]]]]]] $$$Ifgd$%$$$$Ifa$gd$%kd%$$IfH4r0$P@4 Ha(f4 _PD $$$Ifgd$%$$$$Ifa$gd$%kd&$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%"#:M[ $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$% XYxi]]]R] $1$IfgdD $$$Ifgd$%$$$$Ifa$gd$%kdg'$$IfH4r0$P@4 Ha(f4XY/01:?@ACIJQRaxʻʬّʬueueXeXeXehi5B*CJhphhQ7ha5B*CJhphhwz,5B*CJhphhQ7h)5B*CJhphh} B*CJhphhsXhDB*CJhphhQ7hUB*CJhphhQ7hI B*CJhphhQ7hWB*CJhphhiB*CJhphhQ7hS0B*CJhphhwz,B*CJhph"0_PDD $$$Ifgd$%$$$$Ifa$gd$%kd($$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%01489:BSG $$$IfgdUkd($$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%BxGkd)$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$% $$$IfgdqHxKQRYZ[^abkpqrs !նƧƛƀqնbSSƧhQ7h)5B*CJhphhQ7h]B*CJhphh}Evh}EvB*CJhphhqL B*CJhphhQ7hiB*CJhphhiB*CJhphhQ7hB*CJhphhQ7hqL 5B*CJhphhQ7hqL B*CJhphhwz,B*CJhphhQ7ha5B*CJhphhQ7haB*CJhph JKRZ[^bj $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgdi $$$IfgdS$$$$Ifa$gdwz, jks!/0xi]QQQQQQ $$$Ifgd$% $$$IfgdS$$$$Ifa$gdwz,kd;*$$IfH4r0$P@4 Ha(f4 !&.0367:<>@EFGH0=@FGNOPVW`g}Ƿӫӓth[KhQ7h5B*CJhphhwz,5B*CJhphh]B*CJhphhQ7hiB*CJhphhQ7h]5B*CJhphhwz,B*CJhphh} B*CJhphhiB*CJhphhQ7hqL 5B*CJhphh}EvB*CJhphhQ7hqL B*CJhphhQ7h)5B*CJhphhQ7h]B*CJhph037?@H?_PDD $$$IfgdS$$$$Ifa$gdwz,kd*$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%?@GOPSW_`Gkd+$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgdi $$$IfgdS`h $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$% $$$IfgdS $$$IfgdU}M вrcTH<вh} B*CJhphhiB*CJhphhihB*CJhphh QhB*CJhph hsXh)5B*CJaJhph hsXhB*CJaJhph#hsXh;B*CJaJhphhwz,B*CJhphhsXhB*CJhphhQ7h)5B*CJhphhQ7hB*CJhphhQ7h5B*CJhphhQ7h)55B*CJhphMxl```````` $$$Ifgd$% $$$IfgdUkdZ,$$IfH4r0$P@4 Ha(f4 (b_SGGG $$$Ifgd$% $$$IfgdUkd-$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% '(PabnpIJvgWGg:*hQ7hU5B*CJhphhwz,5B*CJhphhQ7hqL 5B*CJhphhQ7h5B*CJhphhQ7hqL B*CJhphhQ7hB*CJhphhsXh)5B*CJhphhsXhI B*CJhphhsXhB*CJhph#hsXhqL ;B*CJaJhphhi;B*CJaJhph#hsXh;B*CJaJhphhsXhqL B*CJhphhwz,B*CJhph]^_SGGG $$$Ifgd$% $$$IfgdUkd-$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%\]^_abcel ó☉whYJ>hhhhiB*CJhphhQ7hiB*CJhphhQ7hB*CJhphhQ7hJ'B*CJhph"hQ7h<h<B*CJhphhQ7hI B*CJhphhQ7hf8-B*CJhphhwz,B*CJhphhQ7h<5B*CJhphhQ7hU5B*CJhphhQ7h)5B*CJhphhQ7hUB*CJhphhQ7h<B*CJhph^_cdem_PDD $$$Ifgd$%$$$$Ifa$gdUkdy.$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% Gkd./$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd< $$$Ifgd$% 79b ERYǸpǸpdUphQ7h} B*CJhphh} B*CJhphhQ7h)5B*CJhphhJ'B*CJhphhQ7hiB*CJhphhiB*CJhph"hQ7h<h<B*CJhphhQ7hf8-B*CJhphhQ7hJ'B*CJhphhwz,B*CJhphhQ7hUB*CJhphhQ7h<B*CJhph!b $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgdi $$$Ifgd$%$$$$Ifa$gdU Exi]]]Q]Q $$$Ifgd} $$$Ifgd$%$$$$Ifa$gdUkd/$$IfH4r0$P@4 Ha(f4_PDD $$$Ifgd$%$$$$Ifa$gdUkd0$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%Q^#$/0ӵӵӵөqcUqh} h5CJaJhh} hJ'5CJaJhhQ7hJ'5B*CJhphhwz,5B*CJhphhJ'B*CJhphhQ7h} B*CJhphh} B*CJhphhQ7hI B*CJhphhQ7h)5B*CJhphhQ7h<B*CJhphhQ7hf8-B*CJhphhQ7hJ'B*CJhph!GkdM1$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd} $$$Ifgd$%0Gkd2$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$% $$$Ifgd\Źŭŏn__SGŹŭh} hJ'CJaJhh} h} CJaJhhQ7h\B*CJhph"hQ7hShSB*CJhphhQ7h)5B*CJhphhQ7hSB*CJhphhQ7hf8-B*CJhphh} B*CJhphhwz,B*CJhphhQ7hJ'B*CJhphh|{hJ'B* CJhphh} B* CJhphhQ7hJ'5B*CJhph $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%$$$$Ifa$gdU [\_cxi]]]OO $$1$Ifa$gd$% $$$Ifgd$%$$$$Ifa$gdUkd2$$IfH4r0$P@4 Ha(f4Zcdefmz "#$%&'.⯠ymm^Qhwz,5B*CJhphh|{h|{B* CJhphhJ'B*CJhphhQ7h:M~B*CJhphh:M~B*CJhphh|{B*CJhphhQ7hf8-B*CJhphh} B*CJhphhwz,B*CJhphh|{hJ'B* CJhphh} B* CJhphhQ7hJ'B*CJhphhQ7hpB*CJhphcefn m^RRRRRR $$$Ifgd$%$$$$Ifa$gdUkdl3$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% #$&'/I_SG $$$Ifgdf8- $$$Ifgd5kd!4$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%.I%&'(18`ൣĔsg[L< *h:M~h5B*CJhphh Qh5B*CJhphh:M~h5CJaJhh:M~h:M~CJaJh"h:M~h:h:B*CJhphh:M~h:B*CJhphh:M~h5B*CJhph"hQ7h:h:B*CJhphhQ7h:B*CJhphhwz,B*CJhphhQ7h55B*CJhphhQ7h5B*CJhphhQ7h5B*CJhphISD$$$$Ifa$gdf8-kd4$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8- $$1$Ifa$gdf8- $$$Ifgdf8-'(+/01Skd5$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8- $$1$Ifa$gdf8- $$$Ifgdf8-19` $1$Ifgdf8- $$1$Ifa$gdf8- $$$Ifgdf8-$$$$Ifa$gdf8-4567@GY[kʾʯʯʐpaOaʀ?h Qh55B*CJhph"hQ7ho.yh:B*CJhphhQ7ho.yB*CJhphhQ7ho.y5B*CJhphhQ7h55B*CJhphhwz,5B*CJhph"hQ7h:h:B*CJhphhQ7h:B*CJhphhwz,B*CJhphhQ7h5B*CJhphh:M~h:M~B*CJhphh:B*CJhphh:M~B*CJhph67:>xi]]]OO $$1$Ifa$gdf8- $$$Ifgdf8-$$$$Ifa$gdf8-kd@6$$IfH4r0$P@4 Ha(f4>?@HkmaUIU $$$Ifgdo.y $$$Ifgdf8- $$$Ifgd5kd6$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8-_PD $$$Ifgdf8-$$$$Ifa$gdf8-kd7$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8- $$1$Ifa$gdf8-: ^_foqxĵĩĵčĵĩčĵqĵĵhQ7h:M~B*CJhphhQ7hgB*hphhQ7hgB*CJhphhQ7ho.yB*hphh:M~B*CJhphhQ7ho.yB*CJhphhQ7h5B*CJhphhwz,B*CJhphhQ7h55B*CJhphh Qh:5B*CJhph'SD$$$$Ifa$gdgkd_8$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8- $$1$Ifa$gdf8- $$$Ifgdo.y ^_bfp $1$Ifgdf8- $$1$Ifa$gdf8- $$$Ifgdo.y $$$Ifgdgpqyxi]]]OO $$1$Ifa$gdf8- $$$Ifgdg$$$$Ifa$gdgkd9$$IfH4r0$P@4 Ha(f4)*+ )+2DEFO]`tklmʾʯ冯wghQ7hg5B*CJhphhQ7h-B*CJhphhQ7h~aB*CJhphhQ7hgB*hphhQ7hPzB*hphhQ7hgB*CJhphh:M~B*CJhphhQ7ho.yB*CJhphhwz,B*CJhphhQ7h5B*CJhphh QB*CJhph(+m^RRRRR $$$Ifgdg$$$$Ifa$gdgkd9$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8- *+3t_PDD $$$Ifgdg$$$$Ifa$gdgkd~:$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8- $$1$Ifa$gdf8-SD$$$$Ifa$gdgkd3;$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8- $$1$Ifa$gdf8- $$$IfgdglmSkd;$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8- $$1$Ifa$gdf8- $$$Ifgdg(-././0346ǸǸǸth Qh5B*CJhphhQ7h`xB*CJhphhQ7hgB*hphhQ7hPzB*hphh QB*CJhphhQ7h-B*CJhphhQ7h~aB*CJhphhwz,B*CJhphhQ7h5B*CJhphhQ7hgB*CJhph-( $1$Ifgdf8- $$1$Ifa$gdf8- $$$Ifgdg$$$$Ifa$gdg./xi]]]]]OO $$1$Ifa$gdf8- $$$Ifgdg$$$$Ifa$gdgkd<$$IfH4r0$P@4 Ha(f4 /03m^RRRD $$1$Ifa$gdf8- $$$Ifgdg$$$$Ifa$gdgkdR=$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8-3789Ac_SSSS $$$Ifgdgkd>$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8- $$1$Ifa$gdf8- 69@RSc*+89BCXY_`ghnopqr0?HI\_entuwԵԩsh:M~B*CJhphhQ7hPzB*CJhphhoB*CJhphhQ7h`xB*CJhphhwz,B*CJhphhQ7hgB*CJhphhQ7h`x5B*CJhphhQ7hg5B*CJhphhwz,5B*CJhphhQ7h5B*CJhph-qrm^RRRRR $$$Ifgdg$$$$Ifa$gdgkd>$$IfH4r0$P@4 Ha(f4 $1$Ifgdf8-ruy_PDD $$$Ifgdg$$$$Ifa$gdgkdq?$$IfH4r0$P@4 Ha(f4 $1$Ifgdg $$1$Ifa$gdgwx{Skd&@$$IfH4r0$P@4 Ha(f4 $1$Ifgdg $$1$Ifa$gdg $$$Ifgdg')2A/01:HLa\,mʾ־־־־־־־־־־־hQ7hPzB*CJhphhoB*CJhphh:M~B*CJhphhQ7h`xB*CJhphhQ7hgB*CJhphhwz,B*CJhphE $1$Ifgdg $$1$Ifa$gdg $$$Ifgdg$$$$Ifa$gdg A xi]]]]]OO $$1$Ifa$gdg $$$Ifgdg$$$$Ifa$gdgkd@$$IfH4r0$P@4 Ha(f4 am^RRRD $$1$Ifa$gdg $$$Ifgdg$$$$Ifa$gdgkdA$$IfH4r0$P@4 Ha(f4 $1$IfgdgGH_PDDD $$$Ifgdg$$$$Ifa$gdgkdEB$$IfH4r0$P@4 Ha(f4 $1$Ifgdg $$1$Ifa$gdgHSD$$$$Ifa$gdgkdB$$IfH4r0$P@4 Ha(f4 $1$Ifgdg $$1$Ifa$gdg $$$Ifgdg,SkdC$$IfH4r0$P@4 Ha(f4 $1$Ifgdg $$1$Ifa$gdg $$$IfgdgmnUuMTjkloĵөӎөsh:M~B*CJhphhQ7hb_B*CJhphhQ7hPzB*CJhphhoB*CJhphhwz,B*CJhphh QhgB*CJhphh Qh QB*CJhphhQ7hgB*CJhphhQ7h`xB*CJhphhQ7hB*CJhph*@A $1$Ifgdg $$1$Ifa$gdg $$$Ifgdg$$$$Ifa$gdg klosxi]]]OO $$1$Ifa$gdg $$$Ifgdg$$$$Ifa$gdgkddD$$IfH4r0$P@4 Ha(f4opsu|'(+,UVWy|'()KNeɹttgZMZZMZhQ7hb_B*hphhQ7hDB*hphhQ7hB*hphhoB*CJhphhQ7hDB*CJhphhwz,B*CJhphhQ7hPzB*CJhphhQ7hb_B*CJhphhQ7hD5B*CJhphhwz,5B*CJhphhQ7hgB*CJhphh:M~hgB*CJhphh QB*CJhphstu}maUUUGG $$1$Ifa$gdg $$$Ifgdg $$$IfgdDkdE$$IfH4r0$P@4 Ha(f4 $1$IfgdgVWm^RRGGR $1$IfgdD $$$Ifgdg$$$$Ifa$gdgkdE$$IfH4r0$P@4 Ha(f4 $1$Ifgdg(_PDD $$$Ifgdg$$$$Ifa$gdgkdF$$IfH4r0$P@4 Ha(f4 $1$Ifgdg $$1$Ifa$gdg()efimrs{Hkd8G$$IfH4r0$P@4 Ha(f4 $1$Ifgdg $$1$Ifa$gdg $1$IfgdD $$$IfgdgeszVWXjQRSUVWԹŪśŌŹsdshQ7hB*CJhphhQ7hDB*hphh:M~B*CJhphhQ7h-B*CJhphhQ7hPzB*CJhphhQ7hb_B*CJhphhwz,B*CJhphhQ7hgB*CJhphhQ7hg5B*CJhphhwz,5B*CJhphhQ7hDB*CJhph'{SkdG$$IfH4r0$P@4 Ha(f4 $1$Ifgdg $$1$Ifa$gdg $$$IfgdgWXj} $1$Ifgdg $$1$Ifa$gdg $$$Ifgdg$$$$Ifa$gdg RSxi]]]Q] $$$IfgdD $$$Ifgdg$$$$Ifa$gdgkdH$$IfH4r0$P@4 Ha(f4V_PDD $$$Ifgdg$$$$Ifa$gdgkdWI$$IfH4r0$P@4 Ha(f4 $1$Ifgdg $$1$Ifa$gdgVWGkd J$$IfH4r0$P@4 Ha(f4 $1$Ifgdg $$1$Ifa$gdg $$$IfgdD $$$IfgdgcdeijkSkdJ$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%dkp 9<F!jo~_`еееееееееееееЋĵhB\B*CJhphhDB*CJhphhQ7hB*CJhphhQ7hPzB*CJhphhQ7h6BB*CJhphhwz,B*CJhphhQ7h5B*CJhphhQ7h6B5B*CJhphhQ7h55B*CJhph1ks QkdvK$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd$% FTF $$1$Ifa$gd$%kd+L$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd6B $1$Ifgd$%6\]`dijr_Q $$1$Ifa$gd$%kdL$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% &H`tvy}_kdM$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$%  $$1$Ifa$gd$% $$1$Ifa$gd_ $1$Ifgd$% $1$Ifgd_ $$1$Ifa$gd$%  ST[`bcduw ɺ庛ɂsgsgs[ssh:M~B*CJhphhB*CJhphhQ7h_B*CJhphh6B*CJhphhwz,5B*CJhphhQ7h;B*CJhphhQ7h55B*CJhphhQ7h5B*CJhphhwz,B*CJhphhQ7h6B5B*CJhphhQ7h6BB*CJhphhB*CJhph#xj___QQ_ $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd$%kdJN$$IfH4r0$P@4 Ha(f4TUYZxmmm__m $$1$Ifa$gd$% $1$Ifgd$%kdN$$IfH4r0$P@4 Ha(f4Z[c  xj_TTFFT $$1$Ifa$gd_ $1$Ifgd_ $1$Ifgd$% $$1$Ifa$gd$%kdO$$IfH4r0$P@4 Ha(f4  3xj___QQ_ $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd_kdiP$$IfH4r0$P@4 Ha(f4  ')3LV Khjoִֻzm]NhQ7h4B*CJhphhQ7h45B*CJhphhwz,5B*CJhph#hQ7hU5CJOJQJ^JaJ/hQ7hU5B*CJOJQJ^JaJhphhK%hQ7hUmHnHu hQ7hUhQ7hB*CJhphhB*CJhphhQ7h5B*CJhphhwz,B*CJhphhQ7h_B*CJhph!6<FKxvth]O]]] $$1$Ifa$gd} $$1$Ifa$ +$^a$gd:kdQ$$IfH4r0$P@4 Ha(f4 Kijr0%% $1$Ifgd5HkdQ$$IfH44rIU%!H> 24%4 Ha(f4p2 $$1$Ifa$_Q $$1$Ifa$gd5HkdS$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H*+49;<  jklx}R S \ a       1 2 9 >        * ƷƷƛƷhQ7hNOB*CJhphhwz,5B*CJhphhQ7h-B*CJhphhQ7h8B*CJhphhQ7h4B*CJhphhwz,B*CJhphhQ7h45B*CJhphhQ7hMZB*CJhph1*+.234LkdS$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5HP$1$If^`Pgd5H4<] $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5H kloswxj___QQ_ $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5HkdlT$$IfH4rIU%!H>4%4 Ha(f4wxxmmmm__m $$1$Ifa$gd5H $1$Ifgd5Hkd!U$$IfH4rIU%!H>4%4 Ha(f4 R S V Z [ xbWWWIIW $$1$Ifa$gd5H $1$Ifgd5H$P$1$If^`Pa$gd5HkdU$$IfH4rIU%!H>4%4 Ha(f4[ \ d       xj___QQ_ $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5HkdV$$IfH4rIU%!H>4%4 Ha(f4    1 2 3 7 8 xmmmm__m $$1$Ifa$gd5H $1$Ifgd5Hkd@W$$IfH4rIU%!H>4%4 Ha(f48 9 A W      xj___QQ_ $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5HkdW$$IfH4rIU%!H>4%4 Ha(f4    + . / 2 6 xj_TT_FF $$1$Ifa$gd5H $1$Ifgd8 $1$Ifgd5H $$1$Ifa$gd5HkdX$$IfH4rIU%!H>4%4 Ha(f4* + Q V w   @ A N O Q V X Y                    ֬scVhB\5B*CJhphhQ7hMZ5B*CJhphhK%5B*CJhphhQ7h45B*CJhphhwz,5B*CJhphhQ7hB\B*CJhphhB\B*CJhphhQ7hMZB*CJhphhQ7hNOB*CJhphhwz,B*CJhphhQ7h4B*CJhphhQ7hwB*CJhph!6 P Q Y w  @ A m^RRRR $$$Ifgd5H$$$$Ifa$gd5Hkd_Y$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5HA D H P Q Y   _PDD $$$Ifgd5H$$$$Ifa$gd5HkdZ$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H         GkdZ$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $$$Ifgd5H $$$IfgdB\   !       $1$Ifgd5H $$1$Ifa$gd5H $$$Ifgd Q $$$Ifgd5H  ! ' l n               :ʾپٯx评k[k[L[hQ7hyKB*CJhphhQ7hyK5B*CJhphh5B*CJhphh4B*CJhphhQ7h4B*CJhphhwz,B*CJhphhQ7h45B*CJhphhQ7hB\B*CJhphh QB*CJhphh}Evh QB*CJhphhE_h QB*CJhphhB\B*CJhphhMZB*CJhph        xi]]OOD $1$Ifgd5H $$1$Ifa$gd5H $$$IfgdB\$$$$Ifa$gd5Hkd~[$$IfH4rIU%!H>4%4 Ha(f4   :maVVaHH $$1$Ifa$gd5H $1$IfgdN, $$$Ifgd5Hkd3\$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H@AVftmaVVVVVV $1$IfgdN, $$$Ifgd5Hkd\$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H ?@Atuwx{|EFGrsuvwyz}KOPƺƫƫƺ՞rrhQ7hB\B*CJhphhK%5B*CJhphhB\hB\5B*CJhphh5B*CJhphhQ7hwUB*CJhphhB\B*CJhphhQ7hN,B*CJhphhQ7hN,5B*CJhphhB*CJhphhQ7hT5B*CJhph'tux|SD$$$$Ifa$gdkd]$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $$$Ifgd5HFGrsvz $1$Ifgd5H $$1$Ifa$gd5H $$$Ifgd5H $1$IfgdN,IJKOPxlll`RRG $1$Ifgd} $ $$1$Ifa$gd} $ $$$Ifgd} $ $$$IfgdB\kdR^$$IfH4rIU%!H>4%4 Ha(f4PQYZaijmxi]Q]QC $$1$Ifa$gd} $ $$$IfgdB\ $$$Ifgd} $$$$$Ifa$gd} $kd_$$IfH4rIU%!H>4%4 Ha(f4PQXZahimpyz"#*/>?[^hhﻫ}nnn}_nnnhQ7h/ B*CJhphhQ7h{B*CJhphhQ7hyB*CJhphhQ7h4B*CJhphhQ7h{5B*CJhphhQ7h45B*CJhphh5B*CJhphhB\B*CJhphhQ7hB\B*CJhphhB*CJhphhQ7hB\5B*CJhph"mqyz"#_SSSS $$$Ifgd5Hkd_$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd} $ $$1$Ifa$gd} $#$()*2h_Q $$1$Ifa$gd5Hkdq`$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H _QFF $1$Ifgd{ $$1$Ifa$gd5Hkd&a$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5Hhjtw#(78TWz23?ACHJK_afĵⵚӵⵎӵscschQ7hB\5B*CJhphhQ7hB\B*CJhphhB\B*CJhphhDB*CJhphhQ7h9B*CJhphhB*CJhphhQ7h4B*CJhphhQ7h/ B*CJhphhQ7hyB*CJhphhQ7h{B*CJhphhQ7hNOB*CJhph%_Q $$1$Ifa$gd5Hkda$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H "#+z23m_ $$1$Ifa$gd5Hkdb$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H 36:BCKX_QFF $1$Ifgd} $ $$1$Ifa$gd} $kdEc$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5HX[_`ai_QF $1$Ifgd $$1$Ifa$gd5Hkdc$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd} $ $$1$Ifa$gd} $f0<=tu} #%OR79Dƹ֩ssssssddhQ7h+B*CJhphhB*CJhphhQ7hB*CJhphhB*CJhphhQ7h4B*CJhphhQ7h45B*CJhphh5B*CJhphhQ7hR5B*CJhphhQ7hNOB*CJhphhB\B*CJhphhQ7hRB*CJhph%tuxy}~Qkdd$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$gd5H $$1$Ifa$gd $1$Ifgd5H  /_QF $1$Ifgd $$1$Ifa$gd8kdde$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H/TF $$1$Ifa$gd5Hkdf$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$gd8 $1$Ifgd8 $1$IfgdEFIMghp_TT $1$Ifgdkdf$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H DEFhmop~ƶ~rcTTTTcrcThsXhB*CJhphhhB*CJhphhB*CJhphhh5B*CJhphhB*CJhphh5B*CJhphhQ7hB*CJhphha=eh5B*CJhphh5B*CJhphhQ7h4B*CJhphhQ7h`mB*CJhphhQ7hyB*CJhph TF $$1$Ifa$gdkdg$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $1$IfgdTF $$1$Ifa$gdkd8h$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $1$IfgdTIA$1$If $1$Ifgd+|kdh$$IfH4rIU%!H>4%4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $1$IfgdRSTtuɹ~thYJh6hvB*CJhphh6hRB*CJhphhB*CJhphh6hUCJhhK%5B*CJhphh6hUB*CJhphh6h+|B*CJhphh6h+|5B*CJhphh6hU5B*CJhphh5B*CJhphhQ7hB*CJhphhhB*CJhphhB*CJhphSTeW $$1$Ifa$gd+|kdi$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$$1$If TcqruyZG$P$1$If^`Pa$kdWj$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$ $1$Ifgd6$1$Ifuvxy|$%GJOP~ĸӮӓxiĸӮēӓZZh6h`mB*CJhphh6hGB*CJhphh+|B*CJhphh6h6B*CJhphh6hRB*CJhphhB*CJhphh6hUCJhhGB*CJhphh6h+|B*CJhphh6hUB*CJhphh6hB*CJhphh6hB*CJhph#  %eW $$1$Ifa$gd+|kd k$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$$1$If %P1eZ $1$IfgdITNkdk$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$$1$If  123689@AklɼuӍfWfWKhK%B*CJhphhQ7h`mB*CJhphhQ7hB*CJhphhB*CJhphhQ7hU5CJhhQ7hITNB*CJhphhQ7hITN5B*CJhphhQ7hU5B*CJhphh5B*CJhphhQ7hUCJhhQ7hUB*CJhphh6h+|B*CJhphh6hUB*CJhph123789AleW $$1$Ifa$gdITNkdvl$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$$1$If Okd+m$$IfH4rIU%!H>4%4 Ha(f4 $1$IfgdITN $$1$Ifa$$1$If $1$IfgdK%[\delm   ' ⸮Ǔ}⸓⸮vjajvjvjhjmHnHuhQ7hUmHnHu hQ7hUhK%B*CJhphhQ7hCJhhQ7hB*CJhphhB*CJhphhQ7hUCJhhQ7hUB*CJhphhQ7h`mB*CJhphhITNB*CJhphhQ7hITNB*CJhphhQ7hK%B*CJhph&[\_cdemOkdm$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$$1$If $1$Ifgd $$1$Ifa$ m eccakdn$$IfH4rIU%!H>4%4 Ha(f4 $$1$Ifa$$1$If  4 ? T Z d i   $$1$Ifa$ +$8^8a$gd:' 4 i        R!W!Y!Z!""##)#7########$${$$$$$%Q%X%]%%%%J&K&²y²²hQ7h`mB*CJhphhQ7hkB*CJhphhB*CJhphhQ7h5HB*CJhphhQ7h5H5B*CJhphh5B*CJhph#hQ7hU5CJOJQJ^JaJ/hQ7hU5B*CJOJQJ^JaJhph hQ7hU*      ;0000 $1$Ifgd5HkdJo$$IfH44r^.J$(VF 2$4 Ha(f4p2       !H!_Q>>P$1$If^`Pgd5H $$1$Ifa$gd5Hkdyp$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5HH!I!L!P!Q!R!Z!{!L> $$1$Ifa$gd5Hkd.q$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5HP$1$If^`Pgd5H{!!!""""""""_kdq$$IfH4rd4J$(\F$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H "#7########Qkdr$$IfH4rd4J$(\F$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5H #####$$$ $_I$P$1$If^`Pa$gd5HkdMs$$IfH4rd4J$(\F$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H $8$q$r$u$y$z${$$$_Q $$1$Ifa$gd5Hkdt$$IfH4rd4J$(\F$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H $$$$$$$$%P%Q%_kdt$$IfH4rd4J$(\F$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H Q%R%V%W%X%`%v%%%%_Q $$1$Ifa$gd5Hkdlu$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H %%%%%%K&L&O&_QFF $1$Ifgdk $$1$Ifa$gd5Hkd!v$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5HK&L&n&s&&&&k'l'n's''''''''''((.(/(Ǹ֝vfYI6A6H6J6K667 7X7Y7[7\7_7`7ӻӻӻӬӻphQ7hB*CJhphhQ7hikB*CJhph"hQ7hhB*CJhphhGB*CJhphhQ7hB*CJhphhjB*CJhphhB*CJhphhQ7hRIB*CJhphhQ7hB*CJhphhQ7hu9B*CJhph,d44D5E5T5b5c5f5j5r5 $1$Ifgd5H $$1$Ifa$gd5H $$$IfgdRI r5s5{557686;6?6xi]]]OO $$1$Ifa$gd5H $$$IfgdRI$$$$Ifa$gdkd$$IfH4rd4J$(\F$4 Ha(f4?6@6A6I66 7 7757H7m^RRRRRR $$$IfgdRI$$$$Ifa$gdkd$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd5H H7X7Y7\7`7h7i7q7SD$$$$Ifa$gdkdd$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H $$$IfgdRI`7c7f7g7i7p7r7s77888 8 88888888"8$8+8-8.8b88888999;9<9?9@9C9F9G9I9N9ʾʲʣ񔲅yʾʲʣlh5B*CJhphhB*CJhphhQ7hjB*CJhphhQ7hB*CJhphhQ7hikB*CJhphhjB*CJhphhB*CJhphhQ7hRIB*CJhphhDB*CJhphhGB*CJhphhQ7hB*CJhph(q7788 88888#8 $1$Ifgd5H $$1$Ifa$gd5H $$$Ifgdj $$$IfgdRI #8$8,8b88888 98999xi]]]]]]]] $$$IfgdRI$$$$Ifa$gdkd$$IfH4rd4J$(\F$4 Ha(f4 99<9@9H9I9Q9|9999_SSSS $$$Ifgd5Hkd·$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H N9]9_9|9999 ::*:-:7:::::::::9;F;S;T;U;w;|;;;;;;;;; < <'<*<M<x<<<<<==ееееееЦееЗееЗЋhO<B*CJhphhDB*CJhphhQ7h9B*CJhphhQ7hB*CJhphhQ7h.B*CJhphhB*CJhphhQ7h5HB*CJhphhQ7h.5B*CJhphhQ7h5H5B*CJhph.9999:7:::::_Q $$1$Ifa$gd5Hkd$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H :::::T;U;X;\;m_TTFF $$1$Ifa$gd5H $1$Ifgd. $$1$Ifa$gd5Hkd8$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd5H\;v;w;;;;;;;;m_QQ $$1$Ifa$gd5H $$1$Ifa$gd5Hkd$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd5H ;;;M<<<<<<<xj______Q $$1$Ifa$gd5H $1$Ifgd5H $$1$Ifa$gd5Hkd$$IfH4rd4J$(\F$4 Ha(f4 <<<==]=>>_QFFF $1$Ifgd# $$1$Ifa$gd#kdW$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd5H $$1$Ifa$gd5H===1=3=6=V=>>">1>2>N>O>P>Q>r>t>>>^?_?d?f?g?i?n???ɺ{պk^NhQ7h5H5B*CJhphh5B*CJhphhQ7h.5B*CJhphhQ7h/XoB*CJhph#hQ7h;B*CJaJhphhQ7hB*CJhphhQ7hf`B*CJhphhQ7h.B*CJhphhB*CJhphhjB*CJhphhQ7hj5B*CJhphhQ7hjB*CJhph>>>>>%>>_QF $1$Ifgdf` $$1$Ifa$gd5Hkd $$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd# $$1$Ifa$gd#>^?_?b?c?g?h?i?q??Qkd$$IfH4rd4J$(\F$4 Ha(f4 $$1$Ifa$gd5H $$1$Ifa$gdf` $1$Ifgd5H ????????@_QF $1$Ifgd=1 $$1$Ifa$gd5Hkdv$$IfH4rd4J$(\F$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H???????? @@9@<@@@@@@@@@@@@@@$A'A2AUA\A]AhA{AAAҺtdWdh=15B*CJhphhQ7h=15B*CJhphh5B*CJhphhQ7hf`B*CJhphhGB*CJhphhQ7h5OB*CJhphhQ7h=1B*CJhphh=1B*CJhphhB*CJhphhQ7h5H5B*CJhphhQ7h/XoB*CJhphhQ7h5HB*CJhph"@@@@@@@@@TF $$1$Ifa$gd5Hkd+$$IfH4rd4J$(\F$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H $1$Ifgd=1@3A6A:ATAUA]A{AAA_TTTT $1$Ifgd8kd$$IfH4rd4J$(\F$4 Ha(f4 $$1$Ifa$gd5H $1$Ifgd5H AAAAAAALBMBxB_Q $$1$Ifa$gd8kd$$IfH4rd4J$(\F$4 Ha(f4 $1$Ifgd8 $$1$Ifa$gd8 AAAAAAAAAAKB}BBBBBBBBBBBBCC CC>P$1$If^`Pgd$% $$1$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%DDDDDDDDL> $$1$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%P$1$If^`Pgd$%DEE=F>FAFEFlFmFFF_kdM$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% FFFFGGG G GGQkd$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd$% G3GpGqGrGvGwGxGG_I$P$1$If^`Pa$gd$%kd$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$%xG}GGGbHdHiH|HHHH*I/IMIIIIIIIIIJ_J`JjJkJJJJJJJUK[K幪囏tdthQ7hJm5B*CJhphhQ7hJmB*CJhphh<2B*CJhphh=1B*CJhphhQ7hiB*CJhphhQ7hvB*CJhphhQ7hwmB*CJhphh5B*CJhphhQ7h!95B*CJhphhQ7h!9B*CJhphhB*CJhph"GGGGGGGGG#H_Q $$1$Ifa$gd$%kdl$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% #HZH[H^HbHcHdHlH|HHH_kd!$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% HHHHHHH I!I$I_Q $$1$Ifa$gd$%kd֗$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $I(I)I*I2IMIIII_QFF $1$Ifgdwm $$1$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%IIIIIJkJJ_PDDD $$$Ifgd$%$$$$Ifa$gd$%kd@$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%JJJJJJJSD$$$$Ifa$gdkd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%JKTKUK\KdKeKhKlKtK $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd<2 $$$Ifgds [K\KcKdKeKgKhKkKlKsKtKuK|K}KKKKKKKKLƷƙ}m]M=M=]mhQ7hi5B*CJhphhQ7hY5B*CJhphhQ7hY5B*CJhphhQ7h!95B*CJhphh5B*CJhphhGhJmB*CJhphhGhGB*CJhphh<2hJmB*CJhphh<2h<2B*CJhphhQ7hJm5B*CJhphhJmB*CJhphhQ7hJmB*CJhphhQ7h<2B*CJhphtKuK}KKLLLLLxll``TlF $$1$Ifa$gd$% $$$Ifgd Q $$$Ifgd<2 $$$Ifgd$%kd$$IfH4r0$P@4 Ha(f4LL LPLRLLLLLLLLLLLLLLLLLM廫teXH8hQ7h<25B*CJhphheHnh<25B*CJhphh5B*CJhphhQ7h<2B*CJhphhfB*CJhphhQ7hfB*CJhphhQ7hf5B*CJhphhB*CJhphhQ7h!95B*CJhphhQ7h!9B*CJhphh QB*CJhphh}Evh QB*CJhphhE_h QB*CJhphh<2B*CJhphLLLLLLL_PD8 $$$Ifgd<2 $$$Ifgdg?$$$$Ifa$gd$%kd_$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%LLLLLLLM_SG $$$Ifgd<2 $$$IfgdeHnkd$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$%MMMEMGMKMMMTMUM_MeMfMMMN N'N*N-N.N/NǷǨ{{k{k{\PD5h<2hfB*CJhphhDB*CJhphhGB*CJhphh<2h<2B*CJhphhQ7hf5B*CJhphhQ7hfB*CJhphhQ7hYB*CJhphhhfB*CJhphhhB*CJhphheHnh<25B*CJhphhQ7h<2B*CJhphh<2B*CJhphhQ7h<25B*CJhphh<25B*CJhphMEMFMGMKMLMMMUMSD$$$$Ifa$gdkdɜ$$IfH4r0$P@4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% $$$Ifgdg?UMMMMN N#N'N/N $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$% $$$Ifgdg?/N0N8NNOOO#Oxi]QQCC $$1$Ifa$gd$% $$$Ifgd$% $$$Ifgdg?$$$$Ifa$gdkd~$$IfH4r0$P@4 Ha(f4/N0N7N8NBNHNINzNNNN OOOOOOO#O:OMOSOZO[OOOOOO P P PPPPPԹԭԭԭԝ~~o~o~~~`h<2h<2B*CJhphhQ7h&B*CJhphhQ7hg?B*CJhphhQ7hg?5B*CJhphhQ7h&5B*CJhphh=1B*CJhphh<2B*CJhphhQ7hYB*CJhphhQ7hfB*CJhphhB*CJhphhQ7hf5B*CJhph##O9O:O[OOOOOO P Pmaaaaaaaa $$$Ifgd$%kd3$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% PPPPP:PPPPP_SSSSS $$$Ifgd$%kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% PPPPP2P9P:PuPvPPPPP0Q1Q3Q4Q7Q8Q;Q>Q?Qɺ~l`QBh<2h<2B*CJhphhQ7h&B*CJhphh=1B*CJhph#hQ7hY;B*CJaJhph#hQ7h;B*CJaJhphhQ7h<@B*CJhphhQ7hYB*CJhphhB*CJhphhQ7hB*CJhphhQ7hf5B*CJhphh<2hfB*CJhphhDB*CJhphhyiB*CJhphPPP0Q1Q4Q8Q@QAQIQSkd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$% ?Q@QAQHQIQQQQQQQQQRR"R8R9RĴ{k\PA2\hQ7hB*CJhphhQ7hYB*CJhphhB*CJhphhQ7h}B*CJhphhQ7h<25B*CJhphh<2h<2B*CJhphhQ7h<2B*CJhphhQ7heHnB*CJhphh<2B*CJhphheHnh<25B*CJhphh<2h<25B*CJhphh5B*CJhphhQ7hY5B*CJhphh<2hYB*CJhphIQQQQQQQQRSkdR$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%R:R}R~RRRRRR $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$% $$$Ifgd9R:RCRJRKROR\R|R}R~RRRRRRRRRRRRRRRӵӵӚsgXH<hB*CJhphhQ7hY5B*CJhphheHnhYB*CJhphhDB*CJhphhyiB*CJhphheHnheHnB*CJhphheHnB*CJhphh<2B*CJhphhQ7hYB*CJhphhQ7hB*CJhphhQ7hB*CJhphhQ7h}B*CJhphhQ7h&B*CJhphhQ7hD&B*CJhphRRRS}S~SSSSxl``lRRG $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd} $$$Ifgd$%kd$$IfH4r0$P@4 Ha(f4RR'S(SpSqStSuS}S~SSSSSSSSSSSTTTT񫞎zizZKhQ7hB*CJhphhQ7hhB*CJhph hO5;B*CJaJhph&h<2h}5;B*CJaJhphh<2h}5B*CJhphh5B*CJhphhQ7hY5B*CJhphheHnB*CJhphh=1B*CJhphhQ7h&B*CJhphhQ7h}B*CJhphhQ7hYB*CJhphSSSSTTTTTxllll^^S $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%kd$$IfH4r0$P@4 Ha(f4TTTT5TO- hQ7hB*CJaJhph hQ7h&B*CJaJhph hQ7hhB*CJaJhph#hQ7h};B*CJaJhphh=1;B*CJaJhph#hQ7h;B*CJaJhph#hQ7hh;B*CJaJhphhQ7h}B*CJhphhB*CJhphhQ7hhB*CJhphhQ7h}5B*CJhphh<2h}5B*CJhphh<2hh5B*CJhphTT=TsTTTTTTxllll^^S $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%kdq$$IfH4r0$P@4 Ha(f4TTTTTTTTUU)U*U,U-U0U1U3ULUSUTUoUpU{U|U}UUUUUUUUUUUUU񴁴oocheHnB*CJhph#hQ7h;B*CJaJhph#hQ7hj4;B*CJaJhphhQ7h&B*CJhph#hQ7h};B*CJaJhph#hQ7hh;B*CJaJhphhB*CJhphhQ7h}5B*CJhphhQ7hhB*CJhphhQ7h}B*CJhph$TTTU)U*U-U1U2Uxllll^^S $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%kd&$$IfH4r0$P@4 Ha(f42U3UTUUUUUUUxllll^^S $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%kdۣ$$IfH4r0$P@4 Ha(f4UUUUUUUUUUU.VZV}V~VVVVŵufWfuK<hQ7h!9B*CJhphhB*CJhphhOhB*CJhphhOh!9B*CJhphhOh!95B*CJhphh QheHn5B*CJhphh Qhf5B*CJhphh Qh!95B*CJhphhQ7h!95B*CJhphh5B*CJhphhQ7h}5B*CJhphheHnh}B*CJhphheHnheHnB*CJhphUUUU|V}V~VVVxllll^^S $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%kd$$IfH4r0$P@4 Ha(f4VVVVVVVVVxj___QQ_ $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd$%kdE$$IfH4r0$P@4 Ha(f4VVVVVVVVVVVVVVWWW(W)W2W3W4W?WWWWWWWWWXXXcXhXwXxXXXXXX[Y\Y{Yʻֻ⑻ֻֻvhDB*CJhphhQ7hJB*CJhphhQ7h,7B*CJhphhB*CJhphhQ7h&B*CJhphhQ7h9OB*CJhphh=1B*CJhphheHnB*CJhphhQ7h!9B*CJhphhQ7hB*CJhph-VVW?WWWWWWxj_TTFF_ $$1$Ifa$gd$% $1$Ifgd,7 $1$Ifgd$% $$1$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4WWW/XUXVXYX]XbXxj___QQ_ $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4bXcXkXX"YDY\YpYrYuYxj______Q $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd$%kdd$$IfH4r0$P@4 Ha(f4 uYyYYYYYZZ_QFFF $1$Ifgd# $$1$Ifa$gd#kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%{Y}YYYYYYYYMZNZxZyZ|Z}ZZZZZZZZZZZZe[f[[[[[[[[;uuuuuuucu"hQ7hJh9OB*CJhphhQ7hJB*CJhph"hQ7heHnh9OB*CJhphh=1B*CJhphheHnB*CJhphhQ7heHn5B*CJhphhQ7heHnB*CJhphhB*CJhphhQ7h!9B*CJhphhO<B*CJhphhyiB*CJhph"ZZZZZZZ[[_QFFF $1$Ifgdejw $$1$Ifa$gdejwkdΨ$$IfH4r0$P@4 Ha(f4 $1$Ifgd# $$1$Ifa$gd#[[[[[[[[[M\N\O\R\T\U\Z\\\]\^\o\q\\\\\]]]]] ]]]"]#]F]ɹvvvvgvh=1h=1B*CJhphh=1B*CJhphhB*CJhphh=15B*CJhphh=1;B*CJaJhphhQ7h=1B*CJhphhQ7h=15B*CJhphh5B*CJhphheHnB*CJhphhQ7hJB*CJhphhQ7hj4B*CJhph#[[[[[[[[M\_TTT $1$Ifgd=1kd$$IfH4r0$P@4 Ha(f4 $1$Ifgdejw $$1$Ifa$gdejwM\N\O\S\T\U\]\TF $$1$Ifa$gd8kd8$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $1$Ifgdt[]\{\\\]]]]]TF $$1$Ifa$gd8kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $1$Ifgd=1].]]]]]]]]]Tkd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $1$Ifgd=1 F]I]Q]]]]]]]]]]]]]]]^^ ^!^"^#^$^+^^^^^^پٮwٮk\wMhQ7hB*CJhphhhB*CJhphhB*CJhphh5B*CJhphh=15B*CJhphh=1h=15B*CJhphh5B*CJhphhQ7h=15B*CJhphh=1h=1B*CJhphhB*CJhphhQ7h=1B*CJhphh=1B*CJhphhB*CJhph]^^^"^#^$^,^Y^TF $$1$Ifa$gdkdW$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $1$Ifgd=1Y^^^^^^^^a_TF $$1$Ifa$gdkd $$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $1$Ifgd=1^^^^____a_h______a`b`o`p`q`r`y`z``aaŹŬԹԹq]N>hQ7h=15B*CJhphhQ7h=1B*CJhph&hQ7h=15;B*CJaJhphhh=15B*CJhphhh5B*CJhphhDB*CJhphhhB*CJhphh5B*CJhphhB*CJhphhQ7hB*CJhphhhB*CJhphhB*CJhphhQ7h5B*CJhpha_d_h________QFFF $1$Ifgd=1 $$1$Ifa$gdkd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%_`"`J`a`b`e`i`q` $1$Ifgd$% $$1$Ifa$gd$% $1$Ifgd=1 $1$Ifgdq`r`z``aaa a axmbbbTTI $1$Ifgd$% $$1$Ifa$gd$% $1$Ifgdt[ $1$IfgdQ kdv$$IfH4r0$P@4 Ha(f4a a aaakaaaaaaaaaabb.bbbbbbbbbbbbbc6c7c>c@cGcHccd dddddYd[dedsd{ddddddddd?e@eGeIeååååååh=1B*CJhphh=1;B*CJaJhphheHnh=1B*CJhph#hQ7h=1;B*CJaJhphhB*CJhphhQ7h=15B*CJhphhQ7h=1B*CJhph< a aakaaaaaaxj___T_T $1$IfgdeHn $1$Ifgdt[ $$1$Ifa$gd$%kd+$$IfH4r0$P@4 Ha(f4aaaaaa.bbb_QFFF $1$Ifgdt[ $$1$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%bbbbbbc6c7c_QFFF $1$Ifgdt[ $$1$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%7c:c>c?c@cHccd d_QFFF $1$Ifgdt[ $$1$Ifa$gd$%kdJ$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% d dddddeddd_QFFF $1$Ifgdt[ $$1$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%ddddddd@eCe_QFF $1$Ifgdt[ $$1$Ifa$gd$%kd$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%CeGeHeIeJeveee_][OD $$1$Ifa$ +$8^8a$gd:kdi$$IfH4r0$P@4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%IeJeie|eeeeeeefffYf`feffffffggghhhhh>i?i@iLiQisiiii0j5jjjjն|m||mhQ7hvB*CJhphhQ7h.|sB*CJhphhB*CJhphhQ7h!9B*CJhphhQ7h!95B*CJhphh5B*CJhph#hQ7hU5CJOJQJ^JaJ/hQ7hU5B*CJOJQJ^JaJhphhQ7hUmHnHu hQ7hU*eeeeee $$1$Ifa$efffXfYf;0000 $1$Ifgd$%kd$$IfH44r0$P*vF 2$4 Ha(f4p2YfZf^f_f`fhfff_Q>>P$1$If^`Pgd$% $$1$Ifa$gd$%kdM$$IfH4r0$P*vN$4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%ffffffffL> $$1$Ifa$gd$%kd$$IfH4r0$P*vN$4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%P$1$If^`Pgd$%fgg~hhhhhhhh_kd$$IfH4r0$P*vN$4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% hhh?i@iCiGiKiLiTiQkdl$$IfH4r0$P*vN$4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% $$1$Ifa$gd$% Tisiiiiiiii_I$P$1$If^`Pa$gd$%kd!$$IfH4r0$P*vN$4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$%ii&j'j*j.j/j0j8jcj_Q $$1$Ifa$gd$%kdָ$$IfH4r0$P*vN$4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% cjjjjjjjjjkk_kd$$IfH4r0$P*vN$4 Ha(f4 $$1$Ifa$gd$% $1$Ifgd$% jjk kkjkokkkll#l(lClHlIlll m!m%m*mmmmmmmmmmmmmmmŧtgh5B*CJhphhyiB*CJhphh!9B*CJhphhQ7h~5B*CJhphh~5B*CJhphhQ7hXB*CJhphhQ7hvB*CJhphhQ7h3jB*CJhphhB*CJhphhQ7h!9B*CJhphhQ7h!95B*CJhph#kk k k kk+k`kakdk_Q $$1$Ifa$gd$%kd@$$IfH4r0$P*vN$4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% dkhkikjkrkklll_QFF $1$Ifgd3j $$1$Ifa$gd$%kd$$IfH4r0$P*vN$4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%ll"l#l+lIllm_PDDD $$$Ifgd$%$$$$Ifa$gd$%kd$$IfH4r0$P*vN$4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$%mmmm"m#m$m%mSkd_$$IfH4r0$P*vN$4 Ha(f4 $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%%m-mZmmmmmmmmm $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$%$$$$Ifa$gd$% mmmmnnn!n"nxl```RRG $1$Ifgd$% $$1$Ifa$gd$% $$$Ifgd$% $$$Ifgd!9kd$$IfH4r0$P*vF$4 Ha(f4mmmmmmnn!n"n#n*n+n;n,X4` <hDp$If. >,X4` <hDp$7$8$H$IfgdqJ$If+BCKQSefqsЗҗ"#%(*./24KNQRbdfmnqsƩƩƩrr2 *hB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH,ØĘŘܘݘߘ  㩌tc[P㩌㩌hQ7hqJ^JaJhqJ^JaJ hQ7hUCJOJQJ^JaJ.hqJhU5CJOJQJ^JaJmHnHu8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtHĘŘݘ M_iYYYYYYYY. >,X4` <hDp$7$8$H$IfgdqJ$Ifqkd$$Ifl0$ 6$T04 la< !*+.0ILQR]^deghopxz|™ʙ̙ΙЙәٙۙݙޙ㌩㌩㌩㌩㌩8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH7ԙߙ1>LMdp_Y$Ifqkd>$$Ifl0$ 6$T04 la<. >,X4` <hDp$7$8$H$IfgdqJ "$/046<=@BJLMdfgno㘍lKl@ *hqJhqJB* CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tHhQ7hU^JaJ hQ7hqJCJOJQJ^JaJ8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtHost߾|߾_B_%_B8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB* CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tHpٚ(DODWiv) >,X4` <hDp$IfgdqJ. >,X4` <hDp$7$8$H$IfgdqJ՚ؚݚޚ !#$'./79;@CIKMNTUhjlmnprƩƩƩƌƩƌƩƌƩƩƌƩƩƌƩƩƌƩƌƩƩƩƌ8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH7Ûěƛɛ˛ћқ՛כ  !"%'@CHJUVZ\ghkmtu㩌㩌8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH/uvwŜʜ̜   '(̯uXuXXuu8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtHhQ7hU^JaJ hQ7hUCJOJQJ^JaJ.hqJhU5CJOJQJ^JaJmHnHuvw YYY. >,X4` <hDp$7$8$H$IfgdqJ$Ifqkd$$Ifl0$ 6$T04 la< )*aiuc]//. >,X4` <hDp$7$8$H$IfgdqJ$Ifqkdl$$Ifl0$ 6$T04 la<) >,X4` <hDp$IfgdqJ()*`abcghklstxyڝܝ $ˮtttttttttt8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtHhQ7hU^JaJhqJ^JaJ hQ7hUCJOJQJ^JaJ hqJhUCJOJQJ^JaJ-u!0j-:& >,X4` <hDp$If. >,X4` <hDp$7$8$H$IfgdqJ$%./45<=_ahinovw㩈gFgFgFg@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB* CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH "+,/189¥ˆ¥ˆgFggFggFg¥@ *hqJhqJB* CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH9:;qrtu|}ƟǟΟϟħeDeDeDeDeD@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB* CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH8 *hqJhqJB*CJOJPJQJ^JaJnHphtHhQ7hU^JaJhqJ^JaJ hQ7hUCJOJQJ^JaJ.hqJhU5CJOJQJ^JaJmHnHu:;r~Ÿ,<KYYYYYYYY. >,X4` <hDp$7$8$H$IfgdqJ$Ifqkd$$Ifl0$ 6$T04 la<   !#*+/1:;?@IJOPWX ߾߾߾߾߾߾߾߾߾c8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB* CJOJPJQJ^JaJmH nHphsH tH&àРѠ82$Ifqkd$$Ifl0$ 6$T04 la<& >,X4` <hDp$If. >,X4` <hDp$7$8$H$IfgdqJ ŠǠΠϠРѠ"#'(/0?AHIMNWX]^ef{}ƩƑxmƩƩƩƩƩƩhQ7hU^JaJhqJ^JaJ hQ7hUCJOJQJ^JaJ.hqJhU5CJOJQJ^JaJmHnHu8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH!$JYɡء 4DSâТ& >,X4` <hDp$If. >,X4` <hDp$7$8$H$IfgdqJǡȡ̡֡͡סܡݡ ߾ߝ߾ߝ߾ߝ߾ߝcFcF߾8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB* CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH)+2379BCGHQRWX_`}߾߾߾߀cFcF߾8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH@ *hqJhqJB* CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH¢ŢǢ΢ϢТѢ߾ߝ߾cK:2'hQ7hU^JaJhqJ^JaJ hQ7hUCJOJQJ^JaJ.hqJhU5CJOJQJ^JaJmHnHu8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH@ *hqJhqJB* CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH ТѢ KZYYYYY. >,X4` <hDp$7$8$H$IfgdqJ$Ifqkd1$$Ifl0$ 6$T04 la<  @BIJNOXY^_fg  ƩƩƩƩƩƩƩƩƑxmƩhQ7hU^JaJhqJ^JaJ hQ7hUCJOJQJ^JaJ.hqJhU5CJOJQJ^JaJmHnHu8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH* _f`22. >,X4` <hDp$7$8$H$IfgdqJ$Ifqkd$$Ifl0$ 6$T04 la<& >,X4` <hDp$If#$TV]^bclmrsz{¤äߤ UW^_delmƩƩƩƩƩƩƩƩƩƩƩƩƩƩƩ8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH;_n `& >,X4` <hDp$If. >,X4` <hDp$7$8$H$IfgdqJ ťƥȥɥХѥե֥ݥޥ<>EFJLUVY[bcdeħmmmmmmmmħ8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtHhQ7hU^JaJhqJ^JaJ hQ7hUCJOJQJ^JaJ.hqJhU5CJOJQJ^JaJmHnHu*ƥҥGWYYYYY. >,X4` <hDp$7$8$H$IfgdqJ$Ifqkd_$$Ifl0$ 6$T04 la<Wdef`22. >,X4` <hDp$7$8$H$IfgdqJ$Ifqkd$$Ifl0$ 6$T04 la<& >,X4` <hDp$IfߦBDKLQRYZacjkoqz{ק٧  $%(*123ƩƩƩƩƩƩƩƩƩƩƩƩƩƩƩƩ8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH?Ml|&34& >,X4` <hDp$If. >,X4` <hDp$7$8$H$IfgdqJ 345Z[]^efjkrsƨȨϨШԨ֨ߨ9ħmmmmmmmm8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtHhQ7hU^JaJhqJ^JaJ hQ7hUCJOJQJ^JaJ.hqJhU5CJOJQJ^JaJmHnHu'45[gѨYYYYY. >,X4` <hDp$7$8$H$IfgdqJ$Ifqkd$$Ifl0$ 6$T04 la<bnf`22. >,X4` <hDp$7$8$H$IfgdqJ$Ifqkd$$$Ifl0$ 6$T04 la<& >,X4` <hDp$If9abdelmqryzéĩ˩̩  ')0157@AEFOPUV]^гггггггггггг8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtHhQ7hU^JaJhC%>^JaJ3 2BQȪت>]m|+8& >,X4` <hDp$If. >,X4` <hDp$7$8$H$IfgdqJƪǪ˪֪ͪת۪ܪ35<=BCJK߾ߝ߾ߝ߾ߝ߾ߝcFcF߾8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB* CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tHKRT[\`bklpqz{֫ث߫߾߾߾߀cFcFcFc8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH@ *hqJhqJB* CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhqJB*CJOJPJQJ^JaJmH nHphsH tH )*-/6789KLNOVW[\cdsu㑀xmS2 *hC%>B*CJOJPJQJ^JaJnHphtHhQ7hU^JaJhC%>^JaJ hQ7hUCJOJQJ^JaJ.hqJhU5CJOJQJ^JaJmHnHu8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH 89LXԬYYYYYYY. >,X4` <hDp$7$8$H$IfgdqJ$Ifqkd$$Ifl0$ 6$T04 la< ɬˬҬӬ׬٬2=fg㑀ymyiymyiyh>0)hQ7hUmHnHu hQ7hU hQ7hUCJOJQJ^JaJ.hqJhU5CJOJQJ^JaJmHnHu8 *hqJhqJB*CJOJPJQJ^JaJnHphtH8 *hqJhqJB* CJOJPJQJ^JaJnHphtH8 *hqJhqJB*CJOJPJQJ^JaJnHphtH"_ĭfdd^VQH $IfgdqJgdqJ$a$gdqJ+$$a$qkdR$$Ifl0$ 6$T04 la<& >,X4` <hDp$Ifĭح٭+4678OmܮCR~Я2^x۰9Oi/ҺҭҺҭҭyҺҺyҺyҺҺyyҺyyҺ2hqJhqJ5>*B*CJPJ\aJnHphtH2jShqJhqJB*CJPJUaJnHphtHhqJhqJPJnHtH/hqJhqJ5B*CJPJ\aJnHphtH)hqJhqJB*CJPJaJnHphtH/hqJhqJ5B*CJ PJ\aJ nHphtH/ĭح٭Nkd$$If0y& 63<4a $IfgdqJ+45 $IfgdqJqkdW$$If\y& 63<4a568ORЯ2^x h^hgdqJgdqJ^kd$$IfFy 6    3<4aOiLrz4}"02}ߵ $Ifgd]u+gdQY$a$gdQYgdQYgdqJ h^hgdqJ/Lrz۲!4u}̳"026JW\m|ϵߵи걨i8 *hqJh>0)B*CJOJPJQJ^JaJnHphtHhQ7h>0)^JaJhQY hQ7hQYhQ7hQYmHnHuhQYmHnHu hQ7hU/hqJhqJ5B*CJPJ\aJnHphtH2hqJhqJ5>*B*CJPJ\aJnHphtH)hqJhqJB*CJPJaJnHphtH"  *+57`atv¶öƶǶɶ̶ζҶӶֶض 4?BƩƩƩƩ㩌ƩƩƩrƩr2 *h>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B* CJOJPJQJ^JaJnHphtH,ĶChi5qkd$$Ifl0$ 6$T04 la<) >,X4` <hDp$Ifgd]u. >,X4` <hDp$7$8$H$Ifgd]uBEFVXZdghi÷ŷƩtc[PƩƩƩƩhQ7h>0)^JaJh>0)^JaJ hQ7h>0)CJOJQJ^JaJ.hqJh>0)5CJOJQJ^JaJmHnHu8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B* CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtHi *B_x¸ո. >,X4` <hDp$7$8$H$Ifgd]u $Ifgd]uŷηϷҷԷ    &)019;=>AHIQSU[^efnprtw}ƩƌƌƌƌƌƌƌƌƩ8 *hqJh>0)B* CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH7ƸȸӸԸظڸ  ƩƩƩƘlK@ *hqJh>0)B*CJOJPJQJ^JaJmH nHphsH tH@ *hQYh>0)B*CJOJPJQJ^JaJmH nHphsH tHhQ7h>0)^JaJ hQ7h>0)CJOJQJ^JaJ8 *hqJh>0)B* CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH5A}VVVVVVV. >,X4` <hDp$7$8$H$Ifgd]u $Ifgd]uqkd$$Ifl0$ 6$T04 la< ')+1489?@E߾|_B_%8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B* CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH@ *hqJh>0)B*CJOJPJQJ^JaJmH nHphsH tH@ *hqJh>0)B*CJOJPJQJ^JaJmH nHphsH tH@ *hqJh>0)B*CJOJPJQJ^JaJmH nHphsH tH@ *hqJh>0)B* CJOJPJQJ^JaJmH nHphsH tHEFHKMZ[^`y|ùŹǹȹ˹ҹӹ۹ݹ߹ .16ƩƩƩƩƩ8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B* CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH7̹2ERc ) >,X4` <hDp$Ifgd]u. >,X4` <hDp$7$8$H$Ifgd]u 68CDHJPQUVabghjmouvy{źƺɺ˺  ƌƌ8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B* CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH1578DOQXZ^_inp˻̻̯uXuXXuu8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B* CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtH8 *hqJh>0)B*CJOJPJQJ^JaJnHphtHhQ7h>0)^JaJ hQ7h>0)CJOJQJ^JaJ.hqJh>0)5CJOJQJ^JaJmHnHu5[VVV. >,X4` <hDp$7$8$H$Ifgd]u $Ifgd]uqkd$$Ifl0$ 6$T04 la<ͻλcZ,. >,X4` <hDp$7$8$H$Ifgd>0) $Ifgd]uqkd$$Ifl0$ 6$T04 la<) >,X4` <hDp$Ifgd]u̻ͻλ ˮlKl*KK@ *h>0)h>0)B*CJOJPJQJ^JaJmH nHphsH tH@ *h>0)h>0)B*CJOJPJQJ^JaJmH nHphsH tH@ *h>0)h>0)B* CJOJPJQJ^JaJmH nHphsH tH@ *h>0)h>0)B*CJOJPJQJ^JaJmH nHphsH tH8 *h>0)h>0)B*CJOJPJQJ^JaJnHphtHhQ7h>0)^JaJh>0)^JaJ hQ7h>0)CJOJQJ^JaJ hqJh>0)CJOJQJ^JaJ?LUab5qkdK$$Ifl0$ 6$T04 la<) >,X4` <hDp$Ifgd>0). >,X4` <hDp$7$8$H$Ifgd>0)"$%&;<>ACJKMOSTUW_`abƩrrrrZIAhO<^JaJ hQ7h>0)CJOJQJ^JaJ.h>0)h>0)5CJOJQJ^JaJmHnHu8 *h>0)h>0)B*CJOJPJQJ^JaJnHphtH2 *h>0)B*CJOJPJQJ^JaJnHphtH8 *h>0)h>0)B*CJOJPJQJ^JaJnHphtH8 *h>0)h>0)B* CJOJPJQJ^JaJnHphtH8 *h>0)h>0)B*CJOJPJQJ^JaJnHphtHb$de@;_. >,X4` <hDp$7$8$H$Ifgd]u. >,X4` <hDp$7$8$H$IfgdO< $Ifgd]uNcGHixyؾؾئzeMe@Meh>0)h>0)PJnHtH/h>0)h>0)5B*CJPJ\aJnHphtH)h>0)h>0)B*CJPJaJnHphtH/h>0)h>0)5B*CJ PJ\aJ nHphtHh>0)mHnHu hQ7h>0)h>0)/h1hO<CJKHOJQJ^JaJmHnHu2 *hO<B*CJOJPJQJ^JaJnHphtH8 *hO<hO<B*CJOJPJQJ^JaJnHphtHh1hO<^JaJ@ywrii $Ifgd>0)gd>0)$a$gd>0) +$$a$gd>0)gd>0)qkd$$Ifl0$ 6$T04 la<6qkd$$If\y& 63<4a $Ifgd>0)Nkd$$If0y& 63<4a !" )PūҧyqjcZNcNcZNchQ7hUmHnHuhmHnHu hQ7hU hQYhQYjh>0)U h>0)0J)$jh]uh]uB*Uphh>0)B*phjh>0)B*Uphh>0)2jh>0)h>0)B*CJPJUaJnHphtHh>0)h>0)PJnHtH)h>0)h>0)B*CJPJaJnHphtH/h>0)h>0)5B*CJPJ\aJnHphtH !P}us+$a$gdggd}gdQY +$$a$gd>0)gd>0)^kdz$$IfFy 6    3<4a $Ifgd>0) PW5d) >,X4` <hDp$IfgdQY. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYPWX`fhz{3478:=?CDGI`cfgwy{ػ؁؞؁؞؁؞؁؁ػ؁ػ؁؞؁؁ػg2 *hQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB* CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJ(㬏rZIA6rhQ7hQY^JaJhQY^JaJ hQ7hQYCJOJQJ^JaJ.hqJhQY5CJOJQJ^JaJmHnHu8 *hqJhQYB* CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH2 *hQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH*bt~VVVVVVV. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYqkd$$Ifl0$ 6$T04 la< !"()./146?@CE^afgrsyz|}㩌㩌㩌㩌㩌8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB* CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH73FSab_qkdN$$Ifl0$ 6$T04 la<. >,X4` <hDp$7$8$H$IfgdQY  /279DEIKQRUW_abyƩƩƌƩƌƩƩƩƌƩƌƩƌ{phQ7hQY^JaJ hQ7hQYCJOJQJ^JaJ8 *hqJhQYB* CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH!by %=Yd Yl~. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYy{|߾|[||>8 *hqJhQYB*CJOJPJQJ^JaJnHphtH@ *hqJhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hqJhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hqJhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH  !$+,4689<CDLNPUX^`bcij}ƩƩƌƩƩƩƩƩƩƩƩƩƩƩƩƌ8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB* CJOJPJQJ^JaJnHphtH7 !"$')67:<UX]_jkoq|}ƩƩƩƩƌƩƩƌƩƩƩ8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB* CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH4~cZ,. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYqkd$$Ifl0$ 6$T04 la<) >,X4` <hDp$IfgdQY  "$<=̯uXuXXuu8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB* CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtH8 *hqJhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJ hQ7hQYCJOJQJ^JaJ.hqJhQY5CJOJQJ^JaJmHnHu!>?5qkd|$$Ifl0$ 6$T04 la<) >,X4` <hDp$IfgdQY. >,X4` <hDp$7$8$H$IfgdQY=>?uvwx|}ˮttttWWWt8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJhQY^JaJ hQ7hQYCJOJQJ^JaJ hqJhQYCJOJQJ^JaJ"?v~ 7{#l(8Gw. >,X4` <hDp$7$8$H$IfgdQY $IfgdQY  <=GIKRSUWlmprwz㩌㩌㩌8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH/  !")*6ACLMTVY[\^jkrsɬrrɬɬrrɬɬrrɬ8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH2 *hQYB*CJOJPJQJ^JaJnHphtH,  ƩƌkJk)@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH&'+-67;<EFKLST|}߾ߝ߾ߝ߾ߝ߾ߝ߾|ߝ|ߝ|ߝߝ߾ߝ߾ߝ@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH' ?DSx") >,X4` <hDp$IfgdQY. >,X4` <hDp$7$8$H$IfgdQY!)*02;>EFPUW_`fhƩƩƩk@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH߾߾߾߾cFc8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH 569;@CHJQRWX_`}~  !ƩƩƩƩƌƩƌƩƌƩƌƩƩƩƩƌƩƌƩƌƩƌ8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH7!"#YZ\]deijqrħmmmPPPm8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJhQY^JaJ hQ7hQYCJOJQJ^JaJ.hQYhQY5CJOJQJ^JaJmHnHu"#Zf+oVVVVVVV. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYqkd$$Ifl0$ 6$T04 la< 01;=?FGIK`adfknsu|}ƩƩƩƌƌkJk@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtHo~>Mr) >,X4` <hDp$IfgdQY. >,X4` <hDp$7$8$H$IfgdQY } ߾߾߾߾߀cFc8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH  /035:=BDKLQRYZgipquwƩƩƩƩƌƩƌƩƌƩƌƩƌtc[hQY^JaJ hQ7hQYCJOJQJ^JaJ.hQYhQY5CJOJQJ^JaJmHnHu8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH#BP_VVVVVVV. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYqkd$$Ifl0$ 6$T04 la< 3479>AEGNOST]^cdklػػػػػػػػػػػػػ8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJ2  #$)*12RS]_ahikm㩌㩌8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH7%M:N]m|.~. >,X4` <hDp$7$8$H$IfgdQY-.1369?ALMRT[\`bklpqz{ !,-ƩƩƩƌƩƌƩƌƩƌƩƌƩƌƩƩƩƩƌƩƌƩƌ8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH7-45FHJOPRTmnqsz}ƩƌƌƩƩƩƩtc[hQY^JaJ hQ7hQYCJOJQJ^JaJ.hQYhQY5CJOJQJ^JaJmHnHu8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH"cZ,. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYqkdA$$Ifl0$ 6$T04 la<) >,X4` <hDp$IfgdQY45?ACػػ}\;}@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJ0s-<LYZ) >,X4` <hDp$IfgdQY. >,X4` <hDp$7$8$H$IfgdQY CJKMOdehjorvx߾߾߾߾|߾|_B_8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH   +,13:;?AJKNPWXYZ[ƩƩƌƌƩƩƩƩtc hQ7hQYCJOJQJ^JaJ.hQYhQY5CJOJQJ^JaJmHnHu8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH&Z[JXgVVVVVVV. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYqkd$$Ifl0$ 6$T04 la< [  ггuT3u@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJhQY^JaJ!"$&;<?AFIMOVW[\efklst߾߾߾߾|߾|_B_8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tHt*+67>?PRTYZ\^vwz|ƩƌƌƩƩƩƩƌƌƩƩƩ8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH7%8\k"/) >,X4` <hDp$IfgdQY. >,X4` <hDp$7$8$H$IfgdQY(*,3468MNQSX[`bijopwx ƌƌ8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH7  !$&-./0IJLMTUYZabƩƩƑxmƩƩPƩP8 *hQYhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJhQY^JaJ hQ7hQYCJOJQJ^JaJ.hQYhQY5CJOJQJ^JaJmHnHu8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH/0JV$VVVVVVV. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYqkdo$$Ifl0$ 6$T04 la<   "#&(/012Ʃƌƌƌƌƌƌtc[hQY^JaJ hQ7hQYCJOJQJ^JaJ.hQYhQY5CJOJQJ^JaJmHnHu8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH!$12cZ,. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYqkd$$Ifl0$ 6$T04 la<) >,X4` <hDp$IfgdQY  %&^_ikmtuwyػػػػػػػػػػػػ8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJ2 Y3BRa!4. >,X4` <hDp$7$8$H$IfgdQY$&1279@AEGPQUV_`efmn㩌㩌8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH7&'23:;LNPSTVXqruw~ƩƩƩƌƩƌƩƌƩƌƩƩƩƩƌƩƌƩƌƩƌ8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH3cZ,. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYqkd$$Ifl0$ 6$T04 la<) >,X4` <hDp$IfgdQY+,68:ABDF[\_afimovwħmmmPPPm8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJhQY^JaJ hQ7hQYCJOJQJ^JaJ.hQYhQY5CJOJQJ^JaJmHnHu'jx.;) >,X4` <hDp$IfgdQY. >,X4` <hDp$7$8$H$IfgdQY w{| !#,-029:;ƩƩƩƩƌƌƩƩƩƩt.hQYhQY5CJOJQJ^JaJmHnHu8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH,;<4BQVVVVVVV. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYqkd4$$Ifl0$ 6$T04 la< ;<ܿdC@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJhQY^JaJ hQ7hQYCJOJQJ^JaJ  %&)+0379@AEFOPUV]^߾߾߾||_B_8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH^  !"+,129:uvƩƌƌƩƩƩƩƩƩk@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH)-pH\k{*?u. >,X4` <hDp$7$8$H$IfgdQYv߾||||ߝ|ߝ|_B_8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH "$;<?ADGMOZ[`bijnpyz~  !().ƩƌƌƩƩƩƩƩƩƌƌƩ8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH7./67DEQ\^cdkmpr{|$%,-ƌƌ8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH7 {au) >,X4` <hDp$IfgdQY. >,X4` <hDp$7$8$H$IfgdQY )+-2357PQTV]`fhsty{ƩƩƩ㩌㩌㩌ƩƩƩ㩌㩌㩌8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH7 *˺mmL+@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtHhQ7hQY^JaJhQY^JaJ hQ7hQYCJOJQJ^JaJ.hQYhQY5CJOJQJ^JaJmHnHu8 *hQYhQYB*CJOJPJQJ^JaJnHphtH^l{VVVVVVV. >,X4` <hDp$7$8$H$IfgdQY $IfgdQYqkd$$Ifl0$ 6$T04 la< *,.568:OPSUZ]acjkopyz߾߾߾||_B_8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH@ *hQYhQYB* CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH@ *hQYhQYB*CJOJPJQJ^JaJmH nHphsH tH   )*-/679;?@ACKLMƩƩƌƌƩƩƩƩƩƩt.hQYhQY5CJOJQJ^JaJmHnHu8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB* CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH8 *hQYhQYB*CJOJPJQJ^JaJnHphtH, +8AM) >,X4` <hDp$IfgdQY. >,X4` <hDp$7$8$H$IfgdQYMNO?@J^}upjj$IfgdQY$a$gdQY +$$a$gdO<gdgqkdb$$Ifl0$ 6$T04 la<MNVW?@IJ]^_ghtu -8d}ukkkukhQY0JHB*phhQY5>*B*\phjchQYB*UphhQYhQYB*phhQY5B*CJ\aJphhQY5B*\phhQYB*CJaJphhQY5B*CJ \aJ phhO< hQ7hO<hUhO<mHnHu hQ7hU hQ7hQYCJOJQJ^JaJ*^_hu9qkdg$$If\y 63<4a$IfNkd$$If0y 63<4a 8}"UGgdQYgdQY^kd$$IfFy 6    3<4a$If"9UqHz+Au~,crVz -.STZ[bcfjl}Ǽ٤٤٤ hQ7h2p hQ7h Eh/lB*hph h/lCJhh/l5B*hph hQ7h/lh/l hQ7hD hQ7hUhQY5>*B*\phhQY0JHB*phhQYB*ph>H+A~,rz>$gdg $$$a$gdggdRsgdQYGgdQYgdQY.3?STGkd$$IfH44F@3&      4 Haf4p $1$IfgdVAC $$1$Ifa$gdVAC+$$$^a$gd/l$$gd/lTVYZ[]ab`kd$$IfH4F@3&      4 Haf4 $1$IfgdVAC $1$Ifgd1bcshh $1$IfgdVAC $$1$Ifa$gdVAC+$$$^a$gdg$$gdg$gdg`kd_$$IfH4F@3&      4 Haf4$&',->@AZ\]qstw{<=\]ab뻷뻃h1hQ7hK&tB*hphhK&tB*hph hK&tCJhhK&t5B*hph hQ7hK&thK&t hQ7h Eh/lB*hphhQ7h/lB*hph h/lCJhh/l5B*hph hQ7hU hQ7h2p hQ7hGMh3%&wlaa $1$IfgdVAC $1$Ifgd1kd$$IfH44F@3&      4 Haf4p&'-?@ $1$IfgdVAC $1$Ifgd1`kd$$IfH4F@3&      4 Haf4@AG[\ $1$IfgdVAC $1$Ifgd1`kdH$$IfH4F@3&      4 Haf4\]crs $1$IfgdVAC $1$Ifgd1`kd$$IfH4F@3&      4 Haf4st shh $1$IfgdVAC $$1$Ifa$gdVAC+$$$^a$gdK&t$$gdK&t$gdg`kdZ$$IfH4F@3&      4 Haf4$;<wlaa $1$IfgdVAC $1$Ifgd1kd$$IfH44F@3&      4 Haf4p<=B[\ $1$IfgdVAC $1$Ifgd1`kd$$IfH4F@3&      4 Haf4\]b $1$IfgdVAC $1$Ifgd1`kdC$$IfH4F@3&      4 Haf4 $1$IfgdVAC $1$Ifgd1`kd$$IfH4F@3&      4 Haf4+0<Prff $$$Ifgd96$$$$Ifa$gd96+$$$^a$gdGMh$$gdg$gdg`kdU$$IfH4F@3&      4 Haf4 *+Q(,.8DW]^Kh  򿻿Ç|ÿÿukkkh1B*hph hQ7h#hQ7hUB* ph hQ7hhQ7h1B*hphhQ7h15B*hphhQ7h1B* ph hQ7h1hKh1 hQ7hUhQ7hEB*hphhQ7h2pB*hphhQ7h2p5B*hph hQ7h2p hQ7hGMh*PQWrswk__ $$$Ifgd96 $$$Ifgd1kd$$IfH44F@3&      4 Haf4pstz $$$Ifgd96 $$$Ifgd1`kd$$IfH4F@3&      4 Haf4 $$$Ifgd96 $$$Ifgd1`kd>$$IfH4F@3&      4 Haf4' $$$Ifgd96 $$$Ifgd1`kd$$IfH4F@3&      4 Haf4'(^ymm $$$IfgdVAC$$$$Ifa$gdVAC +$^a$gd1gd1gd# `kdP$$IfH4F@3&      4 Haf4wk__ $$$IfgdVAC $$$Ifgd1kd$$IfH44F@3&      4 Haf4p$% $$$IfgdVAC $$$Ifgd1`kd$$IfH4F@3&      4 Haf4%&+9: $$$IfgdVAC $$$Ifgd1`kd9$$IfH4F@3&      4 Haf4:;?UV $$$IfgdVAC $$$Ifgd1`kd$$IfH4F@3&      4 Haf4VW\st $$$IfgdVAC $$$Ifgd1`kdK$$IfH4F@3&      4 Haf4tuz $$$IfgdVAC $$$Ifgd1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC $$$Ifgd1`kd]$$IfH4F@3&      4 Haf4 $$$IfgdVAC $$$Ifgd1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC $$$Ifgd1`kdo$$IfH4F@3&      4 Haf4 $$$IfgdVAC $$$Ifgd1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC $$$Ifgd1`kd$$IfH4F@3&      4 Haf4 J $$$IfgdVAC $$$Ifgd1`kd $$IfH4F@3&      4 Haf4JKi|pp $$$Ifgd96$$$$Ifa$gd96 +$^a$gd2pgd# `kd$$IfH4F@3&      4 Haf4wk__ $$$Ifgd96 $$$Ifgd1kd$$IfH44F@3&      4 Haf4p  )* $$$Ifgd96 $$$Ifgd1`kd$$IfH4F@3&      4 Haf4  (+0124L~PQRUV^_`⟕hQ7hVACB*hphhVACB*hphhQ7hVAC5B*hphhQ7h1B*hphhQ7h15B*hphhVAChQ7hUB* phh1 hQ7h hQ7hUh1B*hphhQ7h2pB*hph5*+Mvjj $$$IfgdVAC$$$$Ifa$gdVAC+$$$^a$gd$$gd# `kd|$$IfH4F@3&      4 Haf4wkkk $$$IfgdVACkd$$IfH44F@3&      4 Haf4p1`kde$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd$$IfH4F@3&      4 Haf4Vzk$$$$Ifa$gdVAC +$8^8a$gdggd# gd`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC wkkk $$$IfgdVACkdw$$IfH44F@3&      4 Haf4p1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdN$$IfH4F@3&      4 Haf4%'_ #$&*+/02:<LN34e󷪷ަޢh)NB*hphh{6hgehQ7huYB*hphhuYB*hphhQ7hVAC5B*hphhKhQ7hVACB* ph hQ7hVAChVAChVACB*hphhQ7hVACB*hph<%&`kd`$$IfH4F@3&      4 Haf4 $$$IfgdVAC&'_ymm $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kd$$IfH4F@3&      4 Haf4wkkk $$$IfgdVACkdr$$IfH44F@3&      4 Haf4p  1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdI$$IfH4F@3&      4 Haf4$%&+01`kd[$$IfH4F@3&      4 Haf4 $$$IfgdVAC126:;<1`kdm$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd$$IfH4F@3&      4 Haf4<@LMNRn`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd$$IfH4F@3&      4 Haf4`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC341`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd$$IfH4F@3&      4 Haf44eFkd,$$IfH44F@3&      4 Haf4p $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# *+-KW589HKNOZ]`ahikno нйЫ鞽hD hQ7hKhQ7h)NB*hphhQ7hVAC5B*hphh{6hKhQ7hVACB* phhge hQ7hVAChhVAChVACB*hphh)NB*hphhQ7hVACB*hph7`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC+,-1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd$$IfH4F@3&      4 Haf4- 459Fkd$$IfH44F@3&      4 Haf4p $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# 9IJKO[\`kdu$$IfH4F@3&      4 Haf4 $$$IfgdVAC\]aijk1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd$$IfH4F@3&      4 Haf4ko`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC .ymm $$$Ifgd8$$$$Ifa$gd8 +$8^8a$gdKgdKgd# `kd$$IfH4F@3&      4 Haf4./2OPwkkk $$$Ifgd8kd"$$IfH44F@3&      4 Haf4p /12NQSTor(*-.689bc*,/08:˼˸˴˦˼˸hVACB*hphhQ7hVACB*hphh)NB*hphhQ7hVAC5B*hphh{6hKhQ7hVACB* phhge hQ7hVAChhVAChQ7hKB*hphhKB*hphhQ7hK5B*hph4PQTpqr1`kd$$IfH4F@3&      4 Haf4 $$$Ifgd8`kd$$IfH4F@3&      4 Haf4ru`kd $$IfH4F@3&      4 Haf4 $$$Ifgd81`kd$$IfH4F@3&      4 Haf4 $$$Ifgd8`kd$$IfH4F@3&      4 Haf4.cht|maa $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kd$$IfH4F@3&      4 Haf4 $$$Ifgd8 wkkk $$$IfgdVACkd/ $$IfH44F@3&      4 Haf4p1`kd $$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd $$IfH4F@3&      4 Haf40ns|m$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kd $$IfH4F@3&      4 Haf4 $$$IfgdVAC :;mn/0acfgoqrGILMUWXƹЫЫhKhQ7hVACB* phhgehhVAChKB*hphhQ7hKB*hphhVACB*hphhQ7hVACB*hphh)NB*hphhQ7hVAC5B*hphh{6 hQ7hVAC:wkkk $$$IfgdVACkd $$IfH44F@3&      4 Haf4p1`kd $$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdx $$IfH4F@3&      4 Haf4`kd $$IfH4F@3&      4 Haf4 $$$IfgdVAC0gymm $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kd$$IfH4F@3&      4 Haf4wkkk $$$IfgdVACkd$$IfH44F@3&      4 Haf4p1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kds$$IfH4F@3&      4 Haf4MFkd$$IfH44F@3&      4 Haf4p $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# >?pruv~'wx-23BEڠhuYB*hphh{6hKhQ7hVACB* phhge hQ7hVAChhVAChVACB*hphhQ7hVACB*hphh)NB*hphhQ7hVAC5B*hph?`kd\$$IfH4F@3&      4 Haf4 $$$IfgdVAC1`kdn$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd$$IfH4F@3&      4 Haf4?v|m$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC wkkk $$$IfgdVACkd$$IfH44F@3&      4 Haf4p1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdW$$IfH4F@3&      4 Haf4x ,|m$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdi$$IfH4F@3&      4 Haf4 $$$IfgdVAC ,-3CDwkkk $$$IfgdVACkd$$IfH44F@3&      4 Haf4pDEK[\]1`kdR$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd$$IfH4F@3&      4 Haf4EJKZ]bcrsuz{   & ' M O P X [ ] ^ f i o p q            ! % οʿοʿh)NB*hphhQ7hVAC5B*hphh{6hDhQ7hVACB* phhge hQ7hVAChh8hVAChQ7huYB*hphhVACB*hphhQ7hVACB*hphhuYB*hph8]cstu{`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdd$$IfH4F@3&      4 Haf4' , 8 L M P Fkdv$$IfH44F@3&      4 Haf4p $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# P Y Z [ ^ g h `kdM$$IfH4F@3&      4 Haf4 $$$IfgdVACh i       ymm $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kd$$IfH4F@3&      4 Haf4 ! & / 0 wkkk $$$IfgdVACkd_$$IfH44F@3&      4 Haf4p% & . 1 5 6 H K O P f g i m n           2 3 b f i j r t u                    ! #         οʿοhQ7hVAC5B*hphh{6hDhQ7hVACB* ph hQ7hVAChh8hVAChQ7huYB*hphhVACB*hphhuYB*hphhQ7hVACB*hph>0 1 6 I J K 1`kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd6$$IfH4F@3&      4 Haf4K P g h i n   `kdH$$IfH4F@3&      4 Haf4 $$$IfgdVAC      1`kdZ$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd$$IfH4F@3&      4 Haf4     3 j     |m$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kd$$IfH4F@3&      4 Haf4 $$$IfgdVAC     wkkk $$$IfgdVACkdl$$IfH44F@3&      4 Haf4p      1`kd $$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdC $$IfH4F@3&      4 Haf4      ! " `kdU!$$IfH4F@3&      4 Haf4 $$$IfgdVAC" # ' 2   1`kdg"$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd!$$IfH4F@3&      4 Haf4   M R ^ r s v Fkd"$$IfH44F@3&      4 Haf4p $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd#         L M s u v }                      CDjlm>ƹƹƹƹƯƯƯƯНhB*hphhhVAChVACB*hphhQ7hVACB*hphh)NB*hphhQ7hVAC5B*hphh{6hDhQ7hVACB* ph hQ7hVACh8hge>v ~      `kd#$$IfH4F@3&      4 Haf4 $$$IfgdVAC      1`kd$$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdP$$$IfH4F@3&      4 Haf4      DIUi|m$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdb%$$IfH4F@3&      4 Haf4 $$$IfgdVAC ijmwkkk $$$IfgdVACkd%$$IfH44F@3&      4 Haf4p1`kdK'$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd&$$IfH4F@3&      4 Haf4Fuz|m$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kd'$$IfH4F@3&      4 Haf4 $$$IfgdVAC >BEFNPQtu_` !$%58;ʽʽʽʽʳʳʳʳʽʦ梞ԌhB*hphhuYhgehhVAChQ7hb B*hphhVACB*hphhQ7hVACB*hphhb B*hphhQ7hVAC5B*hphh{6hDhQ7hVACB* ph hQ7hVACh87wkkk $$$IfgdVACkd]($$IfH44F@3&      4 Haf4p1`kd)$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd4)$$IfH4F@3&      4 Haf4`kdF*$$IfH4F@3&      4 Haf4 $$$IfgdVAC1`kdX+$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd*$$IfH4F@3&      4 Haf4`  Fkd+$$IfH44F@3&      4 Haf4p $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd#  !%67`kd,$$IfH4F@3&      4 Haf4 $$$IfgdVAC78<JKL1`kd-$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdA-$$IfH4F@3&      4 Haf4;<IJLOP\]_efg=@AVY\]qtwx   /156\̽׹̵̧ӣ̵̧̹̽hb hQ7hVAC5B*hphh{6huYhQ7hVACB* phhge hQ7hVAChhDhVAChQ7hVACB*hphhB*hphhVACB*hph@LP]^_(<|m$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdS.$$IfH4F@3&      4 Haf4 $$$IfgdVAC <=AWXwkkk $$$IfgdVACkd.$$IfH44F@3&      4 Haf4pXY]rst1`kd<0$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd/$$IfH4F@3&      4 Haf4tx`kd0$$IfH4F@3&      4 Haf4 $$$IfgdVAC6;G[ymm $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdN1$$IfH4F@3&      4 Haf4[\`hiwkkk $$$IfgdVACkd1$$IfH44F@3&      4 Haf4p\_`gjmn{~-/57{|'*+47:;EHKLtuwz{οʿhQ7hVAC5B*hphh{6huYhQ7hVACB* phhge hQ7hVAChhDhVAChQ7hb B*hphhVACB*hphhQ7hVACB*hphhb B*hph$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd=$$IfH4F@3&      4 Haf4[_stuy`kd>$$IfH4F@3&      4 Haf4 $$$IfgdVAC^_rsuxy#%&YZ79z|̹̫̽ߡߡߡߡߡߡߡېh8hQ7hb B*hphhb B*hphhQ7hVAC5B*hphh{6huYhQ7hVACB* ph hQ7hVAChgehDhVAChQ7hVACB*hphhJ-4B*hphhVACB*hph8Z_kymm $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kd^?$$IfH4F@3&      4 Haf4wkkk $$$IfgdVACkd?$$IfH44F@3&      4 Haf4p1`kdGA$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd@$$IfH4F@3&      4 Haf4`kdA$$IfH4F@3&      4 Haf4 $$$IfgdVAC1`kdB$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdYB$$IfH4F@3&      4 Haf4789=C{`kdkC$$IfH4F@3&      4 Haf4 $$$IfgdVAC{|*/;Oymm $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdC$$IfH4F@3&      4 Haf4)*PSTknqr-/23;=>ghȾȾhVACB*hphhQ7hVACB*hphh B*hphhQ7hVAC5B*hphh{6huYhQ7hVACB* phhD hQ7hVAChVAChgeh8BOPTlmwkkk $$$IfgdVACkd}D$$IfH44F@3&      4 Haf4pmnr1`kdE$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdTE$$IfH4F@3&      4 Haf4`kdfF$$IfH4F@3&      4 Haf4 $$$IfgdVAC3hmyymm $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdF$$IfH4F@3&      4 Haf4wkkk $$$IfgdVACkdxG$$IfH44F@3&      4 Haf4p1`kdH$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdOH$$IfH4F@3&      4 Haf4E|m$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdaI$$IfH4F@3&      4 Haf4 $$$IfgdVAC  ?@ADEMOP ?@qrsvwȾȾhQ7h B*hphhVACB*hphhQ7hVACB*hphh B*hphhQ7hVAC5B*hphh{6huYhQ7hVACB* ph hQ7hVAChgehDh8hVAC<wkkk $$$IfgdVACkdI$$IfH44F@3&      4 Haf4p1`kdJK$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdJ$$IfH4F@3&      4 Haf4`kdK$$IfH4F@3&      4 Haf4 $$$IfgdVAC 1`kdL$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd\L$$IfH4F@3&      4 Haf4@wFkdnM$$IfH44F@3&      4 Haf4p $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdEN$$IfH4F@3&      4 Haf4 $$$IfgdVAC1`kdWO$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdN$$IfH4F@3&      4 Haf4()Z[\_`hjk      8 9 j Ժ{wwwhVAChQ7hVAC5B*hphhDh{6mH sH huYmH sH hDhVACmH sH hQ7hVACB* phhDhge hQ7hVACh hgemH sH hDmH sH h hVACmH sH hVACB*hphh B*hphhQ7hVACB*hph.)`FkdO$$IfH44F@3&      4 Haf4p $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdP$$IfH4F@3&      4 Haf4 $$$IfgdVAC1`kdQ$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd@Q$$IfH4F@3&      4 Haf4   9 p     |m$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdRR$$IfH4F@3&      4 Haf4 $$$IfgdVAC j k l o p x z {              !! !!!!T!U!!!!!!!!!!!!""""" ")","/"0"9":"<"?"@"E"F"H"N"O"P"p"s"""""ƹƹƹƹƯƯƹƹƹƹƯƯƯƯhgehVAChVACB*hphhQ7hVACB*hphh B*hphhQ7hVAC5B*hphh{6huYhQ7hVACB* ph hQ7hVAChDh8B     wkkk $$$IfgdVACkdR$$IfH44F@3&      4 Haf4p      1`kd;T$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdS$$IfH4F@3&      4 Haf4  !! !U!!!!!!|m$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdT$$IfH4F@3&      4 Haf4 $$$IfgdVAC !!"""wkkk $$$IfgdVACkdMU$$IfH44F@3&      4 Haf4p"" "*"+","1`kdV$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kd$V$$IfH4F@3&      4 Haf4,"0":";"<"@"F"G"`kd6W$$IfH4F@3&      4 Haf4 $$$IfgdVACG"H"s""""""ymm $$$IfgdVAC$$$$Ifa$gdVAC +$8^8a$gdVACgdVACgd# `kdW$$IfH4F@3&      4 Haf4""""""""""####%#(#+#,#I#J#L#N#O#d#e#g#}############3$4$Z$]$ͶͶͶͶͩ饚whgeB*hphhQ7hge5B*hphhQ7hgeB* ph hQ7hgehDhgehQ7h B*hphhVACB*hphhQ7hVACB*hphh B*hphhQ7hVAC5B*hphh{6huY hQ7hVAChQ7hVACB* ph)"""##wkkk $$$IfgdVACkdHX$$IfH44F@3&      4 Haf4p###&#'#(#1`kdY$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdY$$IfH4F@3&      4 Haf4(#,#J#K#L#O#e#f#`kd1Z$$IfH4F@3&      4 Haf4 $$$IfgdVACf#g#j#}#~##1`kdC[$$IfH4F@3&      4 Haf4 $$$IfgdVAC`kdZ$$IfH4F@3&      4 Haf4###4$9$E$Y$Z$^$Fkd[$$IfH44F@3&      4 Haf4p $$$Ifgdz$$$$Ifa$gdz +$8^8a$gdgegdgegd# ]$^$b$e$h$i$p$s$$$$$$$$$$$%%%-%W%Y%[%\%s%t%%%%%<&y&($(((A(B(***+.+3+G+_+`+,6.ҿǸ⩢} hQ7h`ahQ7ho90JBOJQJhQ7ho96] hQ7ho9 hQ7h# hQ7hEhQ7hU6 hb hb hb hb H* hQ7hb hVAChb h{6h{6H*h{6 hQ7hUhgeB*hphhQ7hgeB*hph1^$c$d$e$i$q$r$`kd\$$IfH4F@3&      4 Haf4 $$$Ifgdzr$s$w$$$$1`kd]$$IfH4F@3&      4 Haf4 $$$Ifgdz`kd,]$$IfH4F@3&      4 Haf4$$$$$$$%-%t%%%%&}}xgdb $a$gdb $a$gdggd# `kd>^$$IfH4F@3&      4 Haf4 $$$Ifgdz &&&'(B(*+7+`+-5.k../00#1$1[1\1$5%586:6^gd$a$gd#gdo9$a$gdo9$a$gdggd# 6.b.c.d.g....//00111!1"1K5L5o5p5~5555566626466686:666799::::::::⵩⵩ՓwwwjhQ7h`aUh]u hQ7h]u hCJ h]uCJj|_h]uhCJUh]uh5CJ\jh]uh5CJU\j^h]uhCJUjh]uhCJUh]uhCJ hQ7h`a hQ7ho9 hQ7h#.:666:.:f::::::;;<== >,>?F?c?$ ^gd#$a$gdggdEgd# $a$gd`a $a$gd`a$a$gd`agd# gd]u:::;;===> >>>>>>??F?c?@@~@@@@AbAmAnAzB{BBBBB뫹򙐙yyynf\XhQYjhQY0J'UhUCJKHhQ7hUCJKH-hQ7h#B*CJPJ^JaJnHphtHhQ7h#CJhQ7h#CJhQ7hU0J)j1`hQ7hUUjhQ7hUUhQ7hUB* phhQ7hU>*hQ7hU>*B*ph hQ7hE hQ7hU hQ7h# hQ7h`a"c?@@~@@@AbAnAyBzB{BBB:DFEE{F|F~FF&$a$gdg$a$gdg ;$pgd}$$gd# $$^gd# $ 8^8gd# $$v^vgd#BB C)CCCCCCCCCC:D;DEE*E+E,ECEDEFEGEEEEEBFCFcFdFeFwFxF{F|F}FFFFFFFFF h2hQYCJOJQJ^JaJh*jbhQYU hQY6 hQY0J)jahQY<UjhQY0J'UhIhQY0J)jahQYU hhQYjhQYUhQYmHnHuhQY hQY5H*-FFFFFFFFF$$& #$/Ifa$b$gd1h$& #$/If]hb$gd1FFFFFFFFFFFFGGGGGGG+G,Gɳɂ~w~ffWJ:Wh+hQY5CJOJQJ^JhQY5CJOJQJ^Jh+hQYCJOJQJ^J h+hQYCJOJQJ^JaJ h1hQYhQYh2hQYOJQJ^J'hN,RhQYCJOJQJ^JmHnHuh2hQY5CJOJQJ^J*hN,RhQY5CJOJQJ^JmHnHuh2hQYCJOJQJ^J h2hQYCJOJQJ^JaJ+hSshQYCJOJQJ^JaJmHnHuFFFFFG,GwrreM6$$& #$/Ifa$b$gdh$& #$/If]hb$gd &dPgdh gd1kdPc$$IfTl0$ ^ t 6 044 lae4T,G-G.G/G0G1GBGPGuppnnRR"$& #$$d/IfNb$gd+gdkdc$$IfTl0$p t 6 0644 lae4T,G-G.G/G1G6G7G=G>G@GAGBGJGOG\GeGGGGGGGGGGGG؄rbbbbRbbhUhQY5CJOJQJ^Jh+hQY5CJOJQJ^J#hSshQYOJQJ^JmHnHu*hN,RhQY5CJOJQJ^JmHnHu(h]u0J!5CJOJQJ^JmHnHu#h(hQY0J!5CJOJQJ^J,jh(hQY0J!5CJOJQJU^Jh(hQY5CJOJQJ^J hhQYhQYh+hQYOJQJ^JPGGGGGGGG xvvbb"$& #$/Ifb$gd+ "hh]h`hgd2bkdd$$IfTl04$ t 6 644 lae4T"$$& #$/Ifa$b$gd+Release 1.0 Draft StandardPage  PAGE 49 November 2005 Copyright 1998-2005 Health Level Seven. All Rights Reserved. Additional Information Specification : Attachment Additional Information Specification : Attachment Page  PAGE 62Copyright Health Level Seven, Inc. All rights reserved. Release Standard Copyright Health Level Seven, Inc. All rights reserved. Release StandardPage  PAGE 1  Copyright Health Level Seven. All Rights Reserved. GG    ! ' ( * + - 5 : ; < = @ L U 򳡳zleaQQahaVhQY5CJOJQJ^JhQY h9hQYh+hQY5OJQJ^J#hSshQYOJQJ^JmHnHu(h]u0J!5CJOJQJ^JmHnHu#h2hQY0J!5CJOJQJ^J,jh2hQY0J!5CJOJQJU^J*hN,RhQY5CJOJQJ^JmHnHuh+hQY5CJOJQJ^JUhQY5CJOJQJ^J - ; < = > ? VIG: hh]h`hgd+ "hh]h`hgd9kdQe$$IfTl0\$ t 6 0644 lae4T"$$& #$$d/IfNa$b$gd+? @ $$& #$/Ifa$b$gd1h$& #$/If]hb$gd1""$a$gdx ÿ{ngW@,jh(hQY0J!5CJOJQJU^Jh(hQY5CJOJQJ^J hhQYh+hQYOJQJ^Jh+hQY5CJOJQJ^JhQY5CJOJQJ^Jh+hQYCJOJQJ^J h+hQYCJOJQJ^JaJ h1hQYhQYh2hQYOJQJ^Jh2hQY5CJOJQJ^Jh2hQYCJOJQJ^J h2hQYCJOJQJ^JaJ wrreM6$$& #$/Ifa$b$gdh$& #$/If]hb$gd &dPgdh gd1kde$$IfTl0$ ^ t 6 044 lae4T  uppnnR"$& #$$d/IfNb$gd+gdkdf$$IfTl0$p t 6 0644 lae4T     U V W Y ֱlZllLE h9hQYh+hQY5OJQJ^J#h2hQY0J!5CJOJQJ^J,jh2hQY0J!5CJOJQJU^JhQY5CJOJQJ^JhQYhUhQY5CJOJQJ^Jh+hQYOJQJ^Jh+hQY5CJOJQJ^J(hQY0J!5CJOJQJ^JmHnHu,jh(hQY0J!5CJOJQJU^J#h(hQY0J!5CJOJQJ^J B U V W X Y xvvbb"$& #$/Ifb$gd+ "hh]h`hgd2bkdRg$$IfTl04$ t 6 644 lae4T"$$& #$/Ifa$b$gd+ VIG:G hh]h`hgd+ "hh]h`hgd9kdg$$IfTl0\$ t 6 0644 lae4T"$$& #$$d/IfNa$b$gd+ ;$pgd}""$a$gdx hUCJKHh*hQYhaVhQY5CJOJQJ^JB 0 000&PP:p+/ =!8"8#@$%`` 8 00&P:p1/ =!8"8#@$%`` 90&PP:p1/ =!8"8#@$%`` < 00&PP:p1/ =!8"8#@$%`` < 00&PP:pU/ =!8"8#@$%`` }DyK _Toc122939381}DyK _Toc122939381}DyK _Toc122939382}DyK _Toc122939382}DyK _Toc122939383}DyK _Toc122939383}DyK _Toc122939384}DyK _Toc122939384}DyK _Toc122939385}DyK _Toc122939385}DyK _Toc122939386}DyK _Toc122939386}DyK _Toc122939387}DyK _Toc122939387}DyK _Toc122939388}DyK _Toc122939388}DyK _Toc122939389}DyK _Toc122939389}DyK _Toc122939390}DyK _Toc122939390}DyK _Toc122939391}DyK _Toc122939391}DyK _Toc122939392}DyK _Toc122939392}DyK _Toc122939393}DyK _Toc122939393}DyK _Toc122939394}DyK _Toc122939394}DyK _Toc122939395}DyK _Toc122939395}DyK _Toc122939396}DyK _Toc122939396}DyK _Toc122939397}DyK _Toc122939397}DyK _Toc122939398}DyK _Toc122939398}DyK _Toc122939399}DyK _Toc122939399}DyK _Toc122939400}DyK _Toc122939400}DyK _Toc122939401}DyK _Toc122939401}DyK _Toc122939402}DyK _Toc122939402}DyK _Toc122939403}DyK _Toc122939403}DyK _Toc122939404}DyK _Toc122939404}DyK _Toc122939405}DyK _Toc122939405}DyK _Toc122939406}DyK _Toc122939406}DyK _Toc122939407}DyK _Toc122939407}DyK _Toc122939408}DyK _Toc122939408}DyK _Toc122939409}DyK _Toc122939409}DyK _Toc122939410}DyK _Toc122939410}DyK _Toc122939411}DyK _Toc122939411}DyK _Toc122939412}DyK _Toc122939412}DyK _Toc122939413}DyK _Toc122939413}DyK _Toc122939414}DyK _Toc122939414}DyK _Toc122939415}DyK _Toc122939415}DyK _Toc122939416}DyK _Toc122939416}DyK _Toc122939417}DyK _Toc122939417}DyK _Toc122939418}DyK _Toc122939418}DyK _Toc122939419}DyK _Toc122939419}DyK _Toc122939420}DyK _Toc122939420}DyK _Toc122939421}DyK _Toc122939421}DyK _Toc122939422}DyK _Toc122939422}DyK _Toc122939423}DyK _Toc122939423}DyK _Toc122939424}DyK _Toc122939424}DyK _Toc122939425}DyK _Toc122939425}DyK _Toc122939426}DyK _Toc122939426}DyK _Toc122939427}DyK _Toc122939427}DyK _Toc122939428}DyK _Toc122939428}DyK _Toc122939429}DyK _Toc122939429}DyK _Toc122939430}DyK _Toc122939430}DyK _Toc122939431}DyK _Toc122939431}DyK _Toc122939432}DyK _Toc122939432}DyK _Toc122939433}DyK _Toc122939433}DyK _Toc122939434}DyK _Toc122939434}DyK _Toc122939435}DyK _Toc122939435}DyK _Toc122939436}DyK _Toc122939436}DyK _Toc122939437}DyK _Toc122939437}DyK _Toc122939438}DyK _Toc122939438}DyK _Toc122939439}DyK _Toc122939439}DyK _Toc122939440}DyK _Toc122939440}DyK _Toc122939441}DyK _Toc122939441}DyK _Toc122939442}DyK _Toc122939442}DyK _Toc122939443}DyK _Toc122939443}DyK _Toc122939444}DyK _Toc122939444}DyK _Toc122939445}DyK _Toc122939445}DyK _Toc122939446}DyK _Toc122939446}DyK _Toc122939447}DyK _Toc122939447}DyK _Toc122939448}DyK _Toc122939448}DyK _Toc122939449}DyK _Toc122939449}DyK _Toc122939450}DyK _Toc122939450}DyK _Toc122939451}DyK _Toc122939451}DyK _Toc122939452}DyK _Toc122939452}DyK _Toc122939453}DyK _Toc122939453}DyK _Toc122939454}DyK _Toc122939454}DyK _Toc122939455}DyK _Toc122939455}DyK _Toc122939456}DyK _Toc122939456}DyK _Toc122939457}DyK _Toc122939457}DyK _Toc122939458}DyK _Toc122939458}DyK _Toc122939459}DyK _Toc122939459}DyK _Toc122939460}DyK _Toc122939460}DyK _Toc122939461}DyK _Toc122939461}DyK _Toc122939462}DyK _Toc122939462}DyK _Toc122939463}DyK _Toc122939463}DyK _Toc122939464}DyK _Toc122939464}DyK _Toc122939465}DyK _Toc122939465}DyK _Toc122939466}DyK _Toc122939466}DyK _Toc122939467}DyK _Toc122939467}DyK _Toc122939468}DyK _Toc122939468}DyK _Toc122939469}DyK _Toc122939469}DyK _Toc122939470}DyK _Toc122939470}DyK _Toc122939471}DyK _Toc122939471}DyK _Toc122939472}DyK _Toc122939472}DyK _Toc122939473}DyK _Toc122939473}DyK _Toc122939474}DyK _Toc122939474}DyK _Toc122939475}DyK _Toc122939475}DyK _Toc122939476}DyK _Toc122939476}DyK _Toc122939477}DyK _Toc122939477}DyK _Toc122939478}DyK _Toc122939478}DyK _Toc122939479}DyK _Toc122939479}DyK _Toc122939480}DyK _Toc122939480}DyK _Toc122939481}DyK _Toc122939481}DyK _Toc122939482}DyK _Toc122939482}DyK _Toc122939483}DyK _Toc122939483}DyK _Toc122939484}DyK _Toc122939484}DyK _Toc122939485}DyK _Toc122939485}DyK _Toc122939486}DyK _Toc122939486}DyK _Toc122939487}DyK _Toc122939487}DyK _Toc122939488}DyK _Toc122939488}DyK _Toc122939490}DyK _Toc122939490}DyK _Toc122939491}DyK _Toc122939491}DyK _Toc122939492}DyK _Toc122939492}DyK _Toc122939493}DyK _Toc122939493}DyK _Toc122939494}DyK _Toc122939494}DyK _Toc122939495}DyK _Toc122939495}DyK _Toc122939496}DyK _Toc122939496}DyK _Toc122939497}DyK _Toc122939497}DyK _Toc122939498}DyK _Toc122939498}DyK _Toc122939499}DyK _Toc122939499}DyK _Toc122939500}DyK _Toc122939500}DyK _Toc122939501}DyK _Toc122939501}DyK _Toc122939502}DyK _Toc122939502}DyK _Toc122939503}DyK _Toc122939503}DyK _Toc122939504}DyK _Toc122939504}DyK _Toc122939505}DyK _Toc122939505}DyK _Toc122939506}DyK _Toc122939506}DyK _Toc122939507}DyK _Toc122939507}DyK _Toc122939508}DyK _Toc122939508}DyK _Toc122939509}DyK _Toc122939509}DyK _Toc122939510}DyK _Toc122939510}DyK _Toc122939511}DyK _Toc122939511}DyK _Toc122939512}DyK _Toc122939512}DyK _Toc122939513}DyK _Toc122939513}DyK _Toc122939514}DyK _Toc122939514}DyK _Toc122939515}DyK _Toc122939515}DyK _Toc122939516}DyK _Toc122939516}DyK _Toc122939517}DyK _Toc122939517}DyK _Toc122939518}DyK _Toc122939518}DyK _Toc122939519}DyK _Toc122939519}DyK _Toc122939520}DyK _Toc122939520}DyK _Toc122939521}DyK _Toc122939521}DyK _Toc122939522}DyK _Toc122939522}DyK _Toc122939523}DyK _Toc122939523}DyK _Toc122939524}DyK _Toc122939524}DyK _Toc122939525}DyK _Toc122939525}DyK _Toc122939526}DyK _Toc122939526}DyK _Toc122939527}DyK _Toc122939527}DyK _Toc122939528}DyK _Toc122939528}DyK _Toc122939529}DyK _Toc122939529}DyK _Toc122939530}DyK _Toc122939530}DyK _Toc122939531}DyK _Toc122939531DyK http://www.LOINC.orgyK ,http://www.loinc.org/$$If<!vh555D5 #v#v#vD#v :V l440    ,555D5 /  / / / 4a<f4$$If<!vh555D5 #v#v#vD#v :V l40    ,555D5 / / / / / 4a<f4$$If<!vh555D5 #v#v#vD#v :V l4C0    ,,555D5 / / / / / 4a<f4$$If<!vh555D5 #v#v#vD#v :V l40    ,,555D5 / / / / / 4a<f4$$If<!vh555D5 #v#v#vD#v :V l40    ,,555D5 / / / / / 4a<f4$$If<!vh555D5 #v#v#vD#v :V l40    ,555D5 /  / / / 4a<f4$$If!vh55P#v#vP:V l4 055P4ap$$If!vh55P#v#vP:V l055P4a$$If!vh55P#v#vP:V l055P4a$$If!vh55P#v#vP:V l055P4a$$If!vh55P#v#vP:V l055P4a$$If!vh55P#v#vP:V l055P4a$$If!vh55P#v#vP:V l055P4a$$If!vh55P#v#vP:V 4  6 ,55P44 e4pT$$If!vh55P#v#vP:V  6 55P44 e4T$$If!vh55P#v#vP:V  6 55P44 e4T$$If!vh55P#v#vP:V  6 55P44 e4T$$If!vh55P#v#vP:V  6 55P44 e4T$$If!vh55P#v#vP:V  6 55P44 e4T$$If!vh55P#v#vP:V  6 55P44 e4T$$If!vh55P#v#vP:V  6 55P44 e4T$$If!vh55t#v#vt:V (44 655t/ / / /  44 (f4pT$$If!vh55t#v#vt:V (4 655t/ 44 (f4pT$$If6!vh55#v#v:V (4 65544 (f4p$$If6!vh55#v#v:V (4 65544 (f4p$$If6!vh55#v#v:V (4 65544 (f4p$$If6!vh55#v#v:V (4 65544 (f4p$$If6!vh55#v#v:V (4 65544 (f4p$$If6!vh55#v#v:V (4 65544 (f4p$$If6!vh55#v#v:V (4 65544 (f4p$$If6!vh55#v#v:V (4 65544 (f4p$$If6!vh55#v#v:V (4 65544 (f4p$$If!vh5"5t#v"#vt:V (44  6 5"5t/ / / /  44 (e4f4p$$If!vh5"5t#v"#vt:V (4  6 5"5t/ 44 (e4f4p$$If!vh5"5t#v"#vt:V (4  6 5"5t44 (e4f4p$$If!vh5"5t#v"#vt:V (4  6 5"5t44 (e4f4p$$If!vh5"5t#v"#vt:V (4  6 5"5t44 (e4f4p$$If!vh5"5t#v"#vt:V (4  6 5"5t44 (e4f4p$$If!vh5"5t#v"#vt:V (4  6 5"5t44 (e4f4p$$If!vh5"5t#v"#vt:V (4  6 5"5t44 (e4f4p$$If!vh5"5t#v"#vt:V (4  6 5"5t44 (e4f4p$$If!vh5"5t#v"#vt:V (4  6 5"5t44 (e4f4p$$If!vh55t#v#vt:V (44 t"55t/ / / /  44 (af4pT$$If!vh55t#v#vt:V (4 t"55t/ 44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (4 t"55t44 (af4pT$$If!vh55t#v#vt:V (44 t"55t/ / / /  44 (af4p$$If!vh55t#v#vt:V (4 t"55t/ 44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55#v#v:V (4 t"5544 (af4p$$If!vh55#v#v:V (4 t"5544 (af4p$$If!vh55#v#v:V (4 t"5544 (af4p$$If!vh55#v#v:V (4 t"5544 (af4p$$If!vh55#v#v:V (4 t"5544 (af4p$$If!vh55#v#v:V (4 t"5544 (af4p$$If!vh55#v#v:V (4 t"5544 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (44 t"55t/ / / /  44 (af4p$$If!vh55t#v#vt:V (4 t"55t/ 44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh5x5#vx#v:V (44  6 5x5/ / / /  44 (e4f4pT$$If!vh5x5#vx#v:V (4  6 5x5/ 44 (e4f4pT$$If!vh5F5#vF#v:V (4  6 5F544 (e4f4pT$$If!vh5F5#vF#v:V (4  6 5F544 (e4f4pT$$If!vh5F5#vF#v:V (4  6 5F544 (e4f4pT$$If!vh5F5#vF#v:V (4  6 5F544 (e4f4pT$$If!vh5F5#vF#v:V (4  6 5F544 (e4f4pT$$If!vh5F5#vF#v:V (4  6 5F544 (e4f4pT$$If!vh5F5#vF#v:V (4  6 5F544 (e4f4pT$$If!vh5F5#vF#v:V (4  6 5F544 (e4f4pT$$If!vh5F5#vF#v:V (4  6 5F544 (e4f4pT$$If!vh5F5#vF#v:V (4  6 5F544 (e4f4pT$$If!vh5F5#vF#v:V (4  6 5F544 (e4f4pT$$If!vh55t#v#vt:V (44 t"55t/ / / /  44 (af4p$$If!vh55t#v#vt:V (4 t"55t/ 44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p$$If!vh55t#v#vt:V (4 t"55t44 (af4p-$$If(!vh5P555@5#vP#v#v#v@#v:V H44 2$(5P555@544 Ha(f4p2$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4$5P555@544 Ha(f4-$$If(!vh5P555@5#vP#v#v#v@#v:V H44 25P555@544 Ha(f4p2$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H4- 5P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4-$$If(!vh5P555@5#vP#v#v#v@#v:V H44 2(5P555@544 Ha(f4p2$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4-$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44 24%5!5H55>544 Ha(f4p2$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4$$If(!vh5!5H55>5#v!#vH#v#v>#v:V H44%5!5H55>544 Ha(f4-$$If(!vh5(5V555F#v(#vV#v#v#vF:V H44 2$5(5V555F44 Ha(f4p2$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5V555F#v(#vV#v#v#vF:V H4$5(5V555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4$$If(!vh5(5\555F#v(#v\#v#v#vF:V H4$5(5\555F44 Ha(f4-$$If(!vh5P555@5#vP#v#v#v@#v:V H44 2(5P555@544 Ha(f4p2$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4$$If(!vh5P555@5#vP#v#v#v@#v:V H45P555@544 Ha(f4-$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H44 2$5P55*5v5F44 Ha(f4p2$$If(!vh5P55*5v5N#vP#v#v*#vv#vN:V H4$5P55*5v5N44 Ha(f4$$If(!vh5P55*5v5N#vP#v#v*#vv#vN:V H4$5P55*5v5N44 Ha(f4$$If(!vh5P55*5v5N#vP#v#v*#vv#vN:V H4$5P55*5v5N44 Ha(f4$$If(!vh5P55*5v5N#vP#v#v*#vv#vN:V H4$5P55*5v5N44 Ha(f4$$If(!vh5P55*5v5N#vP#v#v*#vv#vN:V H4$5P55*5v5N44 Ha(f4$$If(!vh5P55*5v5N#vP#v#v*#vv#vN:V H4$5P55*5v5N44 Ha(f4$$If(!vh5P55*5v5N#vP#v#v*#vv#vN:V H4$5P55*5v5N44 Ha(f4$$If(!vh5P55*5v5N#vP#v#v*#vv#vN:V H4$5P55*5v5N44 Ha(f4$$If(!vh5P55*5v5N#vP#v#v*#vv#vN:V H4$5P55*5v5N44 Ha(f4$$If(!vh5P55*5v5N#vP#v#v*#vv#vN:V H4$5P55*5v5N44 Ha(f4$$If(!vh5P55*5v5N#vP#v#v*#vv#vN:V H4$5P55*5v5N44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If(!vh5P55*5v5F#vP#v#v*#vv#vF:V H4$5P55*5v5F44 Ha(f4$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<l$$If!vh55Y#v#vY:V 6,53<4$$If!vh55Y5v5 #v#vY#vv#v :V 6,53<4u$$If!vh5 5v5 #v #vv#v :V 6,53<4Dd$<P  3 3"(($$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T5/ 4a<l$$If!vh55Y#v#vY:V 6,53<4$$If!vh55Y5v5 #v#vY#vv#v :V 6,53<4u$$If!vh5 5v5 #v #vv#v :V 6,53<4Dd$<P  3 3"((7DyK yK ../../../../../../../../Documents and Settings/bzdtfz/Local Settings/Temp/prescription-glasses.gifDdj,777`  C <A$Antifungal Reportb?u`Ϟ M &dnu`Ϟ M &dPNG  IHDR sRGBgAMA a cHRMz&u0`:pQ<IDATx^Az*FG%d@gizYvp_RZ}sE !@.Fs9 I/@ p6H t%M @$@ q.ةۤׯ_{N~n-.ӓW5\4߿JXCۧO,ϟϟ?v˗U??[3_TbL`~BRmmATgT |v"2B&87NCԕ"խsCUD7/2h+?~_-hdT04#x\:XV+"YR]z]+k?I*.v2B87Oѝ ԕ(A\iKgiإm\v枥)v&NM2s' [Sh1h-AYտUcH8ORWo-6,o.yK ~(Yɫ- X5K7Soʪs[$Nx≪tU8L ֏`;YY[FׁOBKIqZ:fe%%|7ށhsYViR)8uj4wK%€6%fXc[6n-ڒ1d cJ-iL- Л@㤫kh҂+h$c Mx+BnbY썷zdQX"r۲jv$ 2 Aߤ*?ыYj»ʫ݈O!=%P*XXCúB|'N1k@4V3#]K))?.[G+3h~'E6]R]i4KMRXr^JI[G깃[Ŕ:8bfbX4"dn_ő8;cL9Ҏ]̵KuG+(Wk"uw)%(qSmѫ3jkT]7$NݹTb7 N8@b7xZ|o_P;.jOTXdhA%ބjK$N򜶙jW_]\oiH2\,I ,g\b*ⵅ#WRgKFKxM g322@2{)8lg|M1yȧk`ڟ⤢\m5p̵KGqKTlWDzO0=">y=_Q[R_-u Tb٫݈W?bz箂W7|N;UQ{@ p)HKu' @@8x @$Ĺ`$@8 @$Ĺ`$@8 @$Ĺ`$@8 @$Ĺ`$@8 @$Ĺ`$@8 @$Ĺ`$@8 @$Ĺ`$@861l:/89i8I.ۧO,׎FVZQǑ4'_}߿ņ2*؟-F򊵴bk_$]cmܼKb[XKn y>^ c! KWJ%SM^%&K{b|C~QƎe8?9DlOeY*˗/ϟ?5{z+bUeUNJETcgQ %F5"gz&&]b>;.5ŋZ*VqȼJEIVu_e4}:x84zB={UfJcJTđ-uO52_};e &DzNyu%q%~[.qꭈJd֯LI[/FmqMRZ$NK*Y,b"\GǏb bȋ%S\46$Y(Md@ qЋڠeWrk봺W/%Z<[1Zճ.]VVl틤v6/WRZ$NK*8=P,V84Z?g+ƊX2e \SԮv)Lt_8_m\V_VҥkX?[KO h8*)rEb$V}ixfnZx ҄EW2R XLbgLBg?WL:ݩ+^P2I%ț-##e8'T-.+.uyFu>I-{^R UY- OzȜ|wkT~4kފ}Q)qKMZw $N=*sZV-a}&f]s={NE֩QrXON&ȹ qgK^4P7]sc^f\ZZ*q z~"-wX,Kn$ފgwmcJZ|bKQ yuߴMhLnF[䎷ފߖ&[ӴǓ3GNvCH¿u!詥-U> +WX(sI|~{+f !_dŻ]Rh-}4dwmAOY&ԳbE̋tYtXݮ?:豕"I=a c|G*yƪh`%ߨ4vē{ u"$D\TWTcHJnLWKN8F,nD=ıs3|=k=dhīToEZK_m3GC -lXtbK]y|>~cAMRLk*zbWM`}zE#]v$mGH]sNB {$u @u @)"RC { {%@FHH@=@C/QG@6@lFr@z:B g#0C p8K 8 { Ĺ^ l$ $=u @`#$F`$ @ q# @ q6#9 @@sD!@H!@H{%@FHH@=@C/QG@6@lFr@z:B g#0C p8K 8 { Ĺ^ l$ $=u @`#$F`$ @ q# @ q6#9 @@sD!@H!@H{%@FHH@=@C/QG@6@lFr@z:B g#ekk lRCd8;"Ng |{O;hCb|ΐ ^ѽ3A)g(RO& ;ݑ"q"d$NrOR_*2nweׯ_nà o3l(V#P7(W{:L .mvH]VcƈT"k4#َ1g'|^S}>;%V&V|~W6`)|y;oA=e MgstyW_MyI=ݦDU*Ydg7[VIOϟ?`+fwgzǷY9bPPW=?.od f]RDh/(\~ȿc;Q˭d%ΈRrHAO2 YbMl*?jaPw1`Uk[R?ŔfDVY}岔*H(-ڟ),6SUxBJv||nO`C?+|]_I`>}${R%f nǏ&̾ͥbn [-ͬ\>_(4ʛ2TˆbcXnAm+{Iā^</34XTOYk|My[AGr$mjUI;WdMIUZb3/,5Ll"~h:ÎMj(ڟҎ'0Oc Y[xwQ"RӞ%_տp?Cet}O[`y6I_?Ko'9,[JV ѿ%u$,>T}AYdWHBđ&6J_x1X ^qf<g4;;9%dM\2dIڥU)$Wq֏=[zYNV2@ESX;B5}k tvw.ԥFt[\26V VX !3EMc$R*0)I\zxKD,um' /ա}&)Oh"^ⲍ5 +>DvO0z d|eU^  qlOQbWk,GPbO)Lu+U$| ["\jʤ/cU` ĊjpMY`>᛼5 MOK|Kհ, pd`1Yۄ2O*N2~Ӻ," ?P5 ބdq$npJfȎw W4Ҏ!]]SkO l :E[%43>7rEͼOKyʸ_'\$ wxϦ,Š`-,zE,Yg^ 9]JYe̟0m*"LqG&,G'$}ZZY]';ci(✤k<9\砥3SF>O4hsI*+g}ǬEDK&S嫮Y & -ŭVfVBKH=E[H*<(jU͟0bhֲ::<ٔ=:E7TzY?,%35ѥ-pZ,T/~R;"W^\)+#yUZ%_Myvc_{$I%j K#_,5ǝ#f/JXrJ^AVnE~[tkݚ>R Egk+wL<\J,P+AovaL{qlT [kj)\\sf{e6u; %w%? &%}]ɶH:${qKzJiJ$!=وc%;lHwK6=e|hxL5ĚອLvF${'B|aQVE I<[T'ѽ%,Of!ĉO-#yy_ŶODǞ?_nQ񤿁WbiŔqޤqo17 GcAɥzw,o10(Vέ\7? ŋ 8!0($ϥwnoI thǀw(^O ;ݑF q:C&(tz!sFiwHH1>3pbng2otLvG q:'vz!sFiwHH1>3pbng2otLvG q:'vz!sFiwHH1>3pbng2otLvG q:'vz!sFiwHH1>3pbng2otLvG q:'vz!sFiwHH1>3pbng2otLvG q:K:{ÛFxx}@wQ{@88 @$Ĺ`$@8 @$Ĺ`$@8 @$Ĺ`$@8 @$Ĺ`$@8}`F:{Ûkg?up}Jv@ Gsp%Fwiw x;fG^[cR5i#LottvG_bӟ9~ܟU,{ݑ"q!W qԷ9I9'{V;˟۷'AcY>}zI-}- q:W}7'LцL2ܜm&{A|hiy~~ghϿ~Ўf{u|]j/34lڬ䟘ˇd>STryY6}fxikMu?怐8NƦ8؟vʑ7ؙ痃eȲ[:^I+e)~ŎT$ƭ2G*?L,2I,/(3+?cc:49RS^#SOOO/GAap>U 1`O> Hreѧ#M{logrYF'ӧd&Z4GS}lwb8an _eSce3j -S'/sđHʸvVE'2ʠZϲ '*C{KZ,)-$+ޫsTkY)O_'J:z*Gn㊪"q6C5'_hj.CNg&1}Pɇ#}2Iїebzܤ%YI<9KL&b>̃~_sҬgeOVR+e5ӌ7⧼?kdI9NWE]7ufiQ"2ԵfJ>=v^7ܙrq)cBGǕ,l\6PvEԤ~ԮUUKvn$M,8Zւ" I?6Sf׮|JL]cZʄ/ %ًadeiROXqRPz.PtͬIdkƉɼ&\ tں[Ҷ~Vw误%Q)=HS!FѹS8qUI-5G1O..(u,izUuTcP'vS'."uA9#=6N7^IqG7l*z|{_[ =d5srx5OGLJ锥o{_j*NR9]Ҫ>œ]:iU#ܢ.bGTw}IXHzZP;f_oUcc+of5?-9C%#m3uQ[`9{7Ž8IHO͇y)ii@Yc.W17qFl-WZFOœ)^ևhg,zdbKoM0R8gH[P.me/n7Οz2%eˠDpiipw֫Kv&"ǸA7ɇ bwLߴGGurR+a7R06%TU,׸s+bn2e*%W> =+G. 'hh!We}œ'KS8$fO/.=jQи۔u+:V%IY_-ɣy̳gN!=Wc=0t Mz v[yNG^!uIįruv'E$K:f.b>3[P6oI$Ng5KEӊV)M](`$P_on,?qTDc|iRySK>$qt7JEGt_I.q\xUZ%жVU.JVsr?yR 6O!W_1csJich#^`vh jC5( Q$g?8vŷW~4G1 Ocʸ ./cV]pHşss"+;_R$ǽϤLC #FSHFP%~l,}&qkHԊ4k2h0K"h֏S/qmF6|DZ=&* 6H {I6x;fG86$+ ~#(**$OC.T/qǹ^hn01z(,1-fI7>H {I6x;fG86$qq{Ě^Ǿ_gI,ݏ ,=N_T?~8>2m 7v ̎0M!qAmHo7^-^$|OLF?ݻL$RRt|FiIggRގxf)$N# ɢWBE2+*?QU8?Cdj h=F@Kc`.-${qߋן6Nd] q68}&eoa6B4ڐ ?;ݑFa6B4ڐ ?;ݑ"q!WEggzFiwHAHA`8SF>X 00m4pIMS/Խ@&w'¦(@f@"M9 L$ę @E34@ 0g"l @`$,Ҕ@DH)  Y8HS @ q:mogM]=}nY+! |{;h#FS g# ,)ѽA)gR|u7:cǏ;9|{g;R$ '4Ba6vYCσ???E#۷o낈4həKp<Ƅ3|]L7iׯ_3χ9u6 fEc߿ogqg?~K̕>+ҫ8 /ij}ϟo3{_vqxׯHpǸ?@g_^E{{K G@*g.MCGD5 P2栦(ۿӆF00JiF٘E]HX^Q0`%Λy5lQ¢ĔJ-z}ky;{LyӲuWOo>}ڟ>X~^ե"T+QUD :vg{ c⸻wo5<_Agv̂.}w_IGG;vK*<>&XdT> [P_*A>NC$R`2氆[5QZDyLVʒ#lƏK糡, 5-Kc@Qϔ^3?~I5]Jx%%vFKڷv%KDq}SbWV5L(`jguLYq^iE'UMF؄^8.IиQϙJT꺳7=gOv.(&4c\>X y}:tIF5J:+8}J:ח~`lYW i(zrcw,ghy>̡j86If4IkTr[yۧ q QhUVUK@3K>'={M-l-ţ؄^+՗DF1^Cv:ԮZI߄ 6u4"[]e{!"U(TLpKj({}#8G,$A/G {{KcSχ^)W%N>m7\En3WMǦh{ZΛHb.q mW\^*Ύ.yDR&\,·- -Gl='_űEn4 첺r^v /%K^u#;=vu*0k0\ʥx$Vx^'$q!6aE-Zվ13W%_jjOKVGr K$[f)jHp[cU^x`-#8{qZmĉﱫ={[2muMT*n7]$)Ck0d̯ݦou}j_MG|F{n(ň ,Bg]Xć$ad<$Q* !di-G÷]S|/ЦUG~UVo88D$OVKa鉪2{{*j]+ﱫgSO!˟S0ճ1W8ZIIxJD{FP>)!i^aQXZÛw?m.?uJ$Vk,BܤwzW!`:FO\j!vx"R Ю ZMqqR$pL=WSUz_`8ł6ѮUCȹ{=Kb.а*ݥm/fqXϟ{$M74a[am[Y:j/ ҃I_-ٗ/oi}{r jY+>-*} zg)rS W;-5ͭ<1ztG<^Eׯ_إr,;Й?ط:i)OOӧxZ?~fYe-Y8I,InS-I(W@㱢_ȶN꼵 -E$iVXM}YǸdH5q~lMևXI$dɑh.O\;.37x_&Xɢɖgi|M(/n_%J &)w$;B,hsA;?_g;|::)"Gtk~M ^'BYKNCŻP|kqf7de*#77 p54Մ. jP~v20Մ1 Ղc;#MjFBsoye͒OrҗXb}ې[3RB>BgrWuOi&e͇K_8r)7?=|QQO$YcLBGPĭb=a|l[lY.iĖX8!YqmFyT|4D,Ev g\k$Mz(K=/TrzԛT~me~[x*yjpm%+ɪ)\^+73t+~C%աœo늫χZ'#q;lt5I/~>BgKWvp7FѲXQ'>./ѵɔsdgK?iҕdoZ&OSً֖9mD7yڭ(&7\Lr;%,\ U)J<\&*+(q\}2fKfđȔ=a.'3)I*qău*d$](qV$[d|cVWoT-D?//K:yh%&iش7bu/V8&/I}-MHc&`DU"qZ8Fr@^kՋxES[m=vi/Nu 4[JVNskn8˕˟U٢__֯#s^KJ ZlFw,V:ز6Tbq םps/󇪒k|edtbgt}}Nt|wp1 U 8ď-bnzػ-^&I|2<_~ ގpf)$N# Nvj}?#lɭ7NNiS@ Ja6B4ڐ ?;ݑFa6B4ڐL<@H`'n6@C'~@S 6UwQY@ q8  "Ĺ @q" @wEsWEe!@h#iD*@箺B FƉT $]u @ @+H.* @@$N'RA pW8w]T 6H6N @ q, @m8mS 4 k 4u) 4t I60R{ݑFa6z=IIH0ѽA)gR|u؊Y$NqWotIvG_vOS&'7$%:3TР~v۷ʟ>|>~9oQ2>*dt+ԥG?NzT2#㒛ӓiBqt~z U-ҥ~>Bݚ  Jxf1dN<  /sÿK#TC8lHi3uwϟ?s@HUq?mYmQDcfbB3P],GkeڜGêbfZ"2~ .#Ano#KFxq(Is$ J#JO\}Kz[9*0N$G8;3'R! xL-J͌JtI۷ovׯ_;v@vF6F_lw!SjxN/+Ig(}Ԝo= SB> [K|Q4ȃ%n;5}c\>li߿nOƑ/peϲ:0c'[2jn^VDGwo{[` ;StILx,T/]ẇy땷2+^oc#i]sחc|&)#wt j'Me2ʠ/ ɾu-*M;]y,6%ʼnĉr ]dRhMu[A]|z>wiޱo%^kiME1M4_h-M9ɜ}X$qP O.CUw1iC]Y[AI9䷞Z Xh1O6VNVϺ۠;StɱB0:@eVrЫf2d4|,F1Wb+?wydIi&4;'vϭ'&u$O ?ڊ'vGmWHKt:EjQU}AȲĻc.Ȥ,qeZLRjR`Yh0fzu; U ol+aK>4$>I?d:iӆ}f_'J&֤~?f2HA#ׇX'fY- uM?f/Z*Q[Ӿ%׀0i8,)U|4+rЫf54y+G q=F#uuGI")y}@Bx`*{я]VI5̕:eѲfb%݀Řْ,y>c$H/ݔ;$R^kT"hYJ╏ Y=NRv1.ZR܊u}fF`Rٯ=v2H#W܌痛5 dl2 F'p跚J]8,ML Sq8d'ܦ,1_& q|ߌ{]U'Ң>œq"$OrX-jCM "ZQxU .'⟍_)p둥+"Q3-])'&shYZ*"&/)[=VFgEr.>iܲ`~&|~>U~厔)Zաt}.ŵV݇.?E܋ӗ|G:+E56)̘ϡ:^nl~*:+hE73F]4ƻ3o݇\VU%Ű٥8O9oow>Y#KO/&qtbCҗm|څN.`n4-uCԎ2rsqʳ'~خۇO=Yy~֓+Igɦ `G::J+b7ΒpA⨛uS'a1&Z'5o^!_OE}ȡ 72gţC(K7њ/$-ő] >[x+{^I-x)CK%WV\R% Q+7_٠j覰}|նD6:?(wݱ-/ؿAZ?|15glinY_'E~K|i8nʟ;?Vg%<2cn -;}53a^ {~.;;|l|\؟RQOuҿc#yr1x]s'5ߥO9Iu%갡x b Wqm7I?8۾g;?g}*=rɋNCc>^c;%/V5lяUٟF3UfVF[߁vnu|6Rχow+%f6 IgR4~hS +m]G+YσY̬LH:ƬS㸸葨3xݠ7Q֖I'^Tyk/uFqox1nKnC`>^S^bΘD[vDtK+t81)'+gem*=;;B{>̭A")"qOjߛS}$H>>qu]K|.~'2H>|ՀA\fqbu^ڧXnB$wY[0H2JE;/RrWodǸbC^[q#H(MU.S"V=\8WRUx:V0۫pE5&֌{(v5T[HoMINNk 'ncLK'[kF"բ%֊BEI1_P!BNEh&f2Z o/JG=7>cxKigE5n0l86#EAXK8qnළZ$/DЪ/F^GH햠&t4)SO]JW#7snHҪBΒ|`8*ƒTcb\%.h7?+uxx2n2X⶛&%~HY|>zAxi)VO?KzQRV8:MUXcĥL{*b)٪ı|Xۥ.GbqIu=ęc\VNҡ51q"]_]r5R&Dd'nve#YOl?a6VCkY _,.\4ݸ;$~,,Z\$8pǾ=1ɖiN[]=,yɒdid)Yی5|ۍc[dk7r8 < Hy(iI)>صώ#-d*>UJf ]jU4~+[>8'g9"uU/OYR!E!5?[ڀܾ)1EX"'k??p'X^}Vy& U;Y"|IAEr59),l?$Wr vN@1\A+Wl6"UH0=d"|{;R$ HLbޓ 3):,g*X"f <Mj~@ 0{q&¦(@f@"M9 L$ę @E34@ 0g"l @`$,Ҕ@DH)  Y8HS @ q&¦(@f@"M9 L$ę @E34@ 0g"l @`$,Ҕ@DH)  Y8HS @ q&¦(@f@"M9 L$ę @E34@ 0g"l @`$,Ҕ@DH)  Y8HS @ H @#ĹX@^ q@.H`M1 @xh @`&$Lڔ@$HI) 83iS @ q&@f@̤MY L"ęb @I36eA 0gh @`&$Lڔ@$HI) 83iS @ q&@f@̤MY L"ęb @I36eA 0gh @`&$Lڔ@$HI) 83iS @ q&@f@̤MY L"ęb @I36eA 0ghwQ_ G!{'`Qޛpc#FS/1) lh#^`vh d 0m v ̎0M!qA wI ޝ_e[c.oL%ԹrI@Kc=Sj ; a6E2@ 9O.c)-u5%@Pϟ[]%ϟ/,~mDr-}:fKsuN z.:EjtXCO>ٷv'Mi(g 1یMP;ؔI@Eh%F=WNM#bc^Xo-K!Mx(4In5ywvw@O`v4(wRUExe7|fGc5m[,w.PU>\Ž KK3x:$KV狦83m,;Ϣĉ+4,n1=@mQT=Q4[=P69(Xܻ,~HYGD qI%!s&\[w+J#_Q=']bgLnESGUfc 6YG8L$NB⢟%XzHNF))DH*~[8=Hg\2[=P\OLˤѡ{zIC&tc1ȇ0 ` 8&4c*d X&-W9TTKn4sOTKMՖW0oW`a6Ә'Ife|d3E##{6vx;fG:HƒH@;HAv ̎0M!qA 8#mS3{>4\#pB!@@W @`$@lH) 8 S @ qf<@&@LL &ęM @@32E@ 0g6qʃz཮ )) y3/0;l4oT5" pFLC{#FSHFP$Hich#^`vh jg/_o߶Zϟ-ׯ_edqeԇ4 7776۔erAbr+N[|c-Y 9χyZVQ?ߧ'߿T6Ux@l{LۑvgFɧ ӧߟ?/S:i$K'y jY9OtRW8vA-CҾqؐ0ʊOT:g`|4O>ٷv^.YlǾx5m:K,?~YRˋfAIKL2-&5?8îk:%Q}:]?O=0MQXyį%2yK˯90G_Wv|tN$<5(\v/*Tx,r[e@j^$fIGzQDL7!b;?}cj˛L*>Vu`#\e^2bߊQqvLuAROTC;Ќh>G'tq%Y-r(.`7t)>\>Mu]# rd*:~U# mtVV^Vzwfo5#^)s힜YlDhͬvKA(xHKOTU{p~S#|*g)oQ}t2K+'=w@./ NzZ uyTTigbeǽ8*N1o-I^ܗpU]Vi էQW8uɆo[81۵V:ݔ^O1M Xg|/ODO۱U Ƌ/Aw.4VLsq1ۜr0e>Rҵ;b(qTWv~*V28 J[T_W/ JO_ًksE?AۇU> y&6ˋ3`>-3Z`n%v@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q:w@`@go{xshb) t@ 0ʐ@1@i4ގxfӘd@;ݑ"q!WEggzFiwHAHA`[%Nr˗/YʬK>??=FJˏcw|ׯ_j]9)}#|*ccYۦڈށbV~>ޥWdiy/̇y&߼dJ_:}gS(ܔV+ˏ#':e'-;J\7{ٮRPo)nwv|7lI^8Ih2~ygHa?JgKX ӏ?~iѪFcI._ )skW%NT~Nչ%yYڳo%04}-Ӛo(Ԩs'Qwa&q 4߁vXkf>}Lƣ3qpiUAÿ@x<0y~SVqMXرi <3}KcFs}kA3~eSI'!JNZ\VAZaEcb180tVڳ0.K<>oL|74A'svGhY"&ʽ]-Җ {0qգgzE&,Ž}M{R·9Q'/⃶obLgzȔ($=9}>'6&ȏxi'6 e]jEGJ٘}AYxquoK##qj O#+^0'K[ަ) x+c9U̇yߤ2/ofSPO| |Zڱp]-ťI m 1K1b&Dᤞ;z/ u?o%SܹKZQ; RVh7*%'l7T2qd+5qG 9gi5Zz4. w<0ǵ^,)$۟ZΛZw{X,f?*Αq⨒Gί%zg傲%%NENK'8#qⰊ3/iW4k=GstoQXmD'2XTz1i1}מ)/:1ZaՋs빣 {q&*m}3hMF%k(Gw@%Uoӷ机dL]82EKOTU$Z8X*PO_8^lS^h{Wo֔anIؒd/SO<^3ʳ[3e0rn7IUϦ}4]^j>zT-{L(u|J;Gٷ2ro,zQJ=?:[cS4128vĵVXWG4OTw{EqoD^an8ky_5}Wm2swoQDKJ둛^8:8k_[[܍b,CP n(KT^rRk`ӏ%?ӫX7$H#egR|u؊Y$NqWotIvG_3,~<]ot.vG_3,~<]ot.vG_3,~<]ot.vG_Rg5;'i2a)yuwQ[,1x0P~;3vIi/NO}k1|+~SGKpnLJFTHlUⴋF+di~x׎G:iDtz>zK4qna_ձ#mRc'#FSĉߖբT^e/h7j>V([-[V=m. r񝭍\$>ꍴ"cwNV/^%f_㒏NwReݯHTJuy0o 9 -^Y|%N.w&#m$dؕSoW,oy UX[?CG,[;*Wmj*?2D'PH>eox^K~lQ_f Ygb%ُQтč{I$&-e7 DR8q{RG:ig({a6z/KHc}"I4jegb(%"iBqir$Y/?VK5Yj#/,4`>3:%1WJ*yZ&O;AKy}!~.;E_ۋo7?.vPq\G)۱fVEs&xLo{Dz--"uW'&/iK8:Tm]őDP^l[+W5܆V~c#FSoYkGuIEKFc/JXF IgM'n@붫8;X"ӷ":ME7}5JbQ"gۋr>maa6 q8|G9G^U˖@lcU⇮'^~z7qmRˆƗ y=־^Mv@a3m8Ѥ&޶IK1 @`"@.Fs9 @ \炝J @@ \炝J @@ \炝J @@t}$-o \r". n n:C!a7@i4ގxf]Ԙd@;ݑ"q!WEggzFiwHAHA`[%nu%'wT4G_6ˌ|uS<պƠl_r;3v~ϟ?ք/f|\r㰛%۷še(FU;K llzidowўqG* gM3E 潚<|r/?hqaHC;Ɏ;1u[GS%kvǏVWF?X~rSЇƋ%l#ξoH=^h(kb+vdCn|4S9awUSK12ڱ4ߕ$a v0_kdcEQb$j8-O*f*Myʤ-AUckVtk}|&Y{'g{~%Ώq(.8y3Ow>WǩZ6*8{zӧi 6Jit1&a,,ɂiH?ցa͔k'bv%6w|-Va;&`iq>̾Gk/.w);H ,)0i!AH%4 kvFG>mJnc:(VxRiU#%Ypc==*ޢ*N푢=zӼE 9޹E8U8^DbA>7O2}BEYn-S}fm`%O$qVj14/*ݵ:E-,v5"4-R&77I^,h]jq2yĩ6ő! nVbRT츑0-|&࢓10dgbcY&1?m+!n+qN^<.,bJ5%q9N~]ǾcmcU"]8Cs'W8U8^D}:ܒQO:N@ đ?ZktO2 R3U!\Eym5Ljdr15d]%qJC{l75o[kspx5Ojٮtl)B%Y;TfœiK ~sZ]vjqU]KSdڢ 'H`ׯZU [`i8qT᥆;ҥU\,i-ض%-T$NNi} iXtsuexEgKfI6v}.:ZTFq++n^M0$\VZC?Y{qgEvENк?0?-iwUQ$kJ7QZ8*Nq}HU]ʼn3ŪV"&R"F6HXGr|'N%hSo(K;ѿ-ߝY I +z*[zYOTbTgSd +ue,=QJnkF{q$,iwKe$ mip馒Y'UY98SH?k*ov9q>#Fނđ}H(Z#>HP4gǦdʺۢg*UQ[mD]#q`dٔcblzMNһ#A|ؕ6oJ-nzs>]˸e!>mhXT8XyX|ʟxHɛW[uͦsCi 6d78(Pn68Ѥ&) L^ @ g"l @`$,Ҕ@DH)  Y8HS @ q&¦(@f@"M9 L$ę @E34@ 03l^1 pźSݜb"A>7H#/0;l4p6ڐ ?;ݑ"q!W8p3v3 7w&H#E B*qX_|:l2lϟ?K)>߂76/|ӧOIvDU|#V]ef )vlg|N7q m%l4dz_~=Bwg\M2 _hgZsj̇ޘr, mǛZ:ڃ'Ij^5 ;%ϟ?I&WiQX=bhUQI-M6'vb^%I4INF|D[c.! lVä[z^TyȐdLY0SZ:$#]K}?A+ZDA?QIer6Ųvw|z&"ZQe, ]ˁX2|5d3IiSF[iKǻǵ8_eRi\[TE?)E1h] &c>#'KO_rscDLޞbU:z`2T5c4 Jcs$AT,&3El)?y̼9:QQ6[ ~*d;je7-%'\.4"vkQSDǴ1ԣMy?VM'4q##FEcS{EL4yG!8٘;#FޚđL_P^Ŕ6ʿ_ϓWXb{dҩDZ^M94)IjWYu>#9b_}s|/*<$ymo8|PǪd5 ƩXnae2xes$qjNd_ioӛ{@:/0;l4i!ٙ8_Xtf%-t̾ފ)m}5  x;fG86$Ï7zFiwHAHA`+f8^"ѽ'A)gR|uX$TTwUѽ@)gR|uX$TTwUѽ@)gR|uX$TTwUѽ@)gR|uX$TTwU|߰lz[8IWGzfުЛ79YoP_@n1i67Y7v]gz}&rm*WH{.ǻ>\E=$q qcL E5eQ'ѻ_\Ch™mǻjF)^[awIo.֫쿾ңWƂgĶhd_Fֽ8 ۀ1F(T Z)q_8c|>إ_-zS?Eg^A=XH~4گě}#qnHm}#:it7䲆ic{ccޛ8jQO. )ycׄd_(|!qw ~ܟU,<ꌟO_]G\㎶h躪nSpnڝ2]iesG:?(o1.]Z[m}]g10XO|K{q޻[ZsE*ΝK=Az/=5}#.[+ߍK-8y>&.=QU'-h=VĩQWÜ!'/ӿLbqoh]>)1ef%ӣ%1W1XC#=O'&x89{qrMe} V}XPe85H RҶ47 ۪H7iw x;fG86$Ï7zFiwHAHA`+f8^"ѽ'A)gR|uX$T ES} Fx'=2IK1 @`" @E34@ 0g"l @`$,Ҕ@DH)  Y8HS @ q&¦(@f@"M9 L$ WLBB=9m4w17$NH:9|{g;hCb|$Ng@/dޙ 3)'@tN B H8Cb|2'_FTE,Y~~~Q7kz;f!"z7?k4===ٟ?tM ֺޛw8H 82gМۂA[w5Ʉ;TI}ͧO|"v`Jı6t ?8x#g+ı k>%pv藆bhқ7yf;6e P8Qϟ&#ouGZ$_-N~bD|I;+رʲx,# Fф|ЅA,>ƠFn;Ypy_Gz&ϬxgҦ%NtҔM\>iII] QN)o#W`KYFM8nyoaj, ?_v|m;8u'.q*L:+?Ij;X8Xk'M8E |$]{ح5$=fdn?T*8 ^8ŋ3|gh:wj DD6whݹQ2_\F4->$6{q f?aU6NDT7|}rk=yQU .,Z2,n'"1*mHHODՒ:/eY;Aa7goߋ4>7.辰7؇"LcGۍ+{&("y=;F>iwHH1>3pbng2otLvG LLn∹P]AF.iwHH1>3pbng2otLvG q:'vz!sFiwHH1>3pbng2otLvG q:'vz!sFiwHH1>@gc/CnvG{콞0e(b|Qww#7P]|v85DGS1 _#/QD#X}CKY컇j/ނj&GOӫnl_obhKNFbߣj5Q)O8Yi^${Fe%C,ddYX/f?bo'kY񁼪%N^{r T8$k0˚/r}_E"qAVKlTOW~|*YiN"( {F"q1Xedox4еƾƬ~nuysC7l,E_Uvb~bSΝ K*D>U'@?QFϮZCvޜAIPfFe 'gudAo W~> a{Ί$OgC}(EܥX# ՔJ6gP.qV[YtĹ[rJ D~XK8.UK,Gt*Aak؜풢*c3pbng2otLvG q:'vz!sFiwHH1>3pbng2otLvG q:'vz!sFiwHH1>@Q$@!ƞog.}bvYt)%ݻݑ"q"dpZUղ`kMO=mܼbF.iwHH1>@mGcמ;SG NڻU;I^jgW{wbdH8Cb|2ucF?*.!_cO7Xi;o &ǕߩbPG=By H8Cb|2u E+%7&L5\qd4# H8Cb|2Guٔ\vGݍ] H8Cb|2]3)iwHH1>@öc{7*{qDU`>ݑ"q"d}$nN+ێ%&EOT)q.k8`>ݑ"q"dݸ3pbng2otLvG q:'vz!sFiwHH1>3pbng2otLvG q:!>(mo7M] MsG!@(@ \炝J @@ \炝J @@ \炝J @@ \炝J @@ \炝J @@ \炝J @@ \炝J @@ \炝J @@ \炝J @@ \炝J @@ \炝J @@ \炝J @x8@.Fs9 @ \ @z}J @@ pAH v*M @@ pAH v*M @@ pAH v*M @@ pAH v*M @@ pAH v*M @@ pAH v*M @@ pAH v*M @@ pAH v*M @@ pAH v*M @@ pAH v*M @@ pAH v*M @@ pAH v*M @@ pAH v*M @@ pAH v*M @:{ÛFxx`tOaL[b蕀QHAv ̎0MƤ$k$FP 3):l,?s?ӫX7$H#E B*q}ϟ?cWdWd Z3ZC?;hh[vL>v|ϗ?X=>IMU?7s$EM#vF-\=Ձ` =&]cA^$Vkc|Ik~Rz4lJ!|]Zݻ~*ߗ⟖?\ Odܹ"FS!9PF&h>}ņU7V[xvہ3vpN yAݒ#^RX*FlXf|1ϟvKU#~m6tJaKH.qTCx:LJdkV,J1X ([%NE'xC}2 uwޝf>UUܽ64̍ 9s*8rw07,cK ѝ|'^WrE&AMnD|SI|?G"&S3WE;x%}SLS_ʞ܏sÿXxe ; EWHQ>e%pwI$B4xd ^zoZհnF*q|/ |zԏ#Ώqq8[Fψƺ)}?/eh&u8j5Uxm5;$l4ZATG,NjPÿKCZOZ<~8.깶Jb4SĚt8HZ>rrlI4, JvK8%N%IA Ln'~UqkY=|\rvciN eIĥLʎb)n$1 jU8X:-u}̏q~ik@Uߛfǚv`=124F'kܣ]VŸ):O\'rx-~ηXU#NCrQs0V8;Eg\ۍYieGN---A\0'[K,ş<\;+0OZ%vMX:k^bk  oM~gFuƇ{q4[KoU>go4NVqnɉ(iԼΩ&j,nIBNƗ%q#DӥmC}OG'84yGJc^HS@#MHvG? >9-bfsū\AW<^#};zӑV&~?|ζ(2Y/MKAzɟZZrGi װwz2=إRWt:Ǎ^$Nw6vo)d-V#bsIX|y\@ |$/}H<0wHЪtѾNUKN48EO1Ӓ8( EeF's)+i,1G;hp>UpoJd\Fb\fu<fjߵ$Nmϫj/N>Q^+b>_+H gu/Wou(lվ<[!qZ(mKHWJʿMj@ҳ8gmҡ/0;l4i!q?[K^p#is'=n jҡ/0;l4i! S>X H@GMHD`tOaLsH@@CwU{* @88 @$Ĺ`$@8 @$Ĺ`$@8 @$Ĺ`$@8 @$Ĺ`$@8 @$Ĺ`$@8}B@@go{xs8hb)3ݜb((2ѽ@i4ގxfӘd@;ݑ"q!W8 q:cǏ;9|{g;R$ 'e9ur~TbJLcqջ}~~kTi#J2k/_Ԋo߾m5jU}c2nY5"_>lq/R#(U{U/o wP[yJgvǞ/{V/w uh~d7$)m>==ٷ1eWՊZX \# >Z<[凃|o&|ޯV#'Sj7v{ڒٕȎƢF>3d!8:h1DKU؛4t:?QTzaE" KNl Tmr4VVtכǸ2ϼEoffmt- vbgyitnU Q=Viӧ^ǖlF)MZұ[E)kg,ˍ J=fi=3!_q1 '0Wi_>KQ8T]=ǏvOtӧUIXXԱ2Z84fʬik$>bz]>u`sV ,^bDsK":ۘrc,@wX%+U]Z[Q]T@N.JgyYmAF'4vTvRw; I;>ܜr#dyd5cTa|.P< Ո#=bԫQIGχyG6XtXӏ4c'{򞶐j^藀IKovvZ/0O*)9U lw?U -b)L,7}cvOlG @Z(b_#>K\zZ>ZɅ`yY1S\f{U1eh 8t:QNd5KuaҾ|NLkeZ)#IF-mI<.ݥ-+9Gq^^o8I#U5WŔyû*[-i  ᢷR&G..!*vjjWqrZGQPEE?*C8qSHN8=fowhX_qIKTQⰊA[SS*N{\u¼&Y-MؾX>_O/q[&So&jK8 qrX)'~}ů;G1'f[*uUmIqn^X- Yw+:[E4+QƕW',zdɨVǬn4N(qVSZ8}3~r8.A վݣjsaaYZh2$q` f!q,KqG)e^;/Yn"z[h}KQn'>d}ZQ=2s굅oD,E7^良YsWK/]xۑ{Ph8R瞥 ;v,^^u\. g TQ eZt~;GquINz(z) ZD*maRzg+}7HI=`e|y84+5d}"q;bF㏖/^LU-hCZMB(fBc#\"[Kچܦ)\~JJ_z*sRzg!q;31?ӫX7$H#E BjګgMBvz( 3?xQFiwHAHWM4>'mxGOۮK=Ҳf] 3TmuM## u8Awj[jٽUCC,C0YvlgD 6},"M6UxN[w{Vo IFVF\qG\O`{~__eO>EηUQzQU_f6vQ.:'4,'8+k|| tӽ˚91<ƾg+uS(rIydUެͳ"gIHk]K7u?g|^)QOzځojuXT5@jQ9[4]Iy@I'ُ+9n~vӔr]uSJߨtS^Ja cJfp{Qs2g/B2MhaFzo+@)7qߥMr{`"%^=6A2eתeJFA[٧; χwޤʏ:ٴwCnglaRj!Qαo*?a_Ɏ~Xb/۩#X$ھΉ[< lޅުw'*UM~eSqoZUW97=P%EnEycd;c/ vGO(;S||^X'\[K$"Dp("]T-P̮,B'Rb/݃iz-K'`^/Q-k& 1M\zJ=$wΊSŐDtS%Pݑ7R/,Ƅ"`3I&S&t]Ep`L`AӃeuMe )c㟜(w4'wv> Q٧D?{Q 11)miooWę aJVe6&go kU8}諛OغsV ӿ_k_a-\*mS⢑ʍhO8aݍ ,zpŝ*}Qgˎ;N˼(qgG#qv@[BP*= HAv*NG86$#(l`IH8%{qіY$NLbޓ 3iQXY>ɸ}P gӿO^"ѽ'A)gR|u؊Y$NqWotIvG_3,~<]ot.vG_3,P68Ѥ&) L^ @ ~ĦQ @K}O!@&Ĺp4@@֗/_3NV_>lM*pPc[ ~ӟK淵^#5J?1Nxv%41NHګWgKֺ g1ol(A-1RcYaJi¬/_؎팝/~QJ&Y>!<&Ѱ8b-8>dVI #W}t[G"rQ5zLK8[w٩,~9hD/iӧOځٮrZWKKۙC~a*q߿WN;P͢~4%o4Jiq[.+֨cuN.e"a68`Ӌs*NIJOlQJyi͸-RAA+tOZ?ۼmE%}[jLrqa̎uQ4wdZ*~i4`O>x~ yHFwR=3k5$`LxE{۷o%OO| Ӗm̠f^؁i'Ϗ:2܄߷xggꟼ$$f#UK^, ߟR';vl̈́؟vҾrYc'ZvRwγϮ)TbM<ؑeZqA ?E}SIڛ5M"Z8IJAU4haDׁdzKHۼ*&F:b1uKO vz6#NFEeW)˫\ZIf4N5Rd&#}⼧;=褝IF&&M$񴚯V bfRquv2`Tb/Z(QI1{1>Tq֭d\:6I| 3of_[B_C-$Um0QN1klK1O-y=s^Wfmq'U$+-7I⯕.I;( 4 vQēCAOS3W%SF1Yݬ7ra6 udp3$Ƹj O Q={Rbh@}nFyZ}/Uo0ރ8G\Y[Uˬf) b-EW+%wKg*NQ!Ը,t[JptwߝokF]^%ᔸi8%'ʍ}/ս8!aS鵊^{q;no)8Đ覕 {ʭ}}:Y;{&$vq]ARCR\8罏*_܋9&v5qlH1qrRۮZ48+է b8Hv.$bڔwED%0%=e1 mq}g営l8fpiqKYOTlkDUpunpʜZU8 pځ73 2=OO:I-iiZeWJtIճo 'HN#%Hz%v%yRQ-n b*-CLK7ԼJKW|U-6RJE꜇ oK #0c.rui*'^d-NE)q{qsa+Gv}8#A ~R4cQ&hr tDA}8 #=gY9( q::k=7|?ċZo Ppam!'05dv:VlTn]F$N?!(gzFiw x;fG86$Ï7zFiwHAHA`W/%#7+iwHAHA`8SSqUaFiwHAHA`8SSqUaFiw8WϠCS!қXĵiYUq0~[тjo4',qnxg`Nq㘟&ϴ|+ENX| $mkL)g&}۽`v[^ngVM/Mɔ ?xcvQ`V⥗Xv1so&/zU,en\<[ZdJKN;n[3/4]HȇFq.=kmt@s;:bKt|Gj{wyo7JM( 3;ZWJ^UGɚ44ow^0>%]>]м8ݎ KDbwU7ğy foI=Adj%k#_bܾRv2U^% ='t@/?PUL`oе.vm /6sPWlgKd< $h=J''dSuhfqM1_)^0,}I8W.E#-:+IZc_)K(? Q+Tx,]-Ux&w\" 94#xGzwdVx -$McuJ 6kF#>`t\8N5G@[8w=[C͎UWSa=b7|(x,tGfBw Ļ +Ƶ7V[#_ǺK:9G11{eCBK_FU2Ѻ73ǑTK(qV˄R2룸h F#IrbeWS ݧ@Jˏ{;!07tC9򋇊qǝ&dNX~Y2%~2$E%Ԓ.{l8gޢE](5ՓU$q*7V\JmNՌ'vt`\E`^~|d?!K݊ѭzL8ךZb!W4cWt0An-n8XR^0%Nq,NR'A܊fc3FdҺđ2? ^=iek\gTKcAqc.YrjɧG/?T=ސ|%zݙk]X/ű'eLLq@įxꆾr=$ngG^0%Nq/NR^2˾,I?J[_m*`\T$ފ$զ_AMyئ&v_&FybbaHA۷ɚe7!Vc?q/cw{>`sA+8/xfcrI.e1qh'+}+XR*UՄ1$fk?V7xS8qvͶIwQFwPA)BFQ;c\kyχ8/H U7134Sh''aV6qĢ[?u`j@EWi戺'}['WKv). MhP*r -'n٫NjFqDz*YAu)W! ~ 8,"u?86W$E*ed# b#"^ǂ*R\K|յTb>3jYXԺP5}Rkkn]A8( I/;^o\k^,/c[E\ (u+_A(UdMH($44UU7OMQ0)cVG.d?+j+%{q/+sDUH#-!qΗ8˓iyȱjo}rf\8>*i\Vqߗ/=QHi)z߮gJ4n1~2"<xPڒw'U@?*.=Q~}\œǥNӧ $LDmk&ٓilъljY=^U/嗳Or)oHF#c7~;x%c _9oꏥ.NSY|~œCOK_,ʇ*~O(t?[JwZp_x^G}/oͅ45,J@lMq'F᫉6i89HgoG`J?{cbvU[eOF FV7Fw} ގx'|xSHfj47ciw x;fG86$-<>(I$m & $i"0_&9$ @wE&j @9$^@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ q.ة4  $>@ 8˟?ZK>??VT",֪Mu'wB~l&|z⎍zWلܣ)XcQgT}gS5-Bm^ ~ϟ]JvllcCmUr Rz v @H,q(wn;HmlI߿$mJg}j,U5)7oWƌ)UϚfmŽ\Qыo߾_;͸YVUm)N+b7}QMܬ;%'+kflZR,2{\1A2\ujh>= WyGwJefX ;Ds@-j8-4[ ҘQsޜZm@ lZLKncɇ@n쪓tS^zXb%jE7λϛfWzTB;ů*)xRW=5͇(f<&*1QI)ѥI|.lԪLq/K6'T®iǺVT]6XXt+U,_olj}mϤK#2 *6a rlєXKMVo)8˭WfӒ~H<8xoxpϿSFCj@2EK8]*|\3M>[±މ jBr2W+ ㍭G+ѤzKίƋHb&W\Q[Ul,^V#Xn7ȋ[<&*TQ1}#B[2sMzVnu/Nr-[oWk%/.Vn"GlO զ7sgִuu,޲3nZ%MNR[[w*vb⢓SORbf*x#f^ɼ-iQC%$I8gu%,WFɜr-^d2VSiWlEbR˳T>Ň$\U]j3Lp;MJ#%<ޕ Q6$̼ӗNsQ;qU 5+6.zu_-OF2@ / i&.[_?xyܗA]1۾׃=M:Zzxɫﮏ0 .%qTM.t).Eܵ닫k4 sCK.%qf@ H< @\Si @H| @\Si @H| @\Si @H| @\Si @H>@@go{xshb) t@ 0ʐ@1@i4ގxfӘd@;ݑ"q!WEggzFiwHAHA`[%c/cϙu;^nv?=F>߿?XǏyzzOQe>Җf^&|O(oSGχzLAĨ-lXbd,T(H>zJ.#g68o='~TL+x2Z20-Ao#A™b%po0e_e4QetaԷy$OzxyX1ԊaXJǎď;¼Q:髡4bEKH͆FT.8$c"n%^'͙7$%*X|av]La-d FnbXBtFWuɷKI0rnq48ZTtjqIџŁ$6Vm iH O.u|p#x+I&c.m(qbe5zZ<~Ip 0;7!,zeu+ҍq]|ym K^>U;jǎcTYNE,?WPr:"(q8d:P^Ǐt0L|pPI*eLjv*2}Í zy)/Iv:/X8<Ԏ=`*q0 an^ɲW؆,˙؋sOFC8(]IK_-УJo;iۍ<;5\F_SROnV'%ȍ#:]8q/"BdoYJUJv`^^_lTIKy.:H`6IJyd/n3m`p>ޥ_ELUgwM(ęP"0]TZݫ4?(to#߰k _ʵ~Up 0;l4uqt\Ko/~#72H#/0;l4uqHo2/+Y7&H#E B[_+T[8Dx>{)S 3):,g*ظ]c$&N4{ eb @Dܨ @E34@ 0g"l @`$,Ҕ@DH)  Y8HS @ q&¦(@f@"M9 L$ę @E34@ 0g"l @`$,Ҕ@DH)  Y8HS @ q&¦(@f@"M9 L$ę @E34@ 0g"l @`$,Ҕ@DH)  Y8HS @ q:,mo_M]=2nWF(7;H#/0;l4"zHA=`2|{;R$ HLbޓ 3): m-*ו]v㤟;ϟeϟ?-ƕ%ec }dF5Aq~6]2pcAJʚo;3Yu[wGz}ϟvKē ZxI3oO(GxvwݕswU/đ?,2~)HE:[\k{JG2=̏u`i,?Qy:S`3+zh!ϸ'|HFNЋ/ 6xm,X2[͇zB(;OfJ=>S*^1icŮl>l;dUL'}prPsD48};z^)Ky{$bي@]ڟ[v,/K,Nj"Q*%OӪsRDVŌ[?Jqby"vRa+#d3*X6VM\lGLykR1c;w>X&-2+^&^ETqͥ^)X$*4rWŌ[?Jq>Ɗ,2㸫b8&myw.]cOj?fߩ&5l%,V/$I$W"qElZx+I?7ίXXQ:HGzww>#ǷiGGdR/χywֽ$^v;bxXtw v!0?H2{4^lVF2&5hSFL~v#H+vdFgk܋>GIc?·ٱwjCZzr2Y5vB[(g2㲓+|''[j*%k^;{g1}f׾0Х=1g \嘝fV{v>*])|\7#.֣.}Rᓬg|8V-/J|/6/EЄG=PKı3ɬDHZ+ ]rtKY牪xj2PDzתLvg#xÌ(3(-hY)T2!qn~NjN%qwm! ^ 4?(5M-f?h|޼#/`vh T q6mJO!@ 4oGԆdX 3):l,?s?ӫX7$H#E Bę ? 7wH#E Bę ? 7wH#E Bę ? 7wH#E B*q8G5,?>gVF^iwHAHA`[%sǾ>n 3):lđq oL^oa{E+RՓWũTh"mf+W+ߗ;~ܗ畬{ݑ"q!Wm8o8Wv]mS:VFSњ~QPٷ:)`*(Za)%d}}y^ѽ7A)gR|uG9]$-ڏ \<KcG>7窫wzGǏGPM|{?;R$ $BG < K?h%N{zʏ z F~iwHAHA`IFU(IN -wHKUx8ѽ@)gR|un7hF#d &ۂ;:GwSKjRZ@-q4otVvG_UHs艧J&0ޠǦ^5絧]THw K7w+H#E B*q/Ϩ,7m=֟rg\eF[ƏG_FiwHAHA`(q$zLKkrg>^%ǽH^ѽOA)gR|uK a ៼h|{;R$ H`@ES} Fx'="&AIENDB`$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<$$If<!vh5T5#vT#v:V l05T54a<l$$If!vh55#v#v:V 6,53<4$$If!vh555Q5#v#v#vQ#v:V 6,53<4u$$If!vh5 5Q5#v #vQ#v:V 6,53<4Dd$<P  3 3"(($$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H44 555 44 Haf4p$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4$$If!vh555 #v#v#v :V H4555 44 Haf4DyK  www.dea.govyK (http://www.dea.gov/DyK  www.dea.govyK (http://www.dea.gov/DyK http://www.wpc-edi.com/codes/yK <http://www.wpc-edi.com/codes/DyK http://www.LOINC.orgyK ,http://www.loinc.org/DyK yK 0http://www.wpc-edi.com/DyK http://www.hl7.orgyK (http://www.hl7.org/$$If!vh5 5^#v #v^:V<l t 6 05 5^e4T$$If!vh55p#v#vp:V<l t 6 0655pe4T$$If!vh55#v#v:V<l t 6 0655e4T$$If!vh55#v#v:V<l t 6 0655e4T$$If!vh5 5^#v #v^:V<l t 6 05 5^e4T$$If!vh55p#v#vp:V<l t 6 0655pe4T$$If!vh55#v#v:V<l t 6 0655e4T$$If!vh55#v#v:V<l t 6 0655e4TI8@8 t[Normal_HmH sH tH ^@^ Rs Heading 1$ & Fdd@&[$\$5CJKHOJQJT@T Heading 2$ & F<@&5CJOJQJV@V Heading 3$ & F<@&56CJOJQJL@L Heading 4$ & Fx<@&5CJD@D Heading 5 & F<@&CJH@H Heading 6 & F<@&6CJL@L Heading 7 & F<@& CJOJQJP@P Heading 8 & F<@&6CJOJQJR @R Heading 9 & F<@&56CJOJQJDA@D Default Paragraph FontVi@V  Table Normal :V 44 la (k@(No List BOB Wes CommentB*CJOJQJkH@O@ WesCommentB*CJOJQJkHL>@L Title$<@&a$5CJ KHOJQJBB@"B Body Text@<x^@CJP6`2P F/t List Bullet 2$ & F ((a$CJR7@BR List Bullet 3 h8^8`CJ<OaR< Msgheader   >*rOqbr MsgStruct:$  xHP dL1$^ CJOJQJOr Indent NormalP ;h8p @ xHPxx^CJKHvOv TableA1$dL< /h8p @ xHCJKHOJQJ8@8 Header  !CJdOd TableMediumHeader$1$a$56CJhtH u:O: TableMedium 1$fOf SampleMessage0^`0 5B*CJOJQJhmHnHuXOX CommentTable$d((a$5CJOJQJTOT CommentTable1 h8#E^#`ELOL CommentTableInALitte ^POPExample dN^CJOJQJmHnHu.)@. Page NumberB @"B Footer"$d H$5CJJO!2J FooterWide#$d !P254@4 TOC 1 $xx5;2@2 TOC 2 %^:6@b6  Footnote Text&@&@q@ Footnote ReferenceH*:O: Table9pt(CJhtH u0U@0 Hyperlink>*B*DP@D Body Text 2*1$ B*htH u@"@@ Caption+$xxa$5CJL#@L Table of Figures,p^`pFQ@F Body Text 3-1$B*CJhph.@. TOC 3 .^FV@F FollowedHyperlink >*B* phO XMLSampleC0 >,X4` <hDpB*CJOJQJhtH uH@H  Balloon Text1CJOJQJ^JaJO" SampleXMLC2 >,X4` <hDpB*CJOJQJhph>8@2> List Bullet 4 3 & FXO!BX ExampBull#4 & F h^6CJVOaRV Normal List Bullets5x^`>Oqb> Normal List6^VOrV Normal Indented7xx^ KHtH u`O` Other Table Header8$xa$5CJKHtH uTOT Other Table Body 9<<CJKHtH uRY@R  Document Map:-D M OJQJ^JTOT HL7 Table Caption;$$<a$KHj@j aV Table Grid7:V<0<\O\ ]HL7 Table Header =$x5CJKHOJQJROR ]HL7 Table Body >dL<CJKHOJQJROR #tnormal1)7>*CJOJQJS*Y(^JaJo(phDOD `a tnormal681CJOJQJ^JaJo(VOV `atext241/57>*CJOJQJS*Y(\^JaJo(ph.X@!. `aEmphasis6]B'@1B iComment ReferenceCJaJ4@B4 i Comment TextD@j@AB@ iComment SubjectE5\*W@a* Strong5\X^@rX qJ Normal (Web)Gh^hCJPJaJnHtH,O, qJcaption5\GIIJ?ZL      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEF  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJK?GG8? D ~   L AzAzAzAzAzAz #zzzzzzzz z z z z zzzzzzzzzzzzzzzzzzz z!z"z#z$z%z&z'z(z)z*z+z,z-z.z/z0z1z2z3z4z5z6z7z8z9z:z;z<z=z>z?z@zAzBzCzDzEzFzY(PCGG]RLTiZodGny$9ƫ@1u4Q* Rn%\,w3 <AAIcP YLa#dpkrZz*Wdeեإ٥L1el"UMu *(38?{~d  c J  !"#$%&'()*+.,-./0172323434567I68Q9:N9D;<K=>?@6AB3CDXE6F&GH IJ1KKdefghijklT(V(GGGAHIJSK3OPQ]RwRR3SSLTTTTTTTTT5UiUjUUUV:VWVXVtVVVW;W?@H a _NORVWX`DEWm"#:M[XY01489:BxJKRZ[^bjks!/037?@H?@GOPSW_`hM(b]^_cdem bE0[\_cefn #$&'/I'(+/019`67:>?@Hk ^_bfpqy+ *+3tlm(.//03789Acqruywx{ A aGH,@Aklostu}VW()efimrs{WXj}RSVWcdeijks F6\]`dijr&H`tvy}TUYZ[c 3!6<FKijr*+.234<]kloswxRSVZ[\d123789AW+./26PQYw@ADHPQY !:@AVftux|FGrsvzI J K O P Q Y Z a i j m q y z   " # $ ( ) * 2 h                     " # + z    2 3 6 : B C K  X[_`aituxy}~ /EFIMghpSTcqruy  %P123789Al[\_cdem4?TZdi HILPQRZ{7 8qruyz{PQRVWX`vKLOSmnv]^aemnv /   B!C!D!H!I!J!R!S!T!W![!_!d!e!m!!!!!!!!!"M"N"y"z"}""""""########$$$$ $$$A$$$$$$$$$$$$$%% %G%%%%%%&&&&&&&I&&&& '' '#'''/'0'8'a'''''''''''(d(e(((((((((((())) )T))))))))))*{*|*********m+n+q+u+v+w+++R,S,V,Z,[,\,d,,D-E-T-b-c-f-j-r-s-{--7.8.;.?.@.A.I.. / //5/H/X/Y/\/`/h/i/q//00 00000#0$0,0b00000 18191<1@1H1I1Q1|111111127222222222T3U3X3\3v3w3333333333M44444444455]5666666%66^7_7b7c7g7h7i7q7777777778888888883969:9T9U9]9{999999999L:M:x:z:}::::::P;Q;T;X;Y;Z;[;;;;;;;; < <<)<b<c<d<h<i<j<r<<<<<<<<<<===>>>A>E>l>m>>>>>>??? ? ??3?p?q?r?v?w?x??????????#@Z@[@^@b@c@d@l@|@@@@@@@@@ A!A$A(A)A*A2AMAAAAAAAABkBBBBBBBBCTCUC\CdCeChClCtCuC}CCDDDDDDDDDDDDDDDDDEEEFEGEKELEMEUEEEEF F#F'F/F0F8FFGGG#G9G:G[GGGGGG H HHHHH:HHHHHHH0I1I4I8I@IAIIIIIIIIIIJ:J}J~JJJJJJJJK}K~KKKKKKKLLLLLL=LsLLLLLLLLM)M*M-M1M2M3MTMMMMMMMMMM|N}N~NNNNNNNNNNNNO?OOOOOOOO/PUPVPYP]PbPcPkPP"QDQ\QpQrQuQyQQQQQRRRRRRRRSSSSSSSSSMTNTOTSTTTUT]T{TTTUUUUU.UUUUUUUUUVVV"V#V$V,VYVVVVVVVVaWdWhWWWWWWWX"XJXaXbXeXiXqXrXzXXYYY Y Y YYkYYYYYYYYYYY.ZZZZZZZZ[6[7[:[>[?[@[H[[\ \ \\\\\e\\\\\\\\\@]C]G]H]I]J]v]]]]]]]]^^^X^Y^Z^^^_^`^h^^^^^^^^^^__~``````````?a@aCaGaKaLaTasaaaaaaaaa&b'b*b.b/b0b8bcbbbbbbbbbccc c c cc+c`cacdchcicjcrccdddd"d#d+dIddeeee"e#e$e%e-eZeeeeeeeeeeeefff!f"f#f+fUfffffggg ggggLgggggggghIhJhKhOhPhQhYhhhhiiiiiiiii8j:jejfjijmjujvjjjfkgkjknkokpkxkkkkkkkkkk+l,l?lOlllllllllrmsmvmzm{m|mmmmmmmmmn!nwnxnyn}n~nnnnnnno o5o6o9o=oEoFoNoyoooooppppppp8ppppppppqqqqqqqqqqq rHrIrtrurxr|rrrrrssssssssttttttttttt:u;uLMdpْ(DODWivw )*aiu!0j-:;r~—,<KØИј$JYəؙ 4DSÚКњ KZ _n `ƝҝGWdeMl|&345[gѠbn 2BQȢآ>]m|+89LXԤ_ĥإ٥+4568ORЧ2^xOiLrz4}"2}߭ĮChi *B_x°հ5A}̱2ERc 5[ͳγ?LUab$de@Ͷ_@yʸ׸ !PW5dټڼ*bt~н3FSaby %=YdÿԿ Yl~!>?v~ 7{#l(8Gw ?DSx#Zf+o~>MrBP_%M:N]m|.~0s-<LYZ[JXg%8\k"/0JV$12 Y3BRa!4'jx.;<4BQ-pH\k{*?u {au^l{ +8AMNO?@J^_hu 8}"UH+A~,rz>.3?STVYZ[]abc%&'-?@AG[\]crst $;<=B[\]b+0<PQWrstz'(^$%&+9:;?UVW\stuz JKi  )*+MV%&'_  $%&+0126:;<@LMNRn34e+,- 459IJKO[\]aijko ./2OPQTpqru.cht0ns0gM?vx ,-3CDEK[\]cstu{',8LMPYZ[^ghi  !&/016IJKPghin3j !"#'2MR^rsv~DIUijmFuz`     ! % 6 7 8 < J K L P ] ^ _     ( < = A W X Y ] r s t x          6 ; G [ \ ` h i j n | } ~                   . / |     & ' + 5 6 7 ; F G H L u v w {            8o #$%w&'*LMNQYZ[_stuyZ_k789=C{|*/;OPTlmnr3hmyE @w)`9p U *+,0:;<@FGHs&'(,JKLOefgj}~49EYZ^cdeiqrsw-t B "#7#`#%5&k&&'((#)$)[)\)$-%-..Q.].0.0f00000011233 4,45F5c566~6667b7n7y8z888::F;;<<<<<<=,=-=.=0=1=B=P=======>&>4>5>7>y>?$$$$j$$$$$$$$$$$$$y$$v:$>$$v:$$$s$"/ $H$s $s$s$s$s$$s$$H$$sv:v:lv: v:v:v:lv: v: v:v:v:lv: v:1~v:v:v:lv: v:1%v:v:v:lv: v: v: v:v:v:lv: v: v:$s$$v:0sxs0v:xv:t0v:xv:u:0v:xv:u:0v:xv:u:0v:xv:u:0v:xv:u:$$s$$s$s$H$H$s$$v:$s$s$$$s$s$s$s$s$ss0sv:0v:lv:0v:lv:0v:lv:0v:lv:0v:lv:0v:lv:0v:l$$s$$s$$s$s$s$$sj$jij$jij8jij8jij8jij8jij8jij8jij8jij8jij8ji$$sj$jxj$jxj$jij$jij$jij$jij$jij$jij$jij$ji$$sj$jij$jij$jij$jij$jij$jij$jij$jij$jij$jij$jij$jij$jij$jij$jij$jij$jij$jij$jij$ji$s$$sj$jxj$jxj$jij$jij8jij8jij8jij8jij8jij8jij8jij$jij$ji$s$$sj$jxj$jxj$jij$jij$jij$jij$jij$jij$jij$jij$jij$ji$s$$s(jji(jjijjijjijjijjijjijjjjijjijjijjijji$$sj$jxj$jxj$jij$jij$jij$jij$jj$jij$jij$jij$jij$jij$jij$jij$jij$ji$$s$s$s$s$s$s$s$s$s$s$s$$s^^^@^^^j(j(j(j@jjj=j(j(j(j@jjj=j(j(j(j(j(j@jjjjj"j(j(j(j@jjj j(j(j(j@jjj=j(j(j(j@jjjj(j(j(j@jjj=j(j(j(j@jjjj(j(j(j@jjj=j(j(j(j@jjjj(j(j(j(j@jjj j(j(j(j(j(j(j@jjj{ j(j(j(j@jjj j(j(j@jjjj(j(j(j@jjj=j(j(j(j(j(j@jjjj j(j(j(j(j(j(j(j(j@jjj j(j(j(j@jjj j(j(j(j@jjjN j(j(j(j@jjj j(j(j(j@jjjj j(j(j(j@jjjj(j(j(j@jjjj(j(j@jjjj(j(j(j@jjjj(j(j(j@jjj j(j(j(j@jjj{ j(j(j(j@jjjj(j(j(j(j(j(j@jjj j(j(j(j@jjj{ j(j(j(j(j@jjj j(j(j(j@jjjj(j(j(j@jjjj(j(j(j(j@jjj $v:$$s^^(^@^^^j(j(j(j@jjj=j(j(j(j@jjj=j(j(j(j(j(j@jjjjjj(j(j(j@jjj j(j(j(j@jjj=j(j(j(j@jjjj(j(j(j@jjj=j(j(j(j@jjjj(j(j(j@jjj=j(j(j(j@jjjj(j(j(j(j@jjj j(j(j(j(j(j(j@jjj{ j(j(j(j@jjj=j(j(j(j(j(j@jjjj j(j(j(j@jjjj(j(j(j@jjj j(j(j(j@jjj{ j(j(j(j@jjjj(j(j(j(j(j(j@jjjj(j(j(j@jjj j(j(j(j@j@jjjN j(j(j(j@jjjj(j(j(j@jjjj(j(j(j@jjjj(j(j@jjj=j(j(j(j(j(j@jjj{ j(j(j@jjj j(j(j(j@jjj=j(j(j(j(j(j(j@jjj{ j(j(j(j(j(j(j(j@jjjN $v:$$s^^^@^^^j(j(j(j@jjj=j(j(j(j@jjj=j(j(j(j(j(j@jjjjj"j(j(j(j@jjj j(j(j(j@jjj=j(j(j(j@jjjj(j(j(j@jjj=j(j(j(j@jjjj(j(j(j@jjj=j(j(j(j@jjjj(j(j(j(j@jjj j(j(j(j(j(j(j@jjj{ j(j(j(j(j(j@jjj j(j@jjjjj(j(j(j@jjj j(j(j(j(j(j(j(j(j@jjjj(j(j(j@jjj j(j(j(j@jjj j(j(j(j@jjj j(j(j(j(j(j@jjjj j(j(j(j@jjj{ j(j(j(j@jjjj j(j(j(j@jjj j(j(j(j@jjj=j(j(j(j(j(j(j(j@jjjj j(j(j(j(j(j(j(j(j(j@jjj"j(j(j(j(j(j@jjj j(j(j(j@jjj j(j(j(j@jjjj(j(j(j(j(j(j@jjjN j(j(j(j(j(j(j(j@jjjN j(j(j(j(j(j(j@jjj"j(j(j(j@jjjj(j(j(j(j(j(j(j(j@jjj"j(j(j(j@jjj{ j(j(j(j@jjjj(j(j(j(j(j(j@jjjN j(j(j(j(j(j(j@jjjN j(j(j(j(j(j(j@jjjN j(j(j(j(j(j(j@jjj"j(j(j(j@jjj j(j(j(j(j(j(j@jjj j(j(j(j@jjjj(j(j(j(j(j(j@jjjjjN j(j(j(j@jjjj(j(j(j@jjjj(j(j(j@jjjjj(j(j(j@jjj=j(j(j(j@jjjj(j(Uv(j@jjj(y j(j(j(v:(v:(j@jjj j(j(j(j@jjjj(j(j(v:(v:(j@jjjqj(j(j(j@jjjj(j(j(j(v:(j@jjjf}j(j(j(j@jjj j(j(j(v:(v:(j@jjjqj(j(j(j@jjj j(j(j(j@jjj=j(j(j(j(j(j@jjj{ j(j(j(j(j(j@jjj{ j(j(j(j@jjjj(j(j(j(j(j@jjj j(j(j(j@jjjj(j(j(j(j(j@jjjN j(j(j(j@jjj j(j(j(j(j(j@jjjN j(j(j(j@jjj j(j(j(j@jjj=j(j(j(v:(v:(j@jjjz j(j(j(j(v:(j@jjjBj(j(j(j@jjjj(j(j(j(j(j(j(j(j@jjjN j(j(j(j(v:(j@jjjf}j(j(j(j(v:(j@jjjf}j(j(j(j@jjjj(j(j(j@jjj j(j(j(j@jjj{ j(j(j(j@jjjj(j(j(j(j(j(j@jjj j(j(j(j@j@jjj j(j(j(j@jjj j(j(j@jjj=j(j(j(j@jjj j(j(j(j@jjj$v:$$s^^^>^^/^Yjjjj>jj/j=jjjj>jj/j=jjjjjj>jj/j/j/j jjjj>jj/j jjjj>jj/j=jjjj>jj/j=jjjj>jj/j=jjjj>jj/jjjjj>jj/j=jjjjj>jj/j jjjjj>jj/j jjjjjj>jj/j jjjjjj>jj/jN jjj>jj/j/jjjjj>jj/j jjjjjjjj>jj/jN jjjjjj>jj/j jjjj>jj/j jjjjj>jj/jjjjj>jj/jjjjj>jj/j jjjj>jj/j{ jjjj>jj/jjjjjjjj>jj/j jjj>jj/j jjjj>j>jj/j jjjj>jj/jjjjj>jj/jjjjj>jj/jjjj>jj/j=jjjjj>jj/j jjj>jj/j jjjj>jj/j=jjjjjjj>jj/j{ jjjjjj>jj/j jjjj>jj/j jjjj>jj/j=jjjjjjj>jj/j jjjj>jj/j=jjjj>jj/j=$v:$v:$$s^^^@^^^Yjjjj@jjj=jjjj@jjj=jjjjjj@jjjjj jjjj@jjj jjjj@jjj=jjjj@jjj=jjjj@jjj=jjjj@jjjjjjj@jjj=jjjj@jjjjjjjj@jjj jjjjjjj@jjj{ jjjjjj@jjjN jjj@jjjjjjjj@jjjjjjjjj@jjj{ jjjj@jjj{ jjjj@jjj=jjjj@jjjjjjj@jjj=jjjjjjjjj@jjjjjjjjjjj@jjj jjjjjjj@jjj jjjjjj@jjj{ jjjj@jjj=jjjjjj@jjj{ jjjjjj@jjj jjjj@jjj jjjj@jjj{ jjjjjjj@jjj jjjj@jjj{ jjjjjjjjj@jjjjjjjjjj@jjjN jjjjjjjjj@jjj"jjjj@jjjjjjj@jjj jjjj@jjj{ jjjj@jjjjjjjjjj@jjj jjjj@jjj{ jjjj@j@jjjN jjjj@jjjjjjj@jjjjjj@jjj=jjjj@jjj=jjjjjj@jjj{ jjjj@jjj $v:$$s^^^@^^^j(j(j(j@jjj=j(j(j(j@jjj=j(j(j(j(j(j@jjjjj j(j(j(j@jjj j(j(j(j@jjj=j(j(j(j@jjjj(j(j(j@jjj=j(j(j(j@jjjj(j(j(j@jjj=j(j(j(j@jjjj(j(j(j(j@jjj j(j(j(j(j(j(j@jjj{ j(j(j(j(j(j@jjj"j(j(j@jjjjj(j(j(j@jjj=j(j(j(j(j(j@jjj j(j(j(j@jjj{ j(j(j(j(j(j(j(j@jjjN j(j(j(j(j(j(j(j(j@jjj j(j(j(j@jjj j(j(j(j(j(j@jjj j(j(j(j@jjj j(j(j(j@jjj j(j(j(j@jjjj(j(j(j@jjjj(j(j(j@jjjj(j(j(j@jjj j(j(j(j@jjjj(j(j(j@jjj{ j(j(j(j@jjjj(j(j(j(j(j(j@jjj j(j(j(j@jjj j(j(j(j@j@jjj j(j(j(j@jjjj(j(j(j@jjj j(j(j(j@jjjj(j(j(j@jjj=j(j(j@jjjj(j(j@jjjj(j(j(j(j(j(j(j(j@jjj j(j(j(j@jjj j(j(j(j(j(j(j@jjj j(j(j(j@jjj j(j(j(j@jjj j(j(j(j@jjj{ j(j(j(j@jjjj(j(j@jjj$v:$$s^^+^^^^Yj+j+j+jjjj=j+j+j+jjjj=j+j+j+j+j+jjjjjj"j+j+j+jjjj j+j+j+jjjj=j+j+j+jjjjj+j+j+jjjj=j+j+j+jjjjj+j+j+jjjj=j+j+j+jjjjj+j+j+j+jjjjjj j+j+j+j+j+j+jjjj{ j+j+j+jjjj=j+j+j+j+j+j+j+jjjjN j+j+j+jjjj{ j+j+j+jjjjj+j+j+j+j+jjjjj"j+j+j+j+j+jjjj j+j+j+jjjj{ j+j+j+jjjj=j+j+j+j+j+j+j+jjjjN j+j+j+jjjj{ j+j+j+jjjjj+j+j+jjjjj+j+j+j+j+j+j+j+jjjjN j+j+j+j+j+j+j+jjjjN j+j+j+jjjjj+j+j+j+j+j+jjjj j+j+3+j+j+jjjj: j+j+j+jjjj{ j+j+j+j+j+j+jjjj j+j+j+jjjjj+j+j+jjjj=j+j+j+jjjjj+j+j+jjjj=j+j+jjjjj+j+j+j+j+j+jjjjN j+j+j+jjjjj+j+j+jjjjj+j+jjjjj+j+j+jjjj{ j+j+j+jjjjj+j+j+j+j+j+jjjj j+j+j+jjjj j+j+j+jjjjj j+j+j+jjjj j+j+j+j+j+j+j+j+jjjjj"j+j+j+jjjjj+j+j+jjjj j+j+j+jjjj$v:$$$v:$s$s$s$s$s$s$K$j$j$j$j$j$j$j$j$j$j$j$j$j$j$j$j$j$j$j$j$K$K$j$j$j$j$j$j$j$j$K$s$$s$s||:g:g:g:g:gz ||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g#||:g:g:g:g!||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:gN||:g:g:g:g:g:g:g:g:g:g:g?-||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g||:g:g:g:g:g:gl ||:g:g:g:g:g:g:g:g:g:g:g:^||:g:g:g:g:g:gl ||:g:g:g:g:g:g:g:g:g:g:g:^||:g:g:g:g:g:gl ||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g*||:g:g:g:g:g:g:g:g $s$s$s$$ XN4 N:$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$s$s||:g:g:g:g:gz ||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g#||:g:g:g:g!||:g:g:g:g:g:gl ||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g$s$s$s$$ XN4 N:$$v:$s$v:$q$v:$$s$s||:g:g:g:g:gz ||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g#||:g:g:g:g!||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:gN||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g||:g:g:g:g:g:g:g:g:g:g:g:g:^||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g3||:g:g:g:g:g:g:g:g;C||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g||:g:g:g:g:g:g:g:g:g:g:g:g?-||:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g:g||:g:g:g:g:g:g:g:g:g:g:g:g:g:gv$|$s$s$$6v:<v:t6v:xv:v:Av:u:D v:v:Av:u:$v:$v:$$$$v:$$$v:$$$$v:$$v:$$$v:$$v:$$$v:$$v:$$$$$v:$$$s$s$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:tcv:cv: v:`$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:`$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$v:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:t$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:`$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:tcv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:`$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:t$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:`$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$scv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:cv:cv: v:u:$$s$s$$s$s$v:$$s$s$$s$s$$s$s$s$$s$s$s$$s$s$s$s$s$s$s $s$s$s$s$s$$s$s$s$s$s$s$s$s$$v:$s$s$s$s$$s$s$$s$v:$s$v:$s$s$s$v:$s$s$v:$s$v:$v:$v:$v:2v:v:u:$s$s v:v:u:$s$s$v:v:;v:Uv$$v:v:v:;Uv$K$s$jdefghijkl'x/v%B1qRW *  { C # EmM/  B&9'FIy | !!""4###m$$K%% &t&&>'''T(V(X(u(%))\**c++v,,- .|..T//<00,11<22T33`44)55666K77@88N99%::";;,<<2==">>"??'@@AA8BBPCCCDD>EE*FF'GGGGGGGAHIJSK3OPQ]RwRR3SSLTTTTTTTTT5UiUjUUUV:VWVXVtVVVW;W?@H a _NORVWX`DEWm"#:M[XY01489:BxJKRZ[^bjks!/037?@H?@GOPSW_`hM(b]^_cdem bE0[\_cefn #$&'/I'(+/019`67:>?@Hk ^_bfpqy+ *+3tlm(.//03789Acqruywx{ A aGH,@Aklostu}VW()efimrs{WXj}RSVWcdeijks F6\]`dijr&H`tvy}TUYZ[c 3!6<FKijr*+.234<]kloswxRSVZ[\d123789AW+./26PQYw@ADHPQY !:@AVftux|FGrsvzI J K O P Q Y Z a i j m q y z   " # $ ( ) * 2 h                     " # + z    2 3 6 : B C K  X[_`aituxy}~ /EFIMghpSTcqruy  %P123789Al[\_cdem4?TZdi HILPQRZ{7 8qruyz{PQRVWX`vKLOSmnv]^aemnv /   B!C!D!H!I!J!R!S!T!W![!_!d!e!m!!!!!!!!!"M"N"y"z"}""""""########$$$$ $$$A$$$$$$$$$$$$$%% %G%%%%%%&&&&&&&I&&&& '' '#'''/'0'8'a'''''''''''(d(e(((((((((((())) )T))))))))))*{*|*********m+n+q+u+v+w+++R,S,V,Z,[,\,d,,D-E-T-b-c-f-j-r-s-{--7.8.;.?.@.A.I.. / //5/H/X/Y/\/`/h/i/q//00 00000#0$0,0b00000 18191<1@1H1I1Q1|111111127222222222T3U3X3\3v3w3333333333M44444444455]5666666%66^7_7b7c7g7h7i7q7777777778888888883969:9T9U9]9{999999999L:M:x:z:}::::::P;Q;T;X;Y;Z;[;;;;;;;; < <<)<b<c<d<h<i<j<r<<<<<<<<<<===>>>A>E>l>m>>>>>>??? ? ??3?p?q?r?v?w?x??????????#@Z@[@^@b@c@d@l@|@@@@@@@@@ A!A$A(A)A*A2AMAAAAAAAABkBBBBBBBBCTCUC\CdCeChClCtCuC}CCDDDDDDDDDDDDDDDDDEEEFEGEKELEMEUEEEEF F#F'F/F0F8FFGGG#G9G:G[GGGGGG H HHHHH:HHHHHHH0I1I4I8I@IAIIIIIIIIIIJ:J}J~JJJJJJJJK}K~KKKKKKKLLLLLL=LsLLLLLLLLM)M*M-M1M2M3MTMMMMMMMMMM|N}N~NNNNNNNNNNNNO?OOOOOOOO/PUPVPYP]PbPcPkPP"QDQ\QpQrQuQyQQQQQRRRRRRRRSSSSSSSSSMTNTOTSTTTUT]T{TTTUUUUU.UUUUUUUUUVVV"V#V$V,VYVVVVVVVVaWdWhWWWWWWWX"XJXaXbXeXiXqXrXzXXYYY Y Y YYkYYYYYYYYYYY.ZZZZZZZZ[6[7[:[>[?[@[H[[\ \ \\\\\e\\\\\\\\\@]C]G]H]I]J]v]]]]]]]]^^^X^Y^Z^^^_^`^h^^^^^^^^^^__~``````````?a@aCaGaKaLaTasaaaaaaaaa&b'b*b.b/b0b8bcbbbbbbbbbccc c c cc+c`cacdchcicjcrccdddd"d#d+dIddeeee"e#e$e%e-eZeeeeeeeeeeeefff!f"f#f+fUfffffggg ggggLgggggggghIhJhKhOhPhQhYhhhhiiiiiiiii8j:jejfjijmjujvjjjfkgkjknkokpkxkkkkkkkkkk+l,l?lOlllllllllrmsmvmzm{m|mmmmmmmmmn!nwnxnyn}n~nnnnnnno o5o6o9o=oEoFoNoyoooooppppppp8ppppppppqqqqqqqqqqq rHrIrtrurxr|rrrrrssssssssttttttttttt:u;uLMdpْ(DODWivw )*aiu!0j-:;r~—,<KØИј$JYəؙ 4DSÚКњ KZ _n `ƝҝGWdeMl|&345[gѠbn 2BQȢآ>]m|+89LXԤ_ĥإ٥+4568ORЧ2^xOiLrz4}"02}߭ĮChi *B_x°հ5A}̱2ERc 5[ͳγ?LUab$de@Ͷ_@yʸ׸ !PW5dټڼ*bt~н3FSaby %=YdÿԿ Yl~!>?v~ 7{#l(8Gw ?DSx"#Zf+o~>MrBP_%M:N]m|.~0s-<LYZ[JXg%8\k"/0JV$12 Y3BRa!4'jx.;<4BQ-pH\k{*?u {au^l{ +8AMNO?@J^_hu 8}"UH+A~,rz>.3?STVYZ[]abc%&'-?@AG[\]crst $;<=B[\]b+0<PQWrstz'(^$%&+9:;?UVW\stuz JKi  )*+MV%&'_  $%&+0126:;<@LMNRn34e+,- 459IJKO[\]aijko ./2OPQTpqru.cht0ns0gM?vx ,-3CDEK[\]cstu{',8LMPYZ[^ghi  !&/016IJKPghin3j !"#'2MR^rsv~DIUijmFuz`     ! % 6 7 8 < J K L P ] ^ _     ( < = A W X Y ] r s t x          6 ; G [ \ ` h i j n | } ~                   . / |     & ' + 5 6 7 ; F G H L u v w {            8o #$%w&'*LMNQYZ[_stuyZ_k789=C{|*/;OPTlmnr3hmyE @w)`9p U *+,0:;<@FGHs&'(,JKLOefgj}~49EYZ^cdeiqrsw-t B "#7#`#%5&k&&'((#)$)[)\)$-%-..Q.].0.0f00000011233 4,45F5c566~6667b7n7y8z8{888::F;;{<|<~<<<<<<<<<<<<<<=,=-=.=/=0=1=B=P========>&>4>5>6>7>8>9>y>z>{>>>>>>>>>>>>>>>;?N?O?P?Q?R??????????????0000000000000000000000$0%0%0%0%0%0$0%0%0%0%0.0.0.0.0.0.0.0$0%0%0%0%0%0%0%0$0%0.0.0.0$0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0.0.0.0.0%000,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0000 00G 0G 0G0G0G0G0G0G 0GG0]R 0]R 0]R 0]R+0]R0]R 0]R 0]R 0]R 0]R 0]R 0]R 0]R 0]R 0]R 0]R 0]R 40]R 0]R 0]R 0]R 0]R 0]R 40]R 40]R 40]R 0]R 0]R 0]R 40]R 40]R 0]R0]R0]R 0]R 0]R 0]R 0]R 0]R0]R 0]R 0]R 0GG0iZ0iZ 0iZ 0iZ 0iZ 0iZ 0iZ 0iZ &0iZ 0iZ 0iZ &0iZ 0iZ 0iZ &0iZ 0iZ 0iZ &0iZ 0iZ 0iZ &0iZ 0iZ  0GG0Z 0GG0[0[ 0[ 0[0[ 0GG0`0`0` 0 0'e'e03e03e03e03e03e+03e03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 03e 0'e'e0zl 0'e'e0n 0'e'e0Gn0Gn0Gn( 0GnGn+0s0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s 0s ( 0GnGn+0v0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v( 0GnGn+0x0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x 0x( 0GnGn+0|0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0|( 0GnGn+0|0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0|( 0GnGn+0$0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$ 0$( 0GnGn+0V0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V 0V  000000000000 0+000 0 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 000 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 0000 0 0 0 0 0 000000 0 0 0 0 0 000 0 0 0 0 0 00 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 00 0 0 00000000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 00 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 000 0 0 0 0 0 0000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 0000 0 0 0 0 0 0+000 0 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 000 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 0000 0 0 0 0 0 000000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 00 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 000 0 0 0 0 0 000 00 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00 0 0 0 0 0 00000 0 0 0 0 0 00 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 0000000 0 0 0 0 0 0+000 0 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 000 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 0000 0 0 0 0 0 000000 0 0 0 0 0 00000 0 0 0 0 0 0 0 0 00 0 0 000 0 0 0 0 0 00000000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 00 0 0 000 0 0 0 0 0 000 0 0 00 0 0 000 0 0 0 0 0 000 0 0 0 0 0 0000000 0 0 00 0 0 000000000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 0000000 0 0 0 0 0 000000 0 0 0 0 0 000 0 0 0 0 0 00000000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 000000 0 0 0 0 0 000000 0 0 0 0 0 000000 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 000 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 00 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 00000000 0 0 0 0 0 00000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 000 00 0 0 0 0 000 0 0 0 0 0 00 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 0+000 0 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 000 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 0000 0 0 0 0 0 0000 0 0 0 0 0 00000 0 0 0 0 0 00000 0 0 0 0 0 00 0 0 00 0 0 000 0 0 0 0 0 0000000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 0000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 00 0 0 0 0 0 000 00 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00 0 0 0 0 0 0000 0 0 0 0 0 00 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 00 0+000 0 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 000 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 0000 0 0 0 0 0 000000 0 0 0 0 0 00000 0 0 0 0 0 00 0 0 00 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00000000 0 0 0 0 0 0000000 0 0 0 0 0 000000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 000 0 0 0 0 0 00000000 0 0 0 0 0 000000 0 0 0 0 0 00000000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 000000 0 0 0 0 0 000 0 0 0 0 0 000 00 0 0 0 0 000 0 0 0 0 0 000 0 0 0 0 0 00 0 0 0 0 0 000 0 0 0 0 0 00000 0 0 0 0 0 000 0 0 0 0 0 0+0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[;0[;0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[;0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[; 0[; 0[; 0[;0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[;0[;0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[;0[;0[;0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[;0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[;0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[;0[;0[;0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[;0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[;0[; 0[; 0[; 0[; 0[; 0[; 0[;0[; 0[; 0[; 0[; 0[; 0[; 0+0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J]0J]0J]0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J] 0J] 0J] 0J]0J] 0J] 0J] 0J]0J]0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J]0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J]0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J]0J]0J]0J]0J]0J] 0J] 0J] 0J]0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0J]0J]0J] 0J] 0J] 0J] 0J] 0J] 0 00ʁ0ʁ0ʁ0ʁ0ʁ0ʁ+0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ0ʁ( 0ʁʁ0+00 00000 0 0 000000000000000 0 0 00000000000000000000 0 0 0000 0 0 0000000000000000 0 0 00000000000 0 0 000000000000000 0 0 000000 0 0 000000000000 0 0 000000 0 0 000000000000 0 0 000000 0 0 0000000000000000000 0 0 00000000 0 00+0000 0 0 0 0 0 0 0 0 0 0 0 00000000000000000000000000000000( 0ʁʁ02+0202 0202020202 02 02 020202020202020202020202020202 02 02 0202020202020202020202020202020202020202 02 02 02020202 02 02 020202020202 02 02 020202020202020202020202020202 02 0202+02020202 02 02 02 02 02 02 02 02 02 02 02 0202+02020202( 0ʁʁ0+00 00000 0 0 000000000000000 0 0 00000000000000000000 0 0 0000 0 0 0000000000000000000000000000000000000000 0 0 00000000000000000 0 0 0000000000000000000000000000000 0 0 0000000000000 0 0 00000000000000000000000 0 0 00000000 0 0 0000000000000000000000000 0 0 000000000000 0 0 0000000000000000000000000000000000000000000 0 0 00000000000000 0 00+0000 0 0 0 0 0 0 0 0 0 0 0 00G0G0G00G0G00G0G0G00G00G0G00G00G0G00G00G0G0G0G00G00 000 00+00 0 0 0 0 0 0 0 0 0 0 0  00c+0c0c 0c 0c 0c 0c 0c 0c 0c 0c 0c 0c 0c 0c 0c 0c 0c 0c 0c 0c 0c  00t+0t0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t 0t  00+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00(+0(0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0( 0(  00K+0K0K 0K 0K 0K 0K 0K 0K 0K 0K 0K 0K 0K  00++0+0+ 0+ 0+ 0+ 0+ 0+ 0+ 0+ 0+ 0+ 0+ 0+ 0+ 0+ 0+ 0+ 0+ 00+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00'+0'0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0' 0'  0 04+0404 04 04 04 04 04 04 04 04 04 04 04 04 04 04 04  0 0-+0-0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0-  0 0+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00+00 0 0 0 0 0 0 0 0 0 0 0  00+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00+00 0 0 0 0 0 0 0 0 0 0 0  00i+0i0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i 0i  00+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00_ +0_ 0_  0_  0_  0_  0_  0_  0_  0_  0_  0_  0_  0_  0_  0_  0_  0_  0_  0_  0_  0_   00 +0 0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0   00/ +0/ 0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/  0/   00 +0 0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0   00%+0%0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%  00+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  00|+0|0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0| 0|  0 0+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0!0+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0"0+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0#0+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0$0+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0%0 +0 0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0   0&0H+0H0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H  0'0+00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0(00 0)000 0*00 0+00 0,0 0 0  0-07#07#07# 0.0k&0k&0k&0k&0k&0k&0k&0k&0k&0k&0k&0k& 0/0Q.0Q.0Q.0Q.0Q.0Q.0Q.0Q. 000000000000 010 40 4 020F5( 0F5F506( 0F5F50~6( 0F5F506( 0F5F5000;0;00&0&0&00000000000 0 0 0000 0 0 0000"0"0 "0"0 0 "000"0"0 "0"0 0 "0000"0"000000000 0 0 0000"0"0"00"000"0"0 "0 0 "0000"0"0000defghijklV(X(u(GGGGGAHIJSK3OPQ]RwRR3SSLTTTTTTTTT5UiUjUUUV:VWVXVtVVVW;W?@H a _NORVWX`DEWm"#:M[XY01489:BxJKRZ[^bjks!/037?@H?@GOPSW_`hM(b]^_cdem bE0[\_cefn #$&'/I'(+/019`67:>?@Hk ^_bfpqy+ *+3tlm(.//03789Acqruywx{ A aGH,@Aklostu}VW()efimrs{WXj}RSVWcdeijks F6\]`dijr&H`tvy}TUYZ[c 3!6<FKijr*+.234<]kloswxRSVZ[\d123789AW+./26PQYw@ADHPQY !:@AVftux|FGrsvzI J K O P Q Y Z a i j m q y z   " # $ ( ) * 2 h                     " # + z    2 3 6 : B C K  X[_`aituxy}~ /EFIMghpSTcqruy  %P123789Al[\_cdem4?TZdi HILPQRZ{7 8qruyz{PQRVWX`vKLOSmnv]^aemnv /   B!C!D!H!I!J!R!S!T!W![!_!d!e!m!!!!!!!!!"M"N"y"z"}""""""########$$$$ $$$A$$$$$$$$$$$$$%% %G%%%%%%&&&&&&&I&&&& '' '#'''/'0'8'a'''''''''''(d(e(((((((((((())) )T))))))))))*{*|*********m+n+q+u+v+w+++R,S,V,Z,[,\,d,,D-E-T-b-c-f-j-r-s-{--7.8.;.?.@.A.I.. / //5/H/X/Y/\/`/h/i/q//00 00000#0$0,0b00000 18191<1@1H1I1Q1|111111127222222222T3U3X3\3v3w3333333333M44444444455]5666666%66^7_7b7c7g7h7i7q7777777778888888883969:9T9U9]9{999999999L:M:x:z:}::::::P;Q;T;X;Y;Z;[;;;;;;;; < <<)<b<c<d<h<i<j<r<<<<<<<<<<===>>>A>E>l>m>>>>>>??? ? ??3?p?q?r?v?w?x??????????#@Z@[@^@b@c@d@l@|@@@@@@@@@ A!A$A(A)A*A2AMAAAAAAAABkBBBBBBBBCTCUC\CdCeChClCtCuC}CCDDDDDDDDDDDDDDDDDEEEFEGEKELEMEUEEEEF F#F'F/F0F8FFGGG#G9G:G[GGGGGG H HHHHH:HHHHHHH0I1I4I8I@IAIIIIIIIIIIJ:J}J~JJJJJJJJK}K~KKKKKKKLLLLLL=LsLLLLLLLLM)M*M-M1M2M3MTMMMMMMMMMM|N}N~NNNNNNNNNNNNO?OOOOOOOO/PUPVPYP]PbPcPkPP"QDQ\QpQrQuQyQQQQQRRRRRRRRSSSSSSSSSMTNTOTSTTTUT]T{TTTUUUUU.UUUUUUUUUVVV"V#V$V,VYVVVVVVVVaWdWhWWWWWWWX"XJXaXbXeXiXqXrXzXXYYY Y Y YYkYYYYYYYYYYY.ZZZZZZZZ[6[7[:[>[?[@[H[[\ \ \\\\\e\\\\\\\\\@]C]G]H]I]J]v]]]]]]]]^^^X^Y^Z^^^_^`^h^^^^^^^^^^__~``````````?a@aCaGaKaLaTasaaaaaaaaa&b'b*b.b/b0b8bcbbbbbbbbbccc c c cc+c`cacdchcicjcrccdddd"d#d+dIddeeee"e#e$e%e-eZeeeeeeeeeeeefff!f"f#f+fUfffffggg ggggLgggggggghIhJhKhOhPhQhYhhhhiiiiiiiii8j:jejfjijmjujvjjjfkgkjknkokpkxkkkkkkkkkk+l,l?lOlllllllllrmsmvmzm{m|mmmmmmmmmn!nwnxnyn}n~nnnnnnno o5o6o9o=oEoFoNoyoooooppppppp8ppppppppqqqqqqqqqqq rHrIrtrurxr|rrrrrssssssssttttttttttt:u;uLMdpْ(DODWivw )*aiu!0j-:;r~—,<KØИј$JYəؙ 4DSÚКњ KZ _n `ƝҝGWdeMl|&345[gѠbn 2BQȢآ>]m|+89LXԤ_ĥإ٥+4568ORЧ2^xOiLrz4}"02}߭ĮChi *B_x°հ5A}̱2ERc 5[ͳγ?LUab$de@Ͷ_@yʸ׸ !PW5dټڼ*bt~н3FSaby %=YdÿԿ Yl~!>?v~ 7{#l(8Gw ?DSx"#Zf+o~>MrBP_%M:N]m|.~0s-<LYZ[JXg%8\k"/0JV$12 Y3BRa!4'jx.;<4BQ-pH\k{*?u {au^l{ +8AMNO?@J^_hu 8}"UH+A~,rz>.3?STVYZ[]abc%&'-?@AG[\]crst $;<=B[\]b+0<PQWrstz'(^$%&+9:;?UVW\stuz JKi  )*+MV%&'_  $%&+0126:;<@LMNRn34e+,- 459IJKO[\]aijko ./2OPQTpqru.cht0ns0gM?vx ,-3CDEK[\]cstu{',8LMPYZ[^ghi  !&/016IJKPghin3j !"#'2MR^rsv~DIUijmFuz`     ! % 6 7 8 < J K L P ] ^ _     ( < = A W X Y ] r s t x          6 ; G [ \ ` h i j n | } ~                   . / |     & ' + 5 6 7 ; F G H L u v w {            8o #$%w&'*LMNQYZ[_stuyZ_k789=C{|*/;OPTlmnr3hmyE @w)`9p U *+,0:;<@FGHs&'(,JKLOefgj}~49EYZ^cdeiqrsw-t B "#7#`#%5&k&&'((#)$)[)\)$-%-..Q.].0.0f00000011233 4,45F5c566~6667b7n7y8z8{888::F;;{<|<?? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000%000,0000  00  0  0 0 0 0 0 0  0 0+ 0+ 0+ 0++0+0+0+ 0+ 0+ 0+0+0+0+0+0+0+0+ 40+0+0+0+0+0+ 40+40+40+0+0+0+ 40+40+0+0+0+0+0+0+0+0+0+0+0+ 0 0303030303030303&030303&03 0303&03 0303&03 0303&03 03 0 0$4 0 0404 04 0404 0 090909  0 0s>s>0>0>0>0>0>+0>0>0>0>0>0>0>0>0>0>0>0>0>0>0>0>0>0>0>0>0>0>0>0>0>0> 0s>s>0E 0s>s>0`G 0s>s>0G0G0G* 0GG+0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M0)M* 0GG+0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O0O* 0GG+0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q0Q* 0GG+0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V0V* 0GG+0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X0X* 0GG+0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[0p[* 0GG+0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^0^  008b08b08b08b08b08b08b08b08b08b08b 08b8b+0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e 0.e 0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e 0.e 0.e0.e0.e0.e0.e0.e0.e 0.e 0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.et 0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e 0.e0.e0.e0.e0.e0.e0.e0.e0.e 0.e 08b8b+0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~0~0~ 0~ 0~0~ 0~ 0~ 0~ 0~0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~0~0~0~ 0~0~0~0~0~0~0~0~0~0~0~0~ 0~ 08b8b+00000000 00000000 00000000 000000000000 00000000 00000000 00000000 00000000 00000000 00000000 00000000 000000000 00000000000 00000000000000000 00000000 0000000000000 00000000 00000000 00000000 00000000000 00000000 000000000 00000000 00000000 0000000000000 00000000000000 0000000000 00000000 00000000 00000000000 000000000000 00000000000 00000000 0000000000000 00000000 00000000 00000000000 00000000000 00000000000 00000000000 00000000 00000000000 00000000 0000000000000 00000000 00000000 000000000 00000000 00000000 00000000 0000000000 00000000 0000000000 00000000 0000000000 00000000 0000000000 00000000 00000000 0000000000 0000000000 00000000 0000000000 00000000 0000000000 00000000 0000000000 00000000 00000000 0000000000 0000000000 00000000 0000000000000 0000000000 0000000000 00000000 00000000 00000000 00000000 00000000000 000000000 00000000 0000000 00000000 00000000 0 08b8b+00000000 00000000 00000000 000000000000 00000000 00000000 00000000 00000000 00000000 00000000 000000000 000000000 0000000000000000 0000 00000000 00000000 000000000000 0000000000 00000000000000000 00000000 00000000 00000000 00000000 00000000000 0000000 000000000 00000000 00000000 00000000 0 00 0 0 0 00 0000 0 0 0 00 00 0 0 0 0 00000000 00000000000 0000000000 00000000 00000000 00000000000 00000000 00000000 00 08b8b+0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0# 0#0#0# 0# 0# 0# 0#0#0#0#0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0#0#0# 0#0#0#0#0#0#0#0# 0# 08b8b+00000000 00000000 00000000 000000000000 00000000 00000000 00000000 00000000 00000000 00000000 00000000 000000000 0 0000000000 0 00000 0000 000 0 0 000 0 000 0 0 0 00000000000 00000000 000000000000 0000000000000 0 000 0 0 0 00000000000 00000000 00000000 00000000 00000000 00000000 00000000 00000000 00000000 00000000 00000000000 00000000 000000000 0 000 0 0 0 0 0000 0 0 0 0 0000 0 0 0 0 0 000 0 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 0 00000000 0 0 0 0 00000000 0 0000000000 00000000 00000000 00000000 00000000 0000000 0 08b8b+0606060606060606 0606060606060606 0606060606060606 060606060606060606060606 0606060606060606 0606060606060606 0606060606060606 06 060606 06 06 0606 0606060606060606 0606060606060606 0606060606060606 0606060606060606060606 06 06060606060606060606 0606060606060606 060606060606060606060606 0606060606060606 0606060606060606 0606060606060606060606 06060606060606060606 0606060606060606 0606060606060606 060606060606060606060606 0606060606060606 0606060606060606 0606060606060606 06060606060606060606060606 060606060606060606060606 0606060606060606 06 06060606060606060606 06060606060606060606 0606060606060606 0606060606060606060606 06060606060606060606060606060606 0606060606060606 0606060606060606 06060606060606 06 06060606060606060606 0606060606060606 0606060606060606 06060606060606 0606060606060606 0606060606060606 0606060606060606060606 0606060606060606 060606060606060606 0606060606060606 0606060606060606060606060606 0606060606060606 0606060606060606 0606060606060606 06  0 0 [ [0[0[0[0[0[0[+0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[0[* 0[[0f+0f0f0f0f0f0f0f0f 0f 0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f 0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f 0f0f0f0f0f0f 0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f 0f0f0f0f0f0f0f0f0f0f0f0f0f 0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f 0f0f0f0f0f0f0f0f 0f0f0f0f0f0f0f0f0f0f0f0f0f0f 0f0f0f0f0f0f0f0f 0f0f0f0f0f0f0f0f0f0f0f0f0f0f 0f0f0f0f0f0f0f0f 0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f0f 0f0f0f0f0f0f0f0f0f0f 0f0f+0f0f0f0f 0f 0f0f 0f 0f 0f 0f0f 0f 0f 0f0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f`0f* 0[[0+00000000 0 000000000000000 00000000000000000000000 000000 00000000 0000000000000000000+00000000000000000+0000* 0[[0+00000000 0 000000000000000 00000000000000000000000 000000 000000000000000000000000000000000000000000 0000000000000000000 000000000000000000000000000000000 000000000000000 0000000000000000000000000 0000000000 000000000000000000000000000 00000000000000 000000000000000000000000000000000000000000000 0000000000000000 00+000000 00000000000G0G0G00G0G00G0G0G00G00G0G00G00G0G00G00G0G0G0G00G00  00(0( 0((0+0000000000000 0((0+00000000000000 0 0 00 0 0 0 0((0+00000000000000 0 0 00 0 0 0 0((0+00000 0000 0000 0000 0000  0((0w+0w0w0w0w0w 0w0w0w0w 0w0w0w0w 0w0w0w0w 0w0w0w0w 0w0w0w0w 0w0w0w0w 0w0w0w0w 0w0w0w0w 0w0w0w0w 0w0w0w0w 0w0w0w0w 0w0w0w0w  0((0+00000 0000 0000  0((0z+0z0z 0z0z0z 0z0z0z0z 0z0z0z0z 0z 0z 0z 0z0z 0((08+0808 080808 08080808 08080808 08 08 08 0808 08 08 08  0((0v+0v0v 0v0v0v 0v0v0v0v 0v0v0v0v 0v 0v 0v 0v0v0v0v0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v 0v  0 ((0+00 000 0000 0000 0 0 0 0 0 ((0|+0|0| 0|0|0| 0|0|0|0| 0|0|0|0| 0| 0| 0| 0|0|0|0|0| 0| 0| 0| 0|  0 ((0+00 000 0000 0000 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0  0 ((0+00 000 0000 0000 0 0 0 0 0 ((0 +0 0  0 0 0  0 0 0 0  0 0 0 0  0  0  0  0 0 0 0 0   0((0G+0G0G 0G0G0G 0G0G0G0G 0G0G0G0G  0((03+0303 030303 03030303 03030303 03 03 03 0303030303  0((0;+0;0; 0;0;0; 0;0;0;0; 0;0;0;0; 0; 0; 0; 0; 0((0n+0n0n 0n0n0n 0n0n0n0n 0n0n0n0n 0n 0n 0n 0n0n0n0n0n 0n 0n 0n 0n  0((0+00 000 0000 0000  0((0+00 000 0000 0000 0 0 0 00000 0 0 0 0 0 0 0 0  0((0G+0G0G 0G0G0G 0G0G0G0G 0G0G0G0G 0G 0G 0G 0G0G0G0G0G 0G 0G 0G 0G  0((0+00 000 0000 0000 0 0 0 00000  0((0+00 000 0000 0000 0 0 0 0 0((00+0000 000000 00000000 00000000 00 00 00 0000000000 00 00 00 00  0((0`+0`0` 0`0`0` 0`0`0`0` 0`0`0`0` 0` 0` 0` 0`0`0`0`0`  0((0+00 000 0000 0000 0 0 0 00000  0((0+00 000 0000 0000 0 0 0 00000 0 0 0 0 0 0 0 0 0 0 0 0  0((0~+0~0~ 0~0~0~ 0~0~0~0~ 0~0~0~0~ 0~ 0~ 0~ 0~0~0~0~0~ 0~ 0~ 0~ 0~ 0~ 0~ 0~ 0~  0((09+0909 090909 09090909 09090909 09 09 09 09 0((0t+0t0t 0t0t0t 0t0t0t0t 0t0t0t0t 0t 0t 0t 0t0t0t0t0t  0((0+00 000 0000 0000 0 0 0 00000 0 0 0 0 0 0 0 0 0 0 0 0  0((0+00 000 0000 0000 0 0 0 00000  0 ((0+00 000 0000 0000 0 0 0 0 0!((0+00 000 0000 0000 0 0 0 00000 0 0 0 0  0"((0^+0^0^ 0^0^0^ 0^0^0^0^ 0^0^0^0^ 0^ 0^ 0^ 0^ 0#((0I+0I0I 0I0I0I 0I0I0I0I 0I0I0I0I 0I 0I 0I 0I0I0I0I0I  0$((0S+0S0S 0S0S0S 0S0S0S0S 0S0S0S0S 0S 0S 0S 0S 0%((0X+0X0X 0X0X0X 0X0X0X0X 0X0X0X0X 0X 0X 0X 0X0X0X0X0X  0&((0+00 000 0000 0000 0 0 0 00000 0 0 0 0  0'((0+00 000 0000 0000 0 0 0 00000  0(((00 0)((0k0k0k 0*((00 0+((0404 0,((0g0g0g 0-((000 0.((000000000000 0/((00000000 000404040404 010M0M 020* 00G* 00* 002* 0000;00&0&0&00 0$0|X  `78q9;twI r  a 2tv* b"mH(.a& 4! ""#$%&'()*-++,K-..]//U0$1[2b3u45{6S7;8+9;:S;_<(=>>?@ABCDEFGHIJKLMNOSQDZAbms#|}M/3l({Ur(k&_DL^Bc߷& NW&#lHtx!}  .6moe *  PhfDu' K&/(),'/01R4`7N9=?ACxG[KLM/NP?Q9RRTTUV{Y[F]^aIejmoosrtvwxyz|_}~~8;q؊Bou($9 39K/Bŷ E6̻Py=!} -C[t w;^v.*M  :E%  >;\^j "]$6.:BF,GG $')*+,-./012345689:;<=>?@ABCDEFHIJKLMNOPQRSTUVXYZ[\]^_`abcdfghijklmnopqrsuvwxyz{|}~ !#'),.048<>ADHJNRUWZ\_aehknqtz !$'*.9>AIMPTY^bhlps{   !#%'()+-/2479:;=?DEGIJLMOPSUWZ]^`bdefhjlmnoqrstvxy{|~ $+6=EMUZbhmoqsvy|B,T72EO\i]:^^_`ibbbbbbb'm&sjsssstDtxt||}4}Y}}}}~X~~-Y$L;g߁$g˂2_ƃ+P:eŅ Tņ(Rz6bڈSlj"͊-RʋgΌ TCwҎ&XGÐēŔvߙ<dvע9!ťm vyb89hų~vz ط" x'X%YRkzMgB>aW0Bj0?`^cI1>p3r Hs({Vk Z K4w[  8  6 A     tPm#3X/T%1m   H!{!"# $$Q%%O&]'v''D)T))**+,,,-./a//00T112m33d4r5?6H7q7#8999:\;;<>>?@@AxBQCC DcDDDFGG#HH$IIJJtKLLMUM/N#O PPIQRRSTT2UUVVWbXuYZ[M\]\]]Y^a__q` aab7c ddCeeeYfffhTiicjkdklm%mm"nooIppqirnss,tt{uu}v wNwxxyHzz{|;}L}_}}$~~5܀=‡JĘpv u:Т_W48ĭ5ibPb~?"oZ/$;M^Tb&@\s<\Ps'%:VtJ*&1<4-9\k.Pr,D]P h  0 K      "  v   i7L<Xt[i~.&6H&M[{Om   !","G""#(#f##^$r$$&:6c?FF,GPG ?  %(7GWet     "$%&(*+-/1235679:;=?@BCEFGIKLMOPQSTVXY[]^`bcdfgijlmoprsuvwxy{|}~     "#%&()+,-/012345678:;<=?@BCDEFGHJKLNOQRSUVWXZ[\]_`acdefgijkmnoqrtuvwxyz|}~   "$&*,.013568<>@ABCFHKNQRTVXY[\_acgikpuwz}     !"#%&'()*,-./012345789:;<>?@ABCDFGHIJKLNOPQRSTVWXY[\]^_`acdefgijklnprtuwz{}~ & %'GWsuvx*,-/OqUqstv "#%Ec!=?@Bb,./1QrPlnoq1MOPRr6 R T U W w  $ ' ( * J x   . Y u x y {  ! = @ A C c q   ! # C #?BCEe{Kgjkm+GJKMm ),-/Ov5r   -   -g  .l( <?@Bb #$&F3679Y!$%'G$@CDFf'CFGIiWsvwyd"j   % Z v y z | !k!!!!!!!!!!!"b"~"""""""""""#.#1#2#4#T#y###########$K$g$j$k$m$$$$$$$$)%E%H%I%K%k%}%%%%%%%&&& &)&R&n&q&r&t&&&&&&&&'8';'<'>'^'z'''''''''''(2(N(Q(R(T(u(((() )")#)%)E)))))));*W*Y*Z*\*|******+B+^+`+a+c+++++++ ,U,q,s,t,v,,,,,,,-a-}------... .*.Z.v.y.z.|......./2/N/Q/R/T/t///////06090:0<0\0000000 1&1)1*1,1L111111126292:2<2\222222223N3Q3R3T3t3333334>4Z4]4^4`444444445#5&5'5)5I5q55555555566"6b6~66666666667)7E7H7I7K7k77777778:8=8>8@8`8888888,9H9K9L9N9n9999999::":#:%:E:::::::;;; ;";B;v;;;;;; <&<)<*<,<L<<<<<<<=,=/=0=2=R=======>>> >">B>>>>>>>??? ?"?B?r??????@!@$@%@'@G@@@@@@@@AAAA5AAAAAAAB2B5B6B8BXBBBBBBB.CJCMCNCPCpCCCCCCC!D=D@DADCDcDDDDDDDE8E;EE^EEEEEEEF$F'F(F*FJFFFFFFFG!G$G%G'GGGGGGGG RDRYR!()!)K-o-~-- ../00445? X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%̕ X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%X%̕XXXXXXXw~*13w!!!! /DsXXXl ,b$k 3ʴ3U4Hia@ 0(  B S  ?? _Toc115670274 _Toc122939377 _Toc115670275 _Toc122939378 _Toc115670276 _Toc122939379 _Toc115670277 _Toc122939380 _Toc122939381 _Toc122939382 _Toc122939468 _Toc122939383 _Toc122939384 _Toc122939385 _Toc122939386 _Toc122939387 _Toc122939388 _Toc122939469 _Toc122939389 _Toc122939390 _Toc122939391 _Toc122939392 _Toc122939470 _Toc122939393 _Toc122939471 OLE_LINK1 OLE_LINK2 _Toc122939394 _Toc122939472 _Toc122939395 _Toc122939473 _Toc122939396 _Toc122939474 _Toc122939397 _Toc122939475 _Toc122939398 _Toc122939476 _Toc122939399 _Toc122939400 _Toc122939477 _Toc122939401 _Toc122939478 _Toc122939402 _Toc122939479 _Toc122939403 _Toc122939480 _Toc122939404 _Toc122939481 _Toc122939405 _Toc122939482 _Toc122939406 _Toc122939483 _Toc122939407 _Toc122939408 _Toc122939484 _Toc122939409 _Toc122939485 _Toc122939486 _Toc122939410 _Toc122939487 OLE_LINK5 OLE_LINK6 _Toc122939488 _Toc122939489 _Toc122939411 _Toc122939490 _Toc122939491 _Toc122939412 _Toc122939413 _Toc122939492 _Toc122939414 _Toc122939493 _Toc122939415 _Toc122939494 _Toc122939416 _Toc122939495 _Toc122939417 _Toc122939496 _Toc122939418 _Toc122939497 _Toc122939419 _Toc122939498 _Toc122939420 _Toc122939499 _Toc122939421 _Toc122939500 _Toc122939422 _Toc122939501 _Toc122939423 _Toc122939502 _Toc122939424 _Toc122939503 _Toc122939425 _Toc122939504 _Toc122939426 _Toc122939505 _Toc122939427 _Toc122939506 _Toc122939428 _Toc122939507 _Toc122939429 _Toc122939508 _Toc122939430 _Toc122939509 _Toc122939431 _Toc122939510 _Toc122939432 _Toc122939511 _Toc122939433 _Toc122939512 _Toc122939434 _Toc122939513 _Toc122939435 _Toc122939514 _Toc122939436 _Toc122939515 _Toc122939437 _Toc122939516 _Toc122939438 _Toc122939517 _Toc122939439 _Toc122939518 _Toc122939440 _Toc122939519 _Toc122939441 _Toc122939520 _Toc122939442 _Toc122939521 _Toc122939443 _Toc122939522 _Toc122939444 _Toc122939523 _Toc122939445 _Toc122939524 _Toc122939446 _Toc122939525 _Toc122939447 _Toc122939526 _Toc122939448 _Toc122939527 _Toc122939449 _Toc122939528 _Toc122939450 _Toc122939529 _Toc122939451 _Toc122939530 _Toc122939452 _Toc122939531 _Toc122939453 _Toc122939454 _Toc122939455 _Toc122939456 _Toc122939457 OLE_LINK3 OLE_LINK4 _Toc122939458 _Toc122939459 _Toc122939460 _Toc122939461 _Toc122939462 _Toc110231326 _Toc122939463 _Toc110231327 _Toc122939464 _Toc110231328 _Toc122939465 _Toc110231329 _Toc122939466 _Toc122939467llG]RLTiZZ[`'e4ejzlnGnstvv.w.wxx|||$JV,ٻ[;;J]v]ʁ_2@@@ct(K+V'4-.0gMvijF_    /   o%|3Ew`p H ""7#k&Q.0 4F5F566~6~666b7?  !"#$%&'()*+,-./0123456789:;=><?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~bbGvRTyZZ[`2eLe kl*nantxtvv5w5wxy|"}I˅+qػ3;;u]]Ɂҁ:|ޭxyyO-*]hL^dbm/>u&2LCt_   5 {  7vY)g ?(8Tp3,A ##_#&\.1+4b5b566667m7m7?-Numbered Styles 1Numbered Styles 2Numbered Styles 3Numbered Styles 4"Internal Data Integrity (Type 4) 2"Internal Data Integrity (Type 4) 3"Internal Data Integrity (Type 4) 4"Internal Data Integrity (Type 4) 5"Internal Data Integrity (Type 4) 6"Internal Data Integrity (Type 4) 7"Internal Data Integrity (Type 4) 8"Internal Data Integrity (Type 4) 9#Internal Data Integrity (Type 4) 10#Internal Data Integrity (Type 4) 11#Internal Data Integrity (Type 4) 12#Internal Data Integrity (Type 4) 13#Internal Data Integrity (Type 4) 14#Internal Data Integrity (Type 4) 15#Internal Data Integrity (Type 4) 16#Internal Data Integrity (Type 4) 17#Internal Data Integrity (Type 4) 18#Internal Data Integrity (Type 4) 19#Internal Data Integrity (Type 4) 20#Internal Data Integrity (Type 4) 21#Internal Data Integrity (Type 4) 22#Internal Data Integrity (Type 4) 23#Internal Data Integrity (Type 4) 24#Internal Data Integrity (Type 4) 25#Internal Data Integrity (Type 4) 26#Internal Data Integrity (Type 4) 27#Internal Data Integrity (Type 4) 28#Internal Data Integrity (Type 4) 29#Internal Data Integrity (Type 4) 30#Internal Data Integrity (Type 4) 31#Internal Data Integrity (Type 4) 32#Internal Data Integrity (Type 4) 33#Internal Data Integrity (Type 4) 34#Internal Data Integrity (Type 4) 35#Internal Data Integrity (Type 4) 36#Internal Data Integrity (Type 4) 37 Bookmarks 1"Internal Data Integrity (Type 3) 1 Bookmarks 2 Bookmarks 3"Internal Data Integrity (Type 4) 1?  !"#$%&'()*+,?P$$DGH$$lGH,$$GH,$l $GH"$,#$lGH%$&$,GHl($)$*$,+$l,$-$.$,/$l0$1$2$,3$l4$5$6$,7$l8$9$:$ ,;$l<$=$>$,?$l@$A$B$,C$ld$e$ f$<g$ |h$ @Hj$ <k$|l$ m$ GH<o$ |p$ q$r$|s$ t$ u$ <v$ |{@H||@H}@H~@H<@H|AHiAH\jAH,AHdAH aAH\AH AHdnAHdAHy!ؖؖ#NNLL¯¯AA0``   !>!>!DDDDDDDDHHh%i%ipiii''f0f000001]3]3r3}3399::::::::;;'<2<5<?      !"#$%&'()*+,-./01243567:89;?<=>@DABCEIFGHJNKLMOܖܖ%PP PPįįCC4dd   !@!@!DHDHDDDDHHh)i)iriii))~0~00000&1p3{3333::::::::::%<0<4<?<?<?  !"#$%&'()*+,-./012435679:8;=>?<@BCDAEGHIFJLMNKOVBN*urn:schemas-microsoft-com:office:smarttagsplacehttp://www.5iantlavalamp.com/i2,*urn:schemas-microsoft-com:office:smarttagsState0http://www.5iamas-microsoft-com:office:smarttagsh$*urn:schemas-microsoft-com:office:smarttagsCity0http://www.5iamas-microsoft-com:office:smarttagsBPP*urn:schemas-microsoft-com:office:smarttagscountry-regionk"*urn:schemas-microsoft-com:office:smarttagsaddress0http://www.5iamas-microsoft-com:office:smarttags8*urn:schemas-microsoft-com:office:smarttagsdatei!*urn:schemas-microsoft-com:office:smarttagsStreet/http://www.5iantlavalampft-com:office:smarttagsn*urn:schemas-microsoft-com:office:smarttags PostalCode0http://www.5iamas-microsoft-com:office:smarttags  1200423DayMonthYearPPBPPBPPBPPBPPBPPBPPBPPBPPBPPBPPBPPB2BPPBPPBBBB2B2$B2"!$B2"!$2"!$2"!$2"!$2jHwRRTlTCV]VIZqZ]]abggi"i-iAillnRnrrnuux?xzzOj VċߋrwpgWt[7'b#VvyǟڟA[2|Ku_>[ʱбٱ߱%e}дHZy#  ?EK`lrw}-DG *]s:^krz %qUr-w2:@EKf 1   AZEZ47_KW]bhc"|"s##$$%/&((H/_/S3`3f3338888899(9.9>9D9I9O9999[;;?<g<ԅnoxyNjȋrЫV! JDciUtS q   Jv#: =Ai   !!""":']'.(S(((\)_),,./ / //4/00|112234 484#5c5s6~6667/7V78*9599999::::;;{<{<|<|<~<~<<<<<<<<<6=A=>$>??????VTbT1^4^hh&j2j,nEnVXċɋ_e` 29  7_4uSmn]n"#%%&&'(`/h/i/0i778[;;)<r0+A&Fu`~    ' ; %wZ|O3wpB """`#%&[)\)+]..0338::;@<|< ??\?e??????::::::::::::::::::::::'V(u(GGRwRSSLTTjUUXVtV>E>m>>??r????[@l@@@!A2AAAAABBUC}CDDGEUE F8FG[GG:H1IIIIJJJ~KKL=LLLMTMMM~NNNOOOOOVPkP\QQRRSSOT]TTUUUUUV,VVVaWhWWWJXzXYYYYZZ7[H[ \\\\@]v]]^Z^h^^^````@aTaaa'b8bbbccacrcdd#d+de-eeef+fggggKhYhiifjjgkxkkkllsmmmn oNoopppqqurrsstt$>5>9>d>{>>>>>>>>;?O??????????T3T3gg;;g8|<???3u rMc0}9B~Ni;XS$cI(zS XZZWrOnW/faZX}t4x]F"3arvjs@Qhvr ^`OJQJo(h^`OJ QJ o(hHh pp^p`hH.h @ L@ ^@ `LhH.h ^`hH.h ^`hH.h L^`LhH.h ^`hH.h PP^P`hH.h  L ^ `LhH.h ^`hH.h pp^p`hH.h @ L@ ^@ `LhH.h ^`hH.h ^`hH.h L^`LhH.h ^`hH.h PP^P`hH.h  L ^ `LhH.h^`OJQJo(hHh pp^p`hH.h @ L@ ^@ `LhH.h ^`hH.h ^`hH.h L^`LhH.h ^`hH.h PP^P`hH.h  L ^ `LhH.h^`OJQJo(hHh pp^p`hH.h @ L@ ^@ `LhH.h ^`hH.h ^`hH.h L^`LhH.h ^`hH.h PP^P`hH.h  L ^ `LhH. hh^h`OJQJo(P^`PNN^N`.0^`0..``^``... ^` .... ^` ..... ^` ...... `^``....... 00^0`........h^`OJ QJ o(hHh pp^p`hH.h @ L@ ^@ `LhH.h ^`hH.h ^`hH.h L^`LhH.h ^`hH.h PP^P`hH.h  L ^ `LhH.h88^8`OJQJo(hHh^`OJQJ^Jo(hHoh  ^ `OJ QJ o(hHh  ^ `OJQJo(hHhxx^x`OJQJ^Jo(hHohHH^H`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHhCJOJ QJ o(h^`OJQJo(hHh pp^p`hH.h @ L@ ^@ `LhH.h ^`hH.h ^`hH.h L^`LhH.h ^`hH.h PP^P`hH.h  L ^ `LhH.h^`OJ QJ o(hHh pp^p`hH.h @ L@ ^@ `LhH.h ^`hH.h ^`hH.h L^`LhH.h ^`hH.h PP^P`hH.h  L ^ `LhH.hh^h`CJOJ QJ o(;h^`OJ QJ o(hHh pp^p`hH.h @ L@ ^@ `LhH.h ^`hH.h ^`hH.h L^`LhH.h ^`hH.h PP^P`hH.h  L ^ `LhH.SvjsfaZ$cIOnWSSSSMc0u Qhvi;XZZW}9"3ax]˜                 d        d                 d        >T&V~l'?!@<tu)"B  rqciz"B +T& "hA^j@'z!NIb"2-e ]9O r@""'UIV#.qcizym z<($R& Q{ *[0N9R."W."[01V~li1"6"<~8zHr!@qcizj@qciz*AOJ\=[CZBK%`E<($ZBKV~l}L=>ac QqciziS<($IVV~lW#.BY8cOJ\qciz-e ]qciz)F`V~lNIbV~l=>acqciz8cV~ljd[0,ffhYwf,pihYwck@nV~l@nqcizdp)F`7q1zHrqciz ?r |<=sB>hYwym zV~lqciz[~t#<>}gdRwahp;Ry%j4UN5<b Sd # c m u / I Q qL } b h E]209|do9cyK_k:x9K\=mP pZ_"eD&v 'bAcg@ VX ac Wd!o!} $w$d %$%1*%K%#&(&&.&.&J'Ai'fv'.(`=(V(;g(>0) *"*-*}e*+IW,L\,wz,-f8-#$.=.p/q0S0=1Q1T1<2+N3J-4hh5!6+6`6Q7^79o.9/9":i:g: ;; =C%>B6BVAC]JCiCDD E FFRF*G5HOnH|9J$8K" MO`MNITNO5ONO Q[QN,R6RSu,VbKVaVWMWgWrWsX2X8XYFXVXYYQYMZ@Z&\bf\=x]E_$BaSa`a~aI:cbUc=Xdwe 'e'ea=ege ffFg^h?hGMhVGijk:kik/l`m`,mJmFneHnTn42o/XoNp[epp\s.|sK&tF/tAhtcCI kGOdcdfu ~-T5S]^eN>.0+;HwmRIaO<kAaNXoXzcr{46@JsHzg?fi=KsN{ef)5:'QS^3j.s 5PS5L`9OMWgRs|{{ vn]u~Ub__N,yi: T@wU_#qH]iq!9aY'ai(f` {6)N$~596|>Uii6VX$f%B-docI\NK(WebGt]*oDT-{R4NBBuY|+P/qJy 03(KQVffl.2ps+jTTTTTTTT5UiUjUUV:VWVXVtVVW;W?@H  ORVWX`1489:B[^bjks037?@HPSW_`h(^_cdem \_cefn&'/(+/0197:>?@H_bfpqy *+303789Aruyx{  lostu}fimrs{deijks ]`dijrvy}TUYZ[c 6<FKijr+.234<loswxSVZ[\d23789A/26PQYADHPQYux|svzJ K O P Q Y j m q y z  # $ ( ) * 2                " # + 3 6 : B C K X[_`aiuy}~ FIMghpruy %23789A\_cdem4TZdiILPQRZ ruyz{QRVWX`LOSmnv^aemnv C!D!H!I!J!R!T!W![!d!e!m!!!!!!!z"}"""""######$$$ $$$$$$$$$$$$%% %&&&&&& '#'''/'0'8'''''''(((((((())) )))))))******n+q+u+v+w++S,V,Z,[,\,d,c-f-j-r-s-{-8.;.?.@.A.I.Y/\/`/h/i/q/000#0$0,091<1@1H1I1Q1111112222222U3X3\3v3w3333333344445566666%6_7c7g7h7i7q77777778888883969:9T9U9]9999999z:}:::::Q;T;X;Y;Z;;;;;; < <<c<d<h<i<j<r<<<<<<<>>A>E>>>>??? ? ??q?r?v?w?x????????[@^@b@c@d@l@@@@@@@!A$A(A)A*A2AAAAAAABBBBBBeChClCtCuC}CDDDDDDDDDDDDFEGEKELEMEUE F#F'F/F0F8FGG#G9G:G[G HHHHH:H1I4I8I@IAIIIIIIIIJJJJJJJ~KKKKKKLLLLL=LLLLLLL*M-M1M2M3MTMMMMMMM}N~NNNNNNNNNNOOOOOOOVPYP]PbPcPkPrQuQyQQQQRRRRRRSSSSSSNTOTSTTTUT]TTUUUUUUUUUUUVV"V#V$V,VVVVVVVaWdWhWWWWbXeXiXqXrXzXYY Y Y YYYYYYYYZZZZZZ7[:[>[?[@[H[ \ \\\\\\\\\\\@]C]G]H]I]J]v]]]]]]]^^Y^Z^^^_^`^h^^^^^^^``````@aCaGaKaLaTaaaaaaa'b*b.b/b0b8bbbbbbbcc c c ccacdchcicjcrcddd"d#d+deee$e%e-eeeeeeeff!f"f#f+fgg ggggggggggJhKhOhPhQhYhiiiiiifjijmjujvjjgkjknkokpkxkkkkkkkllllllsmvmzm{m|mmmmmmmnxnyn}n~nnn6o9o=oEoFoNoppppppppppppqqqqqqurxr|rrrrsssssstttttt;u?v"#ZZ[/0J12;<MN@J^_hu.3?STVYZ[]abc%&'-?@AG[\]crst $;<=B[\]b+0<PQWrstz'($%&+9:;?UVW\stuz JK  )*+%&'  $%&+0126:;<@LMNRn34+,- 459IJKO[\]aijko ./2OPQTpqruchtns ,-3CDEK[\]cstu{',8LMPYZ[^ghi  !&/016IJKPghin !"#'2MR^rsv~DIUijmuz     ! % 6 7 8 < J K L P ] ^ _   ( < = A W X Y ] r s t x        6 ; G [ \ ` h i j n | } ~                   . /    & ' + 5 6 7 ; F G H L u v w {             #$%&'*LMNQYZ[_stuyZ_k789=C{|*/;OPTlmnrhmy   *+,0:;<@FGH&'(,JKLOefgj}~49EYZ^cdeiqrsw8:::;|<<<<<<=,=-=1=P====>4>5>{>>>>>>>>>>N?O?R?????99@?$4.0=?@6t@@Unknown G: Times New Roman5Symbol3& : Arial;|i0BatangC"MS Sans Serif7&  VerdanaCFComic Sans MS?5 : Courier New5& zaTahoma;Wingdings#hh ff%TL"TL"!4dp7p7Ye I 2QXZ ?x2)Additional Information Specification 0003"Rehabilitation Services AttachmentHL7 Attachments CommitteebzdtfzD         Oh+'0$0<P `l    ,Additional Information Specification 0003$Rehabilitation Services AttachmentHL7 Attachments Committee Normal.dotbzdtfz16Microsoft Office Word@ݾ@X^@,@>,LT՜.+,D՜.+,P px  2Karen Van HentenryckHealth Level Seven, Inc."p7G *Additional Information Specification 0003 Title5 X'444444 5 _PID_HLINKSEditor_AdHocReviewCycleID_NewReviewCycle_EmailSubject _AuthorEmail_AuthorEmailDisplayName _ReviewingToolsShownOnceAT3 Ihttp://www.wpc-edi.com/codes/.mailto:rebert@hcidea.orgt?http://www.dea.gov/)(http://www.samhsa.gov/t?http://www.dea.gov/d1c../../../../../../../../Documents and Settings/bzdtfz/Local Settings/Temp/prescription-glasses.gif Ehttp://www.loinc.org/5_Toc1229395315}_Toc1229395305w_Toc1229395295q_Toc1229395285k_Toc1229395275e_Toc1229395265__Toc1229395255Y_Toc1229395245S_Toc1229395235M_Toc1229395225G_Toc1229395215A_Toc1229395205;_Toc12293951955_Toc1229395185/_Toc1229395175)_Toc1229395165#_Toc1229395155_Toc1229395145_Toc1229395135_Toc1229395125 _Toc1229395115_Toc1229395105_Toc1229395095_Toc1229395085_Toc1229395075_Toc1229395065_Toc1229395055_Toc1229395045_Toc1229395035_Toc1229395025_Toc1229395015_Toc1229395004_Toc1229394994_Toc1229394984_Toc1229394974_Toc1229394964_Toc1229394954_Toc1229394944_Toc1229394934_Toc1229394924_Toc1229394914_Toc1229394904_Toc1229394884_Toc1229394874{_Toc1229394864u_Toc1229394854o_Toc1229394844i_Toc1229394834c_Toc1229394824]_Toc1229394814W_Toc1229394804Q_Toc1229394794K_Toc1229394784E_Toc1229394774?_Toc12293947649_Toc12293947543_Toc1229394744-_Toc1229394734'_Toc1229394724!_Toc1229394714_Toc1229394704_Toc1229394694_Toc1229394684_Toc1229394674_Toc1229394664_Toc1229394654_Toc1229394644_Toc1229394634_Toc1229394624_Toc1229394614_Toc1229394604_Toc1229394594_Toc1229394584_Toc1229394574_Toc1229394564_Toc1229394554_Toc1229394544_Toc1229394534_Toc1229394524_Toc1229394514_Toc1229394504_Toc1229394494_Toc1229394484_Toc1229394474_Toc1229394464_Toc1229394454|_Toc1229394444v_Toc1229394434p_Toc1229394424j_Toc1229394414d_Toc1229394404^_Toc1229394394X_Toc1229394384R_Toc1229394374L_Toc1229394364F_Toc1229394354@_Toc1229394344:_Toc12293943344_Toc1229394324._Toc1229394314(_Toc1229394304"_Toc1229394294_Toc1229394284_Toc1229394274_Toc1229394264 _Toc1229394254_Toc1229394244_Toc1229394234_Toc1229394224_Toc1229394214_Toc1229394204_Toc1229394194_Toc1229394184_Toc1229394174_Toc1229394164_Toc1229394154_Toc1229394144_Toc1229394134_Toc1229394124_Toc1229394114_Toc1229394104_Toc1229394094_Toc1229394084_Toc1229394074_Toc1229394064_Toc1229394054_Toc1229394044_Toc1229394034_Toc1229394024z_Toc1229394014t_Toc1229394003n_Toc1229393993h_Toc1229393983b_Toc1229393973\_Toc1229393963V_Toc1229393953P_Toc1229393943J_Toc1229393933D_Toc1229393923>_Toc12293939138_Toc12293939032_Toc1229393893,_Toc1229393883&_Toc1229393873 _Toc1229393863_Toc1229393853_Toc1229393843_Toc1229393833_Toc1229393823_Toc122939381`|http://www.hl7.org/(=http://www.wpc-edi.com/ Ehttp://www.loinc.org/ Chuck MeyerhcDraft of the PharmPA Attachpenny.sanchez@eds.comSanchez, Penny L  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 5 6 7 8 9 : ; = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W p Root Entry FqANr Data h1Table:<WordDocument5 SummaryInformation(4 DocumentSummaryInformation8< 6CompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q
PRESCRIBER INFORMATION PRESCRIBER INFORMATION, NAME PRESCRIBER INFORMATION, IDENTIFIER PRESCRIBER INFORMATION, SPECIALTY TAXONOMY PRESCRIBER CONTACT INFORMATION PRESCRIBER CONTACT INFORMATION, PHONE NUMBER PRESCRIBER CONTACT INFORMATION, FAX NUMBER DRUG PRESCRIBED DRUG PRESCRIBED, NAME DRUG PRESCRIBED, DRUG CODE DRUG PRESCRIBED, THERAPY TYPE DRUG PRESCRIBED, REASON FOR TOPICAL THERAPY IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS - CONFIRMED BY FUNGAL INFECTION LOCATION CO-MORBID CONDITION INFORMATION CO-MORBID CONDITION INFORMATION, LIVER DYSFUNCTION INDICATOR CO-MORBID CONDITION INFORMATION, LIVER DYSFUNCTION CONFIRMED BY MEDICARE ESRD CERTIFICATION INDICATOR DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG NAME DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG CODE DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DURATION OF THERAPY DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED IMIDAZOLE-RELATED ANTIFUNGALS, PRIOR THERAPY TYPE PRESCRIBER INFORMATION PRESCRIBER INFORMATION, NAME PRESCRIBER INFORMATION, IDENTIFIER PRESCRIBER INFORMATION, SPECIALTY TAXONOMY PRESCRIBER CONTACT INFORMATION PRESCRIBER CONTACT INFORMATION, PHONE NUMBER PRESCRIBER CONTACT INFORMATION, FAX NUMBER DRUG PRESCRIBED DRUG PRESCRIBED, NAME DRUG PRESCRIBED, DRUG CODE DRUG PRESCRIBED, THERAPY TYPE DRUG PRESCRIBED, REASON FOR TOPICAL THERAPY IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS IMIDAZOLE-RELATED ANTIFUNGALS, RELATED DIAGNOSIS - CONFIRMED BY FUNGAL INFECTION LOCATION - OTHER CO-MORBID INFORMATION CO-MORBID INFORMATION, LIVER DYSFUNCTION INDICATOR CO-MORBID INFORMATION, LIVER DYSFUNCTION CONFIRMED BY MEDICARE ESRD CERTIFICATION INDICATOR DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG NAME DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DRUG CODE DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - DURATION OF THERAPY DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED DRUG HISTORY, PRIOR THERAPY FOR DIAGNOSIS - REASON PRIOR THERAPY DISCONTINUED